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Abstract 
The work presented herein focuses on the study of novel metallodrugs and their interaction with 
various possible targets and off-targets in the form of biomolecules such as peptides, proteins, DNA, 
and small molecules via the use of ultra-high resolution Fourier Transform-Ion Cyclotron Resonance 
Mass Spectrometry.  
Beyond traditional platinum(II) metallodrug such as cisplatin and oxaliplatin, new designs of 
metallodrugs are being conceived to attack and kill cancerous cells via new mechanisms of action in 
an effort to exceed the potency, selectivity, and effectiveness of metallodrug treatments. These new 
metallodrugs range from various activation strategies, to specific target binding, and even catalysis 
of cell-disrupting processes. As a result these novel drugs can have a wide array of effects on various 
biomolecule species the may encounter in the body.  
It is the aim of this thesis to show that mass spectrometry, specifically FT-ICR Mass Spectrometry, is 
uniquely suited to studying the wide array of metal-based drugs, their biomolecule targets/off-
targets, and the numerous reaction products produced from their interactions. Though the study of 
metallodrug-modified biomolecules via mass spectrometry was shown to be challenging in many 
cases, mass spectrometry is currently the only analytical technique viable for studying the complex 
systems involved to a useful level of detail. The majority of the thesis focuses on study of isolated 
biomolecules interacting with novel metallodrugs and the MS and tandem-MS based study of the 
resulting observable components.  
A great range of metallodrugs and biomolecule interactions were observed. A photoactivated 
platinum(IV) metallodrug (trans, trans, trans[Pt(py)2(OH)2(N3)2]) was shown to produce a variety of 
platinum(II) based modifications to the peptides studied when activated with blue (463nm) visible 
light, with the ligand configurations varying depending on whether a histidine amino acid residue 
was present, allowing retention of both pyridine ligands, or not, allowing release of any of the bound 
ligands. Tandem MS studies using electron based dissociations showed the primary preference of 
v 
binding to be at the Histidine residues, and when not available the complexes could bind to lysing 
functional groups, distinctly different behaviour to previously studied Pt(II) complexes. Oxidation of 
peptide species was also found to be a significant product of these reactions. Tandem MS studies 
located the oxidation sites to methionine and tryptophan residues, the latter of which provided 
insights into the oxidation mechanism. The oxidation process was found to be due to a hydroxyl 
radical process, not a singlet oxygen mechanism. UV/vis and EPR measurements were also 
undertaken and supported the results found. 
Studies into the interaction of a potent osmium(III) compound with isolated DNA strands showed 
that the metallodrug could bind to both guanine and cytosine sites along the biomolecule. Analysis 
of these species via CAD MS/MS proved challenging due to damage and eventual dissociation of the 
metal complex modifications. Whereas electron detachment dissociation enabled the elucidation of 
the two distinct binding locations. CAD MS/MS was found to be useful for studying hydrogen 
bonded/pi-stacking stabilised structures. 
Further investigations into DNA MS and MS/MS lead to the study of the platinum(IV) compound 
interactions with DNA stands, showing a vastly improved rate of reaction for the compound when 
compared to the previous peptide reactions. In addition uniform retention of pyridine ligands and no 
oxidation was observed, providing further evidence of the biomolecule playing a key role in the 
activation process of the Pt(IV) drugs. MS/MS studies of platinated DNA resulted in similar findings 
to the osmium-based metallodrugs. Experiments with native MS of DNA showed that observation 
and interrogation of duplex-DNA strands is possible, even with DNA strands which are not stabilised 
easily in ammonium acetate solutions, and without annealing. MS, MS/MS, and MS3 was achieved 
on duplex DNA strands using large concentrations of ammonium acetate and potassium chloride 
solutions, along with extremely carefully tuned MS source and transfer parameters.  
The effects of metals on tandem-MS techniques was uniquely apparent during the study of 
functionalised Iridium-based metallodrug modified peptides. The iridium complexes were shown to 
v 
effectively quench many electrons used during ECD MS/MS. Though the species were still able to be 
studied using optimised ECD and CAD MS/MS parameters.  
The reactivity of metal centres was also shown to affect their own bound ligands, as observed herein 
with rhodium(II) compounds. The rhodium piano-stool complexes were shown to vastly accelerate 
and enable room temperature activation of C-H bonds within arene ligands towards hydrogen-
deuterium exchange experiments, with some compounds achieving full exchange of available groups 
within just 1 hour. The process was studied using FT-ICR MS to track the exchange process and 
observe sequential exchange for 10 different rhodium compounds. An iridium analogue was also 
studied, which was ineffective, displaying the Rh metal centre’s unique chemistry for this reaction. 
A novel method for the enhancement of the electrospray ionisation process was conceived and 
developed in order to achieve improvement of analyte charging, so-called “supercharging”. Using a 
combination of standard electrospray ionisation and atmospheric chemical ionisation, CH5+ 
“superacid” ions were introduced into the ESI plume and enabled solution-additive free 
supercharging of analytes under a variety of conditions. The achievement of higher charge 
states/enhancement of charge is of uniform benefit to biomolecule characterisation and could help 
reduce the need for solution phase additives which can disrupt many chemical processes and 
biomolecule structure. 
The final section of the thesis is concerned with the escalation of metallodrug-biomolecule 
interaction from isolated biomolecule up to full-cell proteomes via FT-ICR MS. The great array of 
challenges faced in previous studies is addressed and strategies for accurate and reliable studies of 
large metallodrug-modified systems are outlined and tested. Two major strategies are proposed, 
one based on liquid-chromatography mass spectrometry with modified data processing techniques. 
The other using a niche MS/MS technique known as two-dimensional mass spectrometry, which 
would enable whole proteome characterisation without chromatographic separation. Preliminary 
result using both approaches and future outlook are presented. 
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then be Fourier transformed to produce a mirrored time domain spectrum (b) followed by 
halving, and re-plotting as real numbers to produce a frequency spectrum (c), finally the 
frequency spectrum can be calibrated using a variety of equations (see below), to produce 
an FT-ICR MS mass spectrum (d). Should the data from the FID simply be plotted after 
Fourier transformation as so often recorded it would produce a complex mixture of real and 
imaginary numbers (e) and if it were plotted as simply absolute numbers it would produce a 
plot with an uncalibrated x-axis, though containing the frequency information, with the 
wrong separation to be informative.  Page:   14 
 Figure 1.11: Example MS spectrum showing the complexity of petroleum based samples via 
FT-ICR mass spectrometry, included are insets showing effective resolution of different 
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components isotopic fine structure and the corresponding milli-Dalton range separation 
needed.18     Page:   17 
 Figure 1.12: plots representing the various dependencies of FT-ICR MS performance on 
magnetic field strength, and thus the advantages of increasing magnetic field for FT-ICR Ms 
analysis. Reproduced from Marshall et.al.17  Page:   18 
 Figure 1.13: example of apodisation on an FTMS spectrum showing that apodisation can 
suppress side lobes and broad peak bases, which can improve dynamic range, but negatively 
affects resolving power. Reproduced from Makarov et. al.3  Page:   22 
 Figure 1.14 – FT_ICR MS spectrum of the 10+ charge state of lysozyme protein: un-apodised 
(top) and processed using sine-bell apodisation (bottom), although the resolving power 
drops from 165,000 to 129,000 for the peaks observed the apodisation does improve the 
peak bases and allow visualisation of the low signal-to-noise isotopes. Also note the 
decrease in intensity due to peak broadening. Page:   22 
 Figure 1.15: representation of external calibration procedure to produce a mass spectrum 
(e) from a recorded FID signal (a) by creation of a calibration curve (d) of known peaks in the 
frequency spectrum (c). Example shown is a ubiquitin protein FT-ICR mass spectrum. 
      Page:   25 
 Table 1.1 – Examples of FTMS calibration equations reproduced from Gross et. al.22 Page:   
26 
 Figure 1.16: Various frequency pulses used to excite ions to a larger radius within the ICR cell 
and enable detection. A) and b) are rectangular pulses of different times and magnitudes, c) 
the standard “Chirp” excitation profile used in the vast majority of FT-ICR MS instruments 
and experiments, d) Stored Waveform Inverse Fourier Transform (SWIFT) excitation profile, 
discussed below, and finally e) SWIFT Isolation/ejection excitation profile. Reproduced from 
Marshall et.al.24     Page:   30 
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 Figure 1.17: Heterodyne (narrowband) signals before (left) and after (right) removal of the 
reference frequency used to reduce the sampling rate and extend the available TD for a given 
number of data points. Reproduced from Amster et.al.7 Page:   32 
 Figure 1.18: Mass spectrum of Poly(Ethylene glycol) (PEG) using various trapping voltages 
during FT-ICR MS. The movement and eventual combination of peaks (at Vt 3V)shows the 
effect extreme trapping voltages can have on the resulting mass spectrum, but also shows 
how different ion packets can coalesce into a single peak, despite achieving the resolution to 
separate them. Reproduced from Amster et. al. 7 Page:   35 
 Figure 1.19: examples of various ICR cells which have been effectively used in FT-ICR MS, 
including the (a) Cubic (b) cylindrical (c) segmented end cap cylindrical cell aka the “infinity 
cell” (d) open cylindrical cell (e) open capacitively coupled cylindrical cell (f) dual cubic cell 
(g) “matrix shimmed” cell. E = excitation D = detection T = trapping plates. Reproduced from 
Marshall et. al. 5     Page:   37 
 Figure 1.20: Schematic representation of the Infinity ICR cell, a closed cylindrical cell 
equipped with side-kick electrodes, two excitation plates, to detection plates, and two 
trapping plates. Curtesy of Bruker Daltonics, Bremen, Germany.  Page:   38 
 Figure 1.21: Left: Schematic of the Infinity cell trapping electrodes (a), showing the resistor 
chains and circuitry associated with the Infinity cell design (b) which attempts to mimic an 
infinitely long cell in order to avoid unwanted ejection of ions along the z-axis during 
excitation. Reproduced from Caravatti et.al.30 Right: Image of the Infinity cell mounted on a 
standard 6” stainless steel flange for connection to the end of the flight tube of an FT-ICR 
MS.       Page:   39 
 Figure 1.22: Electron-Impact (EI) generated ions of phenyl hydrazine, the molecular ion 
([M]+•) is observed at high intensity showing the species is able to stabilise a radical 
functionality readily. Other fragments observed provide insights into the molecular structure 
and can be used to characterise and/or identify the species.  Page:   43 
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 Figure 1.23: representation of the ESI process, showing the sample solution (usually from a 
syringe) passing through the ESI needle and forming a Taylor cone, creating ESI droplets 
which will then desolvate, reach their Raleigh limit and undergo coulombic 
explosions/discharge events to form daughter ions, this process will repeat until detectable 
individual ions and/or stable droplets form.  Page:   46 
 Figure 1.24: Charged droplet emission during ESI. (a) Photographs showing taylor cone 
formation and resulting ESI plume (b). (c)-(g) snapshots from Molecular Dynamics 
computational simulations showing the change in atomic configurations inside a 10nm ESI 
droplet of NaI (red) sequestered in formaldehyde (blue) within an electric field of 
0.625V/nm. Reproduced from Meyer et. al.42 and www.newobjective.com (accessed 
12/08/2016)       Page:   47 
 Figure 1.25: measurements from Beauchamp et. al.39 showing the desolvation of a charged 
droplet formed from ElectroSpray Ionisation (ESI). The measurements show the continued 
loss of solvent, during which several “discharge events” occur when the Raleigh limit of 
stability is reached for a given droplet (indicated by arrows).  Page:   48 
 Figure 1.26: Summary of the three main models for ESI ion formation, summarised by 
Konermann et. al.42 From left to right; The Ion Ejection Model, the Charge Residue Model, 
and the Chain Ejection Model.    Page:   49 
 Figure 1.27: Snapshot of a Molecular Dynamics (MD) simulation conducted by Konermann 
et. al.43 showing the solvent structure reorganisation effect of Na+ ions on a water droplet.
        Page:   50 
 Figure 1.28: MD simulation snapshots at different times summarising the Ion Ejection Model 
(IEM) of ESI showing a small ammonium ion (NH4+) being ejected from an ESI droplet. Note 
that the ion is not necessarily ejected as NH4+ but is still associated with several solvent 
molecules, which will then be released during desolvation as they travel into/through the 
mass spectrometer. Reproduced from Konermann et. al. 42 Page:   51 
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 Figure 1.29: MD simulation snapshots of the Chain Ejection Model for ESI showing a long 
chain biopolymer being slowly ejected from an ESI droplet. Reproduced from Konermann et. 
al.42       Page:   53 
 Figure 1.30: summary of the sequential charging process from the CEM for ESI showing long 
chain polymers/biopolymers acquiring multiple charges as it exists different size droplets 
and acquires a different degree of charge. Reproduced from Konermann et. al.42,44 Page:   54 
 Figure 1.31: ESI-FT-ICR MS of Lysozyme protein in positive ionisation mode showing multiply 
charges lysozyme species in the 8+, 9+, and 10+ charge states. Inset: Isotopic distributions of 
the 10+ and 9+ charge states showing the protonated and Sodiated species present at each 
charge state.      Page:   56 
 Figure 1.32: nano-ESI source layout, unlike standard ESI there is no syringe pump to drive the 
sample through the emitter, nor any nebulisation gas needed to assist in generation of the 
ion plume. Sample is drawn out from the emitter tip to the MS inlet via a potential 
difference applied between the two at either the liquid sample (via a wire, shown) or on the 
emitter itself (requires metal/conductive coating). Reproduced from Hiraoka et.al.54  
       Page:   58 
 Figure 1.33: MALDI process involving the ablation of a surface with a UV laser, activating and 
ionising MALDI matrix molecules into ions, which can then undergo proton transfer 
reactions with nearby analyte molecules to produce detectable analyte ions, usually in the 
1+ charge state. Courtesy of Bruker Daltonics, Bremen, Germany. Page:   60 
 Figure 1.34: Common compounds often used as a matrix for MALDI-MS, note that MALDI 
matrices usually contain a benzene ring to assist in absorption of the UV laser photons. 
Matricies labelled with an asterix have been shown to be effective matricies for MAI-MS 
(below) as well as MALDI-MS. Reproduced from Trimpin et.al.60  Page:   61 
xx 
 
 Figure 1.35: Ionisation sources for Atmospheric-Pressure Chemical Ionisation (APCI) and 
Atmospheric-Pressure Photo-Ionisation (APPI). Courtesy of Bruker Daltonics, Bremen, 
Germany.      Page:   64 
 Figure 1.36: representation of an orthogonal ESI-capillary-ion funnel source for MS. The 
figure shows that although both neutral (yellow) and ionised (red) species travel through the 
heated capillary, even after desolvation, the orthogonal injection geometry ensures that 
neutral species are diverted away from the directing ion funnel plates and allows only the 
ions to be collected/directed further into the mass spectrometer for detection, greatly 
reducing background noise and/or interference from neutral molecules. Courtesy of Bruker 
Daltonics, Bremen, Germany.    Page:   67 
 Figure 1.37: Mathieu stability diagram for a given ion in a quadrupole (left) and typical ion 
trajectories for the different labelled areas (right).  Page:   69 
 Figure 1.38: Basis of quadrupole analyser/transport operation, by altering the voltages and 
frequencies applied to the quadrupole the region of stability changes, and thus the species 
able to traverse the entirety of the optic also changes. Once carefully calibrated the ions of a 
certain m/z can be transmitted with voltages corresponding to their m/z and thus if they 
successfully move through the optic, the m/z can be deduced. Reproduced from Chrome-
academy (http://www.chromacademy.com/lms/sco36/Fundamental_LC-
MS_Mass_Analysers.pdf, accessed 28/03/2016). Page:   70 
 Figure 1.39: Examples of CHEF waveforms (left) and CHEF pulses (right) for the 
isolation/ejection of species from an ICR cell using CHEF. Reproduced from de Koning et. al.74 
       Page:   75 
 Figure 1.40: Example of UHR-CHEF isolation performed on particularly close peaks separated 
by just 1.5mD. Reproduced from de Koning et. al.74 Page:   76 
 Figure 1.41: Standard acquisitions taken during an MS/MS experiment, clockwise from ; The 
full mass spectrum of all species observed in a sample (a) followed by isolation of a 
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particular species of interest (e.g. via a quadrupole mass filter) (b), and finally fragmentation 
of the isolated species using an MS/MS technique (c) subsequent analysis of fragments 
reveals information of species structure and composition. Examples shown are from 
Myoglobin protein (16.9 kDa) spectra.   Page:   78 
 Figure 1.42: CAD MS/MS spectrum of Erythromycin A (a), and the assigned fragments 
mapped onto the molecular structure (b). Reproduced from Wills et.al.76 Page:   80 
 Figure 1.43: Summary of the Ropenstoff nomenclature for peptide/protein MS/MS cleavage 
of backbone bonds. Different MS/MS techniques can cause cleavage of different bonds (see 
below).       Page:   82 
 Figure 1.44: representation of peptide backbone showing the bonds cleaved during CAD 
MS/MS and the type of fragments produced (highlighted) Page:   83 
 Figure 1.45: Example CAD MS/MS spectra of the peptide Substance P (RPKPQQFFGLM) in the 
1+ (a) 2+ (b) and 3+ (c) charge states, showing the range of ions types detected and the 
variation of the observable fragments with different charge states. Reproduced from Boyd 
et.al.81       Page:   84 
 Figure 1.46: subsequent reactions to b-ion fragments produced during CAD MS/MS which 
can cause rearrangement (scrambling) of various functional groups within a previously linear 
peptide/protein structure, most importantly the scrambling of the original amino acid 
sequence.82      Page:   86 
 Figure 1.47: Bonds cleaved during peptide/protein IRMPD MS/MS usually include the amide 
(CONH) bond, highlighted, causing the production of b/y ions and a series of neutral, small-
molecule losses such as H2O, NH3, CO, CO2.  Page:   88 
 Figure 1.48: Fragments produced by UVPD MS/MS of poly(amino acids). UVPD causes 
extensive backbone and side chain fragmentation, producing fragments from cleavage of all 
3 backbone bonds.     Page:   89 
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 Figure 1.49: Fragments produced by ECD MS/MS of Poly(amino acids). ECD typically causes 
cleavage of the N-Cα bond and production of c/z• fragments, though many fragmentation 
channels exist and are influenced by various factors and/or functional groups (see main 
text).       Page:   90 
 Figure 1.50: ECD MS/MS spectrum of Substance P in the 2+ charge state ([SubP+2H]2+) (top). 
The parent ion at ~674 m/z is shown to capture an ECD electron to create the charge 
reduced species (CRS) observed at the far right hand side of the spectrum, with assignable 
fragments (middle) produced labelled and then summarised on the fragmentation map 
(bottom)      Page:   92 
 Figure 1.51: representation of the Utah-Washington ECD MS/MS dissociation mechanism, 
showing the two pathways to dissociation ions can follow after electron capture at the 
backbone carbonyl group. Reproduced from Lopez-Clavijo et.al.82 Page:   95 
 Figure 1.52: ECD-induced dissociation of a dipeptide according to the Utah mechanism. 
Reproduced from Lopez-Clavijo et.al.82   Page:   96 
 Figure 1.53: Representation of the reaction products formed after ECD MS/MS cleavage of 
normal amino acids (top) and proline (bottom), explaining the proline effect where no 
fragmentation at the proline amino acid sites in peptides and proteins can be cleaved to 
produce observable fragments in ECD MS/MS.  Page:   97 
 Figure 1.54: Cyclic peptide species studied by O’Connor et.al.96 to show that cyclic peptide 
species can fragment under ECD MS/MS to produce unique sequence-informative 
fragments, despite the cyclic structure tethering fragments together. A) cyclo-LLFHWAVGH, 
B) gramicidin S, and C) cyclosporine A. Reproduced from O’Connor et.al.96 Page:   98 
 Figure 1.55: ECD MS/MS spectra of the [M+2H]2+ ions for A) cyclo-LLFHWAVGH, B) 
gramicidin S, and C) cyclosporine A. Reproduced from O’Connor et.al.96  
 Page:   99 
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 Figure 1.56: The radical-induced cyclic rearrangement reaction proposed by O’Connor 
et.al.96 to explain the sequence-informative fragments produced during ECD MS/MS of cyclic 
peptides.      Page:   100 
 Figure 1.57: Platinum complex loss and Platinum-induced methionine side chain loss due to 
electron capture at / electron transfer to platinum metal centre during ECD MS/Ms analysis 
of platinated protein species. Reproduced from Li et.al.83 Page:   102 
 Figure 1.58: EID and CAD MS/MS fragmentation of polyketide natural products showing the 
complementary MS/MS fragmentation data provided by the different techniques. 
Reproduced from Wills et. al.76    Page:   104 
 Figure 1.59: Fragments produced by EID MS/MS of poly(amino acids). EID produced c/z• and 
a/x fragments, highlighted above.   Page:   105 
 Figure 1.60: Peptide and protein backbone bond cleavages under EDD MS/MS, 
predominantly c, c•, z, z•, a, and a• fragments are formed and detectable. Page:   106 
 Figure 1.61: Structure of DNA/RNA species, unlike peptides and proteins, when fragmented 
via EDD MS/MS produce mainly d and w type ions, centred around fragmentation at the 
backbone phosphate groups.    Page:   106 
 Figure 1.62: Fragmentation nomenclature used for the MS/MS of Glycosaminoglycans 
(GAG’s). Reproduced from Wolff and Amster.134   Page:   107 
 Figure 1.63: EDD, IRMPD, and CAD MS/MS of GAG’s showing the complementary data 
available with each technique, but also the superiority of EDD for the effective 
fragmentation and critical cross-ring cleavages needed to effectively characterise GAG 
polymers. Reproduced from Wolff and Amster.134 Page:   108 
 Figure 1.64: Ions produced during ETD of peptides and proteins, c and z ions are most 
frequently observed as product ions.   Page:   110 
 Figure 1.65: general procedure for achieving Electron Transfer Dissociation (ETD) within a 
multi-pole-coupled mass spectrometer (a). Ions are introduced into the multi-pole trap and 
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confined using voltage barriers (b) the ETD reagent generated via a separated SI source are 
then introduced separately into the trap (c) Both ions of interest and ETD reagent ions are 
then co-confined within the multi-pole trap (d) both ion types are then allowed to react for a 
certain (variable) time to allow interaction and electron transfer (e) the ETD reagent is then 
ejected, leaving the ions of interest and their daughter fragment ions produced due to 
radical directed fragmentation (ETD) all of the remaining ions can then be transferred to the 
mass analyser to be detect and produce an ETD MS/MS spectrum. Reproduced from Syka et. 
al.137       Page:   110 
 Figure 1.66: ETD MS/MS spectrum of a phosphorylated peptide (shown inset), observed c 
and z ions are labelled, ETD provided complete cleavage coverage of the phosphopeptide, 
proving ETD is a viable technique to sequence post-translationally modified biomolecules 
while still retaining the associated fragile modifications.  Page:   111 
 Figure 1.67: Schematic representation of the Bruker 12T SolariX instrument used for the 
majority of the work presented within the thesis. Corresponding labels are referred to in the 
main text. Courtesy of Bruker Daltonics, Bremen, Germany. Page:   113 
 Figure 1.68: Schematic of source region of SolariX with typical tuning parameters in red. 
Courtesy of Bruker Daltonics, Bremen, Germany.  Page:   114 
 Figure 1.69: Schematic representation of a Gas Chromatograph (GC) showing the various 
components and functionalities, the presented detector is an electron capture detector 
rather then the FID described above. Image taken from 
http://www.esrl.noaa.gov/gmd/hats/insitu/insitu.html accessed 15/04/2016. Page:   117 
 Figure 1.70: GC-EI-Q-MS chromatogram of hexane-extracted saturated hydrocarbons 
showing a broad distribution of components separated by GC and characterised by EI-
quadrupole MS, each species will have its own corresponding EI mass spectrum enabling 
characterisation/pattern search for identification. EI-Q-MS spectra are shown for 
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chromatogram peaks labelled a) and b) showing distinctly different peak distributions, yet 
common fragment peaks in areas.   Page:   118 
 Figure 1.71: Clockwise from top-left: Various C18 bonded-phases often used in LCMS 
columns to separate peptides. The organic solvent gradient used to gradually elute 
compounds from the LC column (organic solvent proportion shown, other proportion is 
usually water/acidified water). The resulting LC-MS chromatogram showing a range of 
peptide species all eluting separately at different retention times and with different 
concentrations (proportional to peak area, and MS ionisation/transmission/detection 
efficiency). Page:   121 
 
Chapter 2: Introduction to Cancer: 
 Figure 2.1: Normal and uncontrolled (cancerous) cell growth after DNA damage, large 
growth of cancerous cells (tumour) can put pressure on nearby cells and increase stress 
and/or impair function. Sections of tumour may break off and relocate to other areas of the 
host (metastasis). Reproduced from  
http://www.mun.ca/biology/desmid/brian/BIOL2060/BIOL2060-24/CB24.html, accessed 
23/02/2016.      Page:   134 
 Figure 2.2: representations of the central dogma of cell division (mitosis) (left) and gene 
expression (right) showing how cells divide and use DNA/RNA to produce cellular 
components, such as peptides and proteins. Both reproduced from 
http://www.nature.com/scitable (accessed 12/08/2016).   Page: 135 
 Figure 2.3: Cisplatin mechanism of action against DNA. Reproduced from Hambley et. al.19 
    Page:   138 
 Figure 2.4: Summary of Cisplatin transformations in vivo, and subsequent apoptosis-inducing 
DNA binding and secretion. Reproduced from Bugarcic et. al.29 Page:   140 
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 Figure 2.5: Cisplatin-induced protein-protein crosslink between two Calmodulin proteins, 
causing large structural changes and possible deactivation/limitation of protein function. 
Reproduced from Li et. al.30    Page:   141 
 Figure 2.6: [(η6 –biphenyl)Os(diaminoethyl)Cl]+ piano stool complex proven to be a very 
active anti-cancer metallodrug,45,46 The complex shows a classic  η6 –arene interaction 
exploited by organometallic chemists to tune the reactivity of the complex and ligand sties.
    Page:   147 
 Figure 2.7: a peptide-functionalised Ruthenium metallodrug for increased selectivity for 
binding at a peptide-derrived target within cancer cells. Reproduced from Barragan et.al.55
    Page:   145 
 Figure 2.8: representation of a) the Oxy-PDT agent comprised of the lipid nano-droplets 
containing the photosensitiser and oxygen-rich perfluorocarbon core. b) The active 
photosensitiser IR780. c) The size distribution measurements via dynamic light scattering 
(DLS) of the Oxy-PDT agent. d) Ultrasound images of the Oxy-PDT agent and other solutions 
in test tubes. Reproduced from Cheng et. al.58   Page:   147 
 Figure 2.9: MO energy diagram showing the various transitions available to d6 metal 
complexes with an octahedral geometry (such as the Pt(IV) compounds shown within). Black 
arrows represent electrons with its associated spin, coloured arrows represent electrons 
associated with a given transition. In the singlet state electrons are spin down, while in the 
triplet state they are spin up. Reproduced from Shaili et.al.60 Page:   149 
 Figure 2.10: Light penetration measurements through human tissue, adapted from Shaili 
et.al.68     Page:   152 
 Figure 2.11: Some Pt(IV) Photoactivatable metallodrugs based on the di-amine, di-hydroxido, 
di-azide configuration. Below are the azide-Pt Ligand-to-metal Charge-Transfer (LMCT) band 
values from UV/visible spectroscopy and theoretical calculations, and the wavelength of 
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light they can be successfully activated by, values taken from MacKay et.al.59 and Farrer 
et.al.63    Page:   152 
 Figure 2.12: Catalysed reduction of NAD+ to NADH by a Ruthenium based complex within 
cells (a) and the comparison to two, one Ruthenium, one Iridium, complexes and their 
different mechanisms of action and effects on cancerous cells (b), despite both compounds 
affecting the same NAD+/NADH cycle they have very different influences and biological 
consequences. Reproduced from Soldevila-Barreda et. al.44  Page:   145 
 Figure 2.13: Example of a di-nuclear gold complex able to target redox-active sites via 
binding to neighbouring Cysteine residues. Reproduced from Wai-Yin-Sun et. al.77 Page:   156 
 
Chapter 3: Photoactivatable Pt(IV) biomolecule interactions: 
 Scheme 3.1 : (Left) Trans, trans, trans-[Pt(N3)2(OH)2(py)2] (Complex 1), the photo-activatable 
prodrug used in this study, along with (Right) an illustrative photo-activation pathway 
leading to DNA binding (an inter-strand cross-link).23 Page:   169 
 Figure 3.1: nESI FT-ICR mass spectra of ~1µM aqueous Complex 1+SubP (a) and Complex 1+ 
K3-Bom (b) reaction mixtures (0.5:1 drug:peptide ratio)after 1 and 2 hours of irradiation 
(respectively) with blue visible light (463nm). Inset; various isotopic patterns for the 
observed (obs.) and calculated (calc.) species assigned from the mass spectra – showing the 
Platinum influence on observed isotopic distributions. Green filled circles indicate 
unmodified peptide species, Red indicate oxidised species (both peptide and platinated 
peptides), other colours indicate Platinated peptide species with different Pt(II) based 
modifications.      Page:   175 
 Figure 3.2: Oxidised peptide species observed and fragmented by ECD MS/MS, red squares 
indicate a modification observed on the particular fragment as a result the modifications can 
be readily located to single amino acid residues (modified residues are marked). Fully 
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annotated tandem mass spectra can be found in the supporting information (Figure SF2).
       Page:   177 
 Scheme 3.2 -Possible oxidation products arising from singlet oxygen (KYN and 3OH-KYN) and 
radical oxidation (HTRP and NFK) of a tryptophan residue in a biomolecule5657 along with 
corresponding expected mass changes for the modification. Page:   179 
 Figure 3.3: Platinated K3-Bom peptide species observed and fragmented by ECD MS/MS, 
coloured squares indicate a modification observed on the particular fragment as a result the 
modifications can be readily located to single amino acid residues. Fully annotated spectra 
can be found in the supporting information (Figure SF3).  Page:   183 
 Figure 3.4: Platinated SubP peptide species observed and fragmented by ECD MS/MS, 
coloured squares indicate a modification observed on the particular fragment. Fully 
annotated spectra can be found in the supporting information (Figure SF4). Page:   185 
 Scheme 3.3: Platinum centred side chain losses from methionine commonly observed during 
presented ECD MS/MS studies of platinated peptides.  Page:   189 
 Figure 3.5 – EPR scans for photoactivation (via blue visible light) of (a) Complex 1 (b) 
Complex 1 + Substance P and (c) Complex 1 + [Lys]3-Bombesin - showing spin trap oxidation. 
Inset – Simulations of corresponding patterns.   Page:   192 
 Scheme 3.5: a) DEPMPO spin trap used during the EPR studies of Complex 1 photoactivation, 
b) Usual DMPO spin trap commonly used for EPR, c) DEPMPO+trapped OH radical structure 
detected by EPR, 85 d) Oxidised DEPMPO caused by high concentration of OH radicals 
produced via photoactivation of Complex 1.85  Page:   194 
 Figure 3.6: Summarising figure of the reaction products observed during the study of 
Complex 1 with the model peptides    Page:   200 
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Chapter 3 - SI: 
 SI Figure 3.1 (SF3.1) – nESI-FT-ICR MS spectra of Substance P (a) and K3-Bom (b) Page:  209 
 SI Figure 3.2 – ECD MS/MS spectrum of K3-Bom, peptide was co-isolated with 5 calibrant 
ions in order to improve calibration and compare the use of peptide MS/MS fragments and 
unrelated ions when internally calibrating MS/MS spectra. Page:   209 
 SI Table 3.1 (ST1) – Resulting assignments and associated Mass errors (in parts per million – 
ppm) for each calibration method used during the analysis of the K3-Bom ECD MS/MS 
spectrum shown above.    Page:   210 
 SI Figure 3.3 (SF3.3) ECD MS/MS of unmodified Substance P (top) followed by list of 
assignments (middle) and corresponding fragmentation map (bottom)  Page:   211 
 SI table 3.2 (ST2a): Species observed within the nESI-FT-ICR Mass Spectra of the Complex 
1+SubP solution post-photoactivation.   Page:   212 
 (ST3.2b): Species observed within the nESI-FT-ICR Mass Spectra of the Complex 1+K3-Bom 
solution post-photoactivation.    Page:   212 
 SI Figure 3.4 (SF3.4): ECD MS/MS spectra of Oxidised peptides individually isolated and 
dissociated using ECD within the FT-ICR MS; a) Substance P+O b) K3-Bom+O C) K3-Bom+2O 
d) K3-Bom+3O.  Red labels indicate modified fragments. Assignment table for each species 
can be found below.     Page:   214 
 SI Tables 3.3-6: assignment lists for individual ECD MS/MS spectra for the isolated oxidised 
peptide species; ST3) Substance P+O, ST4) K3-Bom+O, ST5) K3-Bom+2O, ST6) K3-Bom+3O. 
Marked species were used for internal calibration, in tables with no marked species; co-
isolated calibrant ions were used for calibration instead of MS/MS fragments, as discussed in 
the experimental section.    Page:   214 
 SI Figure 3.5 (SF3.5): ECD MS/MS spectra of Platinated K3-bom species individually isolated 
and dissociated using ECD within the FT-ICR MS. Coloured labels indicate modified 
fragments. Assignment table for each species can be found below. Pt* indicates the 
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platinum based modification associated with each species (shown in Figure 3, main text, and 
correlating tables of assignments, below).    Page:   217 
 SI Table 3.7 (ST3.7): ECD MS/MS assignments for the [K3-Bom+Pt(py)2(N3)+H]2+ species 
(calibrated using co-isolated calibrant ions)  Page:   218 
 SI Table 3.8 (ST3.8): ECD MS/MS assignments for the [K3-Bom+Pt(py)2(OH)+H]2+ species 
(calibrated using co-isolated calibrant ions)  Page:   218 
 SI Table 3.9 (ST3.9): ECD MS/MS assignments for the [K3-Bom+Pt(py)2+H]3+ species  
Page:   219 
 SI Figure 3.6 (SF3.6): ECD MS/MS spectra of Platinated Substance P species individually 
isolated and dissociated using ECD within the FT-ICR MS. Coloured labels indicate modified 
fragments. Assignment table for each species can be found below. Pt* indicates the 
platinum based modification associated with each species (shown in Figure 4, main text, and 
correlating tables of assignments, below).  Page:   220 
 SI Table 3.10 (ST3.10): ECD MS/MS assignments for the [SubP+Pt(py)2+H]3+ species Page:   
220 
 SI Table 11 (ST11): ECD MS/MS assignments for the [SubP+Pt(py)2(N3) +H]2+ species  
       Page:   221 
 SI Table 3.12 (ST3.12): ECD MS/MS assignments for the [SubP+Pt(N3)+H]2+ species  
Page:   221 
 SI Figure 3.7 (SF3.7): Bar charts showing the relative intensity changes between the Complex 
1+peptide and Complex 1+peptide+free Trp reaction mixtures for both Substance P (top) 
and  (bottom).       Page:   222 
 SI Table 3.13a (ST3.13a): Relative intensity measurements of assigned species in the 
irradiated Complex1+Substance P reaction mixture FT-ICR MS with and without additional 
tryptophan.       Page:   222 
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 SI Table 3.13b (ST3.13b): Relative intensity measurements of assigned species in the 
irradiated Complex1+K3-Bom reaction mixture FT-ICR MS with and without additional 
tryptophan.        Page:   223 
 SI Figure 3.8 (SF3.8) - Proposed mechanism for the loss from the peptide of the Pt(II) 
modification during ECD, ligands shown vary with the nature of the Pt adduct. Page:   224 
 SI Table 3.14a-c (ST3.14a-c): EPR results for irradiation of complex one in blue visible light 
(a), Complex 1+SubstanceP (b), and Complex 1+[Lys]3-Bombesin (c). Included are previously 
published values acquired for the system, along with references for said values. Page:   224 
 SI Figure 3.9 (SF3.9):  EPR kinetic runs   Page:   225 
 SI Figure 3.10a-c (SF3.9a-c): UV/Vis spectra of Complex 1 (a), Complex 1 + Substance P (b), 
and Complex 1 + [Lys]3-Bombesin (c).   Page:   226 
 SI Figure 3.11 (SF3.11): ECD MS/MS spectra of di-Platinated K3-bom species a) and zoom-in 
of side chain loss (SCL) region (b) resulting from electron capture at a platinum centre, 
causing ligand loss (to create [K3-Bom+Pt+Pt(py)2(N3)]2+. from the [K3-
Bom+Pt(py)2+Pt(py)2(N3)]2+. species) along with unique side chain losses. Unfortunately no 
sequence informative fragments were observed from the ECD MS/MS spectrum, highlighting 
the need for an additional proton to allow standard dissociation.   Page:   227 
 
Chapter 4: Osmium metallodrug-DNA interactions: 
 Scheme 4.1: The OsII arene complex Os1-Cl studied in this work and the detected 
species/modification observed via ESI-MS (Os1).  Page:   234 
 Figure 4.1: nESI Mass spectrum of (a) DNA12 and (b) DNA12+Os1 reaction mixture after 3 h 
incubation at 37°C (b). Inset: nucleotide sequence of the oligonucleotide 12-mer and 
observed vs. Simulated isotope patterns for unreacted DNA12 (top right), DNA12+Os1 
(bottom left), and DNA12+2Os1 (bottom right).  Page:   238 
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 Figure 4.2: FT-ICR CAD MS/MS spectra for [DNA12-7H]7- (a) and [DNA12+Os1-9H]7- (b) 
species, along with corresponding fragmentation maps; osmiated fragments are indicated 
with shaded squares.  Inset: Theoretical simulation of the [a9-BH+Os1-5H]3- fragment and 
the observed isotopic pattern during CAD MS/MS. Page:   240 
 Scheme 4.2: A general EDD reaction pathway, adapted from Zubarev et al.24 Page:   242 
 Figure 4.3: Electron Detachment Dissociation FT-ICR MS/MS spectra of (a) [DNA12-7H]7- and 
(b) [DNA12+Os1-9H]7- ions, along with corresponding fragmentation maps. Shaded squares 
indicate presence and number of osmium complex modifications bound to observed 
fragments. Inset; comparisons of selected theoretical simulations and observed species. 
       Page:   244 
 Figure 4.4: FT-ICR MS/MS spectra of the [DNA12+2Os1-10H]6- species fragmented by (a) 
CAD, (b) EDD,  along with the corresponding fragmentation map for CAD (centre), no 
backbone dissociation was observed via EDD for the (possibly cyclic) species presumably due 
to non-covalent interactions preventing gas phase fragmentation. Shaded squares indicate 
presence and number of osmium complex modifications bound to observed fragments. 
Page:   248 
Chapter 4 – SI: 
 Table S4.1. Fragment assignments for Figure 2A: CAD MS/MS of the [DNA12-7H]7- species.  
Highlighted species (red) were used for internal calibration. Page:   257 
 Table S4.2. Fragment assignments for Figure 2B: CAD MS/MS of the [DNA12+Os1-8H]6- 
species.  Highlighted species (red) were used for internal calibration. Note: the highest 
intensity isotope was used for fragments containing the osmium modification.  Page:   259 
 Table S4.3. Fragment assignments for Figure 3A: EDD MS/MS of the [DNA12-7H]7- species.  
Highlighted species (red) were used for internal calibration. Page:   261 
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 Table S4.4. Fragment assignments for Figure 3A: EDD MS/MS of the [DNA12+Os1-9H]7- 
species.  Highlighted species (red) were used for internal calibration. Note: the highest 
intensity isotope was used for fragments containing the osmium modification. Page:   263 
 Table S4.5. Fragment assignments for Figure 4A: CAD MS/MS of the [DNA12+2Os1-10H]6- 
species.  Highlighted species were used for internal calibration. Note: the highest intensity 
isotope was used for fragments containing the osmium modification. Page:   265 
 Figure S4.1. HPLC trace of the commercially-synthesised DNA12 sample, showing multiple 
shorter oligonucleotides resulting from truncated synthesis and the DNA 12mer (highest 
peak) which was isolated and then re-analysed by HPLC; the resulting trace is inset, showing 
only one remaining product, the DNA 12mer (confirmed by UHR-FT-ICR MS, Figure 4.1A in 
main text).      Page:   267 
 Figure S4.2. The nomenclature devised by McLuckey et al.34 based on the McCloskey et.al. 
system35 for assignment of oligonucleotide MS/MS fragments.  Page:   267 
 
Chapter 5 - Further DNA-metallodrug investigations: 
 Scheme 5.1 : (Left) Trans, trans, trans-[Pt(N3)2(OH)2(py)2] (FM190/Complex 1), the photo-
activatable prodrug used in this study, along with (Right) an illustrative photo-activation 
pathway leading to DNA binding (an inter-strand cross-link).  Page:   269 
 Figure 5.1: Representation of duplex DNA structure in a double-helical structure, showing 
both atomic detail and major and minor groove features of the structure. Because of its 
shape the major groove is particularly accessible to other entities. Reproduced from 
http://www.richardwheeler.net (accessed 12/08/2016).   Page:   271 
 Figure 5.2: nESI-FT-ICR MS spectra of the DNA 12-mer +FM190 metallodrug (both shown 
inset) mixtures after varying irradiation times with Blue visible light (463nm). Each different 
product is marked with a coloured circle, with key shown on the right. Page:   274 
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 Figure 5.3: nESI-FT ICR MS of the DNA 12-mer+FM190 mixture after 60 minutes irradiation 
with Blue visible light (463nm). Each product is marked accordingly. Isotopic simulations 
presented inset show the difference of the platinum metal centre on the overall DNA 
isotopic pattern. The difference is clear, however less drastic than for the Osmium 
metallodrug shown in Chapter 3.   Page:   275 
 Figure 5.4: nESI-FT-ICR CAD MS/MS of the [DNA12+Pt(py)2(N3)-6H]5- species (top). The 
resulting a and w ions assigned are summarised in the fragmentation map (bottom) shaded 
squares indicate fragments containing a metal modification. Highlighted regions indicate 
possible binding site.     Page:   278 
 Figure 5.5: nESI-FT-ICR EDD MS/MS of the [DNA12+Pt(py)2(N3)-6H]5- species (top) using 20.6 
eV electrons. The resulting d and w ions assigned are summarised in the fragmentation map 
(bottom) shaded squares indicate fragments containing a metal modification.  Page:   279 
 Figure 5.6: EDD MS/MS nESI-FT-ICR MS spectra of the diplatinated [DNA12+2(Pt(py)2(N3))-
7H]6- species. Charge reduction, ligand and base loss was observed, but no sequence 
informative fragments could be assigned. Most likely due to the platinum centre disruption 
of normal EDD MS/MS.      Page:   280 
 Figure 5.7: CAD MS/MS nESI-FT-ICR MS spectra of the diplatinated [DNA12+2(Pt(py)2(N3))-
9H]6- species (top) with corresponding fragmentation map summarising assignable 
fragments (bottom). Coloured markers indicate fragments retaining a platinum-based 
modification, Pt* = Pt(py)2(N3)       Page:   282 
 Figure 5.8: nESI-FT-ICR MS spectra of the DNA12 (TAGTAATTACTA) in water (a, top) 200mM 
ammonium acetate (b, middle), and a 200mM ammonium acetate + 1mM KCl solution (c, 
bottom). Though particularly unusual, the addition of KCl to the buffer solution proved 
effective in stabilising the DNA duplex, but required the species to be detected in positive 
nESI mode, instead of negative mode as for the previous samples. Page:   285 
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 Figure 5.9: Structural features of DNA G-quadruplexes shown by Gabelica et.al. Reproduced 
from Gabelica et.al.12     Page:   286 
 Figure 5.10: Results of the potassium-titration experiment performed by Gabelica et.al. to 
show the uptake of K+ ions into the DNA quadruplex-G structure, note the particular 
preference for 2K+ ions in (a) and 3K+ ions in (b) due to the different tertiary structures 
present. Reproduced from Gabelica et.al.12   Page:   277 
 Figure 5.11: Summarising figure for the native Duplex-DNA nESI-FT-ICR MS3 experiments 
conducted. Clockwise from top left: nESI-mass spectrum of the DNA12+200mM AA+ 1mM 
KCl aqueous solution, CAD MS/MS of the quadrupole-isolated DNA12-Duplex 5+ charge 
state, CAD-ECD MS3 of the isolated duplex species, fragmentation map showing the SS-DNA 
peaks observed in the CAD-ECD MS3 experiments, along with comments on the results 
obtained.      Page:   290 
 
Chapter 5 – SI: 
 SI table 5.1: fragmentation assignments for the CAD MS/MS spectrum of the 
[DNA12+Pt(py)2(N3)-6H]5- species. Pt* = Pt(py)2(N3) Page:   293 
 SI table 5.2: fragmentation assignments for the CAD MS/MS spectrum of the 
[DNA12+2(Pt(py)2(N3))-6H]5- species. Pt* = Pt(py)2(N3) Page:   294 
Chapter 6 - Studying electron-quenching Iridium metallodrug-modified biomolecules using CAD 
and ECD FT-ICR MS/MS: 
 Figure 6.1: Iridium based piano-stool complexes used in the study – all compounds possess 
aldehyde functionalised bi-dentate ligands.  Page:   299 
 Figure 6.2: nESI-FT-ICR Mass Spectra of Iridium metallodrug+peptide mixtures, reacted for 
24 hours at 37oC prior to analysis. In the SubstanceP+Ir1 metallodrug (top) only the 
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condensation reaction product ([SubP+Ir1-H2O+H]2+) is observed outside of reagent peaks. In 
the Lys3-Bombesin+Ir2 metallodrug spectrum 2 Iridiated peptide species are observed 
(inset) both the condensation product ([L3BBS+Ir1-H2O+H]2+) and the non-condensation 
(metal bound) product ([L3BBS+Ir2+H]2+). Inset: Observed Iridiated peptide/Iridium 
containing peaks, showing the influence of the transition metal on the observed isotopic 
distribution.      Page:   305 
 Figure 6.3: ECD MS/MS spectrum of SubstanceP+Ir1-H2O condensation product. The 
available aldehyde group on the bidentate ligand binds to lysing residues via a condensation 
reaction to form a covalently bound Imine. ECD MS/MS of the Imine-bonded peptide-Ir 
complex species leads to electron quenching by the Ir centre and little to no dissociation 
(top) though low intensity fragments (<1% of precursor) can be observed with high number 
of summed acquisitions (bottom), so much so that even the suppressed harmonic signals 
from the precursor can be observed (w3).    Page:   307 
 Figure 6.4: ECD MS/MS of the condensation reaction product between Ir2 and L3BBS 
([L3BBS+Ir2-H2O+H]2+). The spectrum shows the Iridium complex modification is effectively 
quenching the ECD electrons producing electron capture, but little dissociation (top). Zoom 
in of the spectrum shows when the small proportion of electrons are captured along the 
backbone, low intensity fragments can be observed (middle), fragments can then be 
assigned (fragmentation map, bottom). Orange squares indicate fragments containing the Ir 
modification.      Page:   310 
 Figure 6.5: ECD MS/MS of the Iridiated K3-Bombesin non-condensation product  
[L3BBS+Ir2+H]2+ (top) and zoom in of ECD fragments produced (middle) by the small 
proportion of electrons captured along the peptide backbone and not quenched at the 
Iridium centre, which caused dissociation of the complex and an abundant unmodified 
peptide peak. Resulting ECD MS/MS fragmentation is summarised in the fragmentation map 
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(bottom), orange squares indicate the iridium modification is present on a given fragment.
       Page:   311 
 Figure 6.6: CAD MS/MS spectrum of Iridium-modified peptide (Ir2+L3BBS) via a covalent 
Imine bond caused by a condensation reaction, allowing the usually fragile metal 
modification to survive CAD MS/MS. Orange squares indicate a fragment modified with the 
Iridium complex. Binding of the complex was readily located to the Lysine3 residue.
 Page:   314 
 Figure 6.7: Summarising figure showing the range of reaction products observed during the 
reaction of functionalised Iridium complexes with the model peptides Page:   316 
Chapter 6 – SI: 
 SI Figure 6.1: X-ray crystal structure of the Ir1 dialdehyde functionalised Iridium(III) piano-
stool complex and associated information.   Page:   320 
 SI Figure 6.2: ECD MS/Ms spectrum, assignments and fragmentation map for the analysis of 
the [SubstanceP+Ir1-H2O+H]2+ species   Page:   321 
 SI Figure 6.3: Assignments and fragmentation map for the ECD MS/MS analysis of the 
[L3BBS+Ir2+H]2+ species.    Page:   322 
 Si Figure 6.4: Assignments and fragmentation map for the CAD MS/MS analysis of the    
[L3BBS+Ir2-H2O+H]2+ species    Page:   324 
 Si Figure 6.5: Assignments and fragmentation map for the CAD MS/MS analysis of the    
[L3BBS+Ir1-H2O+H]2+ species    Page:   325 
 SI Figure 6.6: Assignments and fragmentation map for the IRECD MS/MS analysis of the 
[L3BBS+Ir1-H2O+H]2+ species    Page:   326 
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Chapter 7 – Superacid Supercharging using CH5+: 
 Figure 7.1: Schematic of the ESI-APCI supercharging source (left) and 3D representation 
(right).       Page:   337 
 Figure 7.2: a) Normal ESI-mass spectrum of 1uM aqueous Lysozyme (LZ) solution, showing 2 
main charge states; 8+, 9+, and 10+. b) Supercharged ESI-APCI-mass spectrum of the same 
1uM aqueous Lysozyme solution, showing increased analyte charging, main charge states 
observed now being 9+, 10+, and 11+.   Page:   340 
 Figure 7.3: ESI-MS of 1uM Myoglobin in a water-ACN solution (a) and supercharged ESI-APCI-
MS spectrum of the same Myoglobin-water-ACN solution, showing enhanced charging of 
analyte species.      Page:   343 
 Figure 7.4: Representation of the ESI-APCI supercharging processes – CH4 gas was ionized 
via a glow discharge chamber in close proximity to the ESI needle tip, enabling the newly 
created CH5+ ions to interact with ESI plume and droplets and enhance charging of analytes. 
        Page:   344 
 Figure 7.5 – Native ESI-MS of lysozyme a) and supercharged Native-MS of the same sample 
(b), showing a vast increase in signal of lysozyme peaks due to enhanced charging.  
       Page:   346 
 Figure 7.6: ESI-MS of the Ascorbic acid solution (a) and ESI-APCI-MS spectrum of the same 
Ascorbic Acid solution, showing increased signal intensity due to enhanced charging of 
protonated Ascorbic acid (22% increase) and the Ascorbic acid dimer (291% increase). 
       Page:   348 
 Figure 7.7: Denatured and/or supercharged myoglobin protein spectra produced by acidic 
denatured conditions (top), followed Superacid supercharging (middle), and a combination 
of denatured acidic conditions with m-NBA solution phase supercharging and Superacid-
supercharging (bottom) showing the possibility of combining enhanced charging techniques 
to achieve even higher charge states than individual techniques.  Page:   350 
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 Figure 7.8 - Mean field calculation results of the repulsive force between a CH5+ ion and a 
20um charged ESI droplet at a varying distance and T=300K, each curve represents 
calculations for a varying number of charges (as a percentage of the Raleigh limit for the 
20um droplet: 12.6M e).    Page:   353 
 Figure 7.9 – Initial results from the PPDEM calculations for a 1µm droplet with a very low 
number of surface charges,  showing that although initially repulsive, due to dielectric 
effects within the droplet; at close distances CH5+ ions can be attracted to positively 
charged electrospray droplets, enabling proton transfer and supercharging. Page:   355 
 Figure 7.10 – Final results from the PPDEM calculations showing that at high numbers of 
surface charge the slightly attractive force previously observed becomes unfortunately 
negligible and the calculations approach the mean-field approximation. Page:   356 
 Figure 7.11: Results from the calculation Boltzmann energy curve for CH5+ ions at room 
temperature, assuming the energy of the system to be equal to 3/2kBT. The main proportion 
of species are shown inset, along with the corresponding energy of the most populated 
energy state.      Page:   357 
 Table 7.1: Examples of CI reagent gases used in previous studies possessing a range of 
proton affinities (based on the neutral species), which could be suitable for probing the 
mechanism of superacid-supercharging.    Page:   360 
Chapter 8 – The Rhodium revolver: 
 Figure 8.1: The range of metal complexes synthesised and studied during the course of the 
project. All are Rhodium complexes with varying ligands, aside from one Iridium compound 
as a control/test for Ir metal centres, but was ineffective at achieving the same HDX 
reactions. Reproduced from Soldevila-Barreda et.al.2 Page:   370 
 Figure 8.2: nESI-FT-ICR MS spectra of the deuteration (HDX) of Complex 1 (shown inset), at 
various time points, creating the D15-Complex within 60 minutes and reaching ~equilibrium 
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within 80 minutes, subsequent time point spectra (hourly up to 14 hours, then at 24, 48, 72 
hours and 7 days showed only incremental increase in D15 and little decrease in D<15 
species).      Page:   373 
 Figure 8.3: A Rhodium metallodrug complex (Complex 1, below) simulated mass spectrum of 
the [RhC10H15C10N2H8Cl]+ ion produced during ESI/nESI MS analysis. Inset: a zoom-in of 
the M+1 isotopologue, at two different resolving powers standard performance for a high-
resolution ToF-MS 50,000 resolving power (bottom) and standard performance for the 3.3 s 
transient acquired using the Bruker Solarix UHR-FT-ICR MS used for all spectra within this 
chapter 900,000 at 400m/z (top). The higher performance allows observation and 
assignment of the isotopic fine structure, providing additional elemental composition 
information and reducing overlap between isotopes. Page:   374 
 Figure 8.4: Key structures from DFT calculations produced by Juliusz A. Wolny and Volker 
Schunemann. Molecules with optimised geometry modelled with DFT (CAM-B3LYP/CEP-31G) 
The important weak interactions are shown. a) Rh(Cpx)(bpy)OH b) Ir(Cpx)(bpy)OH c) 
Rh(Me4Cp=CH2) (bpy)∙OH2 d) Rh(Me4Cp=CH2) (bpy)∙OH2 e) Rh(Cpx)(en)OH f) 
Rh(Me4Cp=CH2) (en)∙OH2 g) superimposed structures of Me4Cp=CH2 dianion in the 
optimised structure of Rh(Me4Cp=CH2) (bpy)∙OH2 (in black) and the optimised structure of 
free dianion (in blue).     Page:   375 
 Figure 8.5: Structures, Mass spectra, and theoretical simulations of assignments for the 11 
compounds studied for metallodrug HDX, all samples were analysed after 72 hours in 
deuterated solvent and both with and without excess (1mM) NaCl added, those species for 
which one set of spectra are provided indicate no added salt spectra, as the additional salt 
spectrum did not produce detectable target analyte signal. Page:   377 
 Table 8.1: Assignments of all identifiable species in the metallodrug samples for complexes 
1-11 after 72 hours in deuterated solvent. Please refer to above figure for structure of each 
species.      Page:   382 
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 Figure 8.6 : nESI-FT-ICR MS spectra of the Rhodium compound Rh-(Cp*Me5)-bipy), aka 
Complex 1, above (as the [M(D15)]+ ion, [RhC10D14N2C10H8DCl]+), analysed immediately 
after deuteration and after 7 days in pure protic solvent (H6-MeOH), showing no observable 
back-exchange with protic solvent, and remains deuterated.  Page:   384 
 
Chapter 9 – Scaling up to proteomics: 
 Figure 9.1: Typical Isotopic distributions for a small peptide (top left) and then the same 
peptide modified with an array of transition metal modifications, showing the drastic effect 
on isotopic patterns some metals can induce.  Page:   394 
 Figure 9.2: Basis of SNAP annotation procedure from Bruker Daltonics,17 showing (from top 
left) the least squares fit of the target isotope pattern for a modified peptide species (based 
on Bombesin), an example match of isotopic pattern for a biomolecule with a platinum 
metal centre attached showing SNAP to work with different elements, and the equations 
from Koster et.al.17 which form the least squares fit SNAP uses.  Page:   396 
 Figure 9.3: examples of modified SNAP peak picking to filter a given mass spectrum (top) for 
only Platinum containing biomolecules, then output the matched isotopic patterns (bottom). 
Examples inset are the SNAP algorithm ignoring normal peptide distributions (which do not 
include the Platinum constant unit) and matching Pt containing species accurately with a 
predicted isotopic pattern.    Page:   397 
 Figure 9.4: SNAP-LC script Version 2.0 – brief summary, from top left to bottom right: 
declaration of variables (black), selection of LC data points to search and masses for SNAP 
(red), clear previous data and selection of first LC data point, load first spectrum and clear 
analysis (blue), Declare variables for SNAP LC then apply SNAP using inputted parameters 
followed by export of results to .csv file (underlined) then clear results for next spectrum 
(Black), write intensity results to new separate .csv file outside of loop (orange), clear data to 
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save RAM (purple), finally create new chromatogram from .csv file and re-import into Data 
Analysis for plotting.     Page:   400 
 Figure 9.5: Initial results using SNAP-LC analysis on two ESI-MS samples one metal containing 
(Ir-peptide mixture, left), and one unmodified peptide with no metal (right). SNAP-LC was 
able to distinguish, purely from isotopic patterns which sample contained Iridium species.
       Page:   401 
 Figure 9.6: Example protein digest peptide mixtures reacted with previously studied 
metallodrugs nESI-FT-ICR MS spectra, followed by SNAP-LC metal isotope searching to 
highlight corresponding metal-containing species. Page:   403 
 Figures 9.7a-d: Example nLC-HR-ToF BPC chromatogram (top) followed by a mass spectrum 
from the time point marked (star) and 2 CAD MS/MS spectra from precursors isolated and 
fragmented during the automatic LC MS/MS run (marked). The large peak in the BPC is the 
free Ir2 drug (-Cl).     Page:   404 
 Figure 9.8: nLC-FT-ICR MS analysis of unmodified cytochrome C digest peptides via a 10cm 
c18 column, 2um particles. Effective separation of all peptides was achieved using a 
particularly steep gradient and short run time (see main text). Below: typical peptides 
observed and resolving Figure 9.9: nLC-FT-ICR MS of Lysozyme digest peptides reacted with 
Iridium metallodrug (IR2 – see previous section) producing a base peak chromatogram (BPC) 
of species (top) followed by SNAP-LC analysis to search for Iridium isotope patterns (Blue). 
Examples of non-Ir containing species not counted in SNAP-LC (1) and species with the 
Iridium isotope pattern being successfully picked up (2). Finally, the nLC gradient used for 
separation on the 10cm, C18, 2um particle nLC column. power for annotated peaks. RP= 
~125,000 at 400m/z.     Page:   407 
 Figure 9.9: nLC-FT-ICR MS of Lysozyme digest peptides reacted with Iridium metallodrug (IR2 
– see previous section) producing a base peak chromatogram (BPC) of species (top) followed 
by SNAP-LC analysis to search for Iridium isotope patterns (Blue). Examples of non-Ir 
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containing species not counted in SNAP-LC (1) and species with the Iridium isotope pattern 
being successfully picked up (2). Finally, the nLC gradient used for separation on the 10cm, 
C18, 2um particle nLC column.    Page:   408 
 Figure 9.10: Summary of the SNAP-LC results with auto-CAD MS/MS of an Iridiated peptide 
detected during the nLC-FT-ICR MS analysis of the Iridium-lysozyme digest peptide mixture. 
A series of Iridiated and non-Iridiated peaks can be observed, with sequence, fragmentation 
map and derived location of the modification (based on MS/MS information and results 
from Chapter 6) shown inset.    Page:   410 
 Figure 9.11: The periodic table of elements including commonly observable isotopic 
patterns, all species with multiple isotopologues in distinctly different ratios to CHNOS are 
potential targets for SNAP-LC. Reproduced from 
http://zwz.cz/f/allgood788/KNLS74SW/COMPUTER-periodic-table-isotope-distribution 
(accessed 16/04/2016).     Page:   411 
 Figure 9.12: (A) Pulse sequence of a typical 2DMS experiment, the IRMPD/ECD pulse can be 
replaced with an ExD pulse. etc. (B) the subsequent effects of the 2DMS pulses depending 
on ion radius. Reproduced from Van Agthoven et.al.29 Page:   417 
 Figure 9.13: Representation of ion location during a typical 2D-FT-ICR MS experiment 
following the pulse sequence described above (Figure 9.12). Note: the ions in question will 
be rotating around the centre axis of the ICR cell at their reduced cyclotron frequency, as 
always, the stationary representation of ion location is purely for 
convenience/understanding.    Page:   418 
 Figure 9.14: Axis, informative lines, and nomenclature for the interpretation of 2D mass 
spectra.      Page:   419 
 Figure 9.15: 2D-IRMPD-FT-ICR MS spectrum of Cholesterol ions produced by APPI (a) and 
various lines from the 2D plot, including fragment ion scans (b, c, d, e), precursor ions scan 
(f) and neutral loss lines (g, h, i). Reproduced from Van Agthoven et.al.29 Page:   420 
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 Figure 9.16: Resulting fragmentation of Cytochrome C peptides analysed by 2D-FT-ICR MS 
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Mass Spectrometry: 
 Mass spectrometry is an analytical technique surrounding the analysis of molecules based 
on their mass; however, to do so requires the species in question to become a charged ion, and as a 
result mass spectrometry uniformly measures and studies different species based upon their mass to 
charge ratio (m/z).  
The study of chemical reactions based upon mass changes dates back hundreds of years, but 
the study of a molecule’s mass using charged ions was first successfully achieved by Sir J. J. 
Thompson and Francis Aston in 1913 in the UK. Thompson and Aston had constructed an instrument 
to deflect ions towards a photosensitive plate, they found that although the same force would be 
applied to each ion as it passed though the force region – the ions were affected differently (due to 
their different masses) and so would spread out before hitting the photosensitive plate and leaving 
characteristic and reproducible marks/impact patterns on the plate depending on their mass. Using 
this state of the art “mass spectrograph” Thompson and Aston were able to show the various 
characteristic ion patterns for the components of air, and proved undeniably the presence of 
different isotopes for the same chemical species, a feat which later won Aston the Nobel Prize in 
Chemistry in 1922. Instantly it was obvious that Mass Spectrometry was adept at separating 
mixtures of compounds and providing individualised information on each chemical species within a 
sample. 
100 years after Sir J. J. Thompson and Francis Aston constructed and successfully tested the 
first mass spectrometer, modern mass spectrometry has come a long way, but is still based upon 
these first fundamental ideas; to transform species of interest into manipulateable ions, and to 
separate them based upon their mass to charge ratio in order to provide a mass-based analysis of 
the compounds.  
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In addition, moving on from photosensitive plates, there are many ways of separating and detecting 
ions produced for mass spectrometry analysis including, but not limited to; Time of Flight (ToF), 
Quadrupole-MS, Orbitrap FTMS, Ion-Trap-MS , Magnetic sector-MS, FT-Time of Flight, and FT-ICR 
MS, including hybrid instruments combining components of each. The content of this thesis will be 
focused almost exclusively on the latter; Fourier Transform-Ion Cyclotron Resonance Mass 
Spectrometry, with other methods referred to as needed.  
1.1 Fourier Transform Ion Cyclotron Mass Spectrometry (FT-ICR MS): 
Fourier Transform Ion Cyclotron Resonance Mass Spectrometry, first developed by 
Comisarow and Marshall in 1974,1,2 is based around separating charged analyte ions using a 
phenomenon known as the Lorentz force. The Lorentz force is experienced by charged ions while 
inside a magnetic field (shown in equations 1a and 1b, and depicted in Figure 1.1, below).  
F = ma = mν2/r = m(ωcr)
2/r = q ν B       eqn. 1a 
FLorentz = q ν x B            eqn. 1b 
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Figure 1.1: Top: depiction of the forces exerted on a charged species while within a magnetic field, 
where q is the charge of the ion, ν is the perpendicular speed of the ion, and B is the magnetic field 
strength. Reproduced from Makarov et. al.3 Bottom: a similar representation of the movement of 
both positive and negatively charged ions inside a magnetic field, reproduced from Marshall et.al.4  
Ions orbiting inside the magnetic field will each have a unique frequency based upon their 
mass to charge ratio and the magnetic field strength, this frequency is dubbed the Cyclotron 
frequency (𝜔c) and is simply given by equation 2 below; 
ω𝑐 =
𝑞𝐵
2πm
 
           eqn. 2 
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Due to the cyclotron frequency ions can be separated based on their mass to charge ratio, 
have their frequency measured, and then in theory, a calibration function can be applied to convert 
measured frequency to accurate m/z values, thus providing mass spectral information on analytes.  
For ions to remain inside a magnetic field and have their cyclotron frequencies measured they must 
be trapped. In FT-ICR MS the analyte ions are trapped in an ICR cell (Figure 1.2, below), an ICR cell 
consists of four major components; trapping electrodes (to keep ions confined axially), excitation 
electrodes, detection electrodes, and an amplifier to amplify the small magnitude signals up to a 
transmittable level. 
 
Figure 1.2: Schematic representation of a cubic ICR cell, showing the major trapping, excitation, 
and detection electrodes, along with limited circuitry used during operation, reproduced from 
Marshall et. al.5  
 
As mentioned previously the magnetic field causes ions to rotate and will confine them 
radially within the bore of the magnet, the two trapping electrodes of the ICR cell can be provided 
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with a voltage of equal polarity to that of the ion and will thus keep the ions confined axially within 
the limits of the ICR cell – effectively trapping the ions in all dimensions and allowing 
experimentation.  
In practice ions do not orbit within a magnetic field at their pure cyclotron frequency, 
instead they are  perturbed by electric fields resulting from the trapping plates and from other ion’s 
own electric field (the latter referred to as “Space charge”).6 The resulting cyclotron frequency is 
known as the reduced cyclotron frequency, given by equation 3, below; 
ωmeasured = ωc- ωm         eqn. 3 
The combination of the electric and magnetic forces on the ions produces a second motion; 
the so-called magnetron motion of ions. The magnetron motion acts along the same axis as the 
cyclotron motion, but at a lower frequency (<100Hz), the equation for the magnetron motion is 
shown below: 
𝑓𝑚 =
𝛼𝑉
𝜋𝑎2𝐵
          eqn. 4 
Where fm is the magnetron frequency/Hz, α is a geometry factor, V is the trapping potential used, a 
is the distance between the trapping plates, and B is magnetic field strength/Tesla.7 
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Figure 1.3: depiction of magnetron (low frequency, large (exaggerated) radius) and cyclotron 
(higher frequency, smaller radius) motion of an ion while trapped within a magnetic field. 
Reproduced from Amster et. al.7 
Magnetron motion arises because the electric field generated by the trapping electrodes 
extends over the entire cell, see Figure 1.4 below. Since the electric field at the centre of the ICR cell 
is not zero; ions are repelled from the centre of the cell towards the lowest energy point, while still 
being confined by the magnetic field. The repulsive force away from the centre of the cell acts 
directly against the homogeneous magnetic field confining the ions radially, as a result the 
magnetron motion causes expansion of the ion orbit around the z-axis. 
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Figure 1.4: Representation of the electric fields(red) and magnetic field induced force (Lorentz 
force) (blue) present within an ICR cell a) the ideal fields/force induced by trapping plate voltage 
and magnetic field b) the resulting fields/force produced by electric field being quadratic (to a first 
order approximation) and non-zero at the centre of the cell7 c) The fields within an ICR cell, and 
the depiction of cyclotron and trapping motion within the cell for a given ion (cyclotron radius is 
exaggerated for clarity) d) inclusion of the non-zero electric field exerting an outward force (red 
arrow) on the travelling ion, inducing magnetron motion. 
The magnetron orbit of ions continues to expand with time as the ions are held within the 
ICR cell, at a relatively slow rate, meaning if ions were held within the ICR cell and were otherwise 
stable (from collisions etc.); they would slowly expand their orbit and still eventually be lost from the 
trap.7 Currently the only effective way of returning ions to the centre of an ICR cell, despite 
magnetron motion, is the use of quadrupolar axialisation,8,9 which has been shown to be an effective 
way of not only returning ions to the centre of an ICR cell, but also in converting magnetron motion 
to true, unperturbed cyclotron motion, and allowing re-measurement of stored ion packets,10,9 in 
theory this enables an “infinite sensitivity” measurement, where the same ions are repeatedly 
excited, detected, then returned to the ICR cell; allowing re-measurement many, many times, 
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possibly down to single-ion detection using FT-ICR MS, but also allowing many summed scans of the 
same species, without introduction of new ion packets and subsequent usage of sample. 
 
Figure 1.5: Quadrupolar axialisation - ions at an excited cyclotron orbit and/or large magnetron 
orbit can be returned to the centre of the ICR cell by a) injecting a pulse of collision gas (e.g. Argon) 
and b) causing collisions during excitation, c) following a pumping delay ions can be re-excited to 
be detected as normal, see below.9 Reproduced from Amster et.al.7 
Unfortunately magnetron motion has no tangible analytical use,7 but is amplified if ions 
deviate from the magnetic field axis (z-axis), meaning good alignment of the ICR cell with the centre 
of the homogenous magnetic field region is essential to minimise magnetron motion issues. 
Magnetron motion effects are uniform for all ions, irrespective of mass to charge ratio, meaning 
using ions of known cyclotron frequencies, quantities, and trapping potentials it is possible to 
calculate the magnetron frequency shift in a given spectrum using equation 4, above. 
Finally though the ions are confined within the electric field well created by the trapping plate 
electrode voltages, the ions will still effectively oscillate between the two plates creating a z axis 
motion of ions with a frequency ~10Hz, depending on cell geometry, plate voltages etc.5 This 
frequency is based upon equation 5, below; 
𝜔𝑧 = √
2𝑞𝑉𝑡𝑎
𝑚𝑎2
          eqn. 5 
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The combination of the cyclotron frequency, magnetron motion, and trapping motion 
results in a much more complicated ion motion path than the pure cyclotron frequency, shown in 
Figure 1.6, below: 
 
 
Figure 1.6 – Top: depiction of the 3 main motions of an ion trapped within an ICR held inside a 
magnetic field; cyclotron motion, trapping motion, and magnetron motion. Bottom: a 
representation of the full ion path, courtesy of Bruker Daltonics, Bremen, Germany and 
reproduced from Marshall et. al.5 
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 It is worth noting that the cyclotron frequency of any ion within the magnetic field is 
independent of its kinetic energy, which is often very hard to control and reduce in variance, this is a 
key advantage of FT-ICR MS measurements over other MS platforms which often suffer from ill-
defined/large ranges of ion kinetic energy, such as ToF’s.5 However the motion of ions discussed 
above assumes an ideal vacuum, which is unfortunately unobtainable. Collisions between ions and 
background gas molecules can perturb ion motion in any of the 3 principle motions discussed and 
can cause undesirable effects, most notably the damping of cyclotron motion, the eventual target of 
measurement (see below). The damping of the cyclotron motion of an ion is shown below in Figure 
7, excessive collisions with background gas can quickly lead to loss of ions from the ICR cell, 
preventing measurement. It is for these reasons that the use of ultra-high vacuum conditions is 
consistently used for FT-ICR MS, despite the technical drawbacks of doing so, it is required to allow 
effective ion motion of trapped ions. 
 
Figure 1.7: representation of ion motion inside of an ICR cell in the presence of background gas. 
The cyclotron motion of the ion is quickly damped though magnetron motion continues to slowly 
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increase, and the ion is soon lost from the trap. Pressure shown is 0.01 Torr. Reproduced from 
Amster et. al.7  
1.2 Excitation/detection of ions: 
The Cyclotron motion of ions will occur as soon as the ions enter the magnetic field; 
however the radius of this initial motion is within the range of several millimetres and is incoherent 
(ions of the same frequency are not travelling together), which hinders effective detection of the 
ions inside the FT-ICR MS. As a result the ICR cell is fitted with 2 excitation electrodes, to which an RF 
pulse can be applied in order to excite ions. The RF pulse transfers energy to the ions trapped within 
the cell; exciting them to a higher radius within the ICR cell. As mentioned previously; the cyclotron 
frequency is independent of kinetic energy and so although the added energy will make the ions 
move faster, they will still move with the same frequency around the ICR cell, hence the excited 
radius to compensate. Figure 1.8 summarises the excitation and subsequent deletion of the ions 
within and ICR cell: 
 
Figure 1.8 – a) excitation and b) subsequent detection of a species within an ICR cell. Courtesy of 
Bruker Daltonics, Bremen, Germany. 
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After the ions have been excited out to a detectable radius, the RF pulse is ceased, the ions 
continue to orbit around the ICR cell at the excited radius, as shown above. While orbiting in close 
proximity to the ICR cell plates the ions (for example positively charge ions) will affect a charge onto 
one detection electrode, the so-called “image current”, however a moment later (ωt=π) they will 
have rotated around the cell to the other detection electrode and affect a charge there instead, if 
these two electrodes are linked electronically then there will be an observable net movement of 
charge from one electrode to the other and back again as the charged ions rotates around its 
cyclotron orbit. This movement will have the same frequency as the cyclotron frequency of the 
rotating within the cell and can thus be used as a measure of the ions frequency. This image current 
is very small (<10mV) and so the signal is amplified as soon and closely as possible to the ammeter, 
before being recorded on a data station, shown in Figure 1.8 above, producing a transient signal 
otherwise known as a free induction decay signal (FID). 
 
Figure 1.9: Representation of an ion cloud orbiting an ICR cell post-excitation and the current 
being measured by an ammeter after amplification to produce a transient (FID). Reproduced from 
Amster et.al.7 
Though excitation of ions to a higher cyclotron orbit has the benefit of producing nice, 
coherent ion packets, which are readily detected, the ion motion within the cell is not completely 
ideal. Collisions of travelling ions inside an ICR cell with background gas can quickly damp the ion 
motion, pushing the ions out of their cyclotron orbit and back to the centre of the ICR cell, causing 
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signal damping, and can cause loss of ion coherence. To avoid this process ultra-high vacuum 
conditions are essential inside the ICR cell, greatly reducing the frequency of collisions, and enabling 
transient times on the order of several seconds routinely. However despite studies showing the 
ability to confine ions within an ICR cell for long periods of time (hours even to days) ions exited to a 
larger than natural orbit will damp and return to the centre of the cell/be knocked out of the stable 
confines of the trap usually within several seconds to several minutes.11 This signal damping can 
continue to cause compete loss of ion signal within the ICR cell, despite the FID still being recorded, 
such transient “crashing” can adversely affect the resulting frequency and mass spectra badly,12 and 
so fine tuning of all components within an FT-ICR MS is required to ensure long transient times and 
achieve the ultra-high performance FT-ICR MS is used and famous for.11,13 
1.3 Data processing: 
Though the reduced cyclotron frequency of ions can be effectively measured using the 
process above, it yields a transient signal, not a list of cyclotron frequencies which can be used to 
calculate an ion’s mass to charge ratio. To obtain the consistent ion frequencies from the recorded 
signal a Fourier transform is required to transform the data from a pure FID to a time domain 
spectrum. The process is detailed below and can be found in a number of previous works,5,7,3,14 
briefly (Figure 1.10 below); the pure FID signal from the instrument (a) is fast Fourier transformed (if 
plotted would appear as (b) (e) and (f) for plot real, plot, and plot absolute functions respectively), 
the Fourier transformed real FID (c) is then zerofilled (below), cut in half to remove the redundant 
mirrored section of data (seen in Figure 1.10 (b)), the frequency domain spectrum (Figure 1.10 (c)) is 
then calculated using the acquisition rate (for data points). Finally the frequency domain spectrum is 
calibrated using a given calibration equation (see below) to convert the frequency axis to 
corresponding m/z and produce a mass spectrum (Figure 1.10 (d)). It is often reported that the 
measured FID signal is simply Fast Fourier Transformed and the plotted to retrieve the frequency 
spectrum, which can then be calibrated to produce the final mass spectrum.7,3 Unfortunately this is 
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an oversimplification and simply plotting after the FFT would produce a combination of real and 
imaginary points (Figure 1.10, plot (e)), and even plotting these values as absolute numbers instead 
of the combination, would produce an x-axis distorted spectrum (Figure 1.10 plot (f)). 
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Figure 1.10 – Steps involved in the data processing of a measured FID signal (a) which can then be 
Fourier transformed to produce a mirrored time domain spectrum (b) followed by halving, and re-
plotting as real numbers to produce a frequency spectrum (c), finally the frequency spectrum can 
be calibrated using a variety of equations (see below), to produce an FT-ICR MS mass spectrum (d). 
Should the data from the FID simply be plotted after Fourier transformation as so often recorded 
it would produce a complex mixture of real and imaginary numbers (e) and if it were plotted as 
simply absolute numbers it would produce a plot with an uncalibrated x-axis, though containing 
the frequency information, with the wrong separation to be informative. 
 
1.3.2 Performance metrics – Resolving power and mass accuracy: 
Though mass spectrometers are advanced analytical instruments and contain many 
individual components and techniques (discussed later), the two most widely used metrics to judge 
analytical performance achieved by an instrument/within a spectrum are the resolving power and 
mass accuracy of the measurement.  
The resolving power of a mass spectrometer is a measure of how effectively the instrument 
can resolve (separate) mass spectral peaks; the higher the number, the more effective the 
spectrometer is at separating closely spaced peaks. Resolving power is defined by equation 6 
(below) where m is the mass to charge ratio of the peak in question and Δm is the width of the peak 
at half its own height; Full Width Half Maximum (FWHM). 
Resolving power =    
𝑚
Δm
         eqn. 6 
Resolving powers of around 300-2000 are routinely achieved on quadrupole mass analysers and Ion 
Trap mass spectrometers, which translates into the ability to separate analytes/isotopes of ~1m/z 
difference (often referred to as “unit resolution”), up to ~0.25-0.3m/z for Ion trap performance. 
Whereas high resolution instruments are usually quoted as achieving resolving power performance 
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of >20,000, and Ultra-high resolving power instruments/methods (such as FT-ICR MS) are 
consistently above 100,000; a 12T FT-ICR MS achieves >500,000 trivially and has been shown to 
achieve up to ~9 million resolving power with careful tuning and developments in FT-ICR MS data 
processing techniques.15,11 A peak can be considered fully/baseline resolved if there is clear space 
(baseline noise) between two individual peaks at their base. Currently the highest reported resolving 
power recorded using an FT-ICR mass spectrometer was ~47 million, achieved by Nikolaeve et. al.16 
The resolving power performance of a mass spectrometer tends to change with the m/z 
range being studied, usually with a slow descent towards higher m/z values. Specifically Fourier 
Transform based MS platforms (such as the FT-ICR MS and more recent Orbitrap MS17 platforms) 
show a decrease in resolving power with increasing m/z values. FT-ICR MS shows a linear decrease in 
resolving power of 1/x, so the resolving power at 800m/z is one half of that at 400m/z. 
The FT-ICR MS resolving power increases linearly with the strength of the magnetic field 
used to contain ions within the ICR cell and induce cyclotron motion.5,18 The uses of higher magnetic 
fields thus provides not only a way of more trivially achieving higher resolving power performance 
on a given FT-ICR MS, but also allows a marked increase in the achievable resolving power per 
second of the mass spectrometer,18 which can be critical in time-sensitive measurements, such as 
chromatography-coupled mass spectrometry (discussed in section 1.9).  
Ultra-high resolving power has been shown to be a critical requirement in many 
contemporary MS experiments, especially for the effective analysis of complex mixtures19 
(containing 10,000-100,000 analyte peaks per spectrum) and for effective, resolved tandem mass 
spectra of complex molecules, such as biomolecules (discussed in section 1.7.2). When analysing 
complex hydrocarbon-based mixtures, such as petroleum/oil based samples, analysis frequently 
produces mass spectra containing 10,000+ analyte peaks, within a relatively small mass range (e.g. 
150-800 m/z) creating an extremely dense mass spectrum, with peaks often separated by only a few 
milli-Daltons (mDa). Ultra-high resolution FT-ICR MS is currently the only viable technique to 
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effectively analyse these mixtures in a single mass spectrum, even separating 13C isotopes from 15N 
and Sulphur isotopic components from the same/different analytes; the so-called “Fine structure” of 
compounds. Fine structure analysis arose from the small mass deviations in the M+1 isotope of 
analytes depending on the (hetero)atoms present in the specific analyte (shown in Figure 11, below). 
Whereas the first (“M”) isotopologue of any analyte would appear as a single peak, the M+1 
isotopologue would “split” at ultra-high resolving powers to separate the 13C isotopologue from the 
15N isotopologue (assuming the analyte contained both atoms), calculating the ratio of these peaks 
and taking into account the natural abundance of the individual M+1 isotopes relative to the M 
isotope allowed the elemental composition of analytes to be calculated purely based on accurate 
mass measurements of analytes, and has since enabled the field of complex mixture analysis by 
high-performance mass spectrometry. 
 
Figure 1.11: Example MS spectrum showing the complexity of petroleum based samples via FT-ICR 
mass spectrometry, included are insets showing effective resolution of different components 
isotopic fine structure and the corresponding milli-Dalton range separation needed. Reproduced 
from Barrow et.al.19 
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Particularly large molecule analysis also requires high performance MS and ultra-high 
resolving power values. As particularly large analytes gain multiple charges during ionisation 
(discussed in section 1.6.1) the m/z spacing between isotopes is no longer ~1m/z, instead it will be 
~1/z, if the analyte acquires a significant number of charge carriers (e.g. z=50-100) then the spacing 
between individual isotopologues observed is extremely small (0.02-0.01 m/z respectively for 50 and 
100 charges). As a result the effective analysis of both particularly large analytes and particularly 
small/complex analytes both require ultra-high resolving power performance, such as FT-ICR MS. 
UHR-MS is also particularly suited when studying the extremely complex spectra produced from 
selected fragmentation of ions during tandem mass spectrometry experiments (discussed in section 
1.7). 
   
Figure 1.12: plots representing the various dependencies of FT-ICR MS performance on magnetic 
field strength, and thus the advantages of increasing magnetic field for FT-ICR Ms analysis. 
Reproduced from Marshall et.al.18  
1.3.3 Mass Accuracy: 
The second key parameter for mass spectrometer performance is the inherent accuracy of the mass 
measurement being taken, termed “mass accuracy”, this refers to the deviation of the measured 
m/z value of a certain analyte from the theoretically calculated m/z value for that species then 
expressed in parts-per-million, as shown in equation 7, below: 
 𝑀𝑎𝑠𝑠 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 (𝑝𝑝𝑚) =
(𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑
𝑚
𝑧
−𝐸𝑥𝑎𝑐𝑡
𝑚
𝑧
)
𝐸𝑥𝑎𝑐𝑡
𝑚
𝑧
 𝑥 1,000,000    eqn. 7 
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Unlike many other key analytical techniques such as Nuclear Magnetic Resonance (NMR), UV/visible 
spectroscopy, gas/liquid chromatography, and Infra-red spectroscopy, mass spectrometry analysis 
enables the calculation of the exact mass of an analyte, and thus is the only common analytical 
chemistry technique to provide an exact error calculation for each measurement and provide 
numerically accurate, instead of precise measurements.  
It is this fundamental capability which makes mass spectrometry able to accurately assign unknown 
compounds from complex mixtures,13,19 or to pattern match spectra/masses against databases 
effectively for fast analysis of target compounds (e.g. in explosives detection20 or forensic 
applications21).  
The mass accuracy of mass spectrometers varies depending on the fundamental principles upon 
which they base their mass measurements on. For example a Quadrupole mass analyser bases mass 
measurement on a mass filtering principle (discussed in detail in section 1.6.2.2), allowing ions of 
m/z 50 to pass through and then detecting current, then m/z 51 and so forth, to produce a spectrum 
of ion populations/current detect at each unit m/z values, and so providing unit-resolution. The 
resolving power of a quadrupole mass analyser is therefore dictated by how accurately it can filter 
ions; if this could be done accurately to 0.5m/z then the resolving power of the quadrupole would 
need to be doubled, but could also then increase the mass accuracy. 
The mass accuracy of FT-ICR mass spectrometers is dictated by accurate measurement of the 
cyclotron frequency (ωc), which as previously discussed is negatively affected by magnetron motion 
(ωm), to become the measured reduced cyclotron frequency (ω). Thus if one could decrease 
magnetron motion to zero, and eliminate electric field perturbations on ions of interest then perfect 
accuracy measurements of ions would be possible.5 Unfortunately in practice this is not possible, as 
electric fields are needed to contain ions, they are produced from plates of finite dimensions, and 
magnetron motion is not possible to be eliminated. However the mass accuracy of FT-ICR MS is 
directly proportional to the square of the magnetic field (B2) and so use of higher magnetic fields 
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enables much more accurate mass analysis of target compounds (Figure 1.12 above). Coupled 
together with careful calibrations (Section 1.3.6), FT-ICR MS is currently the most accurate mass 
spectrometry technique in the world, reaching part-per-billion mass accuracy on compounds in 
some applications.22,19 
1.3.4 Zero-filling: 
One of the key performance parameters for MS is the resolving power of the resulting mass 
spectrum, for FTMS this is directly proportional to the length of the transient/acquisition (TD). Thus 
the opportunity to increase TD has been consistently beneficial to FTMS (unless acquiring under 
time-constrained situations). Unfortunately due to collisions, inhomogeneities within ICR cells, and 
ineffective ion trapping, it is not always possible to obtain a non-damped/slowly damping transient 
signal for extreme TD lengths.
5,7 However it is possible for all acquisitions to obtain a transient of 
length TD and then mathematically extend this transient to double its previous size by including an 
equal number of zero’s to the end of the recorded FID signal. The technique, known as Zero-filling, 
doubles the effective length of the transient signal and thus doubles the sampling resolution of the 
FT, while still recording the same TD within the FT-ICR MS instrument. Zero-filling, thus, increases the 
number of points on every peak measured, but does not change the peak shape or peak resolution, 
but improves the accuracy of peak-centre (centroid) calculation via better fitting. Zero-filling FTMS 
spectra is very effective for all acquisitions, both individual long-TD ultra-high resolution scans, and 
time-constrained repeating acquisitions. Zero-filling of FTMS data can be applied more than once, 
thus increasing the number of zero’s added to 3 fold, 5 fold etc., but despite the obvious 
performance increase (with little/no additional effort) is usually only performed once and a 
maximum of twice in order to avoid reported mathematically added artefacts in the resulting mass 
spectrum.7 
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1.3.5 Apodisation: 
Although the pursuit of higher and higher resolving powers has been a distinct driving force in FT-ICR 
MS over the years, not all signal processing directly benefits/increases resolving power, but instead 
provides other benefits crucial to not only obtaining high-quality data but also aiding the 
interpretation of the resulting data. 
FT-ICR MS produces extremely high resolving power mass spectra, meaning very narrow peaks, 
however the base of FTMS peaks broaden greatly with increasing signal-to-noise ratios. Termed 
“spectral leakage”, the FTMS peaks broaden at the base as a by-product of the Fourier Transform, 
and are not considered “real” peaks. Though improved ICR cell design, tuning etc., has been 
achieved to help reduce these unwanted effects, high signal-to-noise peaks will always continue to 
disturb areas of the mass spectrum, and unfortunately can completely over-shadow lower signal-to-
noise peaks (Figure 1.14, below). 
To avoid these negative effects a signal processing technique known as apodisation has been very 
effectively applied to FTMS spectra to reduce the effect of the signal at extremes of the FID. 
Apodisation scales the contribution of each area of a given transient using a mathematical function, 
thus some areas of the transient will then contribute “more” to the resulting spectrum, and some 
will contribute “less”. Examples of apodisation are shown below both for theoretical data (Figure 
1.13) and for actual FT-ICR MS data (Figure 1.14), both are remarkably similar to the unapodised 
spectrum, but suffer from much less “spectral leakage”, i.e. broadening at peak bases and enables 
baseline resolution and observation of low intensity isotopes (Figure 1.14). 
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Figure 1.13: example of apodisation on an FTMS spectrum showing that apodisation can suppress 
side lobes and broad peak bases, which can improve dynamic range, but negatively affects 
resolving power. Reproduced from Makarov et. al.3  
 
Figure 1.14 – FT-ICR MS spectrum of the 10+ charge state of lysozyme protein: un-apodised (top) 
and processed using sine-bell apodisation (bottom), although the resolving power drops from 
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165,000 to 129,000 for the peaks observed the apodisation does improve the peak bases and 
allow visualisation of the low signal-to-noise isotopes. Also note the decrease in intensity due to 
peak broadening. 
Apodisation can be achieved using a variety of different mathematical functions to suit the 
mass spectrometrist’s needs/priorities, each having a different effect on the overall spectrum and 
resolving power performance. 
The major disadvantage to apodisation is that it decreases the resolving power of the 
resulting mass spectrum peaks, usually by around 20-25%, which is a significant drop in analytical 
performance. However due to the extreme amount of spectral leakage caused by high signal-to-
noise peaks, and the distinct loss of low signal-to-noise peaks in these areas, which are often critical 
for accurate MS assignments, apodisation has become a standardised signal processing technique 
and is commonly applied to almost all contemporary FTMS data.5 Apodisation also improves MS 
peak shapes, which directly improves mass accuracy via better fitting, centroids, and thus 
assignments. 
1.3.6 Calibration: 
As mentioned previously; FT-ICR MS detects and records frequencies, which can then be extracted 
via (amongst other operations) the Fourier transform. This is fortunate as not only are frequencies 
one of the easier, more reliable features to detect in analytical chemistry,7 but it also allows FT-ICR 
MS to take advantage of electronics and advances centred around more common frequency-based 
techniques, such as nuclear magnetic resonance spectroscopy (NMR).  
However, the detection of frequencies and representation of a frequency spectrum (Figure 10c, 
above), is not a mass spectrum. Although in theory all cyclotron frequencies detected can be 
converted trivially to m/z ratios using the cyclotron frequency equation (equation 2, above), we do 
not detect the cyclotron frequencies of ions, only the reduced cyclotron frequencies can be detected 
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(Equation 3, above). As a result all frequency domain spectra obtained from FT-ICR MS instruments 
need to be calibrated to convert them into mass spectra.  
Calibration can most simply be achieved externally – i.e. running a sample of known components, 
spanning the analytical mass range, obtaining a frequency domain spectrum and then plotting the 
observed frequencies against the known masses for those compounds (Figure 1.15, below). Applying 
a polynomial fit to the resulting graph will provide the external calibration function needed to 
calibrate future, unknown, frequency domain spectra into mass spectra on-the-fly. 
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Figure 1.15: representation of external calibration procedure to produce a mass spectrum (e) from 
a recorded FID signal (a) by creation of a calibration curve (d) of known peaks in the frequency 
spectrum (c). Example shown is a ubiquitin protein FT-ICR mass spectrum. 
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Though this external calibration procedure seems adequate for FT-ICR MS, the mass accuracy of the 
resulting spectrum will suffer due to differences in magnetron motion, electric fields, and space 
charge differences between the calibrant spectrum and the sample spectrum.3,7,23 
In order to avoid such deviation affecting analysis, many different calibration functions have been 
derived and expanded over the years, some of which are presented below in Table 1.1, from Gross 
et. al.23  
Table 1.1 – Examples of FTMS calibration equations reproduced from Gross et. al.23  
 
The external calibration procedure described above used the Francl et. al. equation f=(a/(m+c) 
however many other, and more accurate calibration equations can be used for both external and 
internal calibration (described below). 
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Internal calibration: 
As mentioned above external calibration can only go so far in achieving high mass accuracy mass-
spectra, typically externally calibrated FTMS spectra are accurate to within 1-2ppm, but can be as 
high as 15ppm if the same electric trapping potentials and ICR cell parameters are not used for both 
the calibrant and sample acquisitions. To further improve mass accuracy of FTMS, the spectra 
acquired can be re-calibrated “internally” using known species within a sample mass spectrum, the 
known species may be ionised at the same time as the analyte (co-ionisation/spiked sample), leaked 
into the MS continuously, or may be species assignments identified from the external calibration and 
then used to further calibrate. Internal calibration can again use any of the calibration equations 
above, some instrument manufacturers use proprietary calibration equations developed and 
corrected in-house to improve calibration for their instruments when using their corresponding 
software packages. Careful internal calibration of FT-ICR MS data has been shown to allow sub-ppm 
and even ppb mass accuracies,22,19 this is especially crucial when assigning unknown/complex 
mixture spectra purely on accurate mass to determine elemental compositions, which has been 
shown to be effective at assigning tens of thousands of compounds in a single, direct-infusion mass 
spectrum.19,24 
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1.4 Detection modes in FT-ICR MS: 
1.4.1 Nyquist frequency: 
Ions of different inherent mass to charge ratios have distinctly different cyclotron frequencies, but as 
mentioned before the relationship of cyclotron frequency and mass-to-charge ratio is inversely 
proportional. Due to the increase of cyclotron frequency with increasing magnetic field strength 
(Equation 2), ions of low/small m/z values have extremely high frequencies and orbit the ICR cell at 
extreme speeds. For instance a singly charged ion of 1000m/z in a 12T magnetic field will have a 
cyclotron frequency of 1.16MHz and a natural orbit radius of ~0.06mm (0.000061m) using equations 
2+8, below: 
𝑟 =
𝑚𝑣𝑥𝑦
𝑞𝐵0
=
1.036427 𝑥 10−8  (
𝑚
𝑧 ) 𝑣𝑥𝑦
𝐵0
 
           Eqn. 8 
Where r is the cyclotron radius in meters for an ion of velocity vxy, contained within a magnetic field 
of B0 Tesla. 
The orbit is therefore 0.3833mm in circumference and so the ion is moving at 443.9 m/s (998.7 miles 
per hour). While a singly charged ion of 100 m/z will have a natural cyclotron frequency of 11.58MHz 
and an orbit of 0.1254mm, meaning the ion is moving at 1683.6 m/s (3788.1 miles an hour), which is 
a very large difference in speed for the two unexcited ions, though this does assume unperturbed 
frequency, no magnetron motion, and no space charge effects, the difference is clear as an example. 
It can therefore be harder to detect such fast moving ions of low m/z, despite the theoretical benefit 
of working in the low m/z domain regarding the ability to resolve peaks. The consequence of such 
fast moving ions is the need to be able to detect such high frequency species, especially the ability to 
sample the detected current fast enough to keep up with those ions of interest. Ions above the 
sampling rate will simply not be detected as they will be making multiple revolutions between each 
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sample event and the net difference between the 2 detection plates will not be detected. As a result 
the highest frequency (i.e. lowest m/z) scan point desired dictates the scan rate needed for a given 
experiment, if the user wishes to scan to lower m/z values then the signals must be sampled faster 
to keep up. The highest frequency desired is known as the Nyquist frequency, the sampling rate for 
the resulting scan is required to be a minimum of twice as fast as the Nyquist frequency to avoid 
aliasing effects and product an accurate representation of the detected signals.7,4 For an acquisition 
containing a given number of data points (for example 4MW – 4194304 points), the Nyquist 
frequency also dictates the length of the resulting transient, and thus influences the maximum 
achievable resolving power for a given m/z in the mass spectrum. As a result for usual operation the 
desire is to have a scan range that encompasses the desired range (e.g. 150-3000 m/z) but without 
impacting negatively on the resolving power performance required. The reverse of this trade-off is 
also an effective way of increasing the achievable resolving power for a given number of data points 
– by scanning at higher m/z values (lower frequencies) much longer transient durations are 
achievable and thus resolving power performance is increased. Thus it is always important to know 
and record the scan range in any FTMS experiment. The use of higher m/z scans to enhance 
performance has been of great use in studies where the size of the resulting data may be a limiting 
factor and smaller end file sizes were required. This was the basis of using heterodyne detection 
(discussed below), and has implications in large-data applications of FTMS such as 2-Dimensional MS 
(discussed later). 
1.4.2 Broadband mode: 
As mentioned previously; ions at a low (natural) cyclotron orbit are excited by a resonant pulse to a 
higher orbit radius within the ICR cell to enable effective, sensitive, detection of coherent ion 
packets. Excitation of single ions is fairly trivial, however excitation of a wide frequency (and thus 
wide m/z) range to view a whole selection of ions in a single FT-ICR MS experiment is less straight 
forward. In order to view ions of many frequencies, many resonant frequencies must be produced to 
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excite ions, this is usually achieved via a frequency “chirp”, see below Figure 16. The chirp as viewed 
in the frequency domain increases in amplitude at the low frequency cut off desired (often back-
calculated via the high m/z range desired in the resulting mass spectrum using the cyclotron 
frequency equation) and then remains at a high amplitude at a reasonably constant (though slightly 
varying) level until the high frequency (low m/z) range value is reached.  
 
Figure 1.16: Various frequency pulses used to excite ions to a larger radius within the ICR cell and 
enable detection. A) and b) are rectangular pulses of different times and magnitudes, c) the 
standard “Chirp” excitation profile used in the vast majority of FT-ICR MS instruments and 
experiments, d) Stored Waveform Inverse Fourier Transform (SWIFT) excitation profile, discussed 
below, and finally e) SWIFT Isolation/ejection excitation profile. Reproduced from Marshall et.al.25 
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The so-called “broadband chirp” (Figure 1.16c) provides the benefit of a wide frequency excitation, 
relatively easily, and so allows the detection of a wide m/z range only limited in theory by the 
frequency generation electronics. However the broadband chirp also exhibits a frequency profile 
which is not completely flat/consistent in the region of interests, and also exhibits “horns” at the 
beginning and end of each pulse, over-exciting ions in these regions and producing irregular 
behaviour and peak shapes at the very extreme frequency values in the resulting mass spectrum.5,25  
1.4.3 Heterodyne mode: 
Another popular detection mode is referred to as heterodyne/narrowband mode.7,26 Heterodyne 
mode uses a smaller number of data points than the average broadband FT-ICR MS spectrum (e.g. 
128k vs 4M data points) but over a much smaller frequency/m/z range (typically 1-50m/z), resulting 
in a higher number of data points per frequency/ m/z, and so much longer transient length and thus 
much higher resolving power for the resulting spectrum.  
The principle of heterodyne mode acquisition relies on the use of a reference frequency alongside 
the usual recorded image current signal. A reference frequency near to the desired experimental 
range is chosen, e.g. 200kHz reference frequency for a measurement of ~215kHz). The image current 
detected will be a sinusoidal transient signal at ~215kHz, this will then be summed with a 
cosinusoidal reference signal at 200kHz, resulting in a composite signal. The composite signal is then 
processed through a low-pass filter producing a heterodyne signal containing frequencies equal to 
the sum and differences of the two signals, leaving the resulting transient of ~15kHz spectral width, 
which can be sampled at 30kHz instead of the broadband/single frequency equivalent which would 
have to be twice the value of the frequency, i.e. 430kHz. As a result the spectrum can be sampled at 
a much lower rate, while still using the same amount of physical memory, this translates to an 
elongation of Tacquisition (TD), which is directly proportional to resolving power. For the example above, 
a standard 4 MegaWord (MW) data set would result in a transient length of 10.2 s at a 430kHz 
sampling rate. Using heterodyne detection and the reference frequency stated the same 4MW data 
32 
 
set at 30kHz results in a TD of 146.1 s, a performance increase of over 14-fold compared to 
broadband/single frequency excitation regimes. However, when using heterodyne mode the 
reference frequency dictates the frequency range scanned, as a result only frequencies in the range 
of 185-215kHz (200kHz +/-15kHz)would be measured during this heterodyne experiment. Increasing 
the width of the heterodyne scanning range would mean changing the difference between the 
reference frequency and that of the measured target, resulting in a decrease in the benefit of 
heterodyne-processing of the signal. 
Heterodyne mode is currently less utilised than broadband mode (due to its narrow field of 
scanning), and less than historically where it was exceptionally useful as a way of attaining ultra-high 
resolving powers while using smaller file sizes, whereas contemporary FT-ICR MS is less limited by 
computer file size/memory requirements than previously. Though heterodyne mode continues to 
find niche applications and is still an excellent method for acquiring ultra-high resolution spectra.13,26  
 
Figure 1.17: Heterodyne (narrowband) signals before (left) and after (right) removal of the 
reference frequency used to reduce the sampling rate and extend the available TD for a given 
number of data points. Reproduced from Amster et.al.7 
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1.4.4 SWIFT: 
As mentioned previously; a broadband chirp excitation profile is not flat and can produce unwanted 
effects at the extremes of excitation frequencies. In order to combat these short-comings Marshall 
et. al. developed another method for exciting ions inside an ICR cell.25 Named the Stored Waveform 
Inverse Fourier Transform (aka SWIFT), the concept behind the method was instead of mimicking a 
flat excitation profile as with the chirp, SWIFT predicts the frequency profile desired (a perfect 
rectangular excitation, Figure 17, above), then uses an inverse Fourier transform to calculate the 
time domain signal required to achieve the perfect excitation profile needed (Figure 1.16d, right). 
The SWIFT time domain excitation pulse looks remarkably different than the standard broadband 
chirp, but it is also clear to see the excitation profile in the frequency domain is clearly flatter and 
more defined than the corresponding chirp, as a result SWIFT is a more ideal excitation profile, on 
instruments where it is available.    
SWIFT has been used effectively to both excite ions ready for detection25 and for isolation of ions 
(see section 1.6.3.2).13,27 SWIFT is also useful for excitation of multiple chosen frequencies (/m/z 
values) using a “notched” excitation profile with excitations at each chosen frequency, providing a 
way of monitoring chosen ions of interest without exciting all ions in a given population. 
1.4.5 Signal averaging: 
As with many analytical techniques, although peaks may be visible using a single scan/experiment, 
the intensity of target peaks may be low. In order to increase the intensity of peaks within the 
resulting mass spectrum, without accumulating an excessive number of ions which can lead to space 
charge effects, FT-ICR mass spectra can be summed during a long multi-spectra acquisition 
experiment. Summing many transient signals prior to Fourier transformation, calibration etc., results 
in an increase in signal intensity for all signals (including noise), and an increase in signal to noise of 
persistent peaks only, meaning random (white noise) peaks will grow slowly (as √n) but remain 
relatively low, while persistent (real) peaks will steadily grow linearly over the course of the 
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experiment. This increase in signal to noise ratio is directly proportional to the square root of the 
number of scans summed, so the benefit of summation can plateau relatively quickly. Aside from the 
long experimental time required for long (100+ summed-scan) acquisitions, the only practical 
disadvantages to long signal averaging experiments are linked to sustainable ionisation/delivery of 
analyte ions to the ICR cell. Scan-to-scan variability in ion population results in a change in the space 
charge and magnetron frequency effects discussed earlier, resulting in very slight changes to the 
observed (reduced) cyclotron frequencies of ions. If the flow of ions for each scan is not consistent 
then a scan of unusually low ion population will produce a peak offset from the otherwise consistent 
and growing peak produced by the “average” ion populations otherwise recorded – leading to split 
peaks and/or peak broadening as multiple, very similar, frequency ion packets are summed together. 
1.4.6 Ion coalescence: 
As mentioned before FT-ICR MS relies on the excitation of incoherent individual ions orbiting within 
a magnetic field into discrete, coherent, and detectable ion packets via the application of an r.f. 
pulse to excite them to a higher cyclotron radius. Excessive ion populations have been shown to 
cause detrimental effects to this process (space charge); most notably frequency shifts and peak 
splitting resulting from dephasing of an individual ion packet into two or more closely spaced, but 
temporally separate ion clouds. Another phenomenon observed in FT-ICR MS is the exact opposite 
of this, i.e. closely spaced ion clouds converging and coalescing into a single detectable entity. Often 
occurring with large ion populations; peak coalescence can be observed most easily when two 
species are present in an analyte spectrum, yet only one peak is observed in the resulting mass 
spectrum, despite having sufficient/excessive analytical performance (resolving power) to separate 
the two species into individual peaks, as shown below in Figure 1.18.  
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Figure 1.18: Mass spectrum of Poly(ethylene glycol) (PEG) using various trapping voltages during 
FT-ICR MS. The movement and eventual combination of peaks (at Vt 3V) shows the effect extreme 
trapping voltages can have on the resulting mass spectrum, but also shows how different ion 
packets can coalesce into a single peak, despite achieving the resolution to separate them. 
Reproduced from Amster et. al. 7 
The effect is enhanced when using high trapping voltages during confinement and detection of ions 
within the ICR cell, as a result most cell designs and FT-ICR MS experiments strive to minimise the 
trapping voltages needed to achieve acceptable performance. Using higher field superconducting 
magnets helps to reduce peak coalescence, making them more suited both for high complexity 
mixtures (to resolve many thousands of peaks simultaneously) and for ultra-high resolution scans of 
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target compounds. Despite the ability for many low field instruments to reach very long transient 
length (TD) scans, higher magnetic fields are more able to effectively mitigate unfavourable 
motions/effects within FT-ICR MS, such as ion coalescence, magnetron motion, and space charge 
effects. 
1.5 FT-ICR MS cells: 
1.5.1 Geometry and development: 
The ICR cell is the heart of the FT-ICR mass spectrometer, it is the mass analyser required in all FT-
ICR MS based experiments, yet ICR cells appear in many varieties, each designed and optimised to 
perform particularly well in certain situations and/or combat one or more challenges during an FT-
ICR MS experiment (trapping field effects, z-axis ejection, peak harmonics, etc). 
The first FT-ICR MS cells were based on the cubic geometry (Figure 1.19, below), with straight 
forward fabrication, able to fit effectively between the poles of permanent magnets, and to a lesser 
degree in superconducting magnets, cubic ICR cells were used for many years on extremely 
successful platforms.26,28,29 Cubic cells had typical electrode configurations – two excitation 
electrodes, two detection electrodes, and two trapping electrodes, all equal in size. Multiple-cell 
instruments were also constructed using Cubic cells for unique experiments,5 more recently this 
approach has been revisited and utilised for fast acquisition using 3 linked cubic cells in a parallel 
acquisition FT-ICR MS experiment.30 However Cubic cells suffered from low ion capacity and were 
not optimised for superconducting magnet geometries now in more common use.  
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Figure 1.19: examples of various ICR cells which have been effectively used in FT-ICR MS, including 
the (a) Cubic (b) cylindrical (c) segmented end cap cylindrical cell aka the “infinity cell” (d) open 
cylindrical cell (e) open capacitively coupled cylindrical cell (f) dual cubic cell (g) “matrix shimmed” 
cell. E = excitation D = detection T = trapping plates. Reproduced from Marshall et. al. 5 
Cubic cells were succeed by cylindrical ICR cells, using rounded, quarter-circumference 
excitation/detection plates, with either circular end cap trapping electrodes (for closed cylindrical 
cells) or cylindrical trapping plates (for open cylindrical cells). The curved shape of the detection 
electrodes used in cylindrical cells enabled a more prolonged interaction with ion-packets as they 
passed the surface during detection, increasing the interaction between ions and available electrons, 
improving sensitivity. End-capped cylindrical cells suffer from electric field permeation throughout 
the ICR cell and disruption of the ion orbit away from the centre of the cell, as discussed previously.31 
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While open cylindrical cells suffer more from z-axis ejection of ions during excitation, due to 
resonant energy transfer into this frequency mode.32 In order to combat these issues ever- 
improving ICR cell designs have been released; the capacitively coupled open-cylindrical cell was 
introduced by Beu et. al.32 in order to capacitively couple the excitation and detection electrodes 
during ion excitation to eliminate z-axis ejection of ions along the magnetic field axis. In another 
approach to avoid the problems caused by using end cap electrodes and a cylindrical cell of finite 
dimensions, Caravatti et. al.33 introduced the aptly named “Infinity cell”, a closed-cylindrical cell with 
special resistively-coupled, surface-mounted trapping electrode wires which are positioned and 
designed to mimic an infinitely long trapping electrode geometry, and thus minimise/eliminate some 
axial excitation and ejection during the ion excitation event.  
The Infinity cell and the capacitively coupled open cylindrical cell are both shown above in Figure 
1.19. The Infinity cell has for many years been the proprietary cell of Bruker Daltonics FT-ICR MS 
instruments, measuring just 6cm in diameter and 6cm in length, the infinity cell has been shown 
(with careful tuning and operation) to achieve performance into the multiple millions of resolving 
power34 and low part-per-million (ppm) to part-per-billion (ppb) accuracy in mass measurement.34 
The majority of the work presented herein was conducted on a Bruker Daltonics FT-ICR MS 
instrument fitted with an Infinity cell FT-ICR cell and so only the infinity cell will be shown in detail. 
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Figure 1.20: Schematic representation of the Infinity ICR cell, a closed cylindrical cell equipped 
with side-kick electrodes, two excitation plates, to detection plates, and two trapping plates. 
Courtesy of Bruker Daltonics, Bremen, Germany. 
 
 
Figure 1.21: Left: Schematic of the Infinity cell trapping electrodes (a), showing the resistor chains 
and circuitry associated with the Infinity cell design (b) which attempts to mimic an infinitely long 
cell in order to avoid unwanted ejection of ions along the z-axis during excitation. Reproduced 
from Caravatti et.al.31 Right: Image of the Infinity cell mounted on a standard 6” stainless steel 
flange for connection to the end of the flight tube of an FT-ICR MS. 
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The Infinity cell has the benefit of virtually eliminating the unwanted ejection of ions along the z-axis 
during ion excitation by using the capacitor-functionalised trapping plates to mimic an infinitely long 
cylindrical cell. This enables higher sensitivity than the corresponding open-cylindrical cell as fewer 
ions are lost during excitation. The Infinity cell has been shown to require slightly more tuning than 
open-cylindrical cell geometries, but can achieve extremely long transients and thus resolving power 
performance. The main disadvantages of the Infinity cell are the need for more tuning at high 
performances, the closed cell geometry producing challenges for application/alignment of 
lasers/electron beams for further experiments, and its small size (6cmx6cm) causing a lower ion 
capacity than a corresponding cylindrical cell which could fit in the same magnet bore. Though the 
Infinity cell suffers from less ion loss and thus increased sensitivity, which reduces the latter point.  
1.5.2 Side-kick electrodes: 
As mentioned previously magnetron motion will increase if ions are displaced from the magnetic 
field axis (z-axis). Ideally with perfect alignment of all ion optics/ICR cell/ionisation source etc. all 
ions would be able to enter the ICR cell perfectly on axis and magnetron motion/electric/magnetic 
field inhomogeneities would not cause any issues during measurements. However since these 
prerequisites are not feasible, adjustment of ions’ position as they enter the ICR cell has become a 
very effective technique in correcting their orbit once in the cell and has enabled much more control 
over ion packets and allowed more ultra-high resolution experiments. Coined “Side-kick” electrodes 
by its inventor Marshal et. al.35 these curved electrodes are placed at the entrance to the ICR cell, 
with a potential difference applied between the two. As the ions approach and pass through the ICR 
cell inlet they experience an asymmetric field from the sidekick electrodes and are deflected slightly 
while moving, altering their end-position within the ICR cell, meaning they begin a different orbit 
than usual. The alteration of an ions orbit can be detrimental to the measurement at hand if not 
balanced correctly, if the ion’s are pushed too far away from the principal axis (z-axis), then this 
increases the magnitude of magnetron motion which can be deleterious to the resulting mass 
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spectra. However if the ICR cell/housing is very slightly off axis with the magnetic field, then a small 
adjustment of the side kick electrodes can often produce much more ideal results and enable much 
more stable ion orbits, resulting in longer stable ion signal, increasing resolution greatly. The sidekick 
electrode have also been shown to have a positive effect when their polarity is inverted during 
detection.35 The sidekick electrode are labelled within the infinity cell, Figure 1.20, above. The 
effective voltage on each side kick electrode is determined by the “side kick voltage” and the “side 
kick offset”, the two values are used in equations 9a and b (below) to dictate experimental 
parameters. 
Side Kick_a = Side Kick Offset – Side Kick/2      eqn. 9a 
Side Kick_b = Side Kick Offset + Side Kick/2      eqn. 9b 
1.6 MS components: 
Though FT-ICR MS can be described purely as the trapping, excitation, and detection of ions within 
the ICR cell, practically there are many individual components and theory to a working FT-ICR mass 
spectrometer before the detection process can occur, including; ion generation, transportation, 
filtering, excitation/cooling, and optional isolation and/or dissociation. These concepts, techniques, 
and their applications are discussed herein, including an overview of the mass spectrometer used in 
the vast majority of the work relating to this thesis. Again, though many of these concepts extend to 
use within many different mass spectrometers, the focus will remain on their use in FT-ICR mass 
spectrometers specifically. 
1.6.1 Generation of ions – ionisation sources: 
As mentioned continuously; mass spectrometry requires that the analyte species are charged ions, 
and so all mass spectrometry studies are gas phase measurements of mass to charge ratios. Though 
most samples /analytes will originally be present as a neutral species prior to analysis and so all 
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samples must be ionised in some fashion in order to be analysed by mass spectrometry. Thus the 
ionisation source is the first critical component in any mass spectrometer.  
There are currently many different ways to ionise species of interest and to introduce them into a 
mass spectrometer for analysis, each with their own unique advantages and disadvantages, and 
suitability for different samples. The ability to ionise such a wide variety of compounds one way or 
another is one of the key features which makes mass spectrometry so widely applicable to studying 
such a vast array of different species, often in one experiment, but also in many individual analyses, 
each focusing on different types of species specifically for tailored analysis. 
1.6.1.1 Electron Impact/ionisation (EI): 
The first widespread ionisation source and still one of the most commonly used methods of 
generating detectable ions today, Electron Impact (EI) ionisation uses high energy electrons, typically 
70eV, to ionise analytes by displacing a bound electron on the analyte species. By losing one electron 
the analyte becomes a radical cation (M+.), this species can often then be detected. Unfortunately 
radical cations are not as stable as their precursors and coupled with the excess energy the 70eV 
electrons add into the molecule, the resulting ions often fragment/dissociate into one or more 
fragment ions before they reach the mass analyser. These fragmentations are radical driven and 
usually strive to produce a more stabilised radical species (e.g. from a primary radical to a 
secondary/tertiary radical species), and a number of neutral species, which increases the entropic 
driving force. Radical re-arrangements are also common and can produce even more peaks in the 
resulting mass spectrum, complicating analysis.  
Thus the main disadvantage of EI is that the M+. species cannot always be observed (if the analyte 
does not contain the structure/functional groups to stabilise the radical effectively), and that 
ionisation of one species produces a very large number of peaks (Figure 1.22, below).  
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Figure 1.22: Electron-Impact (EI) generated ions of phenyl hydrazine, the molecular ion ([M]+•) is 
observed at high intensity showing the species is able to stabilise a radical functionality readily. 
Other fragments observed provide insights into the molecular structure and can be used to 
characterise and/or identify the species. 
The main benefits of EI ionisation are the simplicity and robustness of the EI source, which is able to 
operate effectively with little maintenance and ionise the vast majority of small molecule analytes 
without tuning the electron energy away from 70eV, and that the fragments produced can be used 
to characterise the species they resulted from. The fragments produced by EI ionisation are formed 
from the radical dissociations and/or rearrangements of the molecule ionised. As a result the radical 
chemistry of each analyte is unique and will produce characteristic fragments for each and every 
analyte conceivable. The fragments produced may be as simple as C6H5
+. (produced by release of a 
phenyl group), but correlation with nearby peaks can quickly inform structure and atoms present 
(e.g. series of peaks separated by ~14Da often indicates saturated alkyl chain groups). A large 
amount of literature and experimentation has been conducted into EI fragmentation and application 
for a wide variety of analyte species. However EI ionisation is a gas phase ionisation technique and 
so is usually limited to application with volatile small molecules, as large/large biomolecules produce 
extremely complex EI fragmentation spectra, which yield little/no practical information due to the 
extreme extent of electron-induced fragmentation. The only effective EI-MS characterisation of 
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biomolecules was performed by Biemann et. al. and required extreme (complete) derivatisation of 
every individual functional group within the peptide analyte chosen,36 this is of course not practical 
for wide-scale/routine biomolecule characterisation, which is the focus of the majority of 
contemporary mass spectrometry research groups. The low volatility of most biomolecules is also an 
extremely limiting factor in EI ionisation of biomolecules. 
1.6.1.2 Chemical Ionisation (CI) 
Chemical Ionisation (CI) was introduced by Victor Talrose in Russia37 and subsequently developed 
extensively by Munson and Field.38 Unlike EI ionisation, CI was designed as a proton-transfer 
ionisation source, instead of an electron based ionisation method. Chemical ionisation relies on the 
reaction of analyte species with highly reactive protonated gas ions created in a specialised chemical 
ionisation source. These gas-phase proton transfer reagents usually have an extremely low proton 
affinity, meaning they are extremely reactive Lewis acids (able of donating their extra proton). The 
formation of the gas-phase proton-transfer reagent is usually achieved through a glow-discharge 
source, using a high-energy spark to convert methane into (amongst other products) CH5
+, an 
extremely reactive Lewis acid, this process is shown below in equations 10-12: 
CH4 + e
-
  CH4
+. 
+ 2e
-
        [Eq.10] 
CH4 + CH4
+•  CH5
+ 
+ CH3
•
         [Eq.11] 
The CH5
+ generated can then transfer its excess proton to analytes; 
M+CH5
+ -> [MH]+  + CH4         [Eq.12] 
Chemical ionisation proved to be a particularly effective ionisation method, causing little to no 
fragmentation to analyte species, which was in stark contrast to EI at the time, providing 
predominantly MH+ ions. CI proved to be effective at ionising polar, and semi-polar analyte species.38 
Though CI only produced singly charged ions, making data analysis of analytes trivial, this limited its 
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use to smaller analyte species, as the lack of multiply-charged ions prevented the study of larger 
species and particularly large biomolecules species such as peptides and proteins. 
1.6.1.3 Electrospray ionisation (ESI): 
Developed by John Fenn at Yale university in 1985, electrospray ionisation was not discovered from 
a desire to create ions for mass spectrometry, but instead as a serendipitous discovery while 
investigating molecular beams. Never the less John Fenn’s discovery and then development of 
Electrospray ionisation has become an extremely effective and widely used ionisation method that is 
used almost ubiquitously in laboratories investigating (semi) polar compounds, complex mixtures, 
and most importantly; biomolecules.  
Electrospray ionisation is a solution phase ionisation technique which utilises a fine needle through 
which the solution can be driven in order to create a fine mist/plume of sample, which while 
applying a high potential difference will become charged droplets and can be attracted towards a 
vacuum inlet. The eventual desolvation of these charged droplets liberates charged 
(protonated/deprotonated depending on the direction of the electric field) analyte species; ions, 
which can be manipulated, transferred into a mass spectrometer/analyser and detected.  
The experimental arrangement for ESI is shown below in Figure 1.23. The solution is first exposed to 
a high potential difference between the solution inlet and the mass spectrometer inlet (typically 
3000-6000 V), causing charge separation, the solution is then passed through a fine ESI needle 
(typically ~100um diameter, though this can vary), as the solution exits the needle it is mixed with an 
inert gas (usually nitrogen) to form a Taylor cone and nebulise the solution into a fine mist (ESI 
plume),39 the charged droplets within the plume are then attracted towards the mass spectrometer 
inlet.  
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Figure 1.23: representation of the ESI process, showing the sample solution passing through the 
ESI needle and forming a Taylor cone, creating ESI droplets which will then desolvate, reach their 
Raleigh limit and undergo coulombic explosions/discharge events to form daughter ions, this 
process will repeat until detectable individual ions and/or stable droplets form. 
As the charged droplets move through the electric field region and through the mass 
spectrometer inlet, desolvation of the droplets occurs. As the solvent evaporates, charge within the 
droplet remains relatively constant, meaning the droplets eventually approach the Raleigh limit of 
instability.40 Droplets approaching the Raleigh limit will fission into two or more species (up to 14 in 
some cases)41 the daughter droplets created will then continue to travel along the electric field 
gradient and continue to desolvate, undergoing multiple Raleigh “explosions”/fissions along the 
way, until eventually producing desolvated ions. The ions generated can then be detected within the 
mass analyser. Droplet formation can be visualised using high-resolution and high speed cameras, as 
shown in Figure 1.24, below, and has also been modelled computationally to show not only how 
droplets change shape while under various stress forces, but also how they dissociate and eject 
ions.42 
47 
 
 
Figure 1.24: Charged droplet emission during ESI. (a) Photographs showing taylor cone formation 
and resulting ESI plume (b). (c)-(g) snapshots from Molecular Dynamics computational simulations 
showing the change in atomic configurations inside a 10nm ESI droplet of NaI (red) sequestered in 
formaldehyde (blue) within an electric field of 0.625V/nm. Reproduced from Meyer et. al.42 and 
www.newobjective.com (accessed 12/08/2016) 
The study of droplet desolvation occurring during ESI has been ongoing ever since the 
conception of ESI, unfortunately the process is still not completely understood. However a detailed 
study of droplet fission by Beauchamp et. al. was able to use Doppler Interferometry to study many 
and also individual droplets as they continue to desolvate within and electric field gradient. 41 
Beauchamp et. al. showed that as the desolvation occurs ions undergo multiple “discharge events”, 
upon which 10-25% of droplet charge is lost, whereas only 0-5% overall charge is lost. These 
discharge events continued until the droplets were no longer detectable. Though the fact that at 
least 10% of charge is lost with each event, yet some discharge events occurred with no detectable 
mass lost implies that highly charged species, with negligible mass compared to the droplet as a 
whole, are ejected during the ESI process (Figure 1.25, below). 
48 
 
 
Figure 1.25: measurements from Beauchamp et. al.41 showing the desolvation of a charged droplet 
formed from ElectroSpray Ionisation (ESI). The measurements show the continued loss of solvent, 
during which several “discharge events” occur when the Raleigh limit of stability is reached for a 
given droplet (indicated by arrows). Reproduced from Beauchamp et.al.41 
The key advantages of ESI over EI and CI, mentioned above, are that a) it is an extremely “soft” 
ionisation technique – producing little to no modification of analytes (beyond the 
protonation/deprotonation), and most importantly b) it can produce multiply charged analyte 
species.  
The ability to create multiply charged species greatly facilitated the analysis of particularly large 
molecules, by increasing their charge and lowering the resulting mass-to-charge ratio into a more 
convenient detectable and manipulateable range for most mass spectrometers. Though some mass 
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spectrometers are able to perform reasonably at high m/z values (>10,000 m/z), most notably Time 
of Flight (ToF) mass spectrometers, the majority of mass spectrometers (including ESI-ToF’s), FTMS 
specifically, are at optimum performance at more moderate m/z values (~100-5000 m/z), as a result 
the ability to multiply charge ions and bring them into the 100-5000 m/z region is a benefit to the 
entire MS field. The impact ESI-MS has had on the field as a whole is reflected in the joint awarding 
of the 2002 Nobel prize to John Fenn for his work on ESI, the other recipient Koichi Tanaka for his 
work on laser-based ionisations, discussed below. 
The mechanism of analyte charging and eventual ejection from the solvated-analyte charged droplet 
state to free ion is still under debate, however several models have been proposed, the most widely 
accepted of which are currently the Ion Ejection Model (IEM), Charge Residue Model (CRM), and the 
Chain Ejection Model (CEM)43. Figure 1.26, below, summarises the 3 models, covered recently by 
Konermann et. al.43 
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Figure 1.26: Summary of the three main models for ESI ion formation, summarised by Konermann 
et. al.43 From left to right; The Ion Ejection Model, the Charge Residue Model, and the Chain 
Ejection Model. 
Ion Evaporation Model (IEM): 
The Ion Evaporation Model is mainly applicable to small molecules, usually charged via protons/salt 
ions (such as Na+ or K+) already in solution, these charged species can either reside in the bulk 
solution where they are stabilised via solvent interactions, much like salt ions themselves (see Figure 
1.27, below), or near/at the surface of the droplets, which is where the IEM can take place. The 
location of the species within the droplet will thus be affected by the structure and 
functionality/polarity of the analyte, species with particularly non-polar groups will often be more 
stabilised at the surface of the droplets, and so can undergo the IEM more effectively, under the 
condition that they have functional groups to accommodate a fixed charge in addition to their non-
polar groups. 
 
Figure 1.27: Snapshot of a Molecular Dynamics (MD) simulation conducted by Konermann et. al.44 
showing the solvent structure reorganisation effect of Na+ ions on a water droplet. Reproduced 
from Konermann et.al.44 
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The IEM hypothesises that ions at the surface of charged droplets during ESI can be ejected, 
usually simultaneously with several solvent molecules, producing distinct ions from the parent 
droplet, which can then be analysed. This process is obviously stepwise and relies on the 
reorganisation of many solvent molecules near the droplet surface, several snapshots of the IEM MD 
simulations are shown in Figure 1.28, below. It has been shown that the electric field from a droplet 
near/at the Rayleigh limit of stability is repulsive enough to overcome the energy barrier of 
ejection(~32kJ/mol).43 As can be seen from Figure 1.28 the timescale for the transition from solvated 
ion to ejected ion is ~1ns. 
 
Figure 1.28: MD simulation snapshots at different times summarising the Ion Ejection Model (IEM) 
of ESI showing a small ammonium ion (NH4
+) being ejected from an ESI droplet. Note that the ion 
is not necessarily ejected as NH4
+ but is still associated with several solvent molecules, which will 
then be released during desolvation as they travel into/through the mass spectrometer. 
Reproduced from Konermann et. al. 43 
Charge Residue Model (CRM): 
For large molecules such as proteins and protein complexes the energy barrier for ejection from an 
ESI droplet is far too high to allow the IEM shown above. Instead particularly large molecules are 
often believed to be ionised during ESI via the Charge Residue Model (CRM). During the CRM the 
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protein/large molecule remains within the droplet and it is the solvent which is ejected/removed via 
desolvation, until only the protein remains,43 with the remaining surface charges being deposited on 
available groups on the protein’s accessible surface. As a result the CRM has been mostly applied to 
large, folded protein charging during ESI, as unfolded proteins behave differently (see CEM below), 
and take considerably longer than the IEM (microseconds vs. nanoseconds) as the limiting step in 
the CRM is not the position of the protein inside the droplet, but the amount and nature of the 
solvent present.  
Chain Ejection Model (CEM): 
The CRM model has been shown to effectively explain the ionisation of large folded protein 
structures during ESI, however many proteins are analysed via ESI in denaturing conditions (such as 
organic solvent and/or acidic/basic conditions) which disrupts their tertiary structures, and often 
provide more effective ionisation and/or higher charge states observable in the resulting mass 
spectrum. Also the CRM does not effectively explain the charging of similarly unstructured non-bio 
polymer species. For these situations the most accurate model currently accepted is the Chain 
Ejection Model (CEM). The CEM suggests that disordered/extended chain structures (such as 
polymers/biopolymers) are less stable in the centre of the bulk solution due to the unfolding of their 
structure exposes hydrophobic regions usually concealed within the tertiary structure away from 
external solvent species. Due to this change the chains migrate towards the surface of the droplets. 
Once at the surface the terminus of the protein/polymer can be “ejected” from the droplet while the 
rest of the chain is still tethered to the surface. Over time the rest of the chain will be ejected from 
the droplet and become charged due to exposure and proximity to surface charges. Eventually the 
entire chain will be released from the droplet and become a free ion, possibly with some 
solvent/buffer adduction (as observed in the IEM). The CEM process is summarised in Figure 1.29, 
below: 
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Figure 1.29: MD simulation snapshots of the Chain Ejection Model for ESI showing a long chain 
biopolymer being slowly ejected from an ESI droplet. Reproduced from Konermann et. al.43 
The CRM and CEM help explain the differences in protein ionisation observed under different 
conditions, as the solvent conditions can dictate the protein conformation in solution and thus will 
alter the ionisation mechanism the species undergoes during ESI. It has also been shown43,45 that the 
maximum droplet size the CEM model is applicable is ~10nm, meaning that above this limit there 
may be limited ionisation of unstructured/chain molecules before Rayleigh/Coulombic explosions 
reduce the size of ESI droplets during the desolvation process detailed above. It has also been 
suggested43 that the different amounts of charge which proteins can achieve (varying number of 
protons acquired/released during ESI), see below, could be due to the same protein being ejected 
from droplets of varying diameter and thus varying amounts of charge, as larger droplets are able to 
accommodate higher numbers of charge at their surface. This suggests that larger ESI droplets could 
produce higher charge state protein analytes, though this assumption does not take into account 
many other factors, some of which are described below. 
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Figure 1.30: Summary of the sequential charging process from the CEM for ESI showing long chain 
polymers/biopolymers acquiring multiple charges upon existing different sized droplets and 
acquiring a different degree of charge. Reproduced from Konermann et. al.43,45  
Protein ESI: 
As mentioned above, ESI of large molecules can produce multiply charged species, one of the main 
benefits of the ionisation method, however the ability of say a protein to accommodate said charges 
will dictate the amount of charge acquired and thus influence the species observed via the mass 
spectrometer. 
Peptides and proteins contain multiple functional groups capable of accommodating additional 
charge, most notably side chain residues of Arginine, Lysine, Histidine, a free amine N-terminus, and 
even backbone nitrogen atoms to a degree. Additionally (particularly acidic) proteins can be 
deprotonated and be observed in ESI via deprotonation of acidic amino acid side chains, such as 
Glutamic acid and Aspartic acid. 
The ability for a particular charge-capable site within a protein to become charged is dependent on 
the conditions (solvent, temperature etc.), pH, and conformation of the protein itself. If a protein 
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has a large number of basic amino acids, able to be protonated readily in theory, but is folded into a 
tightly packed conformation with said amino acid groups concealed/protected from the protonating 
solvent, then they will remain uncharged during ESI and a protein may appear at a low charge state 
(if only a small number of sites can be accessed). Though many currently believe that charging of 
proteins during ESI may be more significantly affected by solvent-accessible surface area over purely 
number of accessible basic/acidic sites.These ESI-inhibiting conformational effects are usually 
overcome in protein MS via use of denaturing solvents (such as water-methanol or water 
acetonitrile (50-50 v/v), usually with the addition of an acid (e.g. formic/acetic acid) to decrease pH 
and aid in positively charging available groups.42 The denaturisation of proteins promotes a more 
open structure and exposes more of the protein backbone/side chain residues, which can then be 
charged if possible, enhancing charging of analytes. However this approach, though commonly used, 
is not suitable if the study at hand has any focus on protein structure or conformation, which would 
need to be retained during the ESI process.46 Use of denaturing/harsh solvent conditions for protein 
analysis has also been an issue for the study of fragile protein modifications, especially if their 
binding is pH dependant and/or easily displaced by acid/base/solvent molecules, which is the case 
with many metal-based modifications.47  
Since proteins can be present in different conformations and attain different levels of charge during 
ESI, it is often observed that in ESI-MS of a protein-containing solution, the protein of interest is 
observed in the mass spectrum at multiple different charge states, e.g. Charge state 8+, 9+, and 10+ 
for the lysozyme protein shown in Figure 1.31, below; 
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Figure 1.31: ESI-FT-ICR MS of Lysozyme protein in positive ionisation mode showing multiply 
charged lysozyme species in the 8+, 9+, and 10+ charge states. Inset: Isotopic distributions of the 
10+ and 9+ charge states showing the protonated and Sodiated species present at each charge 
state. 
The 8+, 9+, and 10+ charge states refer to the species [Lysozyme+8H]8+, [Lysozyme+9H]9+, and 
[Lysozyme+10H]10+, respectively. The observation of different charge states has the benefit of 
producing “higher” charge state species for extended experiments (see MS/MS below), at a lower 
m/z ratio (for higher FTMS performance), and the range of states can provide indirect information 
regarding protein structural conformations. However the production of a range of protein charge 
states, instead of a single charge state, “dilutes”/distributes the analyte signal over many, many 
peaks, and reduces the sensitivity of the MS measurement. Thus the ability to use 
techniques/conditions to control the charge states observed can be very beneficial to effective 
protein ESI-MS.48,49  
In addition to the protonation/deprotonation achieved by positive/negative mode ESI (respectively), 
other charge carrying atoms can be adducted/removed from an analyte to achieve an observable 
charged species. The most notable of these species being free/solvated Sodium (Na+), which has 
been a notorious adduct in ESI since its inception. Free Sodium can be found ubiquitously in all 
57 
 
experimental environments, from solvents, to glassware, and plastic-ware, down to fingerprints 
from the sample preparer. Sodium/salt adducts are usually expressed/observed close to the 
protonated/deprotonated peak and in a relatively salt-clean sample will be minor compared to the 
protonated/deprotonated peak of interest, (see Figure 1.30 zoom in, above), though if the sample 
contains too much salt/has been handled badly this balance can change and the salt-containing 
peaks can easily dominate a given spectrum causing the purely protonated/deprotonated peak to 
become unobservable, which can lead to false-positive/negative results for protein identification 
based purely on searches for protonated/deprotonated species. Though some researchers have 
found salt adducts to be particularly useful in the effective study of certain compounds, particularly 
small molecules which are not amenable to protonation/deprotonation (due to lack of functional 
groups/stabilising conformation), but can accommodate certain salt ions.50 
The use of salt/buffer solutions to stabilise protein conformations, and certain protein-protein 
interactions, which can be of great biological importance, can create challenging ESI—MS conditions. 
The so-called Native-MS method, is growing continuously as researchers continue to study protein 
conformations and delicate interactions using mass spectrometry, but the use of salts/buffers and 
non-denaturing conditions (no organic solvent, no acids, and low ESI source temperatures) inevitably 
causes large numbers of salt/buffer adduct peaks from adducted/sequestered salt ions, distributes 
ion signals, and lowers observed charge states due to either in-effective ESI desolvation and/or 
densely folded protein conformations limiting availability of basic/acidic amino acid side chains and 
reducing solvent-accessible surface area.51–53  
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1.6.1.4 nano-Electrospray ionisation (nESI): 
A nano-scale application of ESI has been developed over the years to provide a lower-sample 
consumption while retaining reliable and abundant ion signal, thus an increased sensitivity. The so-
called nano-ESI (nESI) is usually achieved using a much smaller diameter orifice emitter than 
standard ESI (~10-100um) and thus smaller droplets are formed after the Taylor cone emission 
during the electrospray process.54 The generation of smaller ESI droplets enables more effective 
desolvation down-stream, and tends to result in a more effective/efficient conversion of analyte to 
ions, resulting in a more sensitive ionisation source. 
 
Figure 1.32: nano-ESI source layout, unlike standard ESI there is no syringe pump to drive the 
sample through the emitter, nor any nebulisation gas needed to assist in generation of the ion 
plume. Sample is drawn out from the emitter tip to the MS inlet via a potential difference applied 
between the two at either the liquid sample (via a wire, shown) or on the emitter itself (requires 
metal/conductive coating). Reproduced from Hiraoka et.al.55 
Though largely similar to standard ESI, nESI has a few key features and differences to ESI beyond the 
emitter orifice diameter. Due to the low flow rates used (nano-litres/minute, hence nESI), nESI does 
not require an additional inert nebulising gas such as nitrogen to achieve an effective ESI plume. 
Though it has been clearly calculated and shown that flow rate does not affect the length of a Taylor 
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cone,41 the creation of smaller droplets initially eliminates the need for further nebulisation. Due to 
the creation of smaller highly charged droplets earlier in the ESI process, nESI emitters are placed 
closer to the MS inlet than ESI emitters, as they do not require nearly as much space to allow the 
resulting plume to expand and produce ions. As a result of their closer proximity to the MS inlet, 
nESI typically uses much lower voltages to achieve effective ionisation (500-1800V for nESI vs 3000-
6000V for ESI). nESI can also be achieved at lower source temperatures (due to less desolvation 
needed vs the large droplets formed in ESI), this is particularly advantageous for achieving Native MS 
of peptides and proteins, which may denature if heated to higher temperatures.  
nESI tends to use pulled Boro-silicate glass/metal/silica emitter tips, which can often be created in-
house via use of a heated capillary puller (also used for many electrochemistry experiments), or en 
masse from external companies, making nESI tips much more accessible and disposable than ESI 
emitters. Unfortunately nESI tips are generally not re-useable (unlike ESI emitters) and so need to be 
disposed of after use, however this does limit cross-over contamination, and nESI tips can be 
effective made/purchased for £0.05/£1 respectively, and so are economically viable for disposable 
use. The nESI emitter tips are then either coated with a conducting material (e.g. gold sputtered), or 
are bound to an internal conducting wire, to provide electrical contact with the analyte solutions and 
complete the ESI “circuit”.  
1.6.1.5 Matrix Assisted Laser Desorption Ionisation (MALDI): 
MALDI, invented by Karas & Hillenkamp et.al.56 while also developed by Koichi Tanaka (winner of the 
Nobel Prize for said work), along with ESI, are the two most-commonly used soft-ionisation 
techniques used in contemporary mass spectrometry. Unlike ESI, MALDI uses a solid sample, and is 
ionised within a chamber that is under vacuum, not atmospheric pressure (AP) (though MALDI has 
been achieved at ~1mbar by O’Connor et.al.57,58 and at ~AP by Laiko et.al.59) MALDI relies on the 
laser-activation of matrix molecules which are in close proximity to analyte ions of interest, the 
laser-induced plume created just above the point of impact contains protonated/deprotonated 
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matrix ions and neutral analyte ions.60 The protonated/deprotonated matrix ions can then undergo 
proton-transfer reactions to protonate/deprotonate the analyte molecules into (mostly) singly-
charged ions, which are then extracted and transferred into the mass analyser for detection etc. as 
shown in Figure 1.33 below: 
 
Figure 1.33: MALDI process involving the ablation of a surface with a UV laser, activating and 
ionising MALDI matrix molecules into ions, which can then undergo proton transfer reactions with 
nearby analyte molecules to produce detectable analyte ions, usually in the 1+ charge state. 
Courtesy of Bruker Daltonics, Bremen, Germany. 
Common MALDI matrices include aromatic species (to absorb the UV laser radiation used) 
functionalised with acidic/basic groups (for proton-transfer reaction capability), some commonly 
used matrices are shown in Figure 1.34, below: 
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Figure 1.34: Common compounds often used as a matrix for MALDI-MS, note that MALDI matrices 
usually contain a benzene ring to assist in absorption of the UV laser photons. Matricies labelled 
with an asterix have been shown to be effective matricies for MAI-MS (below) as well as MALDI-
MS. Reproduced from Trimpin et.al.61 
In order to achieve effective MALDI generated analyte ions, effective mixing of the MALDI matrix 
ions and analyte molecules is essential, and so mixing of the two solutions either in a solution phase, 
or in a multiple-layer solution deposition process is usually used. The sample is “spotted” onto an 
inert surface (usually a stainless steel MALDI “target”) and then allowed to dry, this can then be 
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covered using a solution of the MALDI matrix, which after drying will form the solid MALDI “spot”, 
able to be ionised and analysed. The optimisation of MALDI sample preparation and creation of 
effective layers onto targets can be a long process and can yield varying results, but has been 
simplified by the use of vapour/spray deposition devices, which can automatically coat targets with 
matrix solution after manual transfer and drying of the analyte sample.  
Unlike ESI, which is a continuous process in terms of ion generation, MALDI generates ions in pulses, 
which are dictated by the laser pulses used to activate the matrix. Thus MALDI ions plumes can be 
sampled individually, transferred into the mass analyser and provide mass spectra from a single ion 
cloud, without the waste of sample consumed/ions generated outside of the sampling period like in 
ESI/EI. The sampling of individual ion clouds via MALDI-MS has allowed for very low detection 
limits/high sensitivity experiments, often down to atto-moles, and even so-called “single-ion 
detection” experiments using MALDI-ToF-MS. 
The main disadvantages of MALDI are a) MALDI, for the vast majority of cases, will only produce 
singly charged ions, which can limit the range of effective/optimal detection for most instruments,  
b) ions created are much “hotter” than those created by say ESI, meaning the ions have more energy 
acquired during the ionisation process and thus usually require more collisional cooling and/or will 
be harder to handle/stabilise in other parts of the MS instrument (e.g. in effective trapping within 
the ICR cell), and c) the activation of the matrix molecules causes ionisation of both matrix molecules 
and other species, producing a high number of non-analyte peaks in the resulting mass spectrum, 
often referred to as a high “matrix background”. The matrix-associated peaks are generally singly 
charged peaks of low m/z (50-500m/z), and so can cause significant problems when attempting to 
analyse molecules at low m/z and/or small molecules.60 Despite these disadvantages MALDI-MS is a 
thriving ionisation technique, which has considerable application in analysis of small molecules, 
complex mixtures (simplified by producing only singly charged species), biomolecules, and especially 
polymer samples, as the creation of singly charged ions at high m/z (3000-300,000 m/z, away from 
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the matrix background) is ideal for showing the varying length of polymer synthesis reaction 
products, and has been effective at calculating molecular weights, statistical averages for products 
(Mn and Mw), dispersities of products (PDI), and even functional end groups present on reaction 
products.62  
1.6.1.6 Niche ionisation methods: 
Other, less commonly used ionisation techniques have found application in the analysis of 
particularly specialised/difficult samples that may be more compatible with certain sample types 
than ESI, MALDI etc. (e.g. analysis of solid samples). These ionisation methods are not utilised for 
any analysis within this thesis and are included very briefly, not comprehensively, simply for 
reference.  
Atmospheric-Pressure Photo Ionisation (APPI) is based upon spraying a solution phase 
sample, usually at a high flow rate (compared to ESI), through a small orifice, ESI like probe, with a 
nebulising gas, creating a Taylor cone and plume (as with ESI). The resulting plume is then exposed 
to a high energy (usually krypton) UV lamp, which excites analyte and solvent species into an 
electronically excited state, causing electron transfer and fragmentation reactions, and generating 
detectable ions.19,63 The high energy lamp can be altered for the effective analysis of different 
compounds if needed, the krypton APPI lamps usually emit photons with an energy of ~10.6eV, 
which have been shown to effectively ionise a range of compounds, including 
hydrocarbon/petroleum mixtures.19 APPI has found particular application for analysis of complex 
mixtures due to its ability to ionise both polar and non-polar species within petroleum/oil derived 
samples.19 However the production of both protonated and radical species for many analytes can 
complicate spectra, and may cause some fragmentation of analytes/solvents, also complicating data 
analysis and hindering accurate assignment of components within the solution. The ionisation setup 
for APPI is shown below in Figure 1.35, next to the more commonly used atmospheric pressure 
Chemical Ionisation, discussed previously: 
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Figure 1.35: Ionisation sources for Atmospheric-Pressure Chemical Ionisation (APCI) and 
Atmospheric-Pressure Photo-Ionisation (APPI). Courtesy of Bruker Daltonics, Bremen, Germany. 
Secondary Ion Mass Spectrometry (SIMS) is a long standing technique which utilises a 
~150nm charged beam of ions impacting a surface to cause secondary ionisation of species within 
the target region, the once surface-bound ions can then be attracted to the MS instrument and 
detected, in a similar fashion to MALDI generated ions (above). SIMS is well known for its spatial 
resolution – the ability to ionise a very well defined and small area at a time, this inherent accuracy 
has allowed SIMS to be widely applied in the field of Mass Spectrometry Imaging (MSi). MSi involves 
the ionisation of many individual locations on a surface and the correlation of the resulting mass 
spectrum with each point, allowing a sampling of an entire region to provide “chemical maps” to 
show distribution of many species. SIMS with high spatial resolution has enabled MSi of sub-cellular 
components and analysis thereof.64  
 Matrix-Assisted Ionisation (MAI) is a recent addition to the atmospheric pressure ionisation 
techniques, and was again a fortunate discovery during routine MALDI experiments. MAI is a very 
similar process to MALDI (described above) but does not utilise a matrix-activating laser to ionise 
species, instead MAI relies on the matrix itself and the vacuum of the instrument inlet to ionise 
analytes of interest and pull them into the MS for analysis. This seemingly unlikely process has been 
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proven to not only be effective at ionising a range of analytes very easily, but also with reduced 
sample preparation compared to MALDI-MS, and reduced tuning of source conditions (compared to 
ESI and nESI-MS), making MAI a very attractive choice for routine/solid samples and non-specialised 
personal. MAI has been shown to ionise small molecules, polymers, peptides, and even 
proteins.61,65,66,67 Most interestingly; unlike MALDI, from which the technique is derived, MAI can 
easily achieve multiple charge states on peptides, proteins, and large polymers, which is in stark 
contrast to MALDI’s well-known 1+ charge state preference. The multiple charge states produced by 
MAI are still a topic of debate, but suggest a distinctly different mechanism of ionisation to 
traditional MALDI. It is currently believed that the matrix used for MAI must have a large 
“triboelectric effect” where shattering analyte containing matrix crystals causes charge separation 
with sparks and allows excess charge to be transferred to analytes, causing ionisation. 
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1.6.2 Movement of ions: 
The range of ionisation sources available to contemporary mass spectrometry allows an 
extensive range of analytes to be transformed into detectable ions readily, from ESI and CI for small 
and/or non-polar molecules, ESI/nESI/MALDI for peptides, proteins, and polymers, to APCI and APPI 
for complex hydrocarbon/petroleum mixtures to name just a few examples of use, with many 
species ionisable via many different methods. However many of these sources operate at 
atmospheric pressure (ESI, nESI, APCI, APPI etc.), and many instrument configurations require the 
ionisation source to be a distance from the ICR cell/mass analyser in order to operate multiple 
pumping regions needed to achieve the ultra-high vacuum (UHV) needed for accurate mass 
measurement in an ICR cell (and other mass analysers). 
1.6.2.1 Ion funnels and ion skimmers: 
When ions are generated they tend to be created in large, distributed clouds, e.g. an ESI plume, or 
MALDI ion plume. These spatially distributed ions are difficult to transport and handle within a mass 
spectrometer, and ideally would be more confined and coherent so that they can be moved as tight 
ion packets. Older mass spectrometers utilised simple cone-shaped conductive metal orifices, known 
as skimmers. As ions exit confined space the ion plume expands rapidly, a process known as 
supersonic adiabatic exspansion,68,69 these ions are thus disperse and again difficult to handle. 
Skimmers are designed to repel ions which deviate from the axis of ion transport and to only allow 
the centre of the expanded plume to pass through the small (~≤1mm) orifice. The voltage applied to 
the skimmer repels ions outside of this centre and increases the energy of those passing through. 
Thus the Skimmer should be considered as a sampling ion optic rather than a confining one. 
Skimmers were effective at producing confined ion clouds and were also useful in reducing the 
orifice between pumping regions (allowing separation and low vacuum pressure to be reached).70 
Increasing skimmer voltages was also an effective means of causing ion-skimmer collisions, which 
were shown to be effective at causing desolvation of large, solvated ESI ions, and clusters, which did 
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not produce individual ions as desired during the ionisation process.71 In order to advance towards 
this Smith et. al.72 developed the ion funnel; an arrangement of capacitively-coupled metal 
plates/rings held at alternating voltages to attract and direct ions from a wide starting area and 
towards a confined exit (hence funnel). Unlike the skimmers, ion funnels were focusing optics, not 
sampling optics, retaining more ions than traditional optics. The ion funnel development was able to 
improve the transmission of generated ions ~10 fold, and thus boost the sensitivity of mass 
spectrometers.72 Although Ion funnels are effective at focusing ions, they are not suited to pure 
transportation as they do not attract ions towards the target orifice. Ions are usually accelerated 
through the ion funnel barrier via use of a repulsive plate/voltage on-axis with the funnel plates. 
 
Figure 1.36: representation of an orthogonal ESI-capillary-ion funnel source for MS. The figure 
shows that although both neutral (yellow) and ionised (red) species travel through the heated 
capillary, even after desolvation, the orthogonal injection geometry ensures that neutral species 
are diverted away from the directing ion funnel plates and allows only the ions to be 
collected/directed further into the mass spectrometer for detection, greatly reducing background 
noise and/or interference from neutral molecules. Courtesy of Bruker Daltonics, Bremen, 
Germany. 
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1.6.2.2 Multipoles: 
Unfortunately, although skimmers and ion funnels can attract and focus ions into other regions 
inside a mass spectrometer, they are not adept at transporting or storing generated ions, nor 
filtering them for analysis. Instead charged, alternating-polarity rods are used as effective “ion 
pipes” to confine ions radially and guide them through vacuum regions inside mass spectrometers. 
Taking a quadrupole (4 charged rods) as an example; by attaining the same polarity as the ions in 
question the rods can repel ions away from two “sides” of the ion guide and prevent radial ejection, 
the polarity is then switched a moment later to repel the ions from the other two sides and attract 
them in the opposite direction. Thus the ions are constantly repelled and attracted, but kept to 
within the centre of the guide and are effectively radially confined. The frequency of the polarity 
switching and the amplitude (often given in terms of voltage peak-to-peak (Vp-p)) used can be tuned 
to stabilise the transmission of different m/z ranges, to achieve the desired range for analysis. 
The stabilisation of ion transmission through multipoles is dictated and controlled via the Mathieu 
stability diagram, below, and the desired range of transmission can be effectively defined by 
tuning/varying values of a and q as shown in Figure 1.36: 
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Figure 1.37: Mathieu stability diagram for a given ion in a quadrupole (left) and typical ion 
trajectories for the different labelled areas (right).  
Evidently achieving transmission of all desirable ions (above a certain low mass cut off – qz=0.908) 
seems possible by simply setting the value of Vdc to 0, and then using different values of q to alter 
the range. However, should one want to only transmit a smaller range of ions then the user can 
simply set the centre of the stable region to the peaks/range of interest (using q) and then increase 
the value of a to narrow the stability region enough to achieve only the desired transmission range. 
The use of m/z specific stability regions is the basis of quadrupole mass filtering, and thus the 
quadrupole mass analyser, simply, a certain m/z scan range is defined (e.g. 50-500 m/z) then the 
values of a and u are tuned to stabilise the first value in the scan range (50 m/z in the example), ions 
are allowed to transmit through the multipole for a set amount of time (usually microseconds to 
milliseconds), the transmitted ions are then detected via a charge detector such as an electron 
multiplier device, then the next m/z value (51 m/z) is stabilised and the process is repeated for the 
entire range of interest. Once the entire range has been sampled at each desired m/z value the mass 
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spectrum can be produced by simply correlating the magnitude of current detected at each time to 
the correct m/z stabilised at that time, thus creating a mass spectrum of counts/intensity vs. m/z. 
 
Figure 1.38: Basis of quadrupole analyser/transport operation, by altering the voltages and 
frequencies applied to the quadrupole the region of stability changes, and thus the species able to 
traverse the entirety of the optic also changes. Once carefully calibrated the ions of a certain m/z 
can be transmitted with voltages corresponding to their m/z and thus if they successfully move 
through the optic, the m/z can be deduced. Reproduced from Chrome-academy 
(http://www.chromacademy.com/lms/sco36/Fundamental_LC-MS_Mass_Analysers.pdf, accessed 
28/03/2016). 
Beyond quadrupoles, hexapoles and octupoles have also been used for ion transport and filtration, 
however it has been shown that although possible hexapoles and octapoles are not as efficient at 
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filtering ions as quadrupoles and are more suited to purely ion transport. Higher order multipoles 
have been shown to be more effective at pure ion transmission than quadrupoles due to a more 
distinct energy barrier as ions approach the poles’ electric confinement region. 
Multipoles for long distance ion transmission, e.g. into the bore of a large superconducting magnet 
to an ICR cell, were shown to be a critical improvement over previous electrostatic designs which 
simply relied on acceleration of ions, “steering” of the ion cloud using static lenses and then 
“catching” of the ions at the other end (the ICR cell), as the optics were notoriously difficult to tune 
and accelerated ions to such high energy that upon capture they still retained a significant energy 
and were still “hot”, which hinders formation of coherent ions packets, and thus ICR performance. 
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1.6.3 In cell isolations/manipulations: 
Before FT-ICR MS was effectively interfaced with quadrupole and multipole technology mass 
spectrometrist's were still able to conduct isolation and ion manipulation experiments within the ICR 
cell due to the ability to use excitation fields within the trap. The ICR cell adds an enormous amount 
of flexibility to mass spectrometry analysis as it enables the control over ion packets and the ability 
to manipulate them in a variety of ways.  
In-cell isolations were conceived from the same methodology as excitation/detection pulses, if ions 
are excited too much they will hit the ICR cell plates, become neutralised and will then be pumped 
out of the cell as neutral gas molecules. As a result one can simply excite unwanted ions to an 
extreme degree, forcing their ejection from the ICR cell, ions of interest can then be excited to a 
lower (normal) radius and be detected as usual.  
1.6.3.1 Sweep, shots, and resonant ejections: 
The application of a large/extreme pulse which is resonant to unwanted ions will result in ejection of 
unwanted ions (as described above). The application of these pulses is usually presented in two 
ways; either a broadband excitation of every undesired species with a small window/notch centred 
on the ion of interest (i.e. the species to remain post-excitation), this excitation profile will excite a 
broad range of unwanted ions and ideally leave the ion(s) of interest, and is known as a sweep 
excitation. The inverse of this procedure is also very common; the application of a small, define, 
pulse centred on an unwanted ion/multiple ions, causing excitation of small windows/notches within 
the mass spectrum, known as a “shot” excitation, multiple shots are easily programmable and 
applied to an individual ion population, the only limiting factor being the overall time, as each shot 
excitation waveform is applied individually, so 10 shots will take ~10x the time as one shot ejection. 
The main disadvantages of using sweep/shots ejections in an ICR cell are the same as previously 
mentioned for a standard chirp broadband excitation procedure; a non-ideal excitation waveform. 
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The sweep and shots ejections use the same profile as the chirp excitation, meaning the beginning 
and end of the profile is distorted and the central section is non-linear, although the ejection profile 
is effective at exciting the species of interest, it may also eject species close to the boundary edges. 
In a usual broadband excitation slight deviations in excitation profile may have little effect if they are 
a distance from ions of interest, however isolation experiments usually require defined isolations 
and the ability to separate species which are close in m/z value, meaning a well-define excitation 
pulse is needed. As a result resonant Sweep and Shots isolations are used usually for ions which are 
separated from other species by a reasonably large m/z range (for an isolation, e.g. 10-20 m/z) and 
so will not be affected by the “horns” distorting the excitation pulse. 
1.6.3.2 SWIFT: 
As mentioned previously SWIFT can be used as an accurate means of exciting ions of interest using 
an excitation profile that is better defined and closer to the ideal rectangular excitation desired 
(Figure 16 above). Though SWIFT is an excellent tool for the excitation of ions for detection,73 it has 
also been shown to be very effective at high-resolution isolations inside the ICR cell.74–76 Back 
calculating a SWIFT pulse from a desired ejection profile is a more accurate means of creating a 
notched isolation pulse, either leaving the ion(s) of interest by ejecting everything else from the ICR 
cell, or by ejecting individual species by creating a smaller ejection region containing the unwanted 
ions. Thus SWIFT can be used to replace both sweep and shots resonant ejections. Due to the more 
ideal ejection pulse, SWIFT has been shown to achieve isolation resolving powers in excess of 
29,000-39,000.25  
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1.6.3.3 Multi-CHEF: 
In addition to SWIFT other In-Cell Isolations (ICI’s) have been developed to provide targeted/multi-
stage Isolation experiments for mass spectrometry. Correlated Harmonic Excitation Fields (CHEF) 
was a method developed by de Koning et. al. in 1997.77 CHEF (single isolation) and Multi-CHEF 
(multiple CHEF isolation events) ejection of ions are achieved by on resonant excitation of unwanted 
species and off-resonant excitations of the species of interest for controlled (correlated) amounts to 
avoid the target gaining energy through off-resonant excitations and being subsequently ejected 
from the ICR cell, resulting in ion loss at smaller isolation window sizes (a key limiting factor in 
quadrupole isolations). Inadvertent energy gain during in cell isolations can be high enough to trigger 
ion-molecule reactions between the isolated ion and background gas in the ICR cell.77 Single/sweep 
excitation profiles, even if tailored to avoid excitation of certain (target) species, will cause 
unwanted excitation of ions. CHEF avoids this unwanted excitation by calculating the unwanted 
excitation of the target species and adjusting the Texcitation and/or the excitation field magnitude (/Vp-
p) to excite and de-excite the retained species an integer number of times. As a result the desired 
ions will be excited and de-excited an even number of times and thus be returned to the centre of 
the ICR cell after the full excitation (/isolation) pulse. For convenience either Texcitation or excitation 
field magnitude can be set and the other varied for the intended target species. CHEF Isolation 
pulses can be applied for many species, modifying the waveform used with the addition of each 
target. Examples of these waveforms and the resulting pulses are shown below in Figure 1.39: 
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Figure 1.39: Examples of CHEF waveforms (left) and CHEF pulses (right) for the isolation/ejection 
of species from an ICR cell using CHEF. Reproduced from de Koning et. al.77  
The advantages of Multi-CHEF are centred around its ability to eject/isolate a varying number of 
species (by application of more and more modifications to the CHEF pulse), the extraordinary 
isolation resolving power (>60,000, c.f. SWIFT = ~29,000), and the zero ion-loss during isolation, 
which follows through from theory to application. The only two disadvantages to Multi-CHEF ICI are 
that the isolation of many species/high resolution ICI requires the use of long CHEF pulses, which 
increases duty cycle and can result in ion loss of higher pressure FT-ICR MS instruments (though this 
shouldn’t be an issue for contemporary FT-ICR MS). CHEF pulses can also slightly alter the ion 
position of isolated species retained within the ICR cell post-activation, though not documented this 
effect can alter tuning parameters needed for particularly sensitive and difficult species during in-cell 
MS/MS (see Chapters 3 and 6 for particularly challenging examples). Regardless Multi-CHEF is a very 
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versatile and often under-used technique widely available on commercial and bespoke FT-ICR MS 
systems, boasting ultra-high resolving power isolations (e.g. shown below in Figure 1.40), and zero 
ion loss,77 Multi CHEF can even be used to isolate individual isotopes of species, which is especially 
useful for overlapping isotopic distributions, an unfortunately common occurrence in MS and 
MS/MS experiments. 
 
Figure 1.40: Example of UHR-CHEF isolation performed on particularly close peaks separated by 
just 1.5mDa. Reproduced from de Koning et. al.77 
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1.7 Tandem Mass Spectrometry (MS/MS): 
As shown above in many cases Mass Spectrometry is a powerful tool for the analysis of both simple 
and complex mixtures, providing mass information on analytes present, and able to perform 
interesting ion manipulation experiments, all to a very high degree of accuracy and performance. 
However this analysis is, for the most part (and for all soft-ionisation analysis), based on the overall 
mass of a particular analyte and although fine structure analysis has been extremely useful in 
providing elemental compositions for (mostly small molecule) species, the analysis of larger, 
particularly biomolecule species is hindered by the different combinations of elements possible as 
mass increases, and the overall mass providing less and less chemical information as the size/mass 
of the analyte increases. However as shown above, techniques such as Electron Impact ionisation 
(EI) have been able to provide both overall mass and structural information for decades based upon 
the fragmentation of analytes produced, with the fragments providing insights into functional 
groups present, branching structures, and stability of remaining fragments.78 However 
fragmentation of analytes during ionisation limits MS analysis to pure/pre-separated compounds in 
order to avoid overlapping fragmentation peaks produced by different analytes. To this end selected 
fragmentation of species separated inside the mass spectrometer (using multipole filtration and/or 
in-cell-isolations, both described above), followed by individual analysis of the parent ion (species 
isolated) and fragment ions has become widely applied and known as tandem-mass spectrometry 
(MS/MS).  
The standard MS/MS experiment is based upon the observation of ions during a normal MS 
experiment, followed by selected isolation of a/many target compound(s) by a mass filtering 
multipole (usually a quadrupole), after the species of interest has been successfully isolated it can be 
selectively fragmented using a range of techniques (discussed below) to produce an MS/MS 
spectrum, analysis of which can provide detailed chemical and structural information of the isolated 
ion. Following this the next species of interest can then be isolated and the process can be repeated 
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until all observable species have been fully characterised by both MS and MS/MS techniques. This 
process is summarised in Figure 1.41, below: 
 
Figure 1.41: Standard acquisitions taken during an MS/MS experiment. The full mass spectrum of 
all species observed in a sample (a) followed by isolation of a particular species of interest (e.g. via 
a quadrupole mass filter) (b), and finally fragmentation of the isolated species using an MS/MS 
technique – electron capture dissociation (c) subsequent analysis of fragments reveals information 
Mass Spectrum of species: Isolated individual species: 
Tandem Mass Spectrum of Isolated species + assignment: 
Q-isolation 
a) b) 
c) 
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of species structure and composition. Examples shown are from Myoglobin protein (16.9 kDa) 
spectra. 
MS/MS techniques vary greatly and can be based on photons, electrons, and collisions, to name a 
few, applications, specifically to biomolecule characterisation, have made a huge impact on the field 
and allowed detailed characterisation of countless compounds. Many different MS/MS techniques 
are discussed below, mainly with a focus on biomolecule characterisation to inform results recorded 
later in this thesis, though many techniques have been shown to be very effective for characterising 
a range of molecular species. 
1.7.1 Collisionally Activated Dissociation / Collisionally Induced Dissociation (CAD/CID): 
The discovery of Collosionally Activated Dissociation (CAD), also known as Collisionally Induced 
Dissociation (CID) was accidental, but opened up the entire field of tandem mass spectrometry. CAD 
was first achieved by Keith Jennings in 1968, and was first noticed during routine scans of small 
molecules, Jennings noticed that there were additional peaks outside the target compound, 
eventually finding that these were caused due to collisions induced by background gas which was 
present inside the MS from a leaking vacuum seal. From this serendipitous discovery and eventual 
application, CAD can now be induced voluntarily by intentionally colliding species of interest with 
background gas molecules and causing fragmentation, this is usually achieved by using an opposite 
polarity voltage to accelerate the ions into a stationary cloud of “collision gas”, which is usually an 
inert gas such as Argon/Neon/He/N2. Forcing ions of interest to collide with neutral gas molecules 
will cause and energy transfer and “heat up” the ion of interest (and the gas molecule, but these are 
continuously added/pumped away). A single collision is rarely enough to cause any dissociation, 
unless extreme voltages are used, however each ion will undergo many collisions as it enters and 
passes through a collision cell (trapping multipole), with each collision increasing the internal (mostly 
vibrational) energy of the ion slightly more, causing a “slow heating” of ions. Eventually the 
deposited energy will exceed the bond strength of a bond within the analyte and the species will 
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dissociate, causing fragments, the contents of the collision cell, both parent ions and fragment ions 
can then be transferred to the mass analyser, whatever configuration that may be, and be detected, 
providing an MS/MS spectrum (Figure 1.42 below). Energy transferred to the ion of interest can be 
calculated using equation 13 below: 
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑝𝑜𝑠𝑠𝑖𝑏𝑙𝑒 𝑒𝑛𝑒𝑟𝑔𝑦 𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑟 =  
𝑚𝑛𝑒𝑢𝑡𝑟𝑎𝑙
𝑚𝑛𝑒𝑢𝑡𝑟𝑎𝑙+𝑚𝑖𝑜𝑛
∗ 𝐸𝑙𝑎𝑏    eqn. 13 
Where mneutral is the mass of the neutral species used as a collision gas, mion is the mass of the 
charged species being accelerated and dissociated, and Elab is the energy used to accelerate the ions 
into the collision gas. Each CAD collision typically deposits <0.1eV of energy into the accelerated 
species, making it a very slow-heating, multiple collision method to dissociate ions. 
 
Figure 1.42: CAD MS/MS spectrum of Erythromycin A (a), and the assigned fragments mapped 
onto the molecular structure (c). Reproduced from Wills et.al.79 
As mentioned, CAD slowly adds energy to an ion, over the course of many, many collisions, each 
depositing a small amount of vibrational/kinetic energy into the ion, eventually causing bond 
dissociation.  Due to this many collision/slow heating mechanism, the ions are brought up to a 
dissociation energy, and the bond to break in the molecule will be the lowest energy bond, as that 
will be the energy reached first during the slow heating process, known as an ergodic dissociation.80 
Because of this ergodic mechanism, the CAD fragmentation of ions is not random, but is dictated by 
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bond energetics/stability and can a) provide information of bond strengths within the system b) be 
predicted based on bond energetics. For small molecule CAD MS/MS the fragments produced differ 
greatly from the radical-directed fragmentation caused by EI ionisation (above), but can still offer a 
great deal of information dictated by functional groups etc. and has been shown to be an effective 
tool for both singly charged and multiply charged small molecule analytes. 81–83 Small molecule CAD 
MS/MS has also been shown to differ greatly depending on the charge-carrying cation adducted to 
ESI generated small molecules, protonated species fragment very differently to sodiated, lithiated, 
lotassiated, and cesiated species, which can form different fragmentation patterns and provide 
complementary (different but supportive) information about the target species.50  
CAD can also be achieved within an ICR cell, and relies on the acceleration of ions via excitation to 
collide with gas molecules pulsed into the ICR cell. Unfortunately in-cell CAD MS/MS raises the 
pressure inside the ICR cell dramatically and requires a pumping delay to reduce this pressure before 
excitation and detection. 
1.7.2 MS/MS of peptides and proteins: 
Biomolecule CAD MS/MS was a huge step forward in biomolecule characterisation and is currently 
the most widely used fragmentation technique for the characterisation of peptides, proteins, DNA, 
RNA, metabolites, and everything in-between.82,83 Unlike small molecules the majority of 
biomolecules are polymeric species (biopolymers) and so are constructed from repeating units, 
often with varying functional groups, but with a consistent/repeating chain/backbone. For peptides 
and proteins these repeating units are amino acids, naturally zwitterionic species that have a core 
amine-carbon-carboxylic acid structure, differentiated only by the carbon-linked side chain group 
(known as the residue/side chain). The individual amino acids link/bond via condensation reactions 
to form amide linked biopolymers, i.e. peptides and proteins, which can then be further expanded 
upon/modified/bound to other species post-transcription within a cell. During MS/MS of peptides 
and proteins the most commonly observed fragmentations occur along the amide-linked backbone, 
with CAD MS/MS causing fragmentation at the amide bond, the weakest bond available due to the 
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ergodic fragmentation mechanism. These amide bond dissociations cause corresponding fragments, 
known as b or y ions (for an amide bond cleavage), with different bond cleavage points producing 
different fragment ions. The nomenclature for peptide/protein MS/MS ions/fragmentation has been 
changed iteratively over the years, however most contemporary MS/MS groups use the Roepstorff 
/Zubarev nomenclature, summarised below: 
 
 
Figure 1.43: Summary of the Roepstorff nomenclature for peptide/protein MS/MS cleavage of 
backbone bonds. Different MS/MS techniques can cause cleavage of different bonds (see below). 
The nomenclature is based upon which bonds are cleaved during the poly(aminoacid) MS/MS 
fragmentation and which part of the molecule resides in the remaining fragment. For instance 
cleavage of the C=carbonyl carbon to nitrogen bond in Figure 1.43 will produce a b-ion towards the 
N-terminus and a y-ion towards the C-terminus, though both may not be observed in the resulting 
MS/MS spectrum if they do not possess a charge. If the bond mentioned was cleaved between the 
2nd and 3rd amino acid in a tri-peptide (e.g. R-G-K) then this would produce a b2-ion as the bond was 
cleaved at amino acid position 2 (numbering from the left for a/b/c ions), and is a b-type ion. The 
other side of this fragmentation would produce a y1-fragment ion, as the bond was cleaved at 
position 1 (numbering from the right for x/y/z ions) and is a y-type ion. This nomenclature can thus 
be easily extended to any size of poly(amino acid) species by simply numbering from the two termini 
and deciphering which fragments have been generated. The fragments can then be summarised in a 
fragmentation map. 
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Figure 1.44: representation of peptide backbone showing the bonds cleaved during CAD MS/MS 
and the type of fragments produced (highlighted). 
The main fragmentation pathway for CAD MS/MS of poly(amino acids) is to form b/y ions, however 
these fragmentations/ions can also cause small neutral molecules losses (such as loss of H2O, CO2, 
CO, NH3, etc.).
83 Extra small molecule/side chain loss pathways increase the complexity of MS/MS 
spectra, though can provide limited information on the amino acids still present within the fragment 
(as only certain amino acids produce each type of neutral loss). CAD MS/MS can also cause 
fragmentation not just in one location in a peptide/protein, but subsequent collisions after the initial 
fragmentation can cause fragmentation elsewhere, e.g. further down the poly(aminoacid) backbone, 
known as secondary/internal fragments83), these fragments can be very difficult to assign accurately 
as the combinations of amino acids lost from either end of a chain to form an internal fragment 
increase dramatically with increasing chain length, thus often are not assigned and become non-
sequence informative fragments, which only serve to increase spectral complexity and reduce ion 
signal in pathways that are more useful for sequence analysis.83  
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Figure 1.45: Example CAD MS/MS spectra of the peptide Substance P (RPKPQQFFGLM) in the 1+ 
(a) 2+ (b) and 3+ (c) charge states, showing the range of ions types detected and the variation of 
the observable fragments with different charge states. Reproduced from Boyd et.al.84 
Example CAD MS/MS spectra for the peptide Substance P (SubP) in the 1+, 2+, and 3+ charge states 
([SubP+H]+ , [SubP+2H]2+ , [SubP+3H]3+) are shown above in Figure 1.45 from Boyd et.al.84 using a ToF 
system.  b/y fragments and many neutral losses, increase of the collision voltage used would result 
85 
 
in many secondary/internal fragments and possibly sequence scrambling. Sequence scrambling is a 
phenomenon in MS/MS where the usual sequence of amino acids/monomers within a certain 
peptide/protein/biomolecule re-arrange after fragmentation to form more thermodynamically 
stable structures, but consequently form species with a different monomer sequence than before. 
Unfortunately this is a purely detrimental effect on MS/MS quality and deleterious to data 
interpretation, and has no analytical use. However, the origin of sequence scrambling is usually the 
ions’ attempt to stabilise an otherwise less stable structure (such as a given b/y ion) by rearranging 
into a more stable structure, where the charge/dissociated bond is on a group more able to stabilise 
the charge due to the electron negativity of the groups around it, e.g. a positive charge resting on a 
benzyl or tertiary carbon instead of a primary carbon/benzene ring. Sequence scrambling can have a 
seriously negative effect on efforts to characterise a biomolecule purely from MS/MS data (so-called 
“de novo sequencing”), as it produces false positives for other sections of sequence. Sequence 
scrambling can also impede efforts to pattern match/assign spectra automatically by including extra 
non-sequence peaks which will not match with the theoretical MS/MS spectra for a given sequence. 
Sequence scrambling, internal fragments, and excessive side-chain losses can usually be 
minimised/eliminated by careful instrument tuning (specifically the voltage/energy used for CAD) 
and delicate handling of ions within the MS during MS/MS and detection. 
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Figure 1.46: subsequent reactions to b-ion fragments produced during CAD MS/MS which can cause 
rearrangement (scrambling) of various functional groups within a previously linear peptide/protein 
structure, most importantly the scrambling of the original amino acid sequence.85 
CAD MS/MS has been very effective at sequencing standard peptides, and has had limited success at 
large peptides/small proteins, but tends to offer limited sequence/cleavage coverage across the 
backbone sequence, with fragmentation often limited to the termini regions.86 Despite this CAD 
MS/MS is very fast (little increase to duty cycle/scan speed of instrument), and can be used on both 
singly charged and multiply charged species, it has been very effective at identifying unknown 
peptides in biological samples  by pattern/sequence matching them against the predicted proteome 
generated from the genome of the host/source organism.83 
Unfortunately CAD MS/MS has also been known to dissociate many post-translational modifications 
(PTM’s) added after the transcription from the host genome, meaning that the key differences 
between modified and unmodified species are often lost when using ergodic fragmentations such as 
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CAD MS/MS, often due to many modifications inherently low bond strength compared to the 
peptide backbone.87,88 
1.7.3 In-Source Dissociation (ISD)/Nozzle-Skimmer Dissociation: 
In Source Dissociation is another form of CAD which can be implemented on almost any modern 
mass spectrometer and causes dissociations by using high skimmer voltages to induce collisions 
between the incoming ions and the skimmer optic.71 ISD has been effectively used to “pre-heat” ions 
before other types of MS/MS (see AI-MS/MS later), but its main use has come in the form of 
assisting in the desolvation/de-clustering of species as they enter the mass spectrometer.89,71 At high 
concentrations many solvents/salt/small molecules (e.g. ACN/CsI/arginine respectively) can form 
clusters and create high m/z species (hundreds up to thousands of m/z) and cause unexpected peaks 
in the resulting spectrum (though these can be used to calibrate MS, see calibration below). ISD has 
been shown to be an effective way of breaking up clusters and buffer/solvent adducts on large 
molecules/proteins, by inducing low energy cleavages that will not break peptide/protein backbone 
bonds or small molecule bonds, but can dissociate non-covalent interactions and buffer adduction. 
ISD has been shown to be particularly useful for the analysis of protein complexes as a method of 
dissociating the native complex before subsequent MS/MS of each subunit.90,91  
1.7.4 Infra-Red Multi-Photon Dissociation (IRMPD): 
Use of laser-generated photons has proven to be another useful way of transferring energy to 
analytes of interest, eventually causing dissociation for MS/MS analysis. 10.6um, i.e. Infra-Red 
photons have been shown to be absorbed effectively by both peptide linkage bonds, and a variety of 
small molecules, and like CAD is a multi-stage process, thus Infra-Red Multi-Photon Dissociation 
(IRMPD) was developed.92 IRMPD usually uses a 10.6um continuous-wave CO2 Laser to irradiate 
trapped ions of interest, usually in an ICR cell, though examples have been shown of use in Ion Trap 
mass spectrometers.93,94 IRMPD of ions inside ICR cells usually occurs after trapping/cooling stages 
and just before excitation/detection occurs.  
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Figure 1.47: Bonds cleaved during peptide/protein IRMPD MS/MS usually include the amide 
(CONH) bond, highlighted, causing the production of b/y ions and a series of neutral, small-
molecule losses such as H2O, NH3, CO, CO2. 
IRMPD of biomolecules such as peptides and proteins tend to produce the same types of fragments 
as CAD, though the tuning of the two techniques differs from tuning of a CAD acceleration voltage to 
the altering the laser power and laser pulse length (irradiation time) for IRMPD. Though other 
factors such as choice of collision gas, alignment of laser, and position of the ions inside the ICR cell, 
can affect the two techniques differently, they can otherwise be used to generate the same 
fragmentation data for peptides and proteins, though this changes for other analytes such as 
DNA/RNA, discussed later.  
1.7.5 Ultra-Violet Photo-Dissociation (UVPD): 
UVPD is extremely similar to IRMPD; selected ions are irradiated with laser-generated 
photons in order to excite molecules and cause dissociation. Though instead of exciting the ions 
purely vibrationally, as with IRMPD, UVPD excites ions vibrationally and electronically using a pulsed 
UV laser, ideally a 193nm Excimer laser, as shown by Broadbelt et. al.,95 though Nd:YAG lasers set at 
216nm have been shown to be viable for UVPD if the molecule is tagged with a chromophore 
capable of absorbing the  particular UV wavelength.96,97 The excited species generated by UVPD have 
been shown to dissociate into many different fragmentation channels, producing b/y ions, c/z ions, 
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and even a/x ions, making UVPD spectra very complex, but provide a great degree of fragmentation 
information in one spectrum.95 
 
Figure 1.48: Fragments produced by UVPD MS/MS of poly(amino acids). UVPD causes extensive 
backbone and side chain fragmentation, producing fragments from cleavage of all 3 backbone 
bonds. 
UVPD can be conducted in the ICR cell4 in much the same way as IRMPD, prior to any 
excite/detect pulses, but has also been implemented in accumulation cells and non-linear 
instrument configurations such as Orbitraps.95 Nevertheless UVPD is entering an increased 
resurgence in popularity within the MS field and has been shown to provide detailed information 
both for Bottom-Up (peptide) studies and Top Down (full protein) MS/MS studies, and including 
metal modified biomolecules, as shown in a recent article centred around the ability for various 
MS/MS techniques to characterise Platinated oligonucleotides.95 
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1.7.6 Electron Capture Dissociation (ECD): 
Developed in the late 1990’s by Zubarev et. al.,98 Electron Capture dissociation was 
discovered during an attempt to achieve Ultra-Violet Photo-Dissociation (UVPD), the UV laser used 
struck a metal plate within an ICR cell and caused photo-emission of electrons, which were 
subsequently captured by trapped analyte ions, causing Electron Capture Dissociation (ECD) and 
producing detectable fragments. The experiment was then repeated with a direct electron source 
and the resulting electrons caused effective dissociation of isolated biomolecules.98 ECD is based on 
the emission of relatively low energy (0.1-3eV, usually ~1eV for biomolecules) electrons into an area 
containing trapped ions of interest, the electrons are then captured by positively charged analytes, 
creating a radical-cation species (known as the charged-reduced species (CRS)). Once captured the 
radical-cation can dissociate into several fragmentation pathways, for ECD MS/MS of poly(amino 
acids), this generally results in breakage of the N-Cα bond (NH-CHR bond), producing c/z• fragment 
ions: 
 
Figure 1.49: Fragments produced by ECD MS/MS of Poly(amino acids). ECD typically causes 
cleavage of the N-Cα bond and production of c/z• fragments, though many fragmentation 
channels exist and are influenced by various factors and/or functional groups (see main text). 
The radical dissociation mechanism responsible for the creation of c/z ions from the charged 
reduced species has been the point of debate for many years, with many mechanisms proposed to 
explain the wide array of fragments, side chain losses, and neutral molecule losses resulting from 
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ECD MS/MS. However recently the most accepted mechanisms for ECD dissociations are the Utah-
Washington mechanism (UW mechanism) which explains the majority of what could be considered 
“standard fragmentations” and the Free Radical Cascade Mechanism (FRCM)99 which covers many 
other specialised circumstances. 
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Fragment Observed mass/ Da Exact mass / Da Error (ppm) 
c2 271.18770 271.187699 0.004 
c4 496.33543 496.335425 0.010 
c5 624.39409 624.394003 0.139 
c6 752.45256 752.452580 -0.027 
a6 708.43884 708.438940 -0.141 
a7 855.50728 855.507350 -0.082 
c7 899.52095 899.520994 -0.049 
c8 1046.58930 1046.589408 -0.103 
a9 1059.59724 1059.597220 0.019 
z9· 1078.56298 1078.562810 0.158 
c9 1103.61086 1103.610872 -0.011 
c10 1216.69476 1216.694936 -0.145 
[M+H]
+.
 1347.73546 1347.735421 0.029 
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Figure 1.50: ECD MS/MS spectrum of Substance P in the 2+ charge state ([SubP+2H]2+) (top). The 
parent ion at ~674 m/z is shown to capture an ECD electron to create the charge reduced species 
(CRS) observed at the far right hand side of the spectrum, with assignable fragments (middle) 
produced labelled and then summarised on the fragmentation map (bottom) 
An example ECD MS/MS spectrum of the peptide Substance P in the 2+ charge state ([SubP+2H]2+) is 
above in Figure 50, The ECD MS/MS spectrum shown is very different to that of the same peptide 
under CAD MS/MS shown previously in Figure 1.45, producing not only different fragment types (c/z 
instead of b/y), but also different cleavage sites, the key differences in the fragmentation 
mechanism (discussed below) allow CAD/IRMPD and ECD to provide complementary data to each 
other.71,98,100,101 ECD has also been shown to have a preference for capture at di-sulphide bond 
functional groups, which have previously been shown to have a detrimental effect on CAD MS/MS 
due to their impressive stabilisation of protein structure and ability to create cyclic regions within 
the biomolecules.102,103 The ability for ECD to cleave disulphide bonds preferentially, then be able to 
further induce electron capture on the now reduced-protein structure has enabled MS/MS 
characterisation of not just large biomolecules but also heavily disulphide-linked 
biomolecules.71,102,103 
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1.7.6.1 Utah-Washington ECD mechanism: 
The Utah-Washington mechanism to explain ECD MS/MS fragmentation is a combination of two 
previously released mechanisms; the Utah mechanism104and the Washington mechanism.105 While 
each individual mechanism focused on different steps in the dissociation mechanism (Utah mainly 
focusing on the electron capture steps while the Washington on the subsequent dissociation), the 
combined UW mechanism is currently the most widely accepted mechanism for ECD MS/MS 
cleavage of biomolecules. 
The UW mechanism postulates that incoming electrons are captured directly into coulomb-stabilised 
OCN amide π* orbitals via Rydberg orbitals (at Rydberg numbers 3-6) which are formed around 
charge sites.106,107  Coulombic stabilisation of the ONC π* orbital lowers the energy barrier of 
electron capture from ~2.5 eV down to an approachable level for the incoming electron (~0.8-3eV), 
thus allowing effective electron capture. Coulombic stabilisation of the π* orbital is believed to be 
caused by electrostatic interactions between the π* orbital and nearby positively charged groups, 
such as –NH3
+ or –NH2Na
+, as suggested by Simons and Sobczyk & Simons103,108,109 The coulomb 
stabilisation requires close proximity, and for the decrease in energy barrier needed the stabilising 
group would need to be within ~6 Å and can be described using equation 14:109 
𝐶 = 14.4(𝑒𝑉Å) ∑
𝑍𝑗
𝑅𝑗(Å)
𝑁
𝑗=1         eqn. 14 
Where Zj is the j
th charge; Rj is the distance between the j
th charge and the OCN amide groups; and 
14.4(eV Å) is the result of the Coulomb constant multiplied by the square of the electron charge. 
The radical can be captured at either a disulphide bond, causing reduction and cleavage of the bond, 
and generally stabilisation of the resulting radical, or at the OCN group as described above, this will 
create an aminoketyl radical in the excited state (see Figure 1.51, below). 
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Figure 1.51: representation of the Utah-Washington ECD MS/MS dissociation mechanism, showing 
the two pathways to dissociation ions can follow after electron capture at the backbone carbonyl 
group. Reproduced from Lopez-Clavijo et.al.85 
The newly formed aminoketyl radical is inherently unstable, but can be partially stabilised by 
charged groups up to 15 Å away,110 and is incredibly basic, the so called “superbase” species has a 
proton affinity of >1200kJ/mol111,85 and rapidly abstracts a proton from a charged site nearby, thus 
forming the fragile charged reduced species (CRS). The CRS can then undergo typical radical 
fragmentation to form c and/or z• ions from cleavage of the N-Cα bond, as shown above in Figure 
51. The enol-imidate intermediate is also a superbase species with a proton affinity of 
>1400kJ/mol111,112,85 and can easily abstract an available proton to form a c ion. Results suggest that 
proton transfer reactions involving c/z• species occur after N-Cα bond cleavage, not before.113 The 
UW mechanism also explains many experimental results showing that low-energy activation of the 
CRS species can produce an array of c/z• fragments, remarkably similar to the usual ECD spectrum of 
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the given species, providing evidence that the CRS is a delicate, hydrogen-bonded species containing 
many pairs of fragment species which although have been effectively cleaved via ECD are still held 
together and can be broken apart using post-ECD activation114,115 as shown in Figure 1.52, structure 
IV, below, from the Utah mechanism.103,108 
 
Figure 1.52: ECD-induced dissociation of a dipeptide according to the Utah mechanism. 
Reproduced from Lopez-Clavijo et.al.85 
1.7.6.2 Free Radical Cascade Mechanism (FRCM): 
The Free Radical Cascade Mechanism (FRCM) was proposed by O’Connor et.al. and is centred 
around uncovering the possible mechanisms that allow observable ECD-induced fragmentation of 
cyclic biomolecule species. Peptide/protein species, if fragmented by ECD MS/MS, generally follow 
the rule that one electron captured equates to one bond cleaved, due to the products formed post-
bond cleavage and stabilisation of the radical post-fragmentation. The perfect example of this rule is 
the proline effect experienced by users of ECD MS/MS,112 where the ECD-induced cleavage at the 
proline residues in peptides and proteins causes no observable fragment ions. The proline effect is 
caused by the fact that although ECD can effectively cleave the N-Cα bond within the proline 
residue, the alkyl functionality of proline is cyclic and so the amino acid may be fragmented in one 
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location, but is effectively tethered to the two sections of the poly(amino acid) backbone via the 
alkyl group, and so does not produce individual fragment ions to be detected. This process is 
summarised in Figure 1.53, below: 
 
Figure 1.53: Representation of the reaction products formed after ECD MS/MS cleavage of normal 
amino acids (top) and proline (bottom), explaining the proline effect where no fragmentation at 
the proline amino acid sites in peptides and proteins can be cleaved to produce observable 
fragments in ECD MS/MS. 
1.7.6.3 Cyclic peptides and the proline effect: 
The proline effect is an unfortunate limitation of electron-based dissociations of poly(amino acid) 
species as it reduces the number of possible cleavage sites in a biomolecule sequence. It is worth 
noting CAD MS/MS does not suffer from this Proline effect as CAD cleaves the amid bond within 
proline, which is not tethered to the backbone, and so can cause fragmentation. There is also a 
“Proline effect” for CAD MS/MS where is was noticed that CAD fragmentation was enhanced at 
amino acids neighbouring proline residues, however this is a minor effect and not of great 
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importance for the results presented herein. For the extent of the thesis work presented the Proline 
effect mentioned will be specific to the electron-based MS/MS proline effect discussed. 
Extending the same initial idea of the election-based MS/MS proline effect, ECD/Electron Transfer 
Dissociation (ETD) MS/MS of cyclic peptide species should also be similarly limited by the tethering 
of fragmented ions. If a cyclic peptide species was fragmented at one location, the ion would still be 
held together at another point in the cyclic structure, and so no smaller fragments could be 
produced/detected beyond small molecule/side chain losses, as the amino acid backbone will 
remain intact. However it was observed by O’Connor et.al.99 that ECD MS/MS of some known cyclic 
peptide species (shown below in Figure 1.54) as the [M+2H]2+ ions, showed both the capture of the 
ECD electron to produce a CRS (as expected) and side chain losses (also expected) O’Connor et.al. 
also produced an array of smaller fragments resulting from cleavage of the amino acid backbone, 
which couldn’t be possible using the currently held ECD mechanisms (discussed above). 
 
Figure 1.54: Cyclic peptide species studied by O’Connor et.al.99 to show that cyclic peptide species 
can fragment under ECD MS/MS to produce unique sequence-informative fragments, despite the 
cyclic structure tethering fragments together. A) cyclo-LLFHWAVGH, B) gramicidin S, and C) 
cyclosporine A. Reproduced from O’Connor et.al.99 
The ECD MS/MS spectra of the cyclic peptides produced an array of fragments shown in the spectra 
below, Figure 1.55: 
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Figure 1.55: ECD MS/MS spectra of the [M+2H]2+ ions for A) cyclo-LLFHWAVGH, B) gramicidin S, 
and C) cyclosporine A. Reproduced from O’Connor et.al.99 
ECD MS/MS of the cyclic peptides produced enhanced degrees of side chain losses compared to the 
expected results for linear counterparts. This enhancement was likely due to the lack of backbone 
cleavages and stabilisation of the radical by movement to the Cα, which commonly results in loss of 
the amino acid side chain, a corresponding entropy increase accompanies these reactions. The most 
interesting observation was the recorded sequence-informative fragments produced during ECD 
MS/MS. These fragments could only be produced by multiple cleavages of the peptide backbone by 
a single ECD electron, which did not follow previously discussed rules/mechanisms. As a result 
O’Connor et.al. believed that the electron could cause dissociations from the already cleaved 
position in the cyclic peptide via a radical-induced cyclic rearrangement reaction, shown below in 
Figure 56: 
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Figure 1.56: The radical-induced cyclic rearrangement reaction proposed by O’Connor et.al.99 to 
explain the sequence-informative fragments produced during ECD MS/MS of cyclic peptides. 
Reproduced from O’Connor et.al.99 
The release of pairs (or more) of cyclic oligo(amino acids) via a radical rearrangement helped assign a 
large number of peaks in the ECD MS/MS spectra produced. The Authors also believed that the 
radical site could propagate along the poly(amino acid) backbone and thus move to different sites 
prior to cyclisation, rearrangement, and release of other amino acid combinations, according to 
Figure 1.56, above. 
The Free Radical Cascade Mechanism (FRCM) is therefore a niche ECD mechanism which is of use to 
non-standard and/or cyclic ion MS/MS spectra, and helps explain why radical mechanism MS/MS 
techniques can not only cause enhanced side chain losses, but also fragment cyclic species in 
multiple locations to produce detectable and, with the FRCM, assignable species to inform the user 
of the biomolecule sequence and structure. 
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1.7.6.4 ECD in biomolecule analysis: 
The use of ECD has, for the most part, been confined to use in ultra-high vacuum regions of 
an MS and usually requiring use of an FT-ICR MS, this is to avoid damage to the electron emitting 
cathode needed to generate and release low energy electrons, though efforts are underway to 
create ECD MS/MS devices for use in other instruments, namely the Chimera branched-RF Ion 
Trap116 and the electromagnetostatic ECD cell.117,118 The benefits of ECD MS/MS are numerous and 
have been studied extensively in ECD’s relatively short lifetime.85,101,112,119,120 ECD has been described 
as a non-ergodic process,98,100 meaning that unlike CAD and IRMPD, bonds are broken before the 
energy of the reaction is evenly distributed throughout the molecule, and so is not a “slow heating” 
or threshold type dissociation, though recent studies have suggested this process to not be strictly 
non-ergodic.105  This also means that if the species of interest contains weakly-bound 
molecules/interactions, these may be preserved in the fragment ions detected, which is a huge 
benefit over threshold techniques such as CAD and IRMPD. The ability to retain delicate/fragile 
modifications/interactions has been an exceptional feature of ECD MS/MS and has enabled the 
study of fragile PTM’s such as carboxylation , sulfation, O-glycosylation, N-glycosylation, disulphide 
bonds, phosphorylation.101,85,115,121 Beyond PTM’s ECD has also enabled the study of non-covalent 
interactions,122,123 protein folding,124 and metallated biomolecules.86,125,126,127,128  
Once captured the ECD induced CRS dissociation is dictated by radical chemistry, unlike 
CAD/IRMPD/threshold based MS/MS, meaning that the rearrangement and dissociation of 
biomolecules, and other species, is usually driven by the stabilisation of the unstable radical. Charge 
location, electronegativity, and tertiary structure are thus now large factors in fragmentation, 
whereas radical stabilising groups (such as electron quenching functionalities) can have a 
detrimental effect on ECD MS/MS due to the stabilisation of the radical in a non-dissociative 
manner.  
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ECD of transition metal complex-containing species is thus a very interesting area to 
consider as the interaction of electrons with metal d-orbitals and more complex electronic 
configurations experienced with heavy metals can complicate and alter the ECD MS/MS process. 
Metal-induced side chain loss during ECD has already been documented by Li et. al.,86 while studying 
platinum complex association with biomolecules. They showed that not only could ECD electrons 
interact with the platinum complex modification, but also dissociate it if the radical were 
sequestered on the platinum centre itself, this could also cause unusual fragmentation of the 
methionine residue previously bound to the complex, as shown in Figure 57 below. It has been 
suggested that this and various other fragmentation behaviour could be used to as a “fingerprint” to 
effectively characterise platinum containing peptides and proteins.126   
 
Figure 1.57: Platinum complex loss and Platinum-induced methionine side chain loss due to 
electron capture at / electron transfer to platinum metal centre during ECD MS/Ms analysis of 
platinated protein species. Reproduced from Li et.al.86 
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1.7.7 Hot-ECD (hECD): 
ECD utilises rather low energy electrons, typically ~0.8-3eV, which can cause extensive 
biomolecule fragmentation, as discussed above, ECD also causes an array of amino-acid side-chain 
losses, some of which can be used diagnostically.85,122 However ECD Side Chain Losses (SCL’s) are not 
only distinctly different from those observed for CAD, which tend to be neutral molecules, they are 
also more diagnostic, and less abundant than those observed in CAD/IRMPD. In certain cases SCL’s 
are characteristic and can be used to confirm/test the presence of certain amino acid groups present 
within a given biomolecule,129 to this end it can sometimes be advantageous to attempt to increase 
the abundance/yield of SCL’s in ECD MS/MS spectra in order to aid this type of analysis. 
hECD typically uses electron energies slightly higher than that of normal ECD (~5-7eV)85,122,130 
and the transition into hECD can be subtle, however extra SCL peaks appear and ECD efficiency can 
lower, as the electron energy moves away from the optimum for normal ECD and increased loss 
through extra SCL pathways. Due to hECD’s ability to cleave unique side chains during dissociation, 
hECD has been used as an effective tool at differentiating between aspartic acid (45Da Side chain 
loss and iso-aspartic acid (57Da Side chain loss)131, which is a key assignment of deamidation at these 
residues and could be used to study the progression of Alzheimer’s patients.131  
1.7.8 Electron Induced Dissociation (EID): 
ECD proved to be a remarkable technique, able to achieve far greater sequence/cleavage 
coverage of proteins than CAD, and could retain fragile PTM’s effectively. However for the analysis 
of some peptides and small molecules, ECD was not a viable technique due to the requirement that 
a parent ion would need to be at least a 2+ charge in order to produce 1+ detectable fragments after 
the electron capture event. This charge-limitation proved difficult for small molecule MS/MS, which 
often only observes 1+ ions, and a distinct proportion of peptide MS/MS in which many peptides 
only present as 1+ ions, or only produce a very limited intensity 2+ or more ion. In order to combat 
this lack of electron-based dissociation for singly charged species Budnik et. al.132 and Fung et. al.133 
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investigated the effect of tuning electron energy during ECD to find a viable region for electron-
based dissociation of 1+ ions. High energy electrons (70eV) were known from EI ionisation to 
interact with small molecules, and induce fragmentation, however lower (medium) energy electrons 
were found to fragment singly charged ions. Using electrons ~9-18eV,85 electron induced 
dissociation (EID) could be performed. For singly charged small molecules this produced a range of 
fragments, akin to EI, but available to selected MS/MS of selected ions, which allowed soft-ionisation 
followed by MS/MS of various analytes. For Singly charged biomolecules EID produced c/z• and a/x 
type fragments. EID has also been shown to cause a series of cross-ring cleavages and enable 
detailed characterisation of small and cyclic species.79  
 
Figure 1.58: EID and CAD MS/MS fragmentation of polyketide natural products showing the 
complementary MS/MS fragmentation data provided by the different techniques. Reproduced 
from Wills et. al.79 
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Figure 1.59: Fragments produced by EID MS/MS of poly(amino acids). EID produced c/z• and a/x 
fragments, highlighted above. 
Recently EID has been shown to be an effective and viable technique for electron-based 
MS/MS of larger, multiply charged biomolecules, such as proteins. Li et. al. have shown that EID 
actually provides complementary data to both ECD and CAD MS/MS, particularly for very large 
biomolecules, where sequence/cleavage coverage during MS/MS can be extremely limited. 
Particular uses of EID and various ExD fragmentation techniques have also been reviewed recently 
by Qi et.al.134 
1.7.9 Electron Detachment Dissociation (EDD): 
Many analytes, and biomolecules, specifically acidic peptides/proteins and RNA/DNA 
species, do not ionise well in positive mode ESI, if at all, though are readily ionised via negative mode 
ESI. Though the effectiveness of ECD had be proven on a range of biomolecules and expanded the 
effective range of MS/MS to larger proteins, it was still an exclusively positive-mode technique, and 
could not work on negatively charged ions. In order to create a viable electron based dissociation 
technique for negatively charged ions Budnik and Zubarev et. al.135 investigated the use of electrons 
on negatively charged analytes trapped in an ICR cell. They showed that using medium energy 
electrons (15-20eV) could induce electron detachment on the target analyte, causing an [M-xH]x- 
species to become an [M-xH](x-1)•- radical species, which would then undergo radical directed 
fragmentation, in a similar way to ECD, but for negatively charged analytes.85 EDD was extremely 
effective at dissociating oligonucleotides136 and a variety of other biomolecules, and most 
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importantly presented many of the same benefits as ECD; including PTM retention and 
complementary MS/MS fragmentation to that obtained via CAD and IRMPD.13685 EDD has been used 
to effectively sequence even large poly(nucleotides) up to 61 base pairs (bp), as shown by Breuker 
et. al.136 presenting an effective way of sequencing biologically relevant poly(nucleotides) via 
MS/MS. EDD of negatively charged peptides causes cleavage of the N-Cα bond to form a and z ions, 
though a ions are also commonly detected, whereas EDD of oligonucleotides has been shown to 
cleave the O-C bonds either side of the phosphorous atom and form d & w ions, both are shown in 
Figure 1.61, below: 
 
Figure 1.60: Peptide and protein backbone bond cleavages under EDD MS/MS, predominantly c, 
c•, z, z•, a, and a• fragments are formed and detectable. 
 
Figure 1.61: Structure of DNA/RNA species, unlike peptides and proteins, when fragmented via 
EDD MS/MS produce mainly d and w type ions, centred around fragmentation at the backbone 
phosphate groups. 
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EDD has also been shown to be critical in the full MS/MS characterisation of 
glycosaminoglycans (GAG’s); Amster et. al. have shown137 the sulfonation of individual sugars within 
the backbone chain (also known as the glycan code)138 are lost using standard CAD MS/MS, but can 
be deciphered using carefully tuned EDD which causes the cross-ring cleavages in the sugar units 
needed to accurately assign PTM locations, shown in Figure 1.62 below: 
 
Figure 1.62: Fragmentation nomenclature used for the MS/MS of Glycosaminoglycans (GAG’s). 
Reproduced from Wolff and Amster.137 
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Figure 1.63: EDD, IRMPD, and CAD MS/MS of GAG’s showing the complementary data available 
with each technique, but also the superiority of EDD for the effective fragmentation and critical 
cross-ring cleavages needed to effectively characterise GAG polymers. Reproduced from Wolff and 
Amster.137 
Negative ion Electron Capture Dissociation (niECD): 
Proposed by Hakansson et.al. in 2011 niECD was an alternative way to dissociate negatively 
charged ions to EDD.139 Believed to be a pure electron capture event, like ECD, niECD requires that 
electrons overcome a repulsive coulombic barrier in order to allow the negatively charged electrons 
to approach the negatively charged analyte of interest. However if this can be overcome then 
electron capture can occur, causing electron transfer to the analyte [M-nH]n-, creation of a radical 
species, in this case a charge increased species [M-nH]n-•, and eventually fragmentation.  
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Hakansson et. al. showed that by using extremely long irradiation times (~10-20 seconds) and 
electron energies of ~5.5eV niECD was possible,139 producing effective fragmentation of oligo 
nucleotides and negatively charged peptide analytes. 
1.7.10 Electron Transfer Dissociation (ETD): 
The dramatic increase in MS/MS performance (both for sequence/cleavage coverage, and 
diagnostic ions) offered by ECD and the ability to probe structural information using radical directed 
dissociations was a very attractive prospect, unfortunately it was limited only to FT-ICR mass 
spectrometers. In an attempt to access electron-based dissociations on other instrument platforms 
Syka et. al. investigated the use of another way of creating charge reduced radical cation species; by 
using a carrier molecule/ion to transfer the electron to the analyte species instead of an electron-
generating cathode.140 Syka et. al. showed that by using negative anion radicals, generated by a 
negative chemical ionisation (nCI) source, electron transfer could be achieved by trapping both the 
positively charged species of interest and the radical anion. Dubbed Electron Transfer Dissociation 
(ETD), this process enabled effective electron based dissociations on any trapping mass 
spectrometer, and although possessing distinct differences and sometimes disadvantages over ECD, 
ETD allowed many different types of mass spectrometers to access these fragmentations and 
improve MS/MS analysis. ETD produces charged reduced species (CRS’s) and c/z ions, similarly to 
ECD, shown below in Figure 1.64. The general process for ETD is also shown below in Figure 65, the 
choice of radical anion reagent can vary from instrument to instrument, but many are based on 
extended ring structures such as anthracene, which when reacted with CH5
+ ions from the CI source 
can produce a range of ion peaks, including active ETD reagent ions such as C14H9
- and C14H11
-.140 
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Figure 1.64: Ions produced during ETD of peptides and proteins, c and z ions are most frequently 
observed as product ions. 
 
Figure 1.65: general procedure for achieving Electron Transfer Dissociation (ETD) within a multi-
pole-coupled mass spectrometer (A). Ions are introduced into the multi-pole trap and confined 
using voltage barriers (B) the ETD reagent generated via a separate CI source are then introduced 
separately into the trap (C) Both ions of interest and ETD reagent ions are then co-confined within 
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the multi-pole trap (D) both ion types are then allowed to react for a certain (variable) time to 
allow interaction and electron transfer (E) the ETD reagent is then ejected, leaving the ions of 
interest and their daughter fragment ions produced due to radical directed fragmentation (ETD) all 
of the remaining ions can then be transferred to the mass analyser to be detect and produce an 
ETD MS/MS spectrum. Reproduced from Syka et. al.140 
ETD has been successfully applied to the study of peptides,141 proteins,142 protein 
complexes,143 antibodies,89 PTM’s,144 and structural protein studies.119 ETD has also been widely 
applied to larger scale proteomics studied to provide complementary data to CAD and allow PTM 
analysis on a proteome wide scale.145 ETD often requires post-electron transfer activation (via CAD 
and/or IRMPD) to add additional energy to the ETD charge reduced species and break non-covalent 
bond in order to liberate more fragments and increase fragment ion yield, increasing sequence 
coverage of many species, especially larger proteins.146 
 
Figure 1.66: ETD MS/MS spectrum of a phosphorylated peptide (shown inset), observed c and z 
ions are labelled, ETD provided complete cleavage coverage of the phosphopeptide, proving ETD is 
a viable technique to sequence post-translationally modified biomolecules while still retaining the 
associated fragile modifications. 
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 Recently various applications of Electron Transfer without dissociation (ETnoD) reactions 
have shown promise as a way of either lowering charge states in situations favouring low-charge 
state analysis, such as polymer mixtures, or study of high charge state species on lower resolution 
instruments seeking to reduce the charge state and achieve isotopic resolution.147 The benefit of 
ETnoD being that ions can always be supplementally activated post-ETnoD to observe c/z ions if 
needed thereafter. 
1.7.11 Multi-stage Tandem MS, MS/MS/MS, MS3, or MSn:  
Ions can also be re-isolated in the ICR cell and IRMPD/UVPD/ECD/ExD (among other in-cell MS/MS 
techniques) can be used to perform tandem MS of the fragments produced (MS/MS/MS or MS3), 
allowing further interrogation of fragment species.5,148  This process can also be repeated further for 
MSn experiments73, though with each stage of MS/MS target fragment intensity will decrease (as no 
new ions are entering the cell) and so practically this places a limit on the number of stages of 
MS/MS. It is worth noting that MSn experiments can also be performed outside of an ICR cell via 
movement in and out of different optic regions of a mass spectrometer, e.g. multiple stages of CAD 
MS/MS via continued exit and entry of fragment ions, though the same intensity limitations still 
apply. 
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1.8 A working hybrid-FT-ICR Mass Spectrometer: 
Figure 1.67, below, shows the Bruker SolariX 12 Tesla FT-ICR Mass Spectrometer used for the 
majority of the work presented herein. The SolariX can be equipped with a range of ionisation 
sources, including but not limited to, ESI, nESI, MALDI, CI, APCI, APPI, and MAI. The SolariX is fitted 
with many features and techniques discussed above, most notably, an Infinity cell,33 Sidekick 
electrodes,35 a dual ion funnel-orthogonal AP-ionisation front end, and a split-octupole-quadrupole-
hexapole-hexapole arrangement for transmission and effective MS/MS of target ions before the ICR 
cell, and an array of MS/MS techniques thereafter. 
 
Figure 1.67: Schematic representation of the Bruker 12T SolariX instrument used for the majority 
of the work presented within the thesis. Corresponding labels are referred to in the main text. 
Courtesy of Bruker Daltonics, Bremen, Germany. 
Ions generated via the AP-capillary entrance (A) of SolariX are orthogonally introduced into 
the vacuum region of the source front end and are then accelerated towards the ion funnels via a 
deflector plate (B), held at an equal polarity to the incoming ions, this allows neutrals to be taken 
away by vacuum, while ions are transmitted further into the FT-ICR MS. Ions generated via MALDI 
are generated in vacuum just under a MALDI extraction lens which will then accelerate ions towards 
the deflector plate, repelling them towards the ion funnels to be focused and transmitted.  
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Ions are focused via the dual-ion funnels (C) into a split octupole region (D) (spit to enable 
orthogonal injection of ions generated by the internal nCI source (see the ETD MS/MS section, 
above)) and then passed through a skimmer into the quadrupole (E).  
 
Figure 1.68: Schematic of source region of SolariX with typical tuning parameters in red. Courtesy 
of Bruker Daltonics, Bremen, Germany. 
The quadrupole can either transmit ions or filter ions depending on the parameters used 
and the mode desired, for standard MS experiments all ions are transmitted through the quadrupole 
(ideally, in practice there is a small discrimination of transmittable m/z range due to the frequency of 
the DC current switching and the amplitude applied to the rods). Ions are then passed into the 
hexapole collision cell (F), which is populated with an adjustable low pressure of Argon gas, which 
aids in ion cooling and accumulation/storage. During CAD MS/MS experiments, the quadrupole can 
be re-tuned to filter ions of interest, which can then be accelerated into the collision cell containing 
the Argon gas, causing CAD. Ions (regardless of transmission) can be continuously accumulated in 
the hexapole collision cell in order to increase the ion population eventually transmitted to the ICR 
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cell for detection, thus providing larger packets of ions and enhanced detected signals. The 
Continuous Accumulation of Selected Ions (CASI) is a Bruker proprietary mechanic for accumulation 
of quadrupole-filtered ions within the hexapole collision cell.  
Ions accumulated in the hexapole collision cell can also be subjected to ion-ion reactions, such as 
ETD and ETnoD (above) via generation of electron transfer reagents from the nCI source (G). ETD 
type reactions (including ETnoD) are dual-trapping experiments requiring confinement of both 
positively charged and negatively charged species, and the resulting fragments. Some instruments 
have also been modified to perform laser-based dissociations within accumulations cells such as 
hexapoles.95 The SolariX is also equipped with a beam valve (H) used to isolate the 
source/accumulation regions of the instrument, and the ultra-high vacuum region, the beam valve of 
course needs to be open during normal operation, but closed when not in use/ for maintenance. 
Once the ions have been accumulated/dissociated as desired they are transferred through 
hexapole transfer optics (I) to the ICR cell (J), they pass through two entrance lenses and through the 
front cell trapping plate and into the homogenous magnetic field region, at which point they are 
confined by raising the front trapping plate to an equal polarity of ions and a similar magnitude to 
the back trapping plate (usually 0.35-1V for the infinity cell). 
Once in the infinity cell ions will precess according to their natural cyclotron frequency, 
perturbed by the electric fields, and can be excited using a broadband/narrowband excitation and/or 
be isolated/dissociated using in-cell-isolations/ in-cell MS/MS, described above. Equipped with a 
hollow-electron-emitting cathode (K) and continuous-wave 25W 10.6um IR laser (L), the SolariX is 
able to achieve a range of electron based dissociations (including, but not limited to ECD, hot-ECD, 
EID, EDD, ni-ECD, EIEIO, and EI).134 The ICR cell is also equipped with a pulsed gas valve enabling in-
cell CAD, SORI-CAD, and even CRAFTI-ion mobility spectrometry inside the ICR cell with careful 
operation.149,150  
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1.9 Liquid/Gas Chromatography-Mass Spectrometry: 
Chromatography has been used for decades to separate mixtures of chemical species into 
either less complex samples or ideally pure, isolated species which can then be analysed using 
various analytical techniques. Chromatography is based on exploiting the different interactions 
(retentions) of compounds with a stationary phase while passing over a mobile phase which will 
slowly partition components out of the stationary phase and move them through the 
chromatograph, as a result compounds can be separated based on their interaction with the 
stationary phase and mobile phase combination (phase partitioning). 
Gas Chromatography (GC), the older of the pair mentioned, has been used for many years to 
separate volatile chemical mixtures capable of easily transitioning to the gas phase for separation. 
GC tends to utilise very long (10-50m) stationary phases (columns), usually functionalised silica, and 
use inert gas as a mobile phase, e.g. Helium. Gas chromatography is a very fast chromatographic 
technique and often separates compounds on the minutes time scale. The column is usually heated 
in a temperature-controlled oven to force the elution of different analytes at certain times within 
the run. As a result a “heat ramp” can be used to start from a relatively low temperature (~50oC) 
which will cause elution of extremely volatile species that have limited interaction with the 
stationary phase, and can be ramped up to high temperatures (~300oC) to cause elution of species 
with a very high interaction with the stationary phase, and with all species in between eluting at 
some point during the ramp. Many detectors for GC have been used over the years, though the 
contemporary detector is known as a Flame Ionisation Detection. Flame ionisation detectors work 
on the principal that all species exiting the GC column are exposed to high-temperature flame, which 
will ionise combustible analytes, the ions move between the cathode (flame source) and towards an 
anode (detector plate) the current generated by movement of ions between the two electrode is 
then recorded and produces an intensity trace directly proportional to the ion concentration 
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produced via combustion.151 This does not necessarily provide a uniform response for each chemical 
species, as obviously some species are more easily ionised via combustion than others.  
 
Figure 1.69: Schematic representation of a Gas Chromatograph (GC) showing the various 
components and functionalities, the presented detector is an electron capture detector rather 
then the FID described above . Image taken from 
http://www.esrl.noaa.gov/gmd/hats/insitu/insitu.html accessed 15/04/2016. 
Though flame ionisation detectors have been shown to produce very accurate detection of 
chemical species and allow quantitation of a great array of compounds, the detector is 
fundamentally a binary detection method; it will provide a signal response based upon the amount 
of analyte passing through it and undergoing effective combustion ionisation, but cannot provide 
any further information beyond abundance. Thus the coupling of GC to a detector which can provide 
a more in depth analysis and provide analyte-specific information, such as mass spectrometry, was a 
perfect partnership. GC-MS was first successfully achieved by McLafferty et. al.152 using an in-house 
built ToF-MS at the Dow chemical company, and has since been used worldwide for the analysis of 
both known and unknown chemical species. As mentioned previously, GC is a fast chromatographic 
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separation technique, despite the use of very long GC columns, thus the MS coupled to the 
chromatograph would ideally have a short duty cycle and thus fast scan rate in order to keep up with 
the various eluting compounds and provide a good chromatographic resolution from the resulting 
detection. Below is an example chromatogram from a GC-EI-Q-MS, showing various hexane 
extracted alkane hydrocarbon species separated effectively on a GC column and detected by EI-
quadrupole-MS: 
 
 
a) 
b) 
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Figure 1.70: GC-EI-Q-MS chromatogram of hexane-extracted saturated hydrocarbons showing a 
broad distribution of components separated by GC and characterised by EI-quadrupole MS, each 
species will have its own corresponding EI mass spectrum enabling characterisation/pattern 
search for identification. EI-Q-MS spectra are shown for chromatogram peaks labelled a) and b) 
showing distinctly different peak distributions, yet common fragment peaks in areas. 
GCMS has been shown to be very effective at the analysis of complex mixtures,153 environmental 
samples,154 pharmaceutical samples,155 pesticides,156 and even forensic samples,20 where the GC can 
separate many species and allow the analysis of target compounds/all detectable compounds in one 
chromatographic-MS run. GC-MS can also be interfaced with various gas-phase ionisation sources 
and is not limited purely to EI.157 
 
Liquid Chromatography (LC) as its name suggests is a slower, liquid based separation 
technique, utilising shorter chromatographic columns (~10-30cm), over longer periods (~30-120 
minutes), and usually at a set temperature instead using combinations of different solvents to 
promote the elution of different chemical species. LC runs usually use a varying mixture of two or 
more solvent systems to alter the retention of compounds within the column, which in this case is 
usually functionalised silica beads with silyl-alkane functionality, though a great range of stationary 
phases are available. The most simple and widely used solvent system for LC separation is the 
acidifies water/Acetonitrile (ACN) system, in which a high percentage of acidified water (~95%) is 
used at the beginning of the chromatographic run, leaving a low percentage of acidified ACN (~5%), 
as the run progresses the proportion of ACN will increase at a given rate, causing elution of various 
compounds which prefer interaction with the higher ACN solvent system rather than the stationary 
phase. This simple elution methodology has been extremely effective at separating a wide range of 
compounds for LC, including small molecules,158 metal complexes,159 polymers,154 and 
biomolecules160–163 to name but a few. Although the Majority of LC analysis utilise UV/visible 
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detectors, like FID mentioned above, these detectors simply provide an abundance response for 
UV/visible interaction at a set wavelength, which can often be less than optimum for the target 
analytes, and so provides no further/structural data beyond the fact the compound has a 
chromophore which can interact with the given wavelength. As a result, and just as with GC above, 
the coupling of LC to MS was a perfect partnership, and with  the advent of Electrospray, became 
easier than ever, as the simple connection of the LC outlet and tuning of the LC flowrate to be ESI-
compatible is enough to couple an LC to an ESI-MS. LCMS has been effective at analysing a huge 
variety of solvent-soluble components, and is currently the leading technique for the analysis of 
complex biological mixtures, especially proteins and peptides for proteomic analysis.164,163,165 An 
example of an LCMS layout and resulting separation of a simple peptide mixture is shown below in 
Figure 1.71, including the resulting chromatogram and example mass spectra for different time 
points, showing the elution of different peptides: 
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Figure 1.71: Clockwise from top-left: Various C18 bonded-phases often used in LCMS columns to 
separate peptides. The organic solvent gradient used to gradually elute compounds from the LC 
column (organic solvent proportion shown, other proportion is usually water/acidified water). The 
resulting LC-MS chromatogram showing a range of peptide species all eluting separately at 
different retention times and with different concentrations (proportional to peak area, and MS 
ionisation/transmission/detection efficiency). 
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Chapter 2: Introduction to Anti-cancer metallodrugs 
2.1 Cancer: 
Cancer is a generic term for a wide array of conditions all connected with the same fundamental 
symptom – uncontrolled cell proliferation (growth and replication). Excessive growth and replication 
of cells is detrimental to individual cell function and is unsustainable for the organism as a whole and 
so is usually carefully controlled and limited by cellular proteins and biological mechanisms. Cancer 
arises from damage/alteration/coding problems within the DNA of the cell itself. This can occur in a 
number of ways, including, but not limited to chemical-induced damage (e.g. by carcinogens), 
radiation induced damage/degradation of DNA, or problems arising during DNA 
replication/transcription.1 A more recently recognised cause of cancer is via virus infection, the 
human papilloma virus currently causes ~70% of cervical cancer cases in women. Damage to host 
cell DNA can cause the cell to proliferate at a much accelerated rate than usual, demanding more 
resources from the host organism, and creating asymmetric growth in that area of the host, often 
resulting a large collection of cancerous cells, known as a tumour. Cancerous cells can often migrate 
from their initial creation point and move to other areas of the host, where they will then continue 
to proliferate and create secondary tumours, a process known as metastasis. The spread of 
cancerous tumours throughout a host organism can put a huge amount of strain on biological 
processes both from the extreme resource demand the cancerous cells present due to accelerated 
growth and replication, but also due to the physical stress of increased mass in delicate internal 
areas which can disrupt normal biological function. Finally cancer can cause a great change in 
cellular function as the cells previously tasked to specific function (e.g. liver cell function of 
metabolising toxins) will no longer take place effectively as the previously functioning cell is now 
damaged, its usual cellular processes interrupted, and proliferating at an uncontrolled rate, putting 
strain on it and the cells around it.  
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Figure 2.1: Normal (left) and uncontrolled (cancerous) cell growth (right) after DNA damage. Large 
growth of cancerous cells (tumour) can put pressure on nearby cells and increase stress and/or 
impair function. Sections of tumour may break off and relocate to other areas of the host 
(metastasis). Reproduced from  http://www.mun.ca/biology/desmid/brian/BIOL2060/BIOL2060-
24/CB24.html, (accessed 23/02/2016). 
Unfortunately Cancer is an inevitable cellular event, and is coded directly into our genome; every 
time a cell divides and replicates DNA there is a chance of causing DNA damage, or the creation of 
damaged DNA,2 as a result due to the countless times host cells divide during a lifetime even if this is 
an extremely rare event, it will happen eventually. Though external factors such as exposure to 
carcinogens, repeated damage to cells/tissue forcing increased replication, and exposure to DNA 
damaging radiation (such as UV/gamma radiation) can lead to increased risk/acceleration of cancer 
development.3 The development of cancer, risk factors, and especially its biological causes are a 
areas of intense and widespread research. Though these phenomena are not completely 
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understood, great progress is being made.4,5 There are a number of genetic factors also affecting 
cancer development and risk, as cancer is predominantly a DNA-related condition, hosts with certain 
DNA features, mismatches, or sequences may be particularly susceptible to certain external factors, 
or may have an accelerated time frame for cancer development than others. 
 
Figure 2.2: representations of the central dogma of cell division (mitosis) (left) and gene 
expression (right) showing how cells divide and use DNA/RNA to produce cellular components, 
such as peptides and proteins. Both reproduced from http://www.nature.com/scitable (accessed 
12/08/2016). 
Cancer seems to be a condition common to all eukaryotes, occurring in many of the same ways as 
humans, and similarly accelerated due to exposure to carcinogens and/or radiation. As a result many 
animal models, especially mice, are used for both the study of native cancer, induced cancer, and 
cancer graphs (xenografts) from human to secondary host (such as mice).6  
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2.2: Treatment: 
Cancer, being intrinsically DNA-related, has been historically treated medically and chemically by 
DNA-targeting reagents, which ideally will attack cancerous DNA, while leaving normal, non-
cancerous DNA unharmed.7 The ratio of cancerous to non-cancerous cells targeted is known as a 
drug’s selectivity.8 These DNA-targeting reagents come in a variety of forms, using small molecules,1 
macromolecules,9 and even heavy/transition metal complexes.10  
The concept behind most metal-based anti-cancer drugs is to bind to target cancerous DNA, within 
cancer cells, and induce a chemical change, either covalent bonding, crosslinking, or deformation of 
structure.11–13 After the DNA has been modified the DNA will no longer be “readable” by the 
transcription proteins and will not be transcribed, thus preventing further cancerous DNA replication 
and thus replication of the cancerous cells. Without the ability to replicate the cancerous cells will 
live out their particularly shortened lifespan (due to excessive resource consumption) and die off. 
Though this is the ideal situation, there is very little difference between a cancerous cell and a non-
cancerous/healthy cell in a specific organism; they have very similar cell function and contents 
(though increasingly there are studies into the subtle differences1),and for the most part they have 
extremely similar DNA encoding, aside from the often small areas causing damage and triggering 
excessive proliferation.9 As a result although creating anti-cancer drugs with great potency and DNA 
binding can be readily achieved,14 creating compounds with good selectivity is very challenging, and 
so many anti-cancer compounds which attack and kill cancerous cells also attack and kill healthy 
host cells, producing many of the extensive side effects experienced during chemotherapy.15  
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2.3 Metal-based chemotherapy: 
Above all others, metal-based chemotherapy has become the dominant method for treating cancer 
by attacking cancerous DNA and preventing proliferation.11,13,16 Specifically it is the Platinum based 
chemotherapeutics which have made the largest impact on cancer therapy in the last few decades. 
So much so that over 50% of all cancer treatments worldwide now contain a Pt(II) metal-based drug 
(metallodrug). 17,18  
The first FDA approved and commercialised platinum drug was Cisplatin 
(Cis(diaminodichlorido)platinum (CDDP)).18 Cisplatin was shown to attack cancerous DNA by binding 
to exposed Guanine nucleobases, causing deformation of DNA tertiary structure, preventing proper 
transcription and eventually preventing proliferation. Cisplatin was also shown to produce intra and 
inter-strand crosslinks within DNA, with the latter preventing transcription very effectively,18 
example shown in Figure 2.3 below: 
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Figure 2.3: Cisplatin mechanism of action against DNA. Reproduced from Hambley et al.19 
Cisplatin has proven to be extremely effective over the years at combatting cancers, especially 
testicular, cervical, and bladder cancers. Cisplatin/Metal based anti-cancer agents exhibit many 
advantages over their purely organic counterparts: 
- High potencies – Cisplatin possesses an IC50 of 1.2 μM (+/- 0.2)
20  
- High selectivity for cancer cells 
- Tuneable activity – due to different ligand configurations  
- Low toxicity compared to many small organic molecules  
- Easy to trace – as a transition metal that is not usually present  
However extensive use of Cisplatin has resulted in the observation of an array of detrimental side 
effects to patients, including liver failure, kidney damage, hair loss, dramatic weight loss, and many 
more.21–23 The widespread use of Cisplatin has also caused the observation and rise in Cisplatin 
resistant strains of cancer.24 As the body is subjected to the toxic treatment it will attempt to adapt 
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and remove the active complexes from the body in order to protect its cells, healthy or cancerous, 
unfortunately the body/cells will protect both. Though Cisplatin was a major medical and chemical 
breakthrough in anti-cancer research its current side effects are great, and its effectiveness is 
decreasing relative to more contemporary treatments. However Cisplatin is still the most widely 
used anti-cancer drug available and is used to treat an array of cancers.15,22 Though many other 
types of Pt(II) drugs are currently used/available, including Oxaliplatin, Strataplatin, and 
PicoPlatin.11,25,26 The analogous compound transplatin, an isomer of Cisplatin was unfortunately 
found to be much less active than its cis counterpart.22  
Studies into the movement, transformation and eventual mechanism of action of Cisplatin and other 
platinum(II) drugs have shown that one or more of the chlorido ligands can be displaced while inside 
the body/cell, producing a much more active aqua-Pt(II) complex, this aqua/di-aqua species can then 
bind to cancerous DNA to cause deformations and prevent proliferation/induce cell death.22,27 
However it has also been shown by a variety of studies that only a very small percentage of the 
administered Pt(II) drug actually makes it to its DNA target.15,28 Unfortunately while DNA functional 
groups such as guanine nitrogen groups present very reactive and viable ligands for Cisplatin, there 
are a plethora of other molecules and functional groups within cells, blood, and extracellular fluid 
which will also readily bind to Cisplatin and any reactive metal species. The binding of Cisplatin to 
cellular/blood/extra cellular components is so great the it has been shown that 90-98% of Cisplatin 
becomes protein bound within just one day of injection. 15,28 It is currently believed that many of the 
side effects experienced by patients may be due to these deactivation reactions with non-target/off-
target compounds. 
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Figure 2.4: Summary of Cisplatin transformations in vivo, and subsequent apoptosis-inducing DNA 
binding and secretion. Reproduced from Bugarcic et al.29 
Cisplatin has been shown to bind very effectively to available sulphur groups, such as those on 
Methionine and cysteine,30,31 both in proteins and in GSH, which is present at milli-molar 
concentrations in some cells.2  This great array of deactivating potential ligands detract from the 
therapeutic effects of Cisplatin and can create damaging reaction products, or at the very least 
prevent/alter the function of species the Pt(II) drug will bind to. Although Cisplatin has been shown 
to bind to various proteins including Human Serum Albumin (HSA),21 Cytochrome c,32 
Calmodulin,30,33,34 and many others,23,35–38 some believe that not all of these interactions are purely 
deactivating and that some may be transient and actually aid in the transportation of metal-based 
compounds in and out of cells and cellular membranes, perhaps much in the same way that 
chaperone proteins have been shown to assist in the uptake of essential metal ions.39  
Regardless platination/metalation of biomolecules has been shown to have both localised and 
significant effects on protein structure,40–42 including crosslinking of proteins which usually function 
independently,42  and disruption of structure reinforcing disulphide bonds.43 
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Figure 2.5: Cisplatin-induced protein-protein crosslink between two Calmodulin proteins, causing 
large structural changes and possible deactivation/limitation of protein function. Reproduced from Li 
et al.30 
Due to these and many other phenomena, the activity, behaviour, and mechanism of action of 
metallodrugs presents an interesting and unique area of study. More importantly the study of these 
interesting and chemically complex drugs varies drastically with the co-ordinating ligands bound to 
the metal centre. With each metal complex’s properties able to be altered differently with varying 
ligands, metallodrugs can be chemically tuned to increase selectivity, reactivity/potency, activation, 
and affinity to a wide array of biological targets. For these reasons study of the effects and targets of 
each drug variant has the potential to greatly inform future drug design, the so-called intelligent 
drug design method.10,44 To this end research has moved beyond square planar Pt(II) complexes such 
as Cisplatin, and onto more complex, chemically tuned compounds, each not only with their own 
activity and potency, but also with specific tactics and targets to attack cancer cell components in 
different ways, in order to bypass resistance, cellular self defence mechanisms, cancer cell 
environmental conditions, or simply to reduce off-target reactions and minimise potential side 
effects.  
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2.4 Novel metallodrug approaches: 
Below are a series of new, and very varied categories of anti-cancer metallodrugs, each with their 
own target/method of attacking cancer cells and either causing cell death (cytotoxic compounds), or 
prevent them from growing/replicating (anti-proliferative compounds). 
2.4.1 Piano-stool complexes: 
Classical square planar complexes such as Cisplatin and octahedral complexes of other transition 
metals have been synthesised for years in co-ordination chemistry and studied for their interesting 
properties and unique metal to ligand bonds. However using large aromatic ligands to bind to metals 
using more than one pair of electrons has been shown to fix/constrain those binding points, and can 
enhance activity of others, these so called piano-stool or half-sandwich compounds often employ 5 
or 6 membered aromatic hydrocarbon rings (benzene-like or cyclopentadienyl-like rings) to bind to 
metals in an η6 fashion, i.e. using 6 electrons. An example of an η6 arene bound to a metal centre 
with a bidentate ligand and a single mono dentate ligand is shown below in Figure 2.6: 
 
Figure 2.6: [(η6 –biphenyl)Os(diaminoethyl)Cl]+ piano stool complex proven to be a very active 
anti-cancer metallodrug.45,46 The complex shows a classic  η6 –arene interaction exploited by 
organometallic chemists to tune the reactivity of the complex and target ligand sties. 
The use of an η6-arene and a bidentate ligand has been shown to greatly enhance activity at the 
mono-dentate site, enabling use as catalysts and active anti-cancer agents.14,47,48,49  
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Study into the use of piano stool complexes as anti-cancer agents show that they can boast 
impressive potencies, often well above Cisplatin, for instance the compound shown above has been 
shown to be 49x more potent than Cisplatin towards A2780 ovarian cancer cell lines,50 the piano 
stool complex is clearly not only more potent, but may possess a different target/mechanism of 
action inside cancer cells.50 
Though piano-stool complexes tend to be more active, and often more selective,45–47 than Cisplatin 
towards attacking cancerous cells, they are still often transformed in vivo from the initial complex to 
a more active species, such as an aqua species,15,22 or an iodido species to a chlorido species,51 in a 
similar fashion to Cisplatin. Some believe/have tried to exploit this transformation  as a mechanism 
of activation, by making the initial injected compound relatively inactive (a pro-drug), until it reaches 
a cancer cell, which has several distinctly different conditions to normal healthy cells, such as lower 
pH, change in temperature, and changes in NaCl and GSH concentrations. Chemists can exploit these 
differences in cell conditions to make intrinsic triggers for pro-drug to become active anti-cancer 
metallodrugs and increase selectivity of complexes.10,13,39 
2.4.2 Functionalised piano-stool complexes: 
Although many organometallic piano-stool compounds have been shown to boast impressive anti-
cancer activity/potency, the selectivity of an anti-cancer drug is one of the key factors in increasing 
effectiveness and reducing side effects during treatment. In an effort to increase piano-stool 
compounds selectivity (and perhaps potency in the process) some researchers have attempted to 
functionalise the ligands within the complex with reactive groups in an effort to target potential 
binding partners (peptide/protein sequences/DNA/RNA etc.), and to tune the anti-cancer activity of 
the complex as a whole.52  
The functionalisation of these complexes has produced a wide array of different metallodrugs, and 
many metallodrug-biomolecule conjugates. The biomolecule bound to the given drug is believed to 
function as a directing group, and enhance the accumulation of the drug in certain areas of the 
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body/cancer cells, and thus not only increase selectivity, but also increase the amount/proportion of 
the drug in the target area of the cell, making it more effective/potent.53 Drug-antibody conjugates 
are currently of great interest due to anti-bodies’ inherent selectivity and biological stability and 
compatibility. These functionalised complexes are also able to be bound to nano-particle 
frameworks in order to take advantage of their various benefits and architectures.54 An example of a 
functionalised metallodrug is below in Figure 2.6, showing the classic piano-stool geometry, but with 
a functionalised mono-dentate ligand, able to bond to a target (bio)molecule before administration, 
or after administration if needed: 
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Figure 2.7: a peptide-functionalised ruthenium metallodrug for increased selectivity for binding at 
a peptide-derrived target within cancer cells. Reproduced from Barragan et al.55 
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2.4.3 Photoactivatable complexes: 
A much more recent direction of research in anti-cancer drug development is the development of 
compounds which can be triggered/activated via an external stimulus, such as temperature, pH, or 
even light.56,13 The idea behind these drugs is to be able to administer a nearly inactive pro-drug, 
which will not bind/attack any molecule/cell, and then be able to activate these molecules directly at 
the cancer/tumour site when and where they are needed. As mentioned before this is sometimes 
achievable by using the subtle differences in cancer cell environment compared to normal 
cells/blood (temperature, pH, etc.) to activate drugs passively. However a more powerful method of 
activation would be to have full control over when and where the compound activates.  
To this end a range of photo-sensitive/photo-activatable complexes have been developed in recent 
years which are inert while in darkness/in the body, but if irradiated with certain wavelengths of 
light will become activated in some fashion, become active species, and then be able to attack 
nearby cancerous cells, creating an effective and controlled chemotherapy treatment.  
The distinction between the activation/mechanism of these compounds has dictated their 
classification. Photo-sensitizers are compounds such as tetra-pyrrole, they function as energy 
transfer molecules; taking photons of light and re-distributing the energy to nearby species. Photo-
sensitizers for cancer therapy usually function by absorbing a convenient wavelength of light (that 
has a good transmission through skin/tissue, but is not harmful e.g. visible light) and then 
transferring the absorbed energy to nearby cellular components, usually oxygen molecules in order 
to activate them and create singlet oxygen. Singlet oxygen is a much more reactive form of 
molecular oxygen which can bind to nearby cellular components, damage them, and generally 
increase the concentration of Reactive Oxygen Species (ROS) within target cells and induce cell 
death and/or apoptosis.2 As a result photosensitisers should be unreactive themselves and usually 
have no mechanism of action against cancerous or healthy cells, but are simply a means to activate 
cellular oxygen using more convenient wavelengths of light. The main disadvantage of using 
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photosensitising molecules for anti-cancer therapy is that they rely on use of cellular oxygen for their 
action, yet cancerous cells are notoriously hypoxic (i.e. have very low levels of available oxygen), and 
so are hindered by the lack of active components to transfer the absorbed energy to effectively.1,57 
However there are strategies to circumvent this obviously limiting factor in the use of 
photosensitisers. The main tactic currently being to co-administer the photosensitising agent with a 
supply of oxygen to then activate where needed, thus eliminating the short supply of reagent. This 
co-administration has been achieved via the use of lipid nano-droplets sequestering both the 
photosensitiser in the lipid monolayer and the oxygen supply within a core of Perfluorocarbon, 
which can then be released with a wavelength of light and thus be available for photosensitising 
chemotherapy soon after.58 
 
Figure 2.8: representation of a) the Oxy-PDT agent comprised of the lipid nano-droplets containing 
the photosensitiser and oxygen-rich perfluorocarbon core. b) The active photosensitiser IR780. c) 
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The size distribution measurements via dynamic light scattering (DLS) of the Oxy-PDT agent. d) 
Ultrasound images of the Oxy-PDT agent and other solutions in test tubes showing uptake of 
IR780 and PFH. Reproduced from Cheng et al.58  
Due to the disadvantages of photosensitising agents, directly photo-activatable compounds have 
been developed and utilised as effective anti-cancer agents.56 Termed Photo-Activated Chemo 
Therapy (PACT),56 these compounds are usually activated by higher-energy wavelengths (such as 
blue/UV light), resulting in metal-ligand bond cleavage, liberating bound ligands (which may or may 
not be anti-cancer agents themselves) and creating a metal complex of different geometry and 
identity, which is usually a much more active and potent anti-cancer agent than the inert pro-
drug.56,59 The activation of these compounds is believed to be due to photon absorption in the Metal 
to Ligand Charge Transfer (MLCT) band of the pro-drug complex, causing excitation of electrons into 
anti-bonding orbitals, and weakening/cleavage of metal-ligand bonds, as shown in the molecular 
orbital diagram below in Figure 2.9: 
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Figure 2.9: MO energy diagram showing the various transitions available to d6 metal complexes 
with an octahedral geometry (such as the Pt(IV) compounds shown within). Blue arrows represent 
electrons with its associated spin in the ground state, coloured arrows represent electrons 
associated with a given transition. In the singlet state the electrons are spin up (coloured arrow 
pointing up) whereas in the triplet state they are spin down (coloured arrow pointing down) 
Reproduced from Shaili et al.60 
Currently there are an array of photoactivatable compounds synthesised and tested for their anti-
cancer activity based on a wide variety of metals including platinum, 8,61 ruthenium,55,56 and 
copper56. Though many options exists, certain complexes have exhibited difficulty becoming truly 
effective PACT agents, for example copper PACT complexes have been shown to exhibit a distinct 
increase in activity upon light-activation, a key factor in PACT strategy, but have also exhibited high 
activity/toxicity when not irradiated (high dark-toxicity), limiting their use as viable PACT agents.56  
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As briefly mentioned, the main target of photoactivated metallodrugs is to activate an inert metal 
complex to create an active anti-cancer metallodrug, however the ligands released from the 
complex may also help towards the anti-cancer effect desired. Even small molecules, if released in a 
high enough number, and in a targeted area may be able to bind to nearby biomolecules/disrupt 
equilibria/bind to metabolites or active target and generally disrupt cell function. The ability to 
disrupt target cancer cell function via both the active metallodrug, but also the released ligands is an 
interesting method of creating a multi-modal attack on cancer cells using varying mechanisms of 
action, and may be a way of combatting resistant strains of cancer, which may have become 
resistant to a certain metal-based treatment, but not to the ligand-release mechanism which has 
been effectively “co-administered” in one drug. PACT agents have also been synthesised with active 
anti-cancer agents tagged onto ligands of the inert complex,62 which upon release will begin to exert 
their own anti-cancer mechanism of action of the target cells. By using effective, proven organic-
based anti-cancer agents in this way the PACT agent is able to exert both an effective metal-based 
therapy (from the activated complex) and an effective organic/small molecule therapeutic (from the 
released ligands), all in a controlled, targeted fashion.56,61,63,64 The targeted release of active species 
is hoped to combat the more “global” side effects of current anti-cancer treatments, such as drugs 
attacking various parts of the body, far away from the actual tumour site, especially those that are 
naturally more similar to cancerous cells, such as hair growth cells which divide rapidly to achieve 
fast hair growth, a common side effect of cancer treatment. 
One of the leading PACT agents currently in development is trans, trans, trans-
[Pt(N3)2(OH)2(pyridine)2], codenamed FM190.
63 FM190 is based on an octahedral platinum(IV) 
geometry and is inert in darkness, possessing a full co-ordination sphere and non-labile ligands, it is 
an ideal basis for an inert pro-drug. Upon irradiation with blue-visible light the Pt(IV) pro-drug is 
activated, via Pt-azide bond activation,63 stimulating the creation of Pt(II) based species, and the 
release of azide radical species.54,64 Boasting very low activity in the dark and a potent IC50 activity of 
8.4µM when irradiated,63 FM190 has been shown to be an effective PACT agent on a variety of 
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cancer cell lines, including Cisplatin-resistant strains of cancer, which is a very impressive 
characteristic as the active species of both compounds are believed to be Pt(II) species. FM190 has 
actually been shown to be 19x more potent than Cisplatin when administered under identical 
conditions. 63  
FM190 contains several interesting features and developments over previous Pt(IV) based 
compounds, including the trans-pyridine ligands, azide release, low wavelength light-activation, and 
the inclusion of hydroxyl ligand release. Pt(IV) based compounds with azide functionality were 
shown to be photo-sensitive and be viable anti-cancer agents in 2006 by Sadler et al.65 However the 
previous compounds were based on ligands used in the widely applicable Cisplatin type molecules, 
such as NH3 ligands, the inclusion of trans-pyridine ligands was interesting as the cis-geometry for 
the amine-containing ligands has consistently been shown to be more effective and cytotoxic against 
cancer cells, the clinically unviable compound trans-platin was the perfect example of this 
phenomenon.61 The generation of Pt(II) species with trans amine ligand geometries which are 
extremely potent anti-cancer agents was a distinct change and proved to be interesting both 
chemically and pharmacogically.66,67 FM190 is activated using a relatively long (lower energy) 
wavelength of light, which is of great advantage to previous PACT agents and platinum(IV) species as 
it both allows the use of safe, non-damaging wavelengths of light, i.e. visible light (compared to the 
UV light required previously,66 but also that longer wavelengths of light show greater 
transmission/permeability through human skin and tissue than the short wavelengths, enabling 
external activation of the drug within the body using lights placed on the skin, These transmissions 
are summarised in Figure 2.10, below: 
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Figure 2.10: Light penetration measurements through human tissue, adapted from Shaili et al.68  
 
Figure 2.11: Some Pt(IV) photoactivatable metallodrugs based on the di-amine, di-hydroxido, di-
azide configuration. Below are the azide-Pt Ligand-to-metal Charge-Transfer (LMCT) band values 
from UV/visible spectroscopy and theoretical calculations, and the wavelength of light they can be 
successfully activated by, values taken from MacKay et al.59 and Farrer et al.63 
FM190 also releases azide radicals during the photoactivation process, extensively studied by Butler 
et al.54,64 by amongst other techniques, Electron Paramagnetic Resonance (EPR), to trap the 
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produced radicals and display characteristic patterns for azide radicals.64 Butler et al. also showed 
that the potency of FM190 against cancer cells when irradiated dropped dramatically when 
additional radical trapping agent (free tryptophan) was added during photoactivation, clearly 
showing that the radicals released during activation have a distinct contribution to the anti-cancer 
activity of the complex. It is also worth noting that the hydroxyl radicals released during activation 
would also have significant biological consequences as HO• molecules are utilised by cells for 
signalling purposes, and have been shown to cause extensive biomolecule damage and even cell 
death if present in high enough concentrations.69–71 Though Butler et al. did not show any significant 
trapping of •OH radicals, they have been shown to be released in this and similar systems. 
 
2.4.4 Catalytic metallodrugs: 
The use of active metal complexes against cancerous cells is well practiced (as discussed above), and 
they have also been used as extremely effective catalysts for decades, especially in the conversion of 
small molecules (dehydrogenation etc.) and polymerisation reactions (for example the Grubb’s 
metathesis catalysts72 etc.). Therefore these active (often piano-stool) transition metal complexes 
have the potential to act as effective “micro-reactors” within the body and act as catalysts to create 
anti-cancer compounds within the cells themselves.44,73,74 Catalytic metallodrugs are based on doing 
just that; remaining inside/outside target cells and using cellular components to create active anti-
cancer compounds (usually small molecules) to disrupt the equilibria inside cancerous cells 
(eventually causing cell death) or create cell damaging molecules (e.g. toxins) to damage cellular 
components directly, all without being used up/deactivated themselves. Effective catalytic 
metallodrugs are able to convert target cellular components, present inside the cell, to their 
products a certain number of times before becoming inactive (the turnover frequency/number), the 
higher this number, the longer the complex can survive the catalytic cycle (Figure 2.11, below) and 
continue to exert its cytotoxic effects. Effective catalytic metallodrugs have been synthesised based 
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on rhodium,44 iridium,74 and ruthenium,44 though many more transition metals should be viable 
based on other organometallic catalysts available. The catalytic cycle for a novel Rhodium 
metallodrug synthesised by Soldevila-Barreda et al.44 is shown below in Figure 2.12, the metallodrug 
catalyses the conversion of NAD+ to NADH, a key biological transformation used in many processes 
such as energy metabolism, mitochondrial function, antioxidation/generation of ROS, gene 
expression, ageing, and cell death.75 The catalytic metallodrug-induced increase in reductive stress 
(in contrast to oxidative stress, ROS, earlier) and disruption of these equilibria can eventually induce 
cell death, but not apoptosis, and so can effectively kill cancerous cells, via different mechanisms of 
action than many other apoptosis-inducing compounds.44 
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Figure 2.12: Catalysed reduction of NAD+ to NADH by a ruthenium based complex within cells (a) 
and the comparison to two, one ruthenium, one iridium, complexes and their different 
mechanisms of action and effects on cancerous cells (b), despite both compounds affecting the 
same NAD+/NADH cycle they have very different influences and biological consequences. 
Reproduced from Soldevila-Barreda et al.44  
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2.4.5 Multi-nuclear compounds 
Transition metal complex have been observed in a wide variety of geometries and forms, with multi-
dentate ligands, counter-ions, tethered complexes, and labile active positions. Also available are 
complexes containing more than one metal centre, often referred to as multi-nuclear complexes. 
These compounds have been observed in many configurations, including compounds containing 
“linker ligands” binding to both metal centres, metal helicates (compounds containing many long 
multi-dentate ligands to bind many metal centres76), and dimer-type complexes containing metal-to-
metal bonds, which ironically is usually a common step in the synthesis of many monomeric 
transition metal complexes. Effective multi-nuclear anti-cancer complexes have been synthesised 
and tested against cancerous cells/tumors,77 with a notable example being based on a gold metal 
centre, and shown in Figure 2.13 below: 
 
Figure 2.13: Example of a di-nuclear gold complex able to target redox-active sites via binding to 
neighbouring cysteine residues. Reproduced from Wai-Yin-Sun et al.77 
The compound shown was designed specifically to target redox active proteins, especially 
selenoenzymes such as Thioredoxin Reductase (TrxR), which contains a disulphide bond between 2 
neighbouring cysteine residues, this disulphide bond is an active site and can be turned on/off by 
reduction/oxidation of the disulphide bridge.77 The gold-based metallodrug is designed to bind 
strongly to the two available sulphur/selenium atoms when the disulphide bond is reduced, 
permanently deactivating the active site and preventing protein function. This deactivation has been 
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shown to be an effective way of attacking cancerous cells and increasing ROS stress to induce/trigger 
cell death.78,79 Since very few proteins contain disulphide bonds between cysteines directly next to 
each other in an amino acid sequence, the drug has shown relatively high selectivity, especially 
compared to its mono-nuclear predecessors79,77 and gold compounds with similar targets.78  
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Chapter 3: 
Multi-targeted Photoactivatable Platinum 
Anticancer Complexes 
The effective targets of most platinum based anti-cancer agents are the damaged strands of 
DNA within cancerous cells, however it has been shown that the vast majority of these active species 
never react with cancerous DNA but instead are believed to react with biomolecules along the way. 
Some believe the reaction of metallodrugs with non-target biomolecules to be purely deactivating, 
however others believe that biomolecule reactions can not only provide crucial benefits in the 
effective transportation of drugs through membranes and into target areas, but also that reactions 
with biomolecules can trigger key drug transformations in solution to create more active species and 
as a result better chemotherapy treatments.  
The chapter ahead investigates a novel next-generation anti-cancer compound (FM190) 
which can be activated by certain wavelengths of light to produce extremely potent, but not fully 
understood active species which effectively bind to biomolecules. The activation and subsequent 
reactions of FM190 towards several model biomolecules of interest are studied and explained. 
Reactions were monitored mainly using UHR-FT-ICR Mass Spectrometry, but also UV/visible 
spectroscopy, and Electron Paramagnetic Resonance spectroscopy (EPR) to monitor radical 
formation. The novel design and activation of Pt(IV) compounds makes them a very attractive area 
of study for chemotherapy, but also for analysis. Almost immediately it was apparent that the Pt(IV) 
compounds behaved very differently to previous Pt(II) metal-based drugs and posed unique 
analytical challenges, especially with relation to MS and subsequent MS/MS analysis. These 
challenges, the fundamental causes behind them, and the effect on MS data are discussed in detail, 
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including investigations into the unique mechanisms of dissociation for biomolecules involving 
platinum-based modifications. 
 
Although the results presented within this chapter are predominantly based on FT-ICR MS and 
MS/MS results from the thesis Author, this was a collaborative project and some elements were 
conducted by collaborating researchers, namely the synthesis of the FM190 compound was 
conducted by Evyenia Shaili, a proportion of the UV/visible spectroscopy was conducted by Evyenia 
Shaili and Carlos Sanchez-Cano, and the EPR spectroscopy was carried out and analysed by Carlos 
Sanchez-Cano. 
A manuscript entitled “Multi-targeted Photoactivatable Platinum Anticancer Complexes” by 
Christopher A. Wootton, Andrea F. Lopez-Clavijo, Carlos Sanchez-Cano, Evyenia Shaili, Mark P. 
Barrow, Peter J. Sadler, and Peter B. O’Connor, has been prepared for submission to the Journal of 
the American Chemical Society (JACS) based directly on the contents and findings of this chapter. 
166 
 
Abstract 
Octahedral platinum(IV) complexes such as trans,trans,trans-[Pt(N3)2(OH)2(pyridine)2] are 
stable in the dark, but potently cytotoxic to a range of cancer cells when activated by UVA or 
visible light, and active in vivo. Photoactivation can lead to reduction and unusual Pt(II) 
lesions on DNA, but radical chemistry is also initiated in the excited state. Here we show that 
peptides and proteins are also potential targets. High resolution FT-ICRMS studies show that 
reactions of trans,trans,trans-[Pt(N3)2(OH)2(pyridine)2] activated by visible light with two 
neuropeptides Substance P, RPKPQQFFGLM-NH2 (Sub P) and [Lys]
3
-Bombesin, Pyr-
QKLGNQWAVGHLM-NH2 (K
3
-Bom) give rise to unexpected products, both oxidized and 
platinated peptides. The non-ergodic character of ECD proved crucial in MSMS analysis, 
enabling retention of the Pt complex during fragmentation. Sub P undergoes one-O oxidation 
of Met
11
, whereas K
3
-Bom not only undergoes one-O oxidation of its C-terminal Met to the 
sulfoxide and two-O oxidation of Trp
7
 to N-formylkynurenine, the latter assignable to 
hydroxyl radical pathways. In EPR experiments on photoactivated 1 using the spin-trap 
DEPMPO, azidyl radicals were detected in the presence of Sub P but not K
3
-Bom which 
induced oxidation of the spin trap, characteristic of hydroxyl radical formation. Platination by 
{Pt(py)2(N3)}
+
 occurs preferentially at His
11
 of K
3
-Bom. Platination by Pt
II
 was observed at 
Lys
3
 and Arg
1
 of Sub P. This work reveals the multi-targeting nature of excited state platinum 
anticancer complexes. Not only can they target DNA but also peptides (and proteins) by 
radical coordination mechanisms, in a manner that that depends strongly on the amino acid 
sequence of the peptide. 
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Introduction 
Transition metal complexes have been explored and utilised as pharmaceuticals for decades, 
showing great promise as anti-cancer,
1
 anti-malarial,
2
 anti-tuberculosis,
3
 and anti-viral
4
 
agents. However it is the platinum based chemotherapeutics which have been of particular 
interest due to their widespread success in combatting many different forms of cancer.
5
  
Many of these metallodrug complexes exert their therapeutic effect by binding to the DNA in 
cancerous cells, causing a conformational change in the double helix and eventually leading 
to apoptosis;
6
 this is usually achieved via the reactive metal centre binding to preferred 
potential ligands on certain residues within the DNA.
7
  
Similarly peptides and proteins possess a range of potential ligands for these reactive 
complexes and can often form strong bonds with metallodrugs in the body,
8
 such that 90-98% 
of some of the most widely used anticancer metallodrugs in the blood plasma become protein 
bound within just 1 day after intravenous injection,
9
 although some believe protein binding 
may be a critical transport step in the overall mechanism of action of the metallodrug.
10,11
  
Differences in mechanism of action and ambiguity regarding how these drugs effectively 
combat cancerous cells has encouraged research into investigating exactly how and where 
these metallodrugs are binding to certain biomolecules, such as proteins.
812
  Mass 
spectrometry has established itself as a key technique for investigating these interactions and 
has been utilised to effectively study many metallodrugs including platinum based drugs 
Cisplatin,
13,14,15
 Transplatin,
16
  Oxaliplatin,
17
 many ruthenium based metallodrugs,
10,18
 and 
recently iridium and osmium based metallodrugs,
19,20
  all of which are injected into the body 
and rely on selectivity alone to direct these active drugs to cancerous cells.  
Moving on from more traditional transition metal compounds, new photoactivatable metal 
based chemotherapy agents are currently being investigated to improve on the promising 
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clinical and medical record of platinum complexes.  Photoactivation of metal complexes 
allows temporal and spatial control over the activation of these very active anti-cancer 
metallodrugs, theoretically reducing the more global side effects on the body from the 
platination of susceptible but non-target cells often seen during treatment with more 
traditional platinum drugs, such as Cisplatin.
21
  These novel anti-cancer compounds are 
injected into the body as an inert prodrug, usually as a six co-ordinate octahedral low-spin d
6
 
complex with non-labile ligands.  The Pt(IV) prodrug can then be activated at the tumour site 
via exposure to certain wavelengths of light;
21,22
 this exposure triggers photo-activated ligand 
release creating a highly active Pt(II) d
4
 species which will then react with nearby biological 
components in a similar fashion to other metallodrugs, by binding selectively to preferred 
ligands found on many biomolecules, such as DNA
23
 and possibly proteins. 
An important requirement for any effective drug to be used in Photo Activated Chemotherapy 
(PACT)
24
 is to exhibit little to no cytotoxicity in the dark, yet possess significant cytotoxicity 
to cancer cells upon irradiation.
23,24
  Dark toxicity has been a limitation for some cobalt and 
copper photoactivatable complexes as they have exhibited a high dark toxicity.
25
  In addition 
photoactivatable Pt(IV) complexes do not require oxygen to carry out their cytotoxic effect 
allowing them to function in the hypoxic conditions often seen in many cancerous 
tumours,
26,27
 a distinct advantage over other more conventional photosensitisers used in 
photodynamic therapy (e.g. those based on tetrapyrrole)
28
 and also over front line reagents 
such as Carboplatin and Cisplatin whose activity can be greatly reduced in hypoxic Ovarian 
cancer cell treatments.
29
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Herein a study is presented using the photoactivatable platinum complex trans, trans, trans-
[Pt(N3)2(OH)2(pyridine)2] (Complex 1), a novel anti-cancer prodrug (precursor to an active 
drug species) which, upon irradiation with certain wavelengths of visible light, will release 
ligands creating an active metallodrug which can bind to nearby targets, such as the DNA in 
cancerous cells, leading to apoptosis
6
 (Scheme 3.1).  It is important when investigating such 
photo-activated processes that both the fate of the metal complex and that of the released 
ligands is investigated as it has been shown that release of these reactive radical species plays 
a significant role not only in the potent cytotoxicity observed when using these complexes
30
 
but also in their activity against Cisplatin resistant strains of cancer.
21
 By studying the 
interactions of these new drugs with model biomolecules, it is possible to investigate these 
unique mechanisms of action and help explain the increased cytotoxicity, effectiveness 
against Cisplatin resistant cancer strains and other phenomena observed during the cytotoxic 
investigations of the metallodrug. 
 
 
 
Top-down tandem Mass Spectrometry (MS/MS) analysis has been successful in studying an 
array of peptides and proteins while retaining vital post-translational modifications 
(PTM’s).31,32,33 Electron capture dissociation (ECD) has been shown to be particularly 
effective for PTM analysis due to its non-ergodic character
34
 and its ability to fragment 
Scheme 3.1 : (Left) Trans, trans, trans-[Pt(N3)2(OH)2(py)2] (Complex 1), the photo-activatable prodrug 
used in this study, along with (Right) an illustrative photo-activation pathway leading to DNA binding (an 
inter-strand cross-link).
23
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species without loss of fragile PTM’s.35 Electron-based dissociations have proven to be 
particularly useful when studying metallodrug interactions where the top down approach has 
allowed the characterisation of entire protein sequences and the unambiguous determination 
of multiple binding sites for metallodrugs to various proteins
15,36,37
 without further chemical 
modifications such as digestion, which can disrupt/dissociate modifications, particularly 
organometallic complexes.  
Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FT-ICR MS) not only 
offers ultra-high resolving power and unparalleled mass accuracy,
38,39,40,41
 but also a large 
array of MS/MS fragmentation techniques including Collisionally Activated Dissociation 
(CAD), Electron Capture Dissociation, Infra-Red Multi Photon Dissociation (IRMPD), 
Electron Transfer Dissociation (ETD), and Electron Detachment Dissociation (EDD) making 
it ideally suited to investigating biomolecules via MS/MS.
42,43,20
 Though previous transition 
metal based metallodrugs have often shown a preference for certain (often sulphur 
containing) residues in biomolecules;
14,19
 the binding sites of new metallodrugs cannot be 
easily predicted based purely on these arguments as the nature of the remaining ligands 
greatly influences the rates and targets of drug binding.  
Other analytical techniques have been employed to study metallodrug-biomolecule 
interactions, such as X-ray crystallography
44
 and NMR spectroscopy,
45
 however these 
techniques are often limited by large sample requirements and/or suffer greatly when 
studying mixtures of compounds. FT-ICR MS offers a much more sensitive alternative which 
can provide accurate sequence information over a large mass range.
37,46,47
  By studying and 
understanding these interactions to a high accuracy on model biomolecules we will provide 
unambiguous identity and binding site information which could be implemented in future 
larger scale investigations on complex biological mixtures where the top down approach may 
not yet be available/viable. 
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Materials and methods 
Substance P (RPKPQQFFGLM-NH2), [Lys]
3
-bombesin (Pyr-QKLGNQWAVGHLM-NH2), 
and formic acid were purchased from Sigma Aldrich (Sigma Aldrich Company Ltd., Dorset, 
UK).  Low concentration Agilent tuning mix was purchased from Agilent Technologies 
(Santa Clara, CA) and used as received. Complex 1 was synthesised and characterised as 
described elsewhere.
21
 EPR tubes were purchased from Wilmad Labglass. The spin trap 5-
(Diethoxyphosphoryl)-5-methyl-1-pyrroline-N-oxide (DEPMPO) was obtained from Enzo 
Life Sciences in high purity and used without any further purification. Ultra-pure water was 
obtained from a Milli-Q UV III system (Milli-Q, Hertfordshire, UK). 
Reactions of peptides with complex 1 
Aliquots of aqueous solutions of Substance P (1 mM) and [Lys]
3
-Bombesin (1 mM) were 
prepared and mixed with an aqueous solution of complex 1 (250 μM) to give solutions of 
0.5:1, 1:1 and 2:1 drug:peptide mol ratio.  The samples were then irradiated under 463 nm 
(blue visible) light at 298 K for various times, before being diluted to MS concentrations (~1 
μM) and frozen at -80 ˚C ready for MS analysis. Freshly prepared samples were compared to 
those frozen for one to several weeks and showed no observable variation in the mass spectra 
obtained.  
FT-ICR Mass spectrometry 
Nano-electrospray (nESI) Mass spectrometry was performed on a Bruker SolariX Fourier 
Transform Ion Cyclotron Resonance Mass spectrometer (FT-ICR MS) fitted with a 12 Tesla 
actively shielded magnet (Bruker Daltonics, Bremen, Germany).  Aqueous peptide samples 
(5 μM) were spiked with 0.3% formic acid to aid ionisation during nESI.  Solutions 
containing Complex 1 (including reaction mixtures) were analysed via nESI in Milli-Q water 
with no added acid. 
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For ECD MS/MS analysis; the species of interest were isolated in the first quadrupole, 
externally accumulated in the collision cell for 0.1-7 seconds and then transferred to the 
Infinity Cell© for Electron Capture Dissociation (ECD) fragmentation and detection. Ions in 
the Infinity Cell© were irradiated with 1.3 eV -1.6 eV electrons from a 1.5 A hollow cathode 
dispenser for 50-600 ms prior to detection.  
For CAD  MS/MS analysis, species of interest were isolated in the first quadrupole and 
accelerated into argon collision gas contained within the hexapole collision cell for 
Collisionally Activated Dissociation (CAD) at 10-30 V and continuously accumulated for 
0.1- 4 seconds before transfer to the Infinity Cell© for detection. 
MS/MS spectra were internally calibrated using the minimal number of unmodified (peptide 
spectra) or modified (Pt adduct spectra) c/z ions and the charge reduced species [M+nH]
n-1+·
 
where possible (species used for calibration are marked). A dual-spray nESI experiment was 
also conducted using the [K
3
-Bom+2H]
2+
 ion and ions from Agilent Tune mix, utilising an 
in-cell isolation  (Multi-CHEF)
48
 and identical ECD parameters to validate the  internal 
calibration of the MS/MS spectra. Similar standard deviations were found for the ECD 
fragmentation spectra when calibrated with either fragment ions or with tune-mix peaks (see 
Supporting Information Figure S3.1 and Table S3.1). This dual-spray Multi CHEF ECD 
approach was also used for some Complex 1 + peptide reaction product ECD spectra to 
improve the internal calibration (spectra and calibration peaks marked accordingly). 
Electron Paramagnetic Resonance (EPR) measurements 
EPR spectra were recorded at ambient temperature on a Bruker EMX (X-band) spectrometer 
fitted with a cylindrical Tm110 mode cavity (Bruker 4103TM). Samples were contained in a 
quartz capillary (I.D. 1.0 mm; O.D. 1.2 mm; Wilmad Labglass) sealed with T-Blu Tac®, 
placed inside larger quartz tubes (O.D. 2.0 mm) to achieve easy and accurate positioning of 
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the sample inside the resonator. Typical key EPR spectrometer settings were modulation 
amplitude 2.0 G, microwave power 0.63 mW, 1.0 ×10
5
 receiver gain, conversion time 81.92 
ms, time constant 81.92 ms, sweep width 200 G, and a repeated number of 10 X-scans with a 
resolution in Y of 5 or 9. Spin-trapping experiments were performed on aqueous solutions of 
the complex with excess of spin trap (1 mM complex, 6 mM DEPMPO) in the presence or 
absence of peptides (1 mM). A visible blue light emitting diode (LED) (l= 463 nm, 64 mW 
cm
-2
) was used as the source of irradiation and placed at a distance of 8.5 cm from the tube in 
the EPR cavity. Irradiations lasted up to 2 h, each slice corresponding to 14 min of irradiation 
(10 scans). The TM110 EPR cavity used is equipped with a grid on one side allowing optical 
access (approximately 50%) transmission. The refractive index of quartz is approximately 
1.55; hence at normal incidence approximately 5% of the incident light is reflected at an air 
quartz interface. EPR spectra were analysed and simulated using the EASYSPIN software.
49
  
 
UV/vis Spectroscopy 
Aqueous solutions of Complex 1 (60 uM), SubP(120 μM), K3-Bom (120 μM), Complex 1 
(60 μM)+SubP (120 μM), and Complex 1 (60 μM)+K3-Bom (120 μM) were analysed via 
UV/vis spectroscopy using a Cary 300 scan UV-visible spectrophotometer (Agilent, 
California, US). Solutions were analysed in Quartz cuvettes (0.5 mL volume, 1 cm path 
length), in the region of 200-800 nm at a rate of 10 nm/s (600 nm/minute), average time = 0.1 
s, data interval 1 nm. 
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Results and Discussion 
Aqueous solutions of Peptide (either Substance P or [Lys]
3
-Bombesin were mixed with an 
aqueous solution of Complex 1 (in varying ratios of 1:1, 1:2, and 2:1 drug:peptide 
respectively). These solutions were then irradiated for 30-120 minutes with Blue-visible light 
(463 nm) to activate Complex 1 and initiate the photoreaction. Samples were immediately 
diluted after the set irradiation period with water and analysed via nESI-FT-ICR Mass 
Spectrometry. All sample preparation, incubations, and mass spectrometry analysis were 
conducted in darkness or with very low levels of red light to avoid activation of the complex, 
control analyses using bright red light showed no activation of the complex over several 
hours. Experiments conducted even in very low levels of white light were shown to alter the 
compositions of samples, as shown by continuous nESI-FT-ICR MS scanning over several 
hours, with continued exposure causing further photoactivation of Complex 1. 
 
nESI FT-ICR mass spectra of ~1 µM aqueous Complex 1+SubP and Complex 1+ K
3
-Bom  
reaction mixtures after 1 and 2 hours (respectively) of irradiation with blue visible light are 
shown in Figures 3.1a and 3.1b, respectively. Bombesin is a known tumour marker peptide 
for small cell lung carcinoma, neuroblastoma, and gastric cancer. Bombesin has also been 
shown to increase the proliferation of some pancreatic cancer cell lines.
50
 Substance P is a 
neuromodulator peptide involved in pain responses and inflammatory disease (amongst other 
processes), elevated levels of Substance P have also been found in several types of cancer 
cells.
51
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Figure 3.1: nESI FT-ICR mass spectra of ~1 µM aqueous Complex 1+SubP (a) and Complex 1+ K
3
-Bom 
(b) reaction mixtures (0.5:1 drug:peptide ratio) after 1 and 2 hours of irradiation (respectively) with blue 
visible light (463nm). Inset, various isotopic patterns for the observed (obs.) and calculated (calc.) species 
assigned from the mass spectra – showing the platinum influence on observed isotopic distributions. 
Green filled circles indicate unmodified peptide species, Red indicate oxidised species (both peptide and 
platinated peptides), other colours indicate platinated peptide species with different Pt(II) based 
modifications. 
An unexpectedly large number of products were observed for both reactions. Many spectral 
peaks can be assigned to adducts of platinum complexes to the peptide along with various 
bound ligands, as a result of the photoactivation process. For the Complex 1+Substance P 
mixture, only mono-platinated peptide adducts were observed containing the modifications 
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{Pt(py)(OH)(N3)}, {Pt(py)2(N3)}, {Pt(N3),},and {Pt(py)2}with reasonable intensity, along 
with a {Pt(py)2(OH)}-modified species at a very low intensity. 
The spectrum from the 1:2 reaction of Complex 1+ K
3
-Bom showed an even larger number 
of reaction products, including both mono- and di-platinated adducts, were observed 
including K
3
-Bom adducted to {Pt(py)2}, {Pt(py)2(N3)}, {Pt(py)2(OH)}, and both {Pt(py)2} 
and {Pt(py)2(N3)} simultaneously.  
Interestingly, for both peptides, oxidation with the addition of one oxygen (by exact mass) to 
the unmodified and platinated Substance P species and addition of one, two, or three oxygen 
atoms to the unmodified and platinated K
3
-Bom species was observed. 
A total of 8 products peaks were assigned for the reactions of Complex 1 and Substance P, 
and 10 for Complex 1 and K
3
-Bom, not including sodiated adducts thereof. This study has 
revealed new photochemical reaction pathways which have not been anticipated on the basis 
of previous work on this photoactivatable metallo-prodrug.
23
 Each new species is discussed 
below, along with the ECD MS/MS performed. 
Oxidised products 
Unexpected oxidation of both peptide and platinated peptide species was observed in the full 
nESI mass spectra of products from both peptides. These species were not observed in the 
mass spectra of the peptides without the addition of the metallodrug, or when either peptide 
was irradiated with blue visible light for the same period of time, and so are produced as a 
result of the photoactivation of the Pt(IV) metallodrug in the presence of biomolecules.  
ECD MS/MS of the individually isolated oxidised peptide species (i.e. [SubP+O+2H]
2+
, [K
3
-
Bom +O+2H]
2+
, [K
3
-Bom +O+2H]
2+
, and [K
3
-Bom +O+2H]
2+
) are summarised in 
fragmentation maps (Figure 3.2, below), showing oxidation at the methionine residue for the 
Substance P+O species and oxidation of the methionine and tryptophan residues within the 
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[Lys]
3
-Bombesin peptide for the K
3
-Bom +O, K
3
-Bom +2O, and K
3
-Bom +3O species. Fully 
assigned ECD MS/MS spectra are included in the supporting information (Figure SF2) along 
with lists of all assigned species (SI Tables ST3-6).  
 
Figure 3.2: Oxidised peptide species observed and fragmented by ECD MS/MS, red squares indicate a 
modification observed on the particular fragment. As a result, the modifications can be readily located to 
single amino acid residues (modified residues are marked). Fully annotated tandem mass spectra can be 
found in the supporting information (Figure SF2). 
The ECD MS/MS spectra of the mono- and di-oxidised K
3
-Bom species ([K
3
-Bom+2H +O]
2+
 
and [K
3
-Bom+2H+2O]
2+
) showed a mixture of products due to the 2 different reaction sites 
of the oxidation. The mono-oxidised K
3
-Bom species showed 2 product fragment 
distributions; one relating to the oxidation occurring at the methionine residue and one 
occurring at the tryptophan residue. The di-oxidised K
3
-Bom species also showed two 
product distributions; one relating to the oxidation of both the methionine and tryptophan 
once each, and the other product showing oxidation of the tryptophan residue twice. These 
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product distributions were clearly separated using high resolution mass spectrometry and 
ECD MS/MS, which produces far fewer side chain/neutral losses (such as H2O, CO, CO2, 
and NH3) which commonly populate CAD/CID MS/MS spectra and can mask multiple 
product distributions.
52
 Distinct products were identified via fragments such as the c12 and 
c12+O in the [K
3
-Bom +2H+O]
2+
 ECD MS/MS spectrum (Figure 3.2) which clearly conflict, 
with each stating a different composition for the [Pyr]
1
 to [His]
12
 region of the species. Since 
ECD is known to preserve such modifications, only when a mixture of components is 
considered do the fragmentation patterns become clear and both product MS/MS fragments 
can be assigned accurately. Unfortunately the two oxidation products for Trp and Met 
oxidised K
3
-Bom have exactly the same mass (K
3
-Bom +15.994915Da) and so cannot be 
resolved/separated purely via MS, even with ultra-high resolving power, but would be 
distinguishable using MS/MS techniques. The species are also unlikely to separate 
definitively via liquid chromatography due to the oxidation producing such a small change in 
conformation, size, and hydrophobicity. 
The terminal methionine residue present in both peptides have been shown previously to 
possess the potential to be oxidised once (to the sulfoxide)
53
 or twice (to the sulfone).
54
 
Despite the multiple stages of oxidation observed as a result the reaction, the methionine 
residues present were shown via ECD MS/MS to be oxidised only once to the sulfoxide 
moiety.  
The tryptophan residue present in the K
3
-Bom peptide was shown to become oxidised up to 
two times during the photoactivation process (Figure 3.2). Tryptophan oxidation however can 
cause a multitude of reaction products,
55
 causing different effects in structure and chemistry 
of the tryptophan residue side chain. Even more interestingly these products can be used 
diagnostically, as each product is characteristic of the process in which they were produced.
55
 
Work by Finley et al.
56
 showed a range of products can be formed upon Trp oxidation, the 5 
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structures are summarised in Scheme 3.2 (below) along with corresponding calculated exact 
mass changes for each reaction. 
Scheme 
3.2 -Possible oxidation products arising from singlet oxygen (KYN and 3OH-KYN) and radical oxidation 
(HTRP and NFK) of a tryptophan residue in a biomolecule
56,57
 along with corresponding expected mass 
changes for the modification. 
Furthermore work by Plowman et. al.
55
 has shown that the nature of the oxidising species 
influences which Trp oxidation products are produced; hydroxy-tryptophan and N-formyl 
kynurenine (NFK) reaction products are formed during the mono and di-oxidation of 
tryptophan residues when the oxidation is achieved via hydroxyl radical induced oxidation, 
while kynurenine (KYN) and 3-hydroxy-kynurenine (3OH-KYN) species are produced when 
the tryptophan oxidation is achieved via singlet oxygen induced oxidation. These studies 
show distinct chemical structure changes upon oxidation of tryptophan residues. However, 
these reaction products also have different mass changes compared to the original reagents, as 
a result accurate-mass mass spectrometry can be used to determine not only the products of 
the oxidation reaction, but also provide insights into the mechanism of the oxidation itself, 
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despite the products residing within a mixture of many reaction products, which would have 
to be carefully separated (e.g. by High Pressure Liquid Chromatography (HPLC)) in order to 
achieve individual accurate H-NMR spectra. Scheme 2 summarises the findings of Finley et 
al. and Taylor et al.,
56
 and also shows the calculated corresponding accurate mass changes 
due to each chemical reaction. From both the UHR-FT-ICR MS spectra of the reaction 
products (Figure 1a-b) and the corresponding MS/MS spectra (Figure S2a-d) the tryptophan 
oxidation products observed during this study are clearly the hydroxy-tryptophan (HTRP) 
and N-formyl kynurenine (NFK) moieties for the mono and di-oxidised species respectively 
showing the corresponding +15.994915 Da and 31.989829 Da mass shift in the mass 
spectrum and for tryptophan containing fragments in all MS/MS spectra (Figure S3.2a-d).  
The HTRP and NFK modified species are both the result of a radical based oxidation reaction 
involving hydroxyl radicals (as shown by Plowman et. al.),
55
 indicating that the release of the 
hydroxyl radicals from Complex 1 can then react with nearby biomolecules and cause 
oxidation of both methionine and tryptophan amino acid residues present.  
Although both methionine and tryptophan oxidation have been observed previously, the 
metallodrug-induced biomolecule oxidation observed here was of particular interest as this 
process had not previously been observed for these Pt(IV) compounds and could present a 
method of inducing oxidative stress in target cancer cells during photoactivatable 
chemotherapy (PACT).
58
 The release of reactive oxygen species (ROS) in cancer cells has 
been shown to trigger apoptosis
59
 and so photoactivated release of these species can be used 
as a targeted method of action against cancer independent of the metal centre’s 
cytotoxic/anti-proliferative characteristics which will carry out their own mechanism of 
action against the target cells upon binding to targets such as cancerous DNA. A platinum-
independent MoA such as release of these ROS species may also help explain Complex 1’s 
continued effectiveness against platinum (namely cisplatin) resistant strains of cancer cells. 
21
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Due to the metal-independent nature of the ROS MoA, cancer cells which have gained 
resistance to platinum-based cancer therapy (for instance due to under-dosing or prolonged 
exposure/treatment)
60
 will still be susceptible to an ROS based MoA, and so Complex 1 can 
continue to be an effective chemotherapy metallodrug. Unlike PDT treatments, since 
Complex 1 does not require an external source of oxygen to cause release of ROS, Complex 
1 can trigger ROS-induced apoptosis in hypoxic cancer cells, such as those from ovarian 
cancer, which have been shown to be particularly resistant to oxygen dependent treatments 
such as PDT, Cisplatin, and Carboplatin,
29
 and circumvents cancer cells “hypoxia-protection” 
towards anti-cancer therapy.
61
 
Interestingly, oxidation of tryptophan to the N-formylkynurenine species is also a critical step 
in the biological production of NAD
+
. By using Complex 1 to increase not only ROS 
concentration, but specifically to oxidise (free) tryptophan into NFK, production of oxidised 
tryptophan can push the equilibrium of this reaction to produce more NAD
+
. Artificially 
altering the NAD
+
/NADH balance inside target cancer cells has been recently shown
62
 to be a 
new and effective mechanism of action to combat cancer cells via the use of catalytic 
metallodrugs to change the concentration of NAD
+
/NADH inside cells and trigger cell death. 
Therefore Complex 1 could be a possible non-catalytic way of triggering cell death by a 
similar mechanism via production of NFK, meaning Complex 1 also has potential as a 
“kynurenergic” therapeutic compound.63 
The effect of free Trp on the photoactivation of Complex 1 was previously reported
30
 and 
showed a distinct change in the cytotoxicity of the complex towards target cancer cells. The 
observed drop in activity was at the time attributed to azide radical quenching by the free 
tryptophan residues, shown via EPR and further interrogated via isotope labelling of the azide 
ligands, followed by changes in the EPR results, correlating with the hypothesis of azide 
radical quenching. No reactions of the released azide radicals were shown to interact with 
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tryptophan residues in the K
3
-Bom peptide studied. Though the released azide radicals are 
effectively quenched by free tryptophan, bound tryptophan appeared to be less susceptible to 
free azide radicals. Observation of a drop in cytotoxicity due to additional free Trp would 
correlate well with the results observed here for Trp oxidation and the hypothesised impact 
on NAD
+
 production. If additional free Trp was added to a target cell environment, OH 
radicals produced during photoactivation of Complex 1 could be quenched, causing Trp 
oxidation to the hydroxyl tryptophan and NKF species (as shown in this study), in addition to 
released azide radical quenching observed previously.
30
  
UHR-MS is shown here to be an effective means of not only observing these modifications, 
but also elucidating and identifying the mechanisms leading to their production, which can 
facilitate further study and design of ROS releasing metallodrugs for treatment of platinum 
resistant and/or hypoxic cancer cells. 
 
Photoactivation of Pt(IV) complex in the presence of histidine-containing biomolecules:  
In addition to biomolecule oxidation, an array of platinum-based modifications were also 
observed following photoactivation of Complex 1 in the presence of biomolecules, discussed 
above and shown in Figure 3.1.  
[Lys]
3
-Bombesin (PyrKLGNQWAVGHLM-NH2 aka K
3
-Bom) contains a terminal 
methionine residue, a single histidine residue and a single lysine residue, all of which have 
the potential to donate electron density to a Pt metal centre (via a Sulphur/Nitrogen lone pair) 
and form a stable dative covalent bond. Extensive previous studies on Pt(II) complexes, such 
as Cisplatin, Carboplatin, and Oxaliplatin, have shown an almost uniform primary preference 
for methionine sulphur binding,
14,37,64–66
 often with a smaller secondary preference for 
histidine residues. Sulphur being a large, soft ligand has been shown to participate in very 
183 
 
strong bonds to platinum complexes, causing deformation of structure and intra-strand 
crosslinks,
37
 strong enough to survive harsh pH digestion conditions and high-energy gas 
phase dissociations in tandem MS experiments.
14
 
Electron capture Dissociation (ECD) MS/MS spectra of platinated K
3
-Bom species are 
summarised and shown in Figure 3.3. Platinum containing species (in both MS and MS/MS 
scans) were readily identified due to platinum’s characteristic isotopic pattern affecting the 
overall pattern observed (shown in Figure 1, inset). Full assignment lists and ECD MS/MS 
spectra can be found in the supporting information ST7-9 and SF3 respectively. The mono-
dentate Pt modifications (namely {Pt(py)2(N3)}
+
 and {Pt(py)2(OH)}
+
) were shown to bind 
unambiguously to the His
12
 residue of K
3
-Bom, despite the methionine sulphur availability at 
the biomolecule terminus.  
 
Figure 3.3: Platinated K
3
-Bom peptide species observed and fragmented by ECD MS/MS, coloured 
squares indicate a modification observed on the particular fragment. As a result the modifications can be 
readily located to single amino acid residues. Fully annotated spectra can be found in the supporting 
information (Figure SF3.3). 
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Uniform retention of pyridine ligands during the photoactivation of Complex 1 correlates 
well with previous 
1
H-NMR experiments.
21,27
 However retention of one azide ligand (in the 
case of the {Pt(py)2(N3)}
+
 modification) was not observed previously, azide release was 
observed via UV/Vis, EPR, and NMR experiments, however these techniques suffer when a 
range of products are formed, the production of {Pt(py)2}
2+
 modified species may mask azide 
retention and/or unreacted Complex 1 may impede spectroscopy data analysis. However, 
clear peaks for various platinated species can be observed simultaneously in the UHR-MS 
data presented, showing release of 1-2 hydroxyl ligands and 1-2 azide ligands. 
ECD MS/MS analysis of the [K
3
-Bom+Pt(py)2]
2+
 species yielded no sequence informative 
fragments, only ligand and/or side chain loss peaks, which is usually attributed to extended 
cyclic structures which can disrupt usual MS/MS fragmentation.
67
 However the presence of 
metal centres present unique challenges to MS and MS/MS analysis due to their unique 
behaviour compared to unmodified peptide/protein MS/MS, here lack of backbone 
fragmentation is attributed to both positive charges present on the ion originating from the 
Pt
2+
 centre, without additional protons along the poly(amino acid) backbone, the normal 
electron capture dissociation mechanism can be disrupted/impeded.
68,67,69,70
 and electron 
capture at the Pt centre would dominate, causing release of bound ligands and side chain 
losses from nearby amino acids (discussed below). ECD MS/MS of the [K
3
-Bom 
+Pt(py)2+H]
3+
 species produced abundant backbone fragmentation (Figure 3d) and enabled 
location of the binding site to be determined as the His
12
 and Met
14
 residues. The available 
proton allows for usual ECD fragmentation along the peptide backbone, however at least two 
electrons can still be captured at the Pt centre causing the previously observed ligand and side 
chain losses described (discussed below).   
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Photoactivation of Pt(IV) complex in the presence of non-histidine-containing 
biomolecules:  
Photoactivation of Complex 1 in the presence of a non-histidine containing peptide (in this 
case Substance P – RPKPQQFFGLM-NH2) was shown to produce a dramatically different 
range of reaction products (Figure 3.1a). Previously (with K
3
-Bom, Figure 3.1b) uniform 
retention of the pyridine ligands was observed and histidine binding was the main pathway 
for all adducts. However Substance P contains no histidine residue, but still possesses a 
terminal methionine residue and a lysine residue at position 3, both of which are able to bind 
to a Pt metal centre, though previous studies indicate Pt compounds would show a heavy 
preference for the Met residue.
14,71,72
  
 
Figure 3.4: Platinated SubP peptide species observed and fragmented by ECD MS/MS, coloured squares 
indicate a modification observed on the particular fragment. Fully annotated spectra can be found in the 
supporting information (Figure SF4). 
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Interestingly the Substance P Pt modifications observed did not show uniform retention of the 
pyridine ligands, instead the main adduct observed was Substance P modified with the 
{Pt(py)(OH)(N3)} moiety. The presence of this adduct (and the dominant intensity of it) 
indicates that not only can any of the bound ligands be released during the photoactivation 
process, but that the products of photoactivation depend directly on the ligands available in 
the vicinity of the complex during the activation, and so products are biomolecule dependant 
as are binding sites (discussed below). 
The [SubP+{Pt(py)(OH)(N3)}+2H]
2+
, [SubP+{Pt(py)2(N3)}+H]
2+
, [SubP+{Pt(N3)+H]
2+
, and 
[SubP+{Pt(py)2+H}]
3+
 species were shown (via ECD MS/MS) to exhibit the platinum 
modification within the N-terminal 4 amino acids of the peptide (RPKP) (Figure 3.4, above), 
annotated MS/MS spectra can be found in the supporting information (SI Figure SF3.4) along 
with lists of assignments (SI Tables ST3.10-12). ECD induced fragmentation is limited by 
proline residues,
73
 although the N-Cα bond of proline is cleaved during ECD MS/MS, the 
overall structure is held together via the cyclic alkyl side chain group of the amino acid 
residue, the so called “proline effect”.74 Unfortunately the proline effect limited 
fragmentation towards the N-terminal region of substance P (RPKP) due to the 2 proline 
residues (P2 and P4), however observation of the z9-H+{Pt(py)(OH)(N3)} fragment showed 
the location of the modification to be between the Lys
3
 and Pro
4
. The 
[SubP+{Pt(py)2(OH)}+H]
2+ 
species was observed at very low intensity at all irradiation 
times, as a result reliable MS/MS fragmentation of this species was not possible. 
It is worth noting that the Complex 1+ K
3
-Bom reaction mixture results shown were 
produced via irradiation for 2 hours since all products formed were present in shorter 
irradiation time samples (30, 60, 90 minutes) and seemed to increase in intensity with 
increasing irradiation time. The Complex 1 + SubP reaction mixture products were observed 
in varying intensities at different time points throughout the reaction; with 
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[SubP+Pt(py)(OH)(N3)+2H]
2+
 remaining the predominant product at shorter irradiation 
times. Increasing irradiation of the Complex 1 + SubP mixture encouraged further ligand 
release, decreasing intensity of multi-ligand complexes and increasing the intensity of the 
[SubP+Pt(N3)+H]
2+
 species over time, indicating that photoactivation is not a single 
transition from a Pt(IV) to Pt(II) species, but can continue after the Pt(II) species is formed, 
releasing further ligands and altering the product intensities observed. As a result all possible 
light was eliminated during sample preparation and mass spectrometry analysis of these 
reaction samples, to avoid further ligand release, which was observed even under low levels 
of distant white light. Low levels of red light were shown not to activate Complex 1 over 
several hours, as a result low levels of red light were used during analysis. Lack of activation 
under low levels of red light used during analysis and high levels used in control spectra, 
correlate well with previous results
21
 (also with UV/vis experiments conducted herein, see 
below) showing Complex 1 absorbs light in the blue region effectively, while also expressing 
a smaller absorbance to green light, which can activate the sample more slowly, yet showing 
no absorbance in the red light region of the visible spectrum.  
Pt induced ligand loss and Pt associated effects during electron dissociations: 
As mentioned previously, the ECD MS/MS spectrum of each Pt adduct showed a series of 
high intensity, singly-charged peaks close to the charge reduced species (SI Figures SF3.3a-d 
and SF3.4a-d). These peaks did not match any calculated usual c or z ion, nor any side chain 
loss commonly observed during ECD,
75
 but the highest m/z peak did correspond to the mass 
of the peptide+Pt (e.g. [Substance P+Pt]
+
 for the [Substance P+Pt(py)2(N3)+H] 
2+
 species), 
indicating an ECD-induced loss of ligands from Pt. The peak spacings were 15.02374 m/z 
and 31.97186 m/z. This corresponds to two separate losses of a terminal methyl group 
.
CH3 (-
0.16 ppm) and loss of 
.
CH3-SH (46.9956 m/z from spectrum, -0.25 ppm) (SI Figure SF3.7). 
Considering the sequences of Substance P (RPKPQQFFGLM-NH2) and K
3
-Bom 
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(PyrQKLGNQWAVGHLM-NH2) the only sulphur atom present is within the side chain 
methionine. The observed side chain loss differs from the usual side chain losses commonly 
observed for methionine which is C3H6S or C2H4S,
75
 suggesting that the Pt centre has 
affected the usual fragmentation of the peptide under ECD.
76
 For this to occur, Pt would have 
to be in close proximity to the methionine residue, as seen in previous work by Li et al.
36
 yet 
all current data points clearly to the binding of Pt to the histidine (His
11
) and lysine (Lys
3
) 
residues, depending on the amino acid sequence. Methionine sulphur is known to be a strong 
ligand for Pt(II),
14,37
 and the side chain losses here indicate a localised interaction. As a result 
this localised reaction must occur after the electron capture-induced loss of the Pt-bound 
ligands, the methionine side chain can then coordinate, to vacant sites on the Pt centre and 
account for the side chain losses observed. A proposed mechanism for the interaction of a 
methionine residue and the subsequent loss of the terminal methyl and CH3-SH species from 
the peptide is shown in Scheme 3.3. This scheme correlates with the side chain losses 
observed during this study, with the predicted interaction with methionine found in several 
reported Pt peptide MS/MS studies,
16,37,77,
 Pt- centred capture of an electron during ECD,
36
 
and commonly observed in Pt-ligand binding studies in solution.
78,79
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Scheme 3.3: Platinum centred side chain losses from methionine commonly observed during presented ECD 
MS/MS studies of platinated peptides. 
Scheme 3.4 (Supporting information (SF3.7)) shows a proposed mechanism for the loss of 
the platinum complex from peptides during electron capture, often observed for singly bound 
Pt modifications in this study (single binding site on peptide).  
ECD MS/MS of the diplatinated K
3
-Bom species produced a similar array of side chain 
losses as observed in mono-platinated species, however a more extensive number and variety 
of unusual sidechain losses and fragmentation channels were observed (SI Figure SF3.10). 
Unfortunately as observed in the ECD MS/MS of the [K
3
-Bom+Pt(py)2]
2+
 species, without an 
additional proton, ECD MS/MS was unable to provide enough sequence informative 
fragments to assign binding positions of the two platinum complexes, though based on the 
data observed for the previous modifications we would tentatively expect these modifications 
to be present on the His
12
 and Met
14
 residues (for {Pt(py)2}) and the Lys
3
 (for 
{Pt(py)2(N3)}
+
). 
Slow heating MS/MS of platinated species: 
It should be noted that more commonly used Collisionally Activated Dissociation (CAD) and 
Infra-Red Multi Photon Dissociation (IRMPD) MS/MS techniques were attempted on the 
observed platinum-peptide adducts, however these ergodic (so called “slow heating”) 
fragmentation methods break bonds in the lowest energy pathways in a molecule;
80,81
 for 
β 
γ 
β 
γ 
γ 
β 
β 
γ 
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peptides, these usually involve the amide bonds along the backbone.  However, CAD and 
IRMPD on the Pt adducts resulted in a series of peaks corresponding to the loss of each 
platinum bound ligand present, loss of the platinum modification (unmodified peptide), and a 
series of unassignable Pt and non-Pt containing peaks due to sequence scrambling commonly 
observed during the study of peptides and (gas-phase) labile post translational modifications 
such as metallation.
82,83
  In contrast, ligand loss was observed due electron capture at the 
metal centre during ECD MS/MS of the Pt adducts studied here, electrons could also be 
captured at points along the backbone according to the accepted ECD MS/MS mechanism,
68
 
allowing normal ECD fragmentation and production of interpretable c/z ions.  
It should also be noted that although the Pt complex showed the potential to bind to multiple 
groups present on the peptides studied; no crosslinking was observed, despite the low drug-
to-peptide mol ratio (0.5:1) which might have promoted this possibility.  The lack of 
crosslinking observed could be due to the short irradiation (reaction) times used (compared to 
the ~24 hour times used for Cisplatin crosslinking studies)
37
 and the low concentrations of 
reagents, reducing the rate of tri-molecular reactions, though this has not been a limitation 
previously.
77
 Square-planar Pt(II) has previously shown an ability to act as an effective 
crosslinking agent, even for proteins such as calmodulin.
77
 Although lack of crosslinking 
could also be attributed to the mechanism of Pt binding to the biomolecules; with Cisplatin-
type complexes relying on a solvent/biomolecule displacement of bound ligands in order to 
form biomolecule-Pt bonds, while the Pt based modifications observed herein were produced 
from a much faster and distinctly different photoactivation process. Due to the lack of a slow 
solvent-assisted ligand displacement reaction mechanism, the fast photo-induced reaction 
may be not as susceptible to further solvent/biomolecule displacement of bound ligands, 
limiting second/third binding of external species to the platinum complex. Lack of solvent 
assisted ligand dissociation correlated well with results found in this study, as no solvent 
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adducts/solvent displaced ligand complex species were observed and no reactions showed 
evidence of being displaced by solvent/biomolecule ligands post photoactivation without 
additional white/blue/green light, even after several hours in solution. A lack of crosslinking 
potential, while still expressing potent cytotoxic activity against cancer cells, suggests 
photoactivated Complex 1 may inhibit cancerous DNA in a different fashion to 
Pt(II)/Cisplatin reagents, which are believed to disrupt cancerous DNA/RNA most 
significantly via intra-strand DNA cross-linkages, preventing transcription of individual DNA 
strands,
6
 which warrants future investigation. 
Electron paramagnetic resonance:  
EPR has previously been used to effectively monitor the radicals released during the 
photoactivation of Pt(IV) metallodrug complexes.
30
 The FT-ICR MS data presented here has 
shown the effect that the (now identified) hydroxyl radicals can have upon nearby 
biomolecules and the extent of oxidation which can be achieved. However previous work has 
shown the release of azide radicals during this photoactivation process.
3084
 These findings 
were mirrored in the work presented here which shows Pt(II) based modifications with only a 
single or no azido ligands remaining bound to the Pt(II) centre post-photoactivation, clearly 
indicating 1-2 azide radicals are released in the process. One would expect such a reactive 
radical species to react with the nearby biomolecules and cause modifications, however no 
azide modification of the peptides or platinated peptides was observed at any point during 
this study. In order to monitor the release of the azide radicals, and to explore the possibility 
that the peptides themselves could be influencing the release of the azide radical species, EPR 
was employed to study the photoactivation of Complex 1, Complex 1+Substance P, and 
Complex 1+[Lys]
3
-Bombesin, the results are shown in Figure 3.5, below (EPR experimental 
values calculated can be found in Supporting information tables ST3.14a-c). 
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Figure 3.5 – EPR scans for photoactivation (via blue visible light) of (a) Complex 1 (b) 
Complex 1 + Substance P and (c) Complex 1 + [Lys]
3
-Bombesin - showing spin trap 
oxidation. Simulations of corresponding patterns are included below their 
corresponding observed signal. 
a) Complex 1+DEPMPO  
Simulation: 
Simulation: 
b) Complex 1+SubstanceP+DEPMPO  
Simulation: 
c) Complex 1+[Lys]
3
-Bombesin+DEPMPO  
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EPR of the samples was conducted using the DEPMPO spin trap, specifically to be able to 
differentiate between azide and hydroxyl radicals, should both be produced simultaneously.
85
 
EPR using the DEPMPO produces more complicated splitting patterns than the more 
commonly used DMPO trap, however Figure 3.5(a) shows clearly that the azide radicals are 
being effectively quenched from the reaction, trapped by the DEPMPO and producing an 
EPR spectrum similar to Butler et al. for this system.
30
 The EPR spectrum of Complex 
1+Substance P shows a similar EPR spectrum to Figure 3.5(a), with a slightly lower intensity 
for  the same time points (SI Figure SF3.9), indicating that Substance P does not appear to be 
interfering with the production of azide radicals during photoactivation, however it does 
suggest fewer are being trapped by the DEPMPO spin trap, this could arise from the 
stabilisation of azido-Pt(II) complexes by the substance P peptide, as shown in the FT-ICR 
MS there are multiple azido-containing species detected, as a result fewer would be released, 
trapped, and detected.  
The EPR spectrum of the Complex 1+[Lys]
3
-bombesin sample was dramatically different to 
the Complex irradiated without a peptide present. The EPR splitting pattern does not 
resemble azide or hydroxyl radical quenching by DEPMPO. Instead it was found that the 
pattern matched that of oxidised DEPMPO (Scheme 3.5, below).
85
 The large extent of 
oxidation occurring during Complex 1 photoactivation in the presence of K
3
-Bom (detected 
via FT-ICR MS) appears to spread to oxidation of the DEPMPO also (shown here in the EPR 
spectra). The FT-ICR MS and MS/MS spectra above show the clear evidence for production 
of hydroxyl radicals reacting with biomolecules when available, but no azide modification. 
The EPR spectra are able to monitor the azide radicals released which do not appear to react 
with the peptide Substance P and create a new radical species (which would have produced a 
different EPR splitting pattern to that of Complex 1 alone). 
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Scheme 3.5: a) DEPMPO spin trap used during the EPR studies of Complex 1 photoactivation, b) Usual DMPO 
spin trap commonly used for EPR, c) DEPMPO+trapped OH radical structure detected by EPR, 
85
 d) Oxidised 
DEPMPO caused by high concentration of OH radicals produced via photoactivation of Complex 1.
85 
UV/Visible spectroscopy: 
Previously,
23
  it has been shown that Complex 1 produces a very pronounced charge transfer 
band when studied by UV/visible spectrometry, this band corresponds to Pt-azide charge 
transfer and can be used to monitor the extent of the bond photoactivation. Photoactivation of 
Complex 1 was again studied, also in the presence of the Substance P /[Lys]
3
-Bombesin 
peptide in order to see if UV/vis spectroscopy could detect any influence the biomolecule’s 
presence was having upon the photoactivation process. Complex 1 and both peptides were all 
scanned individually for baseline measurements, the two peptides showing minimal UV/vis 
absorbance in the region studied. Complex 1 was then photoactivated in the presence of 
either peptide and the mixture was scanned at various time points. The resulting UV/vis 
traces can be found in the supporting information (SI Figure SF3.10a-c). Substance P has an 
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unusually low UV/vis absorbance for a peptide (despite phenylalanine residues), and so 
produced a photoactivation profile almost identical to that of Complex 1 alone (SF3.10a and 
SF3.10b). The observation of a similar spectrum to that of Complex 1 itself suggests 
Substane P is not having a significant effect upon the rate of photoactivation of the Pt-Azide 
bond. K
3
-Bom effectively absorbs UV/visible light and produces a characteristic UV/vis 
spectrum (SI figure SF10.9c). Photoactivation of Complex 1 in the presence of K
3
-Bom 
showed steady production of a new peak shifted ~50nm from the original Pt-azide band, 
which increased with irradiation time, indicating new photoproducts produced during the 
reaction, most likely the azide-containing Platinated K
3
-Bom species observed previously in 
the FT-ICR MS spectra (above). 
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The effect of free tryptophan: 
Addition of free tryptophan during the photoactivation process of Complex 1 was previously 
shown to have a dramatic effect on the cytotoxicity measurements of the metallodrug, this 
was believed to be due to tryptophan’s ability to trap the radicals released during the 
photoactivation process.
30
 Very little additional tryptophan was needed to cause a dramatic 
effect on the cytotoxicity measured, in fact only 1/8
th
 of the concentration of free Trp (with 
respect to Complex 1) was needed to see a 70% change in cytotoxicity, which presented the 
opportunity to use free Trp as a molecular switch for activity of Complex 1 during treatment. 
Due to this dramatic effect during biological tests it was decided to investigate the effect of 
additional free tryptophan on the products and product ratio’s observed for the Complex 
1+peptide reactions studied here.  
Reaction mixtures were prepared as for previous experiments with the exception that 
additional free tryptophan was added before the photoactivation step, end concentration of 
tryptophan was 1/8 the concentration of Complex 1 (end concentration 31.25 µM, 3.1 nMoles 
Trp added). 
The SubstanceP+Complex 1+Trp reaction mixture mass spectrum showed the same reaction 
products as previously observed, no different/previously observed species were/were not 
detected as a result of free Trp addition. Product ion intensities were broadly similar to the 
previous SubstanceP+Complex 1 sample, though oxidised substance P and oxidised 
Substance P+platinum adducts were observed in a lower intensity (29% and 95% lower 
respectively), indicating that the Trp may be reducing the available ROS (namely the 
hydroxyl radicals) and limiting biomolecule oxidation. The K
3
-Bom + Complex 1+Trp 
reaction mixture showed a much greater difference in intensities; every oxidised/Platinated 
species (aside from the [K
3
-Bom+O+2H]
2+
  and [K
3
-Bom+3O+2H]
2+
 species) were reduced 
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in intensity by 32-98% compared to the previous reaction mixture without additional 
tryptophan. The drastic differences in product ion intensities indicated  radical trapping 
agents could play a large role in the formation of certain platinated adducts in solution, 
although intensities may have varied between the two reaction mixtures; all previously 
observed products were also observed in the added tryptophan reaction mixtures. Graphs 
showing the relative ion intensities of the individual reaction products are shown in Figure 
SF3.5, Tables showing the relative intensity changes are shown in the supporting 
information, Tables ST3.13a and b. 
Previous results from Butler et al.
30
 showed a 70% drop in the number of radicals using the 
same 1/8
th
 concentration of free tryptophan. For the SubstanceP+Complex 1+Trp reaction 
mixture an average relative intensity drop of 17% was observed over all reaction products. 
For the K
3
-Bom +Complex 1+Trp reaction mixture an average relative intensity drop of 67% 
was observed, which is very similar to previous results by Butler et al. using NMR and EPR 
studies.
30
 As many peptides and proteins in cells are likely to contain at least one tryptophan 
and/or histidine residue; most of the Complex 1+biomolecule products may resemble those 
observed in the Complex 1+ K
3
-Bom mass spectrum, showing uniform retention of both 
pyridine ligands, and also showing a similar drastic effect to the addition of free tryptophan. 
Substance P on the other hand contains neither tryptophan or histidine residues and so we are 
able to show here the differences in susceptibility to this effect, which appears to be much 
less extreme in the case of a non-His/Trp containing peptide, which is most likely due to the 
nature of the platinum complexes formed, the sequence dependent binding, and the ligands 
released as a result. Though no products involving azide radical reactions/damage were 
observed in any the mass spectra obtained during this study, they may also be affected by the 
addition of free tryptophan (as previously shown the EPR and NMR studies).  
 
198 
 
Conclusions: 
Photoactivatable platinum(IV) complexes have been shown to possess potent anticancer 
potential and provide a new level of spatial and temporal control over the drug activation 
process in photo activated chemotherapy (PACT). Here a novel Pt(IV) PACT agent, trans, 
trans, trans-[Pt(N3)2(OH)2(py)2] (Complex 1), was activated in the presence of model 
biomolecules (Substance P and [Lys]
3
-Bombesin peptides) in order to gain insights into the 
species produced during the photoactivation process and the species which would be 
produced if activated in the body. 
When histidine moieties were available (i.e. when activated in the presence of [Lys]
3
-
bombesin), complete retention of both pyridine ligands was observed (correlating with 
previous 
1
H-NMR studies), however when this residue was not available (i.e. when activated 
in the presence of Substance P) a very different range of products was observed, many of 
which did not retain both, or even one of the pyridine ligands. The discovery of the multiple 
possible platinum modifications due to the photoactivation process has helped provide 
limited explanation for the interesting biological data observed for these metallodrugs, most 
notably the obvious differences in chemistry and mechanisms of action observed for this 
compound in comparison with previous generations of platinum(II) based anti-cancer 
metallodrugs, such as Cisplatin.  
Other interesting features observed included the large extent of oxidation caused by 
irradiation of this compound in the presence of biomolecules. Release of multiple hydroxyl 
ligands was seen to cause multiple stages of oxidation to nearby peptides, both with and 
without the platinum complex modification. For Substance P; one incidence of oxidation was 
observed at the methionine residue. However for [Lys]
3
-bombesin, up to three stages of 
oxidation were observed; high resolution MS/MS experiments showed oxidation at the 
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methionine residue (x1) and the tryptophan residue (x2), using the mass differences observed 
and previous oxidation studies of biomolecules
56
 it was confirmed that the hydroxy-
tryptophan (HTRP) and N-formylkynurenine (NFK) moieties were formed. The preference 
for the tryptophan site, an electron acceptor and redox active amino acid,
86
 and the formation 
of the HTRP and NFK moieties both re-enforce the conclusion that this was a radical based 
oxidation process, not a singlet-oxygen process as previously believed for some Pt(IV) 
photoactivated compounds.
84
  
Though addition of free tryptophan had been previously shown to cut the number of radicals 
by 70% by EPR and NMR studies of in cell reactions,
30
 a much more modest reduction in 
product ion intensities of 17% was observed for a SubstanceP+ Complex 1+tryptophan 
reaction mixture of comparable reagent ratios. A much greater reduction of 67% was 
observed for the K
3
-Bom + Complex 1+tryptophan reaction mixture, and showed decreases 
in relative intensity of up to 98% for certain reaction products, indicating that radical trapping 
agents can have a dramatic effect on the products observed in photoactivatable processes 
involving homolytic bond cleavage.  
The multitude of reactions which occur following the photoactivation of Pt(IV) compounds 
have been shown to produce a range of products, varying greatly, and producing a mixture of 
different species which would be challenging to separate and study with commonly used 
analytical techniques. UHR-MS and MS/MS experiments offer a unique and highly accurate 
method of studying these species and can provide unambiguous determination of 
modifications and modification binding site, despite the wide variety of products produced. 
Study into the fundamental mechanism of action of these new and interesting compounds is 
key to informing and developing improved anti-cancer strategies such as photoactivated 
chemotherapy therapy, and UHR-MS is becoming increasingly desirable to use when 
attempting to study such complex problems.  
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Figure 3.6: Summarising figure of the reaction products observed during the study of 
Complex 1 with the model peptides 
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 Supporting information for Chapter 3:
 
SI Figure 3.1 (SF3.1) – nESI-FT-ICR MS spectra of Substance P (a) and K3-Bom (b)  
 
 
SI Figure 3.2 (SF3.2) – ECD MS/MS spectrum of K3-Bom, peptide was co-isolated with 5 calibrant ions 
in order to improve calibration and compare the use of peptide MS/MS fragments and unrelated 
ions when internally calibrating MS/MS spectra.  
K3-Bom: 
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SI Table 1 (ST3.1) – Resulting assignments and associated Mass errors (in parts per million – ppm) for 
each calibration method used during the analysis of the K3-Bom ECD MS/MS spectrum shown above. 
Using co-isolated HP mix calibrant ions:  Using K3-Bom fragment ions: 
Assign
ment 
Theoretical 
m/z 
Observed 
m/z 
Error/ 
ppm 
 Assign
ment 
Theoretical 
m/z 
Observed 
m/z 
Error/ 
ppm 
c6 669.367290 669.36780 0.76  c6 669.367290 669.36729 0.00 
z7 796.404850 796.40441 -0.55  z7 796.404850 796.40386 -1.24 
c7 797.425870 797.42642 0.69  c7 797.425870 797.42587 0.00 
z8 924.463430 924.46324 -0.21  z8 924.463430 924.46270 -0.79 
z8. 925.471255 925.47090 -0.38  z8. 925.471255 925.47035 -0.98 
c8. 982.497355 982.49757 0.22  c8. 982.497355 982.49703 -0.33 
c8 983.505180 983.50543 0.25  c8 983.505180 983.50489 -0.29 
z9 1038.506360 1038.50604 -0.31  z9 1038.506360 1038.50552 -0.81 
z9. 1039.514185 1039.51385 -0.32  z9. 1039.514185 1039.51333 -0.82 
c9. 1053.534465 1053.53491 0.42  c9. 1053.534465 1053.53439 -0.07 
c9 1054.542290 1054.54262 0.31  c9 1054.542290 1054.54211 -0.17 
z10 1095.527820 1095.52701 -0.74  z10 1095.527820 1095.52652 -1.19 
z10. 1096.535645 1096.53490 -0.68  z10. 1096.535645 1096.53440 -1.14 
c10. 1152.602875 1152.60309 0.19  c10. 1152.602875 1152.60262 -0.22 
c10 1153.610700 1153.61108 0.33  c10 1153.610700 1153.61061 -0.08 
z11 1208.611880 1208.61158 -0.25  z11 1208.611880 1208.61114 -0.61 
z11. 1209.619705 1209.61878 -0.76  z11. 1209.619705 1209.61834 -1.13 
c11. 1209.624335 1209.62488 0.45  c11. 1209.624335 1209.62444 0.09 
c11 1210.632160 1210.63259 0.36  c11 1210.632160 1210.63215 -0.01 
z12 1336.706840 1336.70647 -0.28  z12 1336.706840 1336.70612 -0.54 
c12 1347.691070 1347.69166 0.44  c12 1347.691070 1347.69133 0.19 
c13 1460.775130 1460.77538 0.17  c13 1460.775130 1460.77515 0.01 
z13 1464.765420 1464.76540 -0.01  z13 1464.765420 1464.76520 -0.15 
CRS-H 1591.815620 1591.81624 0.39  CRS-H 1591.815620 1591.81617 0.35 
 Average error 0.40    Average error 0.47  
Standard deviation 0.44  Standard deviation 0.51 
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SI Figure 3.3 (SF3.3) ECD MS/MS of unmodified Substance P (top) followed by list of assignments 
(middle) and corresponding fragmentation map (bottom) 
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SI table 3.2 (ST3.2a): Species observed within the nESI-FT-ICR Mass Spectra of the Complex 1+SubP 
solution post-photoactivation. 
 
(ST3.2b): Species observed within the nESI-FT-ICR Mass Spectra of the Complex 1+K3-Bom solution 
post-photoactivation. 
Species Elemental composition Modification to peptide 
observed 
[K3-Bom+H]+ C71H110N22O18SH N/A 
[K3-Bom+2H]2+ C71H110N22O18SH2 N/A 
[K3-Bom+O+2H]2+ C71H110N22O18SH2O +O 
Species Elemental composition Modification to peptide 
observed 
[SubP+2H]2+ C63H98N18O13SH2 N/A 
[SubP+H]+ C63H98N18O13SH N/A 
[SubP+O+2H]2+ C63H98N18O13SH2O +O 
[SubP+{Pt(py)2}+H]3+ C63H98N18O13SPtC10H10N2H 
 
[SubP+{Pt(py)2(N3)}+H]2+ C63H98N18O13SPtC10H10N5H 
 
[SubP+{Pt(py)2(OH)}+H]2+ C63H98N18O13SPtC10H10N2OHH 
 
[SubP+{Pt(N3)}+H]2+ C63H98N18O13SPtN3H 
 
[SubP+{Pt(py)(OH)(N3)}+2H]2+ C63H98N18O13SPtC5H5NOHN3H2 
 
[SubP+{Pt(py)(OH)(N3)}+O+2H]2+ C63H98N18O13SPtC5H5NOHN3H2O 
 
+O 
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[K3-Bom+2O+2H]2+ C71H110N22O18SH2O2 +2O 
[K3-Bom+3O+2H]2+ C71H110N22O18SH2O3 +3O 
[K3-Bom+{Pt(py)2}]2+ C71H110N22O18SHPtC10H10N2 
 
[K3-Bom+{Pt(py)2}+H]3+ C71H110N22O18SHPtC10H10N2H 
 
[K3-Bom+{Pt(py)2(OH)}+H]2+ C71H110N22O18SHPtC10H10N2OHH 
 
[K3-Bom+{Pt(py)2(N3)}+H]2+ C71H110N22O18SHPtC10H10N2N3H 
 
[K3-Bom+{Pt(py)2(N3)}+O+H]2+ C71H110N22O18SHPtC10H10N2N3OH 
 
+O 
[K3-Bom+{Pt(py)2(N3)}+2O+H]2+ C71H110N22O18SHPtC10H10N2N3O2H 
 
+2O 
[K3-Bom+{Pt(py)2(N3)}+3O+H]2+ C71H110N22O18SHPtC10H10N2N3O3H 
 
+3O 
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SI Figure 3.4 (SF3.4): ECD MS/MS spectra of Oxidised peptides individually isolated and dissociated 
using ECD within the FT-ICR MS; a) Substance P+O b) K3-Bom+O C) K3-Bom+2O d) K3-Bom+3O.  Red 
labels indicate modified fragments. Assignment table for each species can be found below. 
SI Tables 3.3-6: assignment lists for individual ECD MS/MS spectra for the isolated oxidised peptide 
species; ST3) Substance P+O, ST4) K3-Bom+O, ST5) K3-Bom+2O, ST6) K3-Bom+3O. Marked species 
were used for internal calibration, in tables with no marked species; co-isolated calibrant ions were 
used for calibration instead of MS/MS fragments, as discussed in the experimental section. 
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SI Table 3.3 (ST3.3): ECD MS/MS assignments for the SubP+O species:  
Fragment Exact mass Observed mass Error/ppm 
[c2]+ 271.187690 271.18770 0.04 
[c4]+ 496.335410 496.33543 0.04 
[c5]+ 624.393990 624.39400 0.02 
[c6]+ 752.452570 752.45257 0.00 
[c7]+ 899.520980 899.52094 -0.04 
[c8]+ 1046.589390 1046.58935 -0.04 
[c9]+ 1103.610850 1103.61064 -0.19 
[c10]+ 1216.694910 1216.69471 -0.16 
[SubP+O+2H]+. 1364.738145 1364.73817 0.02 
[z9]+ 1094.557725 1094.55765 -0.07 
  Absolute average 0.06 
  Standard deviation 0.08 
SI Table 3.4 (ST3.4): ECD MS/MS assignments for the K3-Bom+O species:  
Fragment Exact mass Measured mass Error/ppm 
[c6]+ 669.367290 669.36794 0.97 
[c7]+ 797.425870 797.42638 0.64 
[c9]+ 1070.537205 1070.53756 0.33 
[c10]+ 1169.605615 1169.60610 0.41 
[c11]+ 1226.627075 1226.62770 0.51 
[c12]+ 1363.685985 1363.68616 0.13 
[c13]+ 1476.770045 1476.77013 0.06 
[K3-Bom+O+2H-H]+. 1607.810535 1607.80981 -0.45 
[c8.]+ 998.492270 998.49250 0.23 
[c9.]+ 1069.529380 1069.52972 0.32 
[c10.]+ 1168.597790 1168.59847 0.58 
[z7]+ 812.399765 812.40030 0.66 
[z8]+ 940.458345 940.45818 -0.18 
[z9]+ 1054.501275 1054.50101 -0.25 
[z10]+ 1111.522735 1111.52226 -0.43 
[z11]+ 1224.606795 1224.60649 -0.25 
[z12]+ 1352.701755 1352.70124 -0.38 
[z13]+ 1480.760335 1480.75951 -0.56 
[z7.]+ 813.407590 813.40772 0.16 
[z8.]+ 941.466170 941.46654 0.39 
[z9.]+ 1055.509100 1055.50884 -0.25 
[z10.]+ 1112.530560 1112.53004 -0.47 
  Absolute average 0.39 
  standard deviation 0.43 
 
 
216 
 
SI Table 3.5 (ST3.5): ECD MS/MS assignments for the K3-Bom+2O species:  
Fragment Exact mass  Observed Mass  Error/ppm 
[c6]+ 669.36729 669.36795 0.99 
[c7. ]+ 796.41805 796.41856 0.65 
[c7]+ 797.42587 797.42640 0.66 
[z7-H+2O]+ 827.38740 827.38688 -0.63 
[z8+2O]+ 956.45326 956.45340 0.15 
[z8.+2O]+ 957.46109 957.46118 0.10 
[c8.+O]+ 998.49227 998.49253 0.26 
[c8.+2O]+ 1014.48719 1014.48791 0.71 
[c8+2O]+ 1015.49501 1015.49604 1.01 
[c9.+O]+ 1069.52938 1069.53030 0.86 
[c9+O]+ 1070.53721 1070.53746 0.24 
[z9+2O]+ 1070.49619 1070.49576 -0.40 
[z9.+2O]+ 1071.50402 1071.50399 -0.02 
[c9+2O]+ 1086.53212 1086.53442 2.12 
[c10.+O]+ 1168.59779 1168.59867 0.75 
[c10+2O]+ 1185.60053 1185.60047 -0.05 
[c11.+O]+ 1225.61925 1225.61937 0.10 
[c11+O]+ 1226.62708 1226.62731 0.19 
[z11+2O]+ 1240.60171 1240.60117 -0.44 
[z11.+2O]+ 1241.60954 1241.60878 -0.61 
[c11+2O]+ 1242.62199 1242.62276 0.62 
[c12+O]+ 1363.68599 1363.68585 -0.10 
[z12+2O]+ 1368.69667 1368.69605 -0.45 
[c12+2O]+ 1379.68090 1379.68053 -0.27 
[c13+O]+ 1476.77005 1476.77044 0.27 
[c13+2O]+ 1492.76496 1492.76449 -0.31 
[z13+2O]+ 1496.75525 1496.75359 -1.11 
[z13.+2O]+ 1497.76308 1497.76135 -1.15 
  Absolute average 0.54 
  Standard deviation 0.69 
 
SI Table 3.6 (ST3.6): ECD MS/MS assignments for the K3-Bom+3O species:  
Fragment Exact Mass Observed Mass Error/ppm 
[c7]+ 797.42587 797.42619 0.40 
[c9+2O]+ 1086.53212 1086.53357 1.33 
[c11+2O]+ 1242.62199 1242.62120 -0.64 
[c12+2O]+ 1379.68090 1379.68204 0.83 
[c13+2O]+ 1492.76496 1492.76538 0.28 
[K3-Bom+3O+2H-H]+. 1639.80037 1639.80098 0.38 
[c8.+2O]+ 1014.48719 1014.48766 0.47 
217 
 
[c10.+2O]+ 1184.59271 1184.59291 0.17 
[c13.+2O]+ 1491.75714 1491.75668 -0.31 
[z11+3O]+ 1256.59663 1256.59580 -0.66 
[z12+3O]+ 1384.69159 1384.69032 -0.91 
[z13+3O]+ 1512.75017 1512.74992 -0.16 
[z8.+3O]+ 973.45600 973.45558 -0.43 
[z9.+3O]+ 1087.49893 1087.49961 0.63 
 Absolute average  0.54 
Standard deviation 0.62 
 
 
SI Figure 3.5 (SF3.5): ECD MS/MS spectra of Platinated K3-bom species individually isolated and 
dissociated using ECD within the FT-ICR MS. Coloured labels indicate modified fragments. 
Assignment table for each species can be found below. Pt* indicates the platinum based 
modification associated with each species (shown in Figure 3, main text, and correlating tables of 
assignments, below). 
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SI Table 3.7 (ST3.7): ECD MS/MS assignments for the [K3-Bom+Pt(py)2(N3)+H]2+ species (calibrated 
using co-isolated calibrant ions):  
Fragment Exact mass Observed mass Error/ppm 
[c7.]+ 796.418045 796.41805 0.01 
[c10.]+ 1152.602875 1152.60367 0.69 
[z7+ Pt(py)2(N3)]+ 1189.453306 1189.45339 0.07 
[c11.]+ 1209.624335 1209.62400 -0.28 
[z8+Pt(py)2(N3)]+ 1317.511886 1317.51124 -0.49 
[z9+Pt(py)2(N3)]+ 1431.554816 1431.55358 -0.86 
[z10+Pt(py)2(N3) ]+ 1488.576276 1488.57688 0.41 
[z11+Pt(py)2(N3)]+ 1601.660336 1601.66124 0.56 
[z12+Pt(py)2(N3)]+ 1729.755296 1729.75603 0.42 
[c13+Pt(py)2(N3)]+ 1853.823586 1853.82508 0.81 
[z13+Pt(py)2(N3)]+ 1857.813876 1857.81385 -0.01 
  Absolute average -0.18 
  standard deviation 0.50 
 
SI Table 3.8 (ST3.8): ECD MS/MS assignments for the [K3-Bom+Pt(py)2(OH)+H]2+ species (calibrated 
using co-isolated calibrant ions):  
Fragment Exact mass Observed Mass Error/ppm 
[c6]+ 669.367290 669.36729 0.00 
[z3.+Pt(py)2(OH)]+ 752.248358 752.24755 -1.07 
[c7]+ 797.425870 797.42614 0.34 
[c10.]+ 1152.602875 1152.60293 0.05 
[z7.+Pt(py)2(OH)]+ 1165.454648 1165.45505 0.34 
[c11]+ 1210.632160 1210.63215 -0.01 
[z10.+Pt(py)2(OH)]+ 1464.577618 1464.57681 -0.55 
[z11+Pt(py)2(OH)]+ 1576.653853 1576.65538 0.97 
[c12+Pt(py)2(OH)]+ 1715.733043 1715.73301 -0.02 
[c13+Pt(py)2(OH)]+ 1828.817103 1828.81907 1.08 
[z13+Pt(py)2(OH)]+ 1832.807393 1832.80709 -0.17 
[K3-Bom+Pt(py)2(OH)+H]+ 1959.857593 1959.85800 0.21 
 Absolute average 0.40 
Standard deviation 0.56 
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SI Table 3.9 (ST3.9): ECD MS/MS assignments for the [K3-Bom+Pt(py)2+H]3+ species: 
Fragment Exact mass Observed Mass Error/ppm 
[c3]+ 385.21880 385.21880 0.00 
[c4]+ 498.30290 498.30280 -0.26 
[c5]+ 555.32440 555.32430 -0.05 
[c6]+ 669.36730 669.36740 0.12 
[c7]+ 797.42590 797.42600 0.16 
[c8]+ 983.50520 983.50480 -0.43 
[c9]+ 1054.54200 1054.54200 -0.36 
[c10]+ 1153.61100 1153.61100 0.33 
[c11]+ 1210.63200 1210.63200 0.17 
[z6-H-H+Pt]+ 802.27310 802.27200 -1.40 
[z7-H-H+Pt]+ 988.35240 988.35220 -0.21 
[z8-H-H+Pt]+ 1116.4110 1116.41100 -0.29 
[z9-H-H+Pt]+ 1230.4540 1230.45300 -0.43 
[z10-H-H+Pt]+ 1287.4750 1287.47500 -0.63 
[z11-H-H+Pt]+ 1400.55900 1400.55900 -0.65 
[z11-2H++Pt(py)2]2+ 779.82560 779.82470 -1.12 
 Absolute average: 0.41 
Standard deviation: 0.46 
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SI Figure 3.6 (SF3.6): ECD MS/MS spectra of Platinated Substance P species individually isolated and 
dissociated using ECD within the FT-ICR MS. Coloured labels indicate modified fragments. 
Assignment table for each species can be found below. Pt* indicates the platinum based 
modification associated with each species (shown in Figure 4, main text, and correlating tables of 
assignments, below). 
SI Table 3.10 (ST3.10): ECD MS/MS assignments for the [SubP+Pt(py)2+H]3+ species:  
Fragment Exact mass Observed mass Error/ppm 
[c4.+Pt]+ 688.282420 688.28242 0.00 
[c5.+Pt]+ 816.341000 816.34120 0.24 
[c6.+Pt]+ 944.399580 944.39917 -0.43 
[c7.+Pt]+ 1091.467990 1091.46803 0.04 
[c8.+Pt]+ 1238.536400 1238.53627 -0.10 
[c9.+Pt]+ 1295.557860 1295.55822 0.28 
[c10.+Pt]+ 1408.641920 1408.64168 -0.17 
[c5.+Pt-NH3]+ 799.314455 799.31421 -0.31 
[c6.+Pt-NH3]+ 927.373035 927.37283 -0.22 
[c7.+Pt-NH3]+ 1074.441445 1074.44128 -0.15 
[c8.+Pt-NH3]+ 1221.509855 1221.50967 -0.15 
[c9.+Pt-NH3]+ 1278.531315 1278.53071 -0.47 
[c10.+Pt-NH3]+ 1391.615375 1391.61515 -0.16 
[SubP+Pt]+.-H. 1539.681866 1539.68187 0.00 
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[SubP+Pt]+.-H.-Me 1524.658939 1524.65993 0.65 
[SubP+Pt]+.-MeS 1493.694694 1493.69432 -0.25 
[SubP+Pt]+.-MeS-NH3 1476.668145 1476.66816 0.01 
[SubP+Pt]+.-MeS-Leu C4H8 1437.632094 1437.63193 -0.11 
[SubP+Pt]+.-MeS-Glu C3H5NO 1422.65758 1422.65785 0.19 
  Absolute average 0.21 
  Standard deviation 0.26 
 
SI Table 3.11 (ST3.11): ECD MS/MS assignments for the [SubP+Pt(py)2(N3) +H]2+ species: 
Fragment Exact mass Observed mass Error/ppm 
[c4+Pt(py)2(N3)]+ 889.383866 889.38374 -0.14 
[c5+Pt(py)2(N3)]+ 1017.442446 1017.44264 0.19 
[c6+Pt(py)2(N3)]+ 1145.501026 1145.50134 0.27 
[c7+Pt(py)2(N3)]+ 1292.569436 1292.57007 0.49 
[z9-H.+Pt(py)2(N3)]+ 1470.603986 1470.60669 1.84 
[c10+Pt(py)2(N3)]+ 1609.743366 1609.74471 0.83 
[SubP+Pt(py)2(N3)+H]+. 1740.783856 1740.78386 0.00 
[SubP+Pt]+ 1540.690813 1540.69154 0.47 
[SubP+Pt-Me]+ 1525.667338 1525.66709 -0.16 
[SubP+Pt-S]+ 1493.695268 1493.69489 -0.25 
  Absolute average 0.47 
  Standard deviation  0.59 
 
SI Table 3.12 (ST3.12): ECD MS/MS assignments for the [SubP+Pt(N3)+H]2+ species: 
Fragment Exact mass Observed mass Error/ppm 
[c4.+Pt]+ 688.28242 688.28242 0.00 
[c5.+Pt]+ 816.34100 816.34078 -0.27 
[c6dot+Pt]+ 944.39958 944.39958 0.00 
[c7.+Pt]+ 1091.46799 1091.46827 0.26 
[c8.+Pt]+ 1238.53640 1238.53767 1.03 
[c9.+Pt]+ 1295.55786 1295.55875 0.69 
[c10.+Pt]+ 1408.64192 1408.64181 -0.08 
[SubP+Pt(N3)+H]+. 1582.69837 1582.69848 0.07 
  Absolute average 0.30 
  Standard deviation 0.41 
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SI Figure 3.7 (SF3.7): Bar charts showing the relative intensity changes between the Complex 
1+peptide and Complex 1+peptide+free Trp reaction mixtures for both Substance P (top) and  
(bottom). 
SI Table 3.13a (ST3.13a): Relative intensity measurements of assigned species in the irradiated 
Complex1+Substance P reaction mixture FT-ICR MS with and without additional tryptophan.  
Species Relative Intensity/% 
Without additional Trp With additional Trp 
[SubP+2H+O]2+ 11.02 7.82 
[SubP+Pt(py)2]2+ 0.81 1.24 
[SubP+Pt(py)(OH)(N3)+H]2+ 4.97 3.94 
[SubP+Pt(py)(OH)(N3)+H+O]2+ 0.81 0.04 
[SubP+Pt(N)3+H]2+ 2.46 2.54 
[SubP+Pt(py)2(N)3+H]2+ 4.28 3.01 
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SI Table 3.13b (ST3.13b): Relative intensity measurements of assigned species in the irradiated 
Complex1+K3-Bom reaction mixture FT-ICR MS with and without additional tryptophan. 
Species Relative Intensity/% 
Without additional Trp With additional Trp 
[K3-Bom+2H+O]2+ 3.04 4.04 
[K3-Bom+2H+2O]2+ 11.97 7.19 
[K3-Bom+2H+3O]2+ 15.7 16.13 
[K3-Bom+Pt(py)2(N3)+H]2+ 24.40 7.20 
[K3-Bom+Pt(py)2(N3)+H+O]2+ 0.50 0.07 
[K3-Bom+Pt(py)2(N3)+2H+O]3+ 0.03 0.01 
[K3-Bom+Pt(py)2(OH)+H]2+ 2.28 0.05 
[K3-Bom+Pt(py)2]2+ 15.34 0.80 
[K3-Bom+Pt(py)2+H]3+ 28.87 1.23 
[K3-Bom+Pt(py)2+H+O]3+ 0.47 0.01 
[K3-Bom+Pt(py)2+H+2O]3+ 1.90 0.05 
[K3-Bom+Pt(py)2+Py(py)2(N3)]3+ 0.86 0.02 
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SI Figure 3.8 (SF3.8)- Proposed mechanism for the loss from the peptide of the Pt(II) modification 
during ECD, ligands shown vary with the nature of the Pt adduct. 
SI Table 3.14a-c (ST3.14a-c): EPR results for irradiation of complex one in blue visible light (a), 
Complex 1+SubstanceP (b), and Complex 1+[Lys]3-Bombesin (c). Included are previously published 
values acquired for the system, along with references for said values. 
Complex 1+DEPMPO (irradiation blue light) 
 g aNNO aP aHβ aNα 
Experimental 2.012 13.89 46.16 13 2.79 
Published1 - 13.93 46.05 12.39 2.80 
 
 
Complex 1+Substance P+DEPMPO (irradiation blue light) 
 g aNNO aP aHβ aNα 
Experimental 2.012 13.89 46.16 13 2.79 
Published1 - 13.93 46.05 12.39 2.80 
 
 
Complex 1+[Lys]3-Bombesin+DEPMPO (irradiation blue light) 
 g aNNO aP aHβ 
Experimental 2.012 7.08 38.75 3.76 
Published2/3 - 7.8/7.14 41.2/38.69 4.1/3.69 
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SI Figure 9 (SF3.9):  EPR kinetic runs:  
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SI Figure 10a-c (SF3.10a-c): UV/Vis spectra of Complex 1 (a), Complex 1 + Substance P (b), and 
Complex 1 + [Lys]3-Bombesin (c). 
 
 
 
  
a) b) 
c) 
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SI Figure 3.11 (SF3.11): ECD MS/MS spectra of di-Platinated K3-bom species a) and zoom-in of side 
chain loss (SCL) region (b) resulting from electron capture at a platinum centre, causing ligand loss 
(to create [K3-Bom+Pt+Pt(py)2(N3)]2+. from the [K3-Bom+Pt(py)2+Pt(py)2(N3)]2+. species) along with 
unique side chain losses. Unfortunately no sequence informative fragments were observed from the 
ECD MS/MS spectrum, highlighting the need for an additional proton to allow standard dissociation. 
 
a) 
b) 
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Chapter 4: 
Osmium metallodrug-DNA interactions 
studied by FT-ICR MS and MS/MS 
 Transition metal complexes offer a range of geometries, reactivities, and activities against 
many forms of cancer and have been proven to be effective at treating a wide array of conditions. 
With the increased use of platinum anti-cancer agents a marked increase in platinum-resistant 
cancer cases has developed, often due to non-ideal dosing regiments and treatments. After 
cancerous cells become resistant to platinum-based therapies chances of survival diminish greatly. 
For these and other reasons investigations into non-platinum metallodrugs is becoming a thriving 
field, with many metals not just matching platinum drug effectiveness but often exceeding them. 
Potent piano-stool compounds such as those based on ruthenium, rhodium, iridium, and even 
osmium have been shown to be extremely effective, and selective against cancerous cells, and 
importantly, platinum-resistant cancerous cells. Many of these heavy metal drugs are now in/being 
considered for clinical trials and may soon become available for widespread use.  
With new metals, geometries and functional groups come new mechanisms of action, and 
these different mechanisms of action are believed to be the key not only to these metallodrugs 
increased potencies, but also to their ability to circumvent metal-resistance in cancer cells and attack 
cellular components in different ways. For this reason a promising osmium-based piano-stool 
complex (referred to as Os1) was chosen to investigate the interaction of osmium compounds with 
model DNA strands (namely 10-mer and 12-mer oligonucleotides) and use a variety of MS/MS 
techniques to fragment the resulting reaction products effectively while retaining these unique 
biomolecule modifications. The use of specialised electron-based dissociation Electron Detachment 
Dissociation (EDD) was shown to be challenging to achieve, but produced extensive fragmentation 
information, retained the osmium modifications effectively, and enabled effective characterisation 
of multiple osmium-DNA interaction products. This was also compared to more commonly used 
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techniques such a CAD and IRMPD, which showed limited effectiveness, but still provided key 
information for some species.  
The work presented in chapter is mostly based directly on the publication by C. A. Wootton et al. 
“Binding of Organo-Osmium(II) anticancer Compounds to Guanine and Cytosine on DNA Revealed by 
Electron-based Dissociations in High-Resolution FT-ICR Mass Spectrometry”, Dalton Transactions, 44, 
8, 2015, 3624-3632. DOI: 10.1039/C4DT03819C. The collaborators on the project offered the 
Osmium compounds, the purified oligonucleotides, and showed preliminary data for the reactions of 
the drug with the DNA. However all data presented herein (outside of the HPLC purification) was 
produced, analysed and written by the thesis Author. The extensive DNA purification was conducted 
by Carlos Sanchez-Cano. 
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Abstract 
The OsII arene anticancer complex [(η6-bip)Os(en)Cl]+ (Os1-Cl; where bip = biphenyl, and 
en = ethylenediamine) binds strongly to DNA. Here we investigate reactions between Os1-Cl 
and the self-complementary 12-mer oligonucleotide 5′-TAGTAATTACTA-3′ (DNA12) 
using ultra high resolution Fourier Transform-Ion Cyclotron Resonance Mass 
Spectrometry(FT-ICR MS). Identification of the specific sites of DNA osmiation with {(η6-
bip)Os(en)}2+ was made possible by the use of Electron Detachment Dissociation (EDD) 
which produced a wide range of assignable osmiated MS/MS fragments. In contrast, the more 
commonly used CAD and IRMPD techniques produced fragments which lose the bound 
osmium. These studies reveal that not only is guanine G3 a strong binding site for {(η6-
bip)Os(en)}2+  but, unexpectedly, so too is cytosine C10. Interestingly, the G3/C10 di-osmiated 
adduct of DNA12 also formed readily but did not undergo such facile fragmentation by EDD, 
perhaps due to folding induced by van der Waal’s interactions of the bound osmium arene 
species. These new insights into osmium arene DNA adducts should prove valuable for the 
design of new organometallic drugs and contribute to understanding the lack of cross 
resistance of this organometallic anticancer complex with cisplatin.  
Introduction 
Metal based therapeutics are currently at the forefront of anticancer therapy, with compounds 
such as cisplatin being used extensively in chemotherapy treatments.1  Potent cytotoxic and 
anti-proliferative compounds have also been developed based on a range of transition metals, 
including ruthenium2 , iridium3, vanadium4, cobalt5, osmium6, as well as platinum7–9.  
Though many of these compounds have been shown to exhibit different and interesting 
mechanisms of action (MoA), many metal-based drugs are believed to achieve their 
cytotoxic/ anti-proliferative effect via binding to the strands of DNA within the nuclei of 
cancer cells.10  This binding of metallodrugs to DNA residues often causes a change in the 
conformation/structure of the DNA strands, and the deformation of tertiary structure can then 
trigger the cytotoxic and/or anti-proliferative effects, e.g. via apoptosis.10,11 
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It is therefore of much interest to study how these new metallodrugs can bind to DNA, which 
nucleotide residues are preferred binding partners, whether certain nucleotide sequences are 
targeted selectively, and to characterise the coordination sphere of the bound metal. Many 
metallodrugs change their composition during their journey to DNA, often multiple times, 
depending on various environmental factors (e.g. pH changes, chloride concentration, 
small/large biomolecule binding) and so the metallodrug injected into a system may not be 
the active species eventually causing the desired anticancer effects.12  Due to the multiple 
activation pathways in which injected pro-drugs become active metallodrugs, and many 
pathways of deactivation of these compounds, it has often been observed that a variety of 
reaction products are observed when metal based compounds encounter biomolecules.13  
Many analytical techniques have been utilised in order to study metal complex-DNA 
interactions, often 1H-NMR or x-ray crystallography, with both techniques providing 
powerful structural information and sometimes identifying the location of DNA 
modification.14,15  However, the mixture of products produced pose problems for both NMR 
and x-ray crystallography, and although separation of reaction products, e.g. via High 
Pressure Liquid Chromatography (HPLC), can assist in the acquisition of purer samples for 
analysis, this invariably ends in further dilution of samples and can often affect equilibria in 
dynamic systems, which may render separations ineffective via decomposition, hydrolysis 
etc.  
To address these issues, other analytical techniques are being explored which offer superior 
sensitivity (and reduced sample requirements) and can handle mixtures of adducts more 
effectively.  Mass spectrometry is increasingly being utilised to study biological and complex 
chemical systems, due to its inherent high sensitivity and ability to cope with extremely 
complex samples (over 100,000 species have been detected in a single mass spectrum16).  
With the advent of tandem mass spectrometry (MS/MS), the ability to fragment and 
interrogate ionised species in the gas phase has paved the way for in-depth chemical and 
structural analysis of complex systems17, with biomolecules being the main focus for 
contemporary tandem mass spectrometry studies.  An extensive array of ion dissociation 
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techniques have been developed including Collisionally Activated Dissociation (CAD)18, 
Electron Capture Dissociation (ECD),19 Electron Transfer Dissociation (ETD),20 Infra-Red 
Multi Photon Dissociation (IRMPD),21 Electron Induced Dissociation (EID),22 Ultra-Violet 
Photo Dissociation (UVPD),23 and Electron Detachment Dissociation (EDD).24 There are 
now many established methods for interrogating and studying biomolecules and their 
modifications via MS/MS analysis, each suited to a variety of different analytes, and many 
able to offer complementary data to provide increased confidence in analysis. 
Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FT-ICR MS) uses electric 
and magnetic fields to trap ions of interest within a Penning trap during MS/MS experiments 
and detection,25,26 allowing ultra-high resolving powers of 500,000-10,000,000+ with the 
latest commercial setups.27  Combining the flexibility of the ICR cell with quadrupole 
isolation and collisional activation, FT-ICR MS offers the largest array of fragmentation 
techniques and the highest mass accuracy of any mass spectrometer, providing the highest 
possible confidence in spectral assignment, with mass errors into the sub part per million 
(ppm) and even ppb (part per billion) ranges. Importantly, FT-ICR MS is uniquely and 
perfectly suited to Top Down fragmentation studies.28 
Here we study the metallation of a DNA 12-mer oligonucleotide by the organometallic OsII 
arene anticancer complex, Os1-Cl·PF6 (Fig. 4.1). We use Ultra High Resolution Mass 
Spectrometry (UHR-MS) together with MS/MS analysis to locate the osmium binding sites 
and to identify the coordinated ligands. In particular we use a range of fragmentation 
techniques to gain new insights into the nature of the osmium binding sites on DNA. 
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Scheme 4.1: The OsII arene complex Os1-Cl studied in this work and the detected 
species/modification observed via ESI-MS (Os1). 
Experimental 
[(η6-bip)Os(en)Cl]PF6 (Os1-Cl·PF6) was synthesised and characterised as described 
previously.29 
The 12-mer DNA oligonucleotide DNA12 (defined here for MS purposes as fully protonated, 
i.e. each of the 11 phosphates is protonated)  
5′-TAGTAATTACTA-3′ (DNA12) 
 DNA12 (Tm 28°C) was purchased desalted from DNA Technology (Denmark).  Further 
purification was performed by HPLC, using an Agilent 1200 series liquid chromatography 
system.  The oligonucleotide was separated from shorter oligonucleotides (present as minor 
impurities in the commercial sample) using a PL-SAX ion exchange column (1000 Å pore 
size; 8 µM particle size; 150 mm length, 4.6 mm diameter; Polymer Laboratories, Amherst, 
USA); buffer A: 7% acetonitrile + 0.1 M triethylammonium acetate (TEAA), pH 7; buffer B: 
7% acetonitrile + 0.1M TEAA + 1 M sodium acetate, pH 7; temp 40oC; flow rate 1.5 ml/min; 
gradient: 0-5 min 0% B, 5-45 min 0-40% B, 45-55 min 40-100% B, 55-65 min 100% B, 65-
75 min 0% B (see Supporting Information Figure S1: HPLC traces of commercial sample and 
inset; the resulting purified fraction).  The solvent was removed on a freeze-drier, and a 
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reverse phase chromatography PLRP-S column (100 Å pore size; 8 µM particle size; 300 mm 
length, 7.5 mm diameter; Polymer Laboratories, US) was used to remove sodium acetate; 
buffer A: 50 mM TEAA, pH 7; buffer B: 70% acetonitrile + 50 mM TEAA, pH 7; temp 
40oC; flow rate 2 ml/min; gradient: 0-5 min 5% B, 5-35 min 5-100% B, 35-45 min 100% B, 
45-45 min 0% B.  The solvent was removed again on a freeze-drier. 
Aqueous solutions of the oligonucleotide (250 µM) and osmium complex Os1-Cl·PF6 (250 
µM) were mixed in 0.5:1 and 1:1 Os:oligonucleotide ratios.  Under these conditions of low 
ionic strength, DNA12 would be present largely as a single strand.  Osmium-oligonucleotide 
samples were then incubated in the dark at 37°C for 3 hours before dilution with purified 
(Milli-Q) water to mass spec concentrations (ca. 0.5- 1 µM total concentration) for FT-ICR 
MS analysis.  
FT-ICR mass spectrometry analysis.  All samples were analysed via nano-electrospray 
ionisation (nESI) for increased sensitivity and lower sample consumption compared to 
traditional electrospray ionisation (ESI).30  All experiments were carried out on a SolariX FT-
ICR Mass Spectrometer, fitted with a 12 tesla actively shielded magnet (Bruker Daltonik 
GmbH, Bremen, Germany), and samples were sprayed in negative ion mode unless otherwise 
stated.  For MS experiments, ions were accumulated for 0.01 s in the hexapole-based 
collision cell before transfer to the infinity cell31 for detection.  
For Collisionally Activated Dissociation (CAD) MS/MS experiments, ions of interest were 
isolated in the front end quadrupole using an isolation window of 3-10 m/z to isolate 
deprotonated species only.  Ions were then accelerated into argon collision gas at 8 V (for 
unmodified DNA species) and 10-12 V (for Os-modified species).  Ions were continuously 
accumulated for 0.1-2 s before transmission and detection. 
For Infra-Red Multi Photon Dissociation (IRMPD) experiments, ions of interest were 
isolated, accumulated for 0.1-2 s, then transferred and trapped in the infinity cell.  Trapped 
ions were then subjected to infra-red photons prior to detection.  IR photons were produced 
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from a continuous wave, 25 W, CO2 laser (Synrad Inc., Washington, USA) held at 60% 
power output and pulsed into the infinity cell for 30-100 ms. 
For Electron Detachment Dissociation MS/MS experiments, ions of interest were isolated in 
the front end quadrupole, accumulated in the hexapole for 0.7-3 s, then transferred and 
trapped in the infinity cell.  Trapped ions were then irradiated for 0.8 s with 20.2 eV electrons 
produced from a 1.5 A indirectly-heated hollow cathode dispenser via an extraction lens held 
at 18 V.  
All spectra were internally calibrated using a quadratic calibration function32 and then 
manually interpreted and assigned via Data Analysis v4.2 (Bruker Daltonik GmbH, Bremen, 
Germany).  All fragments in the low to sub-ppm range were assigned; tables of assignments 
can be found in the supporting information for each MS/MS spectrum assigned here. 
Results and discussion 
Electrospray ionisation (including nESI) forms ions via the addition or removal of protons 
during the desolvation process occurring after the emission of sample droplets from the 
electrospray needle tip and while passing through the electric fields in the source region of 
the mass spectrometer.33  Due to the high density of phosphate groups in oligonucleotides, 
negative mode electrospray produces abundant [M-nH]n- ions in the resulting mass spectrum, 
with the phosphate groups stabilising the negative charges.  This stabilisation is much greater 
than that seen in most peptide and protein mass spectra.  As a result, DNA and RNA 
ESI/nESI spectra show charge states higher (per monomer) than commonly observed for 
poly(amino acid) species, even without the addition of additives such as bases to aid 
deprotonation.  
Figure 1A shows the full mass spectrum of the 12-mer DNA produced by nESI.  Isotopic 
simulations (Figure 4.1A inset) match the expected pattern for the 12-mer DNA (sequence 
inset) and show no modification of the DNA before reaction.  CAD MS/MS of the 7- charge-
state species is shown in Figure 4.2a; although very stable in solution, the high charge states 
(per nucleotide) of the DNA precursor make the gas phase species more fragile, causing it to 
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dissociate under lower than average collision energies.  The CAD MS/MS spectrum showed 
many abundant sequence fragments, most notably w ions and a-base ions.34  The 
nomenclature devised by McLuckey et al.34 based on the McCloskey et.al. system35 for 
assignment of oligonucleotide MS/MS is summarised in Figure 4.2a (inset, with assignments 
listed in Table S4.1 in SI) and was used for all assignments.  Nucleotide base loss is a 
common fragmentation channel for CAD MS/MS, especially for a ions, which was also 
observed during these experiments.  The overall sequence coverage was excellent, with 100% 
cleavage coverage for the unmodified species produced during one experimental run (Figure 
4.2a).  It is worth noting that, due to the fragility of DNA ions in the gas phase, careful tuning 
of transmission and extraction voltages was essential to preserve ions of interest as they move 
through the mass spectrometer to avoid unwanted fragmentation of precursor ions before and 
after MS and MS/MS experiments.  Due to the large extent of fragmentation (even at low 
voltages) numerous internal fragments are often observed in DNA CAD MS/MS spectra.36  
These species are most often produced via fragmentation in two separate areas of the 
molecule, creating peaks not easily identified using a “linear” fragmentation model, though 
are still often predictable to some extent.37 
Figure 4.1b shows the full mass spectrum of a 1:1 solution of Os1-Cl·PF6:DNA12 (1 µM) 
after 3 h of reaction.  The unreacted DNA peaks were readily observable as before, as were a 
series of peaks of osmiated DNA.  Osmium-containing species are easily identifiable by 
UHR-MS due to the characteristic isotope pattern for osmium isotopes (Figure 4.1b inset).  It 
was immediately apparent from the full MS spectrum that the osmium complex had lost the 
monodentate chloride ligand, and was bound as {(η6-bip)Os(en)}2+.  Since the 
oligonucleotides were analysed in negative ion mode and the Os1 modification is doubly 
charged, two additional protons have to be removed from the precursor to achieve the same 
charge state as the corresponding unmodified species, as detected by comparison with the 
theoretical isotope simulation shown in Figure 1b (inset) depicting the simulation and 
observed spectrum for [DNA12+Os1-9H]7-.  Additionally two distinct Os containing 
oligonucleotide isotopic distributions were observed, one for the mono-osmiated DNA 12mer 
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([DNA12+Os1-(n+2)H]n-) and one for the di-osmiated DNA 12 mer ([DNA12+2Os1-
(n+4)H]n-).  
 
Figure 4.1: nESI Mass spectrum of (a) DNA12 and (b) DNA12+Os1 reaction mixture after 3 h incubation at 37°C (b). Inset: 
nucleotide sequence of the oligonucleotide 12-mer and observed vs. Simulated isotope patterns for unreacted DNA12 
(top right), DNA12+Os1 (bottom left), and DNA12+2Os1 (bottom right). 
The usual binding site for RuII and OsII organometallic complexes within DNA is N7 of 
guanine, due to its high basicity and availability, even in the DNA duplex.38  However, the 
DNA 12mer used during this study contained only one guanine residue.  This suggested that 
in the present case a nucleotide other than guanine could also be a target for this metallodrug.  
The CAD MS/MS spectrum for the [DNA12+Os1-8H]6- ion is shown in Figure 4.2b.  Again, 
as with the corresponding unmodified DNA, CAD produced a spectrum with a large number 
of fragments, some osmiated, some not, and a range of assignable fragments (Figure 4.2b and 
Table S4.2 in SI).  Analysis of the MS/MS data showed Os-containing fragments could be 
used to assign the binding location to the A2-G3 region of the oligonucleotide.  CAD is based 
upon multiple collisions of the species of interest with background gas (in this case Ar), 
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producing a “slow heating effect” of ions until the weakest bonds within the molecule break, 
causing the dissociation.18  Unfortunately, due to the slow heating caused by CAD, 
biomolecule modifications are often dissociated along with the biomolecule backbone;39 this 
effect was also observed for the CAD spectra of osmiated DNA in this study, as shown by the 
observation of [DNA12-xH]x- species in the CAD spectra and further fragmentation.  There 
are clear peaks showing the loss of the en ligand, followed by the loss of the whole complex 
during CAD, producing the unmodified species ([DNA12-xH]x-), which then fragments again 
under the multiple collisions in CAD and produces a string of unmodified fragments.  These 
fragments from the unmodified species can lead to problems during data analysis, such as 
creating fragments which contradict the location of the modification sites, and can add extra 
fragment peaks to already dense MS/MS spectra.  Unfortunately the loss of the DNA 
modification under CAD meant that unmodified fragments could not be used to locate the 
modification, instead only the Os-containing fragments were used during this analysis.  
However, despite this limitation the modification was narrowed down to the A2-G3-T4 region 
for the DNA 12-mer from the CAD MS/MS spectrum. 
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Figure 4.2: FT-ICR CAD MS/MS spectra for [DNA12-7H]7- (a) and [DNA12+Os1-9H]7- (b) species, along with corresponding 
fragmentation maps; osmiated fragments are indicated with shaded squares.  Inset: Theoretical simulation of the [a9-
BH+Os1-5H]3- fragment and the observed isotopic pattern during CAD MS/MS. 
In order to identify the osmium binding sites unequivocally, further fragmentation techniques 
were investigated to explore their ability to fragment the backbone, while maintaining the 
osmium modification.  It has been recently shown by Xu et al.40 that although different slow 
heating MS/MS techniques produce very similar MS/MS spectra of poly(amino acids) (CAD 
vs. IRMPD), if tuned correctly, these dissociations show a much greater difference for 
oligonucleotides; with changes in the proportion of fragments exhibiting base loss, internal 
fragmentation, and proportions of different types of ions (e.g. a & w).  IRMPD was 
conducted on the same isolated osmiated DNA species as the CAD shown in Figure 4.2b.  
Unfortunately, although the laser-based fragmentation produced many fragments, IRMPD 
dissociated the osmium modification to an even greater extent than CAD, despite varying the 
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laser power and pulse length.  Due to the extensive secondary fragmentation and modification 
loss; IRMPD was shown to be unsuitable for studying the osmiated DNA species here. 
In view of the problems associated with dissociations caused by slow heating when studying 
biomolecule modifications, many reported studies now utilise electron-based fragmentations, 
which can cleave backbone bonds while preserving modifications/adducts.  By transferring or 
creating radical sites on/at the backbone, fragmentation is achieved via radical 
reactions/rearrangements.19,41  These electron-based fragmentations have been effective in 
studies of modifications in positive ion mode via electron capture, both for natural 
modifications42 and for metal/metallodrug binding to peptides/proteins.13,43  However for 
negative ions, capture of electrons, such as those from Electron Capture Dissociation (ECD), 
is less likely due to the negative nature of the analyte, causing electrostatic repulsion. Instead 
other electron-based techniques such as Electron Detachment Dissociation (EDD) have been 
developed to allow electron-based fragmentation of negative ions.24  EDD is a dissociative 
technique unique to FT-ICR MS, which causes backbone cleavage by irradiating 
oligonucleotides or other biomolecules, with medium energy electrons (ca. 14-24 eV).4445 
The incoming electrons interact with the negative ions and cause emission/release of an 
electron from the analyte, creating a radical site, which, like other electron based 
fragmentations, can then cause dissociations along the backbone. A general pathway for this 
process is shown in Scheme 4.2. 
[N]n-    [N]n- + e-fast    [N](n-1)-. + Fragments + 2e- 
 
Scheme 4.2: A general EDD reaction pathway, adapted from Zubarev et al.24 
EDD requires very fine tuning of the electron energy and other cathode parameters to cause 
effective dissociation, but once tuned can result in extremely high quality fragmentation 
patterns.  Figure 4.3a shows the EDD MS/MS spectrum created by irradiation of the 
[DNA12-7H]7- species with 20.2 eV electrons.  Due to the removal of electrons from the 
original ion, so called “Charge Reduced Species” (CRS) for the [DNA12-7H]6- and [DNA12-
7H]5- ions are observed as high intensity peaks in the spectrum.  Along with the CRS peaks, 
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an extensive series of w and d ions can be observed and assigned, summarised in the 
oligonucleotide fragmentation map in Figure 4.3a (and Table S4.3 in SI).   
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Figure 4.3: Electron Detachment Dissociation FT-ICR MS/MS spectra of (a) [DNA12-7H]7- and (b) [DNA12+Os1-9H]7- ions, 
along with corresponding fragmentation maps. Shaded squares indicate presence and number of osmium complex 
modifications bound to observed fragments. Inset; comparisons of selected theoretical simulations and observed 
species. 
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EDD was then carried out on the [DNA12+Os1-9H]9- species using the same parameters as 
for the unmodified species. The resulting MS/MS spectrum is shown in Figure 4.3b.  Again, 
as with the previous EDD MS/MS spectrum, very intense peaks for the CRS were produced, 
as were a string of lower intensity fragments.  Assigned fragments are summarised in the 
fragmentation map in Figure 4.3b (and Table S4.4 in SI).  EDD produced 100% cleavage 
coverage of the isolated species.  The resulting spectrum also contained far fewer internal 
fragment ions, mainly consisting of w and d ions, meaning that a larger proportion of spectral 
peaks corresponded to sequence informative fragments.  The fragments assigned indicate two 
different binding locations for the bound {(η6-bip)Os(en)} complex.  Fragmentation analysis 
clearly shows the T1-A2 and T4-A12 regions are free from osmium modification, while the G3-
A12 region is modified by the osmium modification, which clearly indicated the osmium 
modification was bound to the Guanine (G3) nucleotide.  Analysis also showed a second 
product in which the T1-A9 region was free from osmium modification, however the T1-C10 
and T1-T11 regions were Os1 modified, clearly showing the osmium complex was bound to 
cytosine (C10) nucleotide.  Unlike CAD MS/MS scans shown above, EDD cleaved the A2-G3 
bond and narrowed down the exact site of the modification to one nucleotide.  A peak 
corresponding to the unmodified oligonucleotide was produced during the EDD experiment; 
[DNA12-5H]5- at m/z~727 indicating that cleavage  of the metallodrug from the DNA is only 
a minor fragmentation channel during EDD for this species.  However, unlike CAD, further 
fragmentation of the DNA12 ion was not observed, a CRS at sufficient intensity for the 
DNA12 ion was not present, indicating that after dissociation of the metallodrug, the species 
did not undergo enough further electron capture to cause further dissociation and affect the 
peak intensities of fragments.  The lack of further fragmentation of the unmodified [DNA12-
xH]x- ions indicated that use of unmodified fragments for fragment analysis was viable and 
allowed the determination of the two reaction products in two discrete locations.  The loss of 
the biphenyl ligand from the metallodrug complex was also observed, indicating the 
influence of OsII on the electron dissociation process, though MS/MS analysis was not 
hindered in this instance. 
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MS/MS experiments were then conducted on the di-osmiated species at m/z~740 
[DNA12+2Os1-10H]6-.  Effective CAD was achieved at a slightly higher value of 12 V, 
which could indicate a stabilising effect from the osmium complex in the gas phase.  Figure 
4a shows the CAD MS/MS spectrum obtained.  The fragments assigned are summarised in 
the fragmentation map in Figure 4.4a (and Table S4.5 in SI).  The osmiated fragments were 
more numerous than for the mono-osmiated DNA12 MS/MS described earlier, and indicated 
binding to the A2-G3 region (correlating with the previous CAD result) and to the terminal 3 
nucleotides at the 3′ end of DNA12 (C10-T11-A12).  The results correlate well with the CAD 
and EDD results obtained for the mono-osmiated species, and are consistent with discrete G 
and C binding, with CAD showing poor fragmentation directly next to the osmiated 
nucleotide.  The lack of fragmentation adjacent to the osmiated nucleotide via slow heating 
dissociation might indicate interactions between the osmium complex and its neighbouring 
nucleotides/bases; for instance, the biphenyl ligand might interact with the A2, hindering 
dissociation of the A2-G3 bond, and likewise for the thymine residue neighbouring the 
osmiated cytosine at position 10.  Since CAD MS/MS of the unmodified species produced 
such extensive fragmentation, analysis of the differences compared to the osmiated product 
may be indicative of interactions with neighbouring groups. 
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Figure 4.4: FT-ICR MS/MS spectra of the [DNA12+2Os1-10H]6- species fragmented by (a) CAD, (b) EDD,  along with the 
corresponding fragmentation map for CAD (centre), no backbone dissociation was observed via EDD for the (possibly 
cyclic) species presumably due to non-covalent interactions preventing gas phase fragmentation. Shaded squares 
indicate presence and number of osmium complex modifications bound to observed fragments. 
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EDD MS/MS was also attempted on the [DNA12+2Os1-10H]6- species using the same EDD 
parameters as before.  The resulting spectrum, shown in Figure 4.4b, shows consistent 
electron capture events as before, with the observation of the [DNA12+2Os1-10H]5- and 
[DNA12+2Os1-10H]4-species.  Loss of the bip ligand was also observed as before. 
Unfortunately very little fragmentation of the DNA backbone was observed during EDD 
MS/MS of the di-osmiated species, which was unexpected compared to the 100% sequence 
coverage observed for the unmodified species and mono-osmiated oligonucleotide described 
above.  Lack of fragmentation during electron based dissociation such as this is usually the 
result of electron quenching/capture (e.g. by electron traps such as metal ions) with no 
resulting fragmentation thereafter, otherwise it is usually the indication of cyclisation by 
either covalent or non-covalent interactions, with dissociation of the backbone producing two 
fragments which would stay bound together by the interaction elsewhere in the macrocycle, 
hindering sequence informative fragmentation.  Since the osmium complex {(η6-
bip)Os(en)}2+  was shown to bind to different nucleotides during the EDD MS/MS of the 
mono-osmiated species above, and the mass of the precursor clearly showed retention of all 
but the chloride ligand of Os1-Cl, it can be concluded that the osmium modifications at 
discrete locations at either end of the oligonucleotide (as shown by the EDD MS/MS) hinder 
the electron based fragmentation when both binding sites are occupied simultaneously (as 
shown by the EDD here).  These observations could be explained by the osmium arene 
complexes causing  folding of the oligonucleotide, most likely involving π-π stacking of two 
biphenyl ligands, one from each osmium complex, meaning when the oligonucleotide 
backbone fragments, the resulting fragments remain bound non-covalently, in a similar 
fashion to a poly(amino acid) CRS during electron based dissociations.46   
Conclusions 
The organometallic half-sandwich ’piano-stool’ osmium(II) complex Os1-Cl, is thought to 
exert its anticancer activity partly through binding to DNA.28  The clinical anticancer drug 
cisplatin also has DNA as a target site, causing deformation of the DNA structure and, 
eventually, leading to apoptosis.  However, since Os1-Cl is not cross-resistant with cisplatin, 
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the mode of interaction with DNA would be expected to be different.  Indeed Os1-Cl is 
monofunctional and cannot readily crosslink DNA bases, in contrast to bifunctional cisplatin. 
The base specificity of Os1-Cl may also be different from cisplatin.  Prior to the current work 
previous studies had indicated that guanine N7 is a preferred binding site for Os1-Cl on DNA 
as it is for cisplatin. 
In this work, [(η6-biphenyl)Os(en)Cl]+ was reacted with a 12mer DNA oligonucleotide 
containing single guanine and cytosine sites under conditions (low ionic strength) in which it 
was single-stranded.  Using ultra-high resolution-FT-ICR MS up to two osmium complexes 
were shown to bind to DNA12.  Each reaction product was fragmented via tandem mass 
spectrometry (MS/MS) and the identity and binding location of the modifications were 
elucidated.  
{(η6-biphenyl)Os(en)}2+ was shown to bind to both the guanine and cytosine residues, both 
independently in the mono-osmiated [oligonucleotide+[(η6-biphenyl)Os(en)]-(n+2)H]n- 
species, and in the di-osmiated [oligonucleotide+2[(η6-biphenyl)Os(en)]-(n+4)H]n- species. 
Though Collision Activated Dissociation (CAD) produced extensive fragmentation and 
excellent sequence coverage with the unmodified oligonucleotide, the metallodrug 
modification dissociated from the mono-osmiated oligonucleotides.  With the retention of the 
complex in only a fraction of the fragments, CAD was able to narrow the location of the 
binding site of the modification to the A2-G3-T4 region of the sequence.  However Electron 
Detachment Dissociation (EDD) allowed unambiguous identification of both guanine (G3) 
and cytosine (C10) binding from assignment of fragmentation patterns.  Fragmentation of the 
di-osmiated DNA12 species proved more difficult, since the two bound osmium complexes 
appeared to stabilise the oligonucleotide toward EDD fragmentation.  Such stabilisation 
toward EDD fragmentation observed here for DNA12-2Os1 species may result from folding 
of DNA12 due to π-π stacking interactions between the two biphenyl ligands from separate 
guanine- and cytosine-bound osmium complexes (as previously characterised by NMR for 
related guanine bound Ru arene-oligonucleotide adducts)46, creating a cyclic gas phase 
species and hindering fragmentation via using electron detachment.  Collisional dissociation 
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methods were able to dissociate the species due to a multiple collision/slow heating 
mechanism providing results in agreement to those for the mono-osmiated species studied. 
This work demonstrates the flexibility and aptitude of FT-ICR Mass Spectrometry for Top-
Down fragmentation of DNA-metallodrug reaction products, and shows how a multi-
platform fragmentation approach is often needed to fully characterise metallodrug binding to 
biomolecules of interest.  FT-ICR MS provides the highest resolving power and mass 
accuracy performance of any mass spectrometry platform available, and offers the highest 
possible reliability and confidence in mass spectral assignment, coupled with the largest 
range of fragmentation techniques.  FT-ICR MS is therefore uniquely suited to Top-Down 
fragmentation of metallodrug-biomolecule adducts. 
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Table S4.1. Fragment assignments for Figure 4.2A: CAD MS/MS of the [DNA12-7H]7- species.  
Highlighted species (red) were used for internal calibration. 
Assignment Observed m/z Exact mass/ m/z Mass error/ppm 
[w3]3- 307.04607 307.046068 0.01 
[w2]2- 316.54956 316.549554 0.02 
[w1]1- 330.06062 330.060346 0.83 
[w4]3- 411.39860 411.398603 -0.01 
[w7]5- 430.66642 430.666187 0.54 
[w6]4- 460.32002 460.320152 -0.29 
[w3]2- 461.07251 461.072740 -0.50 
[w8]5- 493.27759 493.277708 -0.24 
[w5]3- 512.74725 512.747282 -0.06 
[DNA12-7H]7- 519.22994 519.230058 -0.23 
[w7]4- 538.58456 538.584553 0.01 
[a2]1- 536.12963 536.130584 -1.78 
[a4]2- 584.11046 584.110931 -0.81 
[a8]4- 600.10311 600.103648 -0.90 
[w6]3- 614.09573 614.095961 -0.38 
[w4]2- 617.60162 617.601542 0.13 
[w10]5- 619.89740 619.897419 -0.03 
[w8]4- 616.84874 616.848954 -0.35 
[a9-BH]4- 644.60404 644.604562 -0.81 
[w2]1- 634.10696 634.106383 0.91 
[y11]5- 666.51578 666.515674 0.16 
[w9]4- 692.86094 692.860463 0.69 
[a7]3- 699.12472 699.125277 -0.80 
[w7]3- 718.44837 718.448496 -0.17 
[a5]2- 740.63912 740.639733 -0.83 
[a10-BH]4- 722.86938 722.868963 0.58 
[w5]2- 769.62440 769.624561 -0.21 
[w10]4- 775.12451 775.123593 1.18 
[a8]3- 800.47396 800.473956 0.005 
[a6-B]2- 829.64287 829.641559 1.58 
[a3]1- 865.18203 865.183104 -1.24 
[a6]2- 897.16734 897.168536 -1.33 
[w6]2- 921.64754 921.647579 -0.04 
[w3]1- 923.15106 923.152755 -1.84 
[d3]1- 963.15877 963.158902 -0.14 
[a7-B]2- 986.16924 986.170361 -1.14 
[a7]2- 1049.19067 1049.191554 -0.84 
[w7]2- 1078.17740 1078.176382 0.94 
[a8-B]2- 1138.19271 1138.193380 -0.59 
[a4]1- 1169.22763 1169.229141 -1.29 
[w4]1- 1236.21034 1236.210360 -0.02 
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Table S4.2. Fragment assignments for Figure 4.2B: CAD MS/MS of the [DNA12+Os1-8H]6- species.  
Highlighted species (red) were used for internal calibration. Note: the highest intensity isotope was 
used for fragments containing the osmium modification. 
Assignment Observed m/z Exact mass/ m/z Mass error/ppm 
[w2]2- 316.54955 316.549554 -0.01 
[w1]1- 330.06062 330.060346 0.83 
[w4]3- 411.39854 411.398603 -0.15 
[w6]4- 460.32003 460.320152 -0.26 
[w3]2- 461.07265 461.072740 -0.19 
[w7-BH]4- 504.82084 504.821065 -0.45 
[w5]3- 512.74730 512.747282 0.04 
[w7]4- 538.58431 538.584553 -0.45 
[w6]3- 614.09598 614.095961 0.03 
[w4]2- 617.60194 617.601542 0.64 
[w2]1- 634.10680 634.106383 0.66 
[w11]5- 682.50854 682.508940 -0.59 
[w9]4- 692.86044 692.860463 -0.03 
[w7]3- 718.44849 718.448496 -0.01 
[a9-BH+Os1]4- 745.62715 745.627830 -0.91 
[w11+Os1]5- 763.12695 763.126400 0.72 
[w5]2- 769.62518 769.624561 0.80 
[w10]4- 775.12384 775.123593 0.32 
[a5-BH+Os1]2- 875.15856 875.158910 -0.40 
[w6]2- 921.64732 921.647579 -0.28 
[w3]1- 923.15207 923.152755 -0.74 
[a9-BH+Os1]3- 994.50451 994.506200 -1.70 
[a6-BH+Os1]2- 1031.68664 1031.687800 -1.12 
[a5-BH+Os1]1- 1749.32253 1749.322510 0.01 
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Table S4.3. Fragment assignments for Figure 4.3A: EDD MS/MS of the [DNA12-7H]7- species.  
Highlighted species (red) were used for internal calibration.  
Assignment Observed m/z Exact mass/ m/z Mass error/ppm 
[d2+H]2- 316.54955 316.549555 -0.02 
[d1+H]1- 321.04900 321.048777 0.69 
[w1]1- 330.06060 330.060346 0.77 
[w6]4- 460.31995 460.320152 -0.44 
[w3]2- 461.07274 461.072740 0.00 
[w5]3- 512.74716 512.747282 -0.24 
[w7]4- 538.58460 538.584553 0.09 
[w9]5- 554.08685 554.086915 -0.12 
[w6]3- 614.09572 614.095961 -0.39 
[w4]2- 617.60167 617.601542 0.21 
[w10]5- 619.89676 619.897419 -1.06 
[d8+H]4- 624.59780 624.597600 0.32 
[d6+H]3- 630.43500 630.435200 -0.32 
[d4+H]2- 633.09880 633.098834 -0.05 
[d2+H]1- 634.10650 634.106382 0.19 
[w11]5- 682.50894 682.508940 0.00 
[w9]4- 692.86046 692.860463 0.00 
[d9+H]4- 702.86181 702.862001 -0.27 
[w7]3- 718.44892 718.448496 0.59 
[d7+H]3- 731.78376 731.783879 -0.16 
[w5]2- 769.62471 769.624561 0.19 
[d10+H]4- 775.12384 775.123594 0.32 
[d11+H]4- 851.13487 851.135103 -0.27 
[w6]2- 921.64801 921.647579 0.47 
[w3]1- 923.15276 923.152755 0.01 
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Table S4.4. Fragment assignments for Figure 4.3A: EDD MS/MS of the [DNA12+Os1-9H]7- species.  
Highlighted species (red) were used for internal calibration. Note: the highest intensity isotope was 
used for fragments containing the osmium modification. 
Assignment Observed m/z Exact mass/ m/z Mass error/ppm 
[d2+H]2- 316.54955 316.549555 -0.02 
[d1+H]1- 321.04908 321.048777 0.94 
[w1]1- 330.06057 330.060346 0.68 
[w6]4- 460.32029 460.320152 0.30 
[w3]2- 461.07274 461.072740 0.00 
[w6]3- 614.09596 614.095961 0.00 
[w4]2- 617.60160 617.601542 0.09 
[d6+H]3- 630.43488 630.435200 -0.51 
[d4+H]2- 633.09931 633.098834 0.75 
[w2]1- 634.10669 634.106383 0.48 
[w9]4- 692.86083 692.860463 0.53 
[d9+2H]4- 703.11513 703.113821 1.86 
[w7]3- 718.44839 718.448496 -0.15 
[d7+H]3- 731.78402 731.7838793 0.19 
[w5]2- 769.62436 769.624561 -0.26 
[d5+H]2- 789.62774 789.627636 0.13 
[z10+Os1]4- 851.65110 851.651640 -0.63 
[d10+Os1+H]4- 876.14725 876.147330 -0.09 
[w6]2- 921.64677 921.647579 -0.88 
[w3]1- 923.15289 923.152755 0.15 
[d11+Os1+H]4- HP 952.40935 952.409350 0.00 
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Table S4.5. Fragment assignments for Figure 4.4A: CAD MS/MS of the [DNA12+2Os1-10H]6- species.  
Highlighted species were used for internal calibration. Note: the highest intensity isotope was used 
for fragments containing the osmium modification. 
Assignment Observed m/z Exact mass/ m/z Mass error/ppm 
[w2]2- 316.54955 316.549554 -0.01 
[w1]1- 330.06062 330.060346 0.83 
[w4]3- 411.39864 411.398603 0.09 
[w6]4- 460.32015 460.320152 0.00 
[w3]2- 461.07277 461.072740 0.07 
[w5]3- 512.74745 512.747282 0.33 
[w7]4- 538.58470 538.584553 0.27 
[w6]3- 614.09589 614.095961 -0.12 
[w8]4- 616.84921 616.848954 0.42 
[w4]2- 617.60154 617.601542 0.00 
[w2]1- 634.10670 634.106383 0.50 
[w11]5- 682.50881 682.508940 -0.19 
[w9]4- 692.86033 692.860463 -0.19 
[w7]3- 718.44879 718.448496 0.41 
[w6+Os1+H]3- 748.79373 748.794030 -0.40 
[w5]2- 769.62505 769.624561 0.64 
[w9+Os1+H]4- 793.63323 793.632200 1.30 
[w11+2Os1-9H]5- 843.54589 843.544500 1.65 
[w7+Os1+H]3- 853.14599 853.146620 -0.74 
[a5-BH+Os1-4H]2- 875.15842 875.158910 -0.56 
[w6]2- 921.64778 921.647579 0.22 
[w3]1- 923.15296 923.152755 0.22 
[a9-BH+Os1-5H]3- 994.50590 994.506200 -0.30 
[a6-BH+Os1-4H]2- 1031.68728 1031.687800 -0.50 
[w6+Os1+H]2- 1123.69411 1123.694680 -0.51 
[a7-BH+Os1-4H]2- 1188.21684 1188.216690 0.13 
[a8-BH+Os1-4H]2- 1340.23851 1340.239810 -0.97 
[a5-BH+Os1-3H]1- 1749.32253 1749.322510 0.01 
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Figure S4.1. HPLC trace of the commercially-synthesised DNA12 sample, showing multiple shorter 
oligonucleotides resulting from truncated synthesis and the DNA 12mer (highest peak) which was 
isolated and then re-analysed by HPLC; the resulting trace is inset, showing only one remaining 
product, the DNA 12mer (confirmed by UHR-FT-ICR MS, Figure 4.1A in main text). 
 
 
 
Figure S4.2. The nomenclature devised by McLuckey et al.34 based on the McCloskey et.al. 
system35 for assignment of oligonucleotide MS/MS fragments. 
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Chapter 5: 
Further study into metallodrug-DNA 
interactions by tandem mass spectrometry 
Introduction: 
 The study of metallodrug-biomolecules interactions can be greatly facilitated by the use of 
mass spectrometry and especially tandem mass spectrometry. UHR-FT-ICR MS and MS/MS were 
effective at studying the wide range of platinum metallodrug-modified peptides in Chapter 3. 
Unfortunately >90% of common metallodrugs do end up protein-bound within hours of introduction 
into the body.1 FT-ICR MS/MS was also shown to be well suited to the study of osmium metallodrug-
DNA interactions in Chapter 4. As a result it was logical to expand the study of photoactivatable 
platinum(IV) complexes into observing and interrogating their interactions with model strands of 
DNA, which is the focus of Chapter 5 herein. 
Cancerous DNA is the idealised target for many anti-cancer metallodrugs, including platinum(II) 
drugs such as Cisplatin and Oxaliplatin, and photoactivatable platinum(IV) compounds such as 
FM190 shown in Chapter 3, and below in Scheme 5.1. As mentioned previously by binding to 
cancerous DNA strands preferentially, metallodrugs can cause deformations in DNA tertiary 
structure and at the least prevent reading/replication of DNA, or at most induce apoptosis/cell 
death.  
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The main target of further investigation into metallodrug-DNA interactions was focused around the 
photo-induced reaction of FM190 with the model DNA strand studied in Chapter 4; DNA12, and the 
interrogation of subsequent reaction products by a range of MS/MS techniques within the FT-ICR 
Mass Spectrometer. With the wide array of platinum modifications observed for the two peptides in 
Chapter 3 showing release of any of the bound ligands during photo-activation and unexpected 
oxidation of nearby amino acid residues, reactions with DNA were expected to produce a similarly 
wide array of species, with various modifications.  
The study of DNA by Mass spectrometry can be challenging due to oligonucleotides’ extreme affinity 
for salts such as sodium and potassium, which in solution are key to stabilising their tertiary 
structure, and their complex fragmentation pathways. As a result of these challenges higher levels of 
sample clean up and desalting procedures are usually required for study of DNA/RNA species 
compared to similar sized poly(amino acids). In addition DNA monomer units (nucleotides) have a 
much higher mass than amino acids, meaning relatively short oligonucleotides quickly achieve large 
masses and become more difficult to fully characterise with MS and MS/MS. As a comparison 
poly(amino acids) (such as proteins) of 100+ kDa such as the 147kDa protein complex ADH-tetramer 
studied by Li et al.2 translating to 1496 amino acids, however currently large oligonucleotides such as 
those studied by Breuker et al. equate to single strands of ~61 nucleotides, but this returns a mass of 
~19.5 kDa.3  
Scheme 5.1 : (Left) Trans, trans, trans-[Pt(N3)2(OH)2(py)2] (FM190/Complex 1), the photo-activatable 
prodrug used in this study, along with (Right) an illustrative photo-activation pathway leading to DNA 
binding (an inter-strand cross-link).  
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Another challenge to DNA study via MS is the retention of tertiary structure. In solution DNA is most 
often viewed as a double-helical structure of two coiled oligonucleotide stands , stabilised by inter-
base hydrogen bonding interactions, but also by high levels of cations, such as Na+ and K+, which 
interact with the vast number of negatively charged phosphate groups present along the DNA 
backbone at physiological pH. Of course for ideal analysis by ESI/nESI-MS these salt ions must be 
removed from solution to enable the detection of purely protonated/deprotonated species. Though 
this is challenging, it is possible to achieve an acceptable level of salt concentration to allow effective 
ionisation and observation of purely deprotonated DNA species, as shown in Chapter 4. However the 
question will continue to remain; is this representative of biological conditions? DNA is most 
commonly found in the duplex form. Although it has been argued, quite accurately, that the reason 
most anti-cancer metallodrugs selectively bind to cancerous DNA and kill target cells is not some 
long-sought after cancer DNA sequence specificity, but simply that the compounds bind most 
effectively to DNA when it is both uncoiled and single stranded, so that the most preferential binding 
sites, the nucleobases (usually Guanine nucleobases for many Pt(II) compounds etc.), are fully 
exposed and able to co-ordinate to the metal centres. Because of this, the study of metallodrug-DNA 
interactions on single stranded DNA could be considered a reasonable representation of how a given 
metallodrug would interact with replicating DNA, and since cancerous cells replicate far more than 
usual cells this would be a common occurrence and available target. However it also suggests that 
the reactivity (and possible binding sites) of the metallodrug towards DNA could vary greatly 
between the single stranded, duplex helical, and folded-protein bound duplex DNA structures 
available within cell nuclei.  
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Figure 5.1: Representation of duplex DNA structure in a double-helical structure, showing both 
atomic detail and major and minor groove features of the structure. Because of its shape the 
major groove is particularly accessible to other entities. Reproduced from 
http://www.richardwheeler.net (accessed 12/08/2016). 
The retention of DNA duplex structure is similar to that of Native MS of peptides, proteins, and 
protein complexes, often requiring less than ideal ESI/nESI solvents, but often achievable with 
extreme care. To this end an investigation of the ability of nESI-MS to retain DNA-DNA interactions 
and produce gas phase ions for duplex DNA, to be then observed by MS, and interrogated for 
sequence informative information via MSn, was conducted using the model DNA strand DNA 12 
studied in Chapter 4. The ability to react metallodrug with duplex DNA could inform us about the 
varying mechanisms of action and DNA bond-disruptions which often accompany binding of 
metallodrugs to DNA strands. The opportunity to retain duplex DNA structure during nESI-MS could 
also progress into the ability to study DNA-protein interactions and provide further information on 
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metallodrug impact on nuclear proteins and their ability to interact with DNA, another mechanism of 
action to exploit/disrupt in target cancer cells. 
Materials and Methods: 
DNA12 was isolated and purified as described in the previous Chapter for Os1-DNA reactions, to 
recapitulate: 
The 12-mer DNA oligonucleotide DNA12 (defined here for MS purposes as fully protonated, i.e. each 
of the 11 phosphates is protonated)  
5′-TAGTAATTACTA-3′ (DNA12) 
 DNA12 (Tm 28°C) was purchased desalted from DNA Technology (Denmark).  Further purification 
was performed by HPLC, using an Agilent 1200 series liquid chromatography system.  The 
oligonucleotide was separated from shorter oligonucleotides (present as minor impurities in the 
commercial sample) using a PL-SAX ion exchange column (1000 Å pore size; 8 µM particle size; 150 
mm length, 4.6 mm diameter; Polymer Laboratories, Amherst, USA); buffer A: 7% acetonitrile + 0.1 
M triethylammonium acetate (TEAA), pH 7; buffer B: 7% acetonitrile + 0.1M TEAA + 1 M sodium 
acetate, pH 7; temp 40oC; flow rate 1.5 ml/min; gradient: 0-5 min 0% B, 5-45 min 0-40% B, 45-55 min 
40-100% B, 55-65 min 100% B, 65-75 min 0% B (see Supporting Information Figure S1: HPLC traces of 
commercial sample and inset; the resulting purified fraction).  The solvent was removed on a freeze-
drier, and a reverse phase chromatography PLRP-S column (100 Å pore size; 8 µM particle size; 300 
mm length, 7.5 mm diameter; Polymer Laboratories, US) was used to remove sodium acetate; buffer 
A: 50 mM TEAA, pH 7; buffer B: 70% acetonitrile + 50 mM TEAA, pH 7; temp 40oC; flow rate 2 
ml/min; gradient: 0-5 min 5% B, 5-35 min 5-100% B, 35-45 min 100% B, 45-45 min 0% B.  The solvent 
was removed again on a freeze-drier. 
Reaction mixtures of FM190+DNA12 were created at 1-1 and 0.5-1 (metallodrug:biomolecule) ratios 
at using aqueous stock solutions of FM190 (250 μM) and DNA12 (1 mM). samples were irradiated 
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with 463 nm blue visible light using an LED lamp (23 mW/cm-2) for set time intervals and then 
diluted with pure water prior to nESI-FT-ICR MS analysis, as before the use of acids/organic 
solvents/disrupting buffers was strictly avoided, as was any activating light (white/blue/green) 
before and during nESI-FT-ICR MS analysis. All sample preparation and analysis was conducted in 
darkness and/or very low levels of red light to avoid unwanted activation of the photoactivatable 
Pt(IV) metallodrug. 
All FM190+DNA12 samples were analysed by nESI-FT-ICR MS operated in the negative mode, in a 
similar fashion to the osmiated DNA in Chapter 4. CAD, IRMPD, and EDD MS/MS techniques were 
applied to observed adducts, selected informative results are shown and discussed below. 
Native (duplex) DNA experiments are detailed in the text below and were operated in both positive 
and negative mode nESI, from buffered aqueous conditions.  
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Photoactivatable Pt(IV) + DNA12 reactions: 
FM190 was shown to react with model peptides in Chapter 2 to an observable degree when 
activated with 463 nm blue visible light for just 1-2 hours. This photo-activation-induced binding was 
much faster than previous Pt(II) agents such as Cisplatin which rely on ~24 hour solution based 
displacement reactions in order to create active aqua-Pt(II) species and allow subsequent Pt 
complex-biomolecule binding.4–6 For the FM190+DNA12 reactions required solutions of the 
metallodrug+DNA were irradiated as for the peptides as previously, but for shorter periods of time 
i.e. t = 30, 60, 90, 120 minutes, longer irradiation times were attempted, but as discussed below 
were not required. The photo-activation produced an array of products, many of which resemble 
those previously observed during the reactions with peptides in Chapter 3. The mass spectra for 
each irradiation time are shown below in Figure 5.2, with different species marked according to the 
key below: 
 
275 
 
Figure 5.2: nESI-FT-ICR MS spectra of the DNA 12-mer +FM190 metallodrug (both shown inset) 
mixtures after varying irradiation times with blue visible light (463 nm). Each different product is 
marked with a coloured circle, with key shown on the right. 
 
Figure 5.3: nESI-FT ICR MS of the DNA 12-mer+FM190 mixture after 60 minutes irradiation with 
blue visible light (463 nm). Each product is marked accordingly. Isotopic simulations presented in 
the inset show the effect of the platinum metal centre on the overall DNA isotopic pattern. The 
difference is clear, however less drastic than for the osmium metallodrug shown in Chapter 3. 
Immediately surprising was the extremely fast rate of reaction observed, with only a very small 
proportion of the unmodified DNA12 species observable after just 30 minutes. Indeed the FM190 
compound was much more reactive towards DNA species than the peptides studied in Chapter 3, 
reacting to near completion within 30 minutes, and only minor changes from then on, in contrast to 
the hours for peptides species observed before. Similarly to the [Lys]3-Bombesin peptide all of the 
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Pt-bound reaction products had retained the trans-pyridine groups on the platinum complex. This 
uniform retention of pyridine functional groups, if in a trans configuration, is in direct difference to 
the ineffective trans-platin compound, whose NH3 amine groups bound to the Pt centre hindered 
DNA interaction due to a trans configuration, leading to the possibility of either a) the pyridine 
groups are able to re-orientate during the photo-activation/biomolecule binding steps and move out 
of the trans, trans, trans configuration, or b) the photo-activated compound retains its 
stereochemistry and is still able to bind to oligonucleotides, which could cause different distortions 
of tertiary structure than previous Pt(II) compounds such as Cis- and trans-platin.  
Also surprising was the absolute lack of biomolecule oxidation. Previously in Chapter 3, unexpected 
but clearly observable levels of oxidation were observed in both platinum-modified and unmodified 
peptide species, which were then studied using tandem mass spectrometry and found to be oxidised 
at the tryptophan and methionine amino acid residues. However both the platinum-modified and 
unmodified DNA12 species observed here were present without any oxidation products, despite the 
ability for nucleobases to be oxidised in the presence of either hydroxide radicals7 or singlet oxygen.8 
The lack of oxidation products shows a clear indication that, as with the peptide species above, the 
activation and resulting platinated reaction products are influenced by the identity, structure and 
functional groups of nearby biomolecules and in this case the DNA12 species did not enable the 
stabilisation/reactions leading to oxidation of oligonucleotides through release of hydroxide radicals.  
As mentioned above the reaction between DNA12 and FM190 occurred very quickly, with a near 
complete platination of DNA12 species within just 30 minutes irradiation with 463 nm blue visible 
light. Also, similar to the two peptides studied in Chapter 3, after a certain time point longer 
irradiations simply caused further activation of the platinum complex and release of further ligands, 
as seen in Figure 5.2 above, the DNA12+Pt(py)2(N3) species decreased in relative intensity with 
further irradiation while the DNA12+Pt(py)2 species increased, due to further activation of the Pt-
azide bond and further release of Azide species. Despite these differences, fragility post-ionisation, 
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and extreme light sensitivity, as with the peptides, each reaction product was effectively isolated 
and fragmented using a range of dissociation techniques in order to characterise the platinum 
complex modifications and their location within the DNA strand. 
MS/MS of platinated reaction products: 
Each observable platinated-DNA reaction product was isolated and fragmented using CAD and EDD 
MS/MS, in a similar fashion to the osmiated DNA in Chapter 4. General CAD collision 
energies/voltages were 2-12V, EDD was achieved through the use of a 1.5A heater electron-
dispensing cathode emitting 20.6 eV electrons for 1.0 seconds using a lens held at 18V.  
Unfortunately, as observed for the platinated peptides in Chapter 3, CAD MS/MS of the singly 
platinated species caused dissociation of platinum-bound ligands, followed by dissociation of the 
platinum metal centre from the DNA strand. The main fragmentation channels seemed to be loss of 
the pyridine ligands (if available) forming high intensity peaks, followed by subsequent loss of other 
Pt-bound ligands, and eventually the metal. It is desirable to use CAD/IRMPD for fragmentation of 
oligonucleotides, both for the ease of operation and the increased sequence coverage they can 
provide for these species via MS/MS, as recently shown by Shaw et al.,9 but also in Chapter 4. 
Regardless EDD MS/MS, shown in Chapter 4 as being a viable method for retention of metal 
complex-based modifications, can also be adopted for fragmentation of the platinated DNA species. 
Successful EDD MS/MS can require very fine tuning of both the electron cathode parameters, but 
also the ICR cell parameters in order to optimise the overlap of parent ion with the incoming 
electron beam in a way that produces the maximum backbone fragmentation of the target species 
and enough fragments to be detected. The CAD MS/MS of the [DNA12+Pt(py)2(N3)-6H]5- species is 
shown below in Figure 5.4:  
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Figure 5.4: nESI-FT-ICR CAD MS/MS of the [DNA12+Pt(py)2(N3)-6H]5- species (top). The resulting a 
and w ions assigned are summarised in the fragmentation map (bottom) shaded squares indicate 
fragments containing a metal modification. Highlighted regions indicate possible binding site. 
From the analysis of CAD MS/MS spectrum the Pt(py)2(N3) modification could have been bound to 
any or all of three different positions, the G3, A6, and/or C10. Due to the CAD-induced loss of the 
modification secondary fragmentation afterwards complicated the spectrum and analysis, causing 
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conflicting fragments, in a similar fashion to the osmiated DNA studied in Chapter 4. As a result EDD 
MS/MS was employed to provide complementary fragmentation data, as shown in Figure 5.5, 
below: 
 
Figure 5.5: nESI-FT-ICR EDD MS/MS of the [DNA12+Pt(py)2(N3)-6H]5- species (top) using 20.6 eV 
electrons. The resulting d and w ions assigned are summarised in the fragmentation map (bottom) 
shaded squares indicate fragments containing a metal modification. 
Analysis of the EDD MS/MS spectrum for the [DNA12+Pt(py)2(N3)-6H]5- species clearly shows that the 
platinum complex modification seemed to be binding to the guanine3 residue of the DNA 12-mer. 
The binding of the platinum complex to the guanine residue is in line with various Pt(II) based 
metallodrugs such as Cisplatin and Transplatin, which have both been shown to have a preference 
for binding at the exposed guanine nucleobases in DNA.9–11 The interesting observation particular to 
the products observed in the nESI-FT-ICR MS in Figure 5.3, above, was the two di-platinated species 
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([DNA12+2(Pt(py)2(N3))-9H]6- and [DNA12+Pt(py)2(N3)+Pt(py)2-9H]6-), due to the singular guanine 
nucleobase, the observation of diplatinated species suggested that the platinum complex 
modifications could bind to residues other than the guanine sites, which could be a distinct 
difference in behaviour compared to many Pt(II) based compounds. EDD MS/MS of the diplatinated 
[DNA12+2(Pt(py)2(N3))-7H]6- species is shown below in Figure 5.6: 
 
Figure 5.6: EDD MS/MS nESI-FT-ICR MS spectra of the diplatinated [DNA12+2(Pt(py)2(N3))-7H]6- 
species. Charge reduction, ligand and base loss was observed, but no sequence informative 
fragments could be assigned. Most likely due to the platinum centre disruption of normal EDD 
MS/MS. 
Unfortunately the EDD MS/MS proved ineffective in providing significant sequence informative 
fragments of the di-Platinated oligonucleotide. This could be due to the effect of the platinum metal 
centres influencing the electron-based dissociation. Peaks were observed for the charge-reduced 
species, showing that electrons were captured effectively by the ions. Peaks were also observed 
showing base loss and ligand loss, but no significant backbone fragmentation was observed despite 
this. The platinum metal centres could be particularly effective at stabilising the electron deficient 
radical site created by  EDD MS/MS, either via the metal centre, or via loss of a platinum-bound 
ligand. 
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CAD MS/MS was also attempted on the diplatinated [DNA12+2(Pt(py)2(N3))-9H]6- species, shown 
below in Figure 5.7. The CAD MS/MS of the diplatinated oligonucleotide showed an array of 
platinated and non-platinated fragments, which is in stark contrast to the CAD MS/MS of the mono-
platinated reaction product shown above. The assignable fragments are included in the Figure below 
and suggest binding of the metal complexes both at the guanine site (as seen above) and at either 
the C10 or T11 sites. Unfortunately CAD MS/MS also causes dissociation of Pt-bound ligands and 
entire Pt-based modifications, which caused conflicting fragments. However when using the 
unmodified fragments as well as the platinated fragments it could be suggested that the second 
Pt(py)2(N3) modification is binding at the C10 site, in a similar fashion to the osmium drug studied in 
Chapter 4. However this is unlikely based on previous reports of Pt(II) species and their preferential 
binding locations in oligonucleotides and larger DNA construct, and so would require more study and 
experiment to confirm the binding location, hopefully using dissociations which either fully retain 
the Pt modifications or which can cleave the C10-T11 bond to allow confident single-nucleotide 
assignment of the binding location. Analysis of both EDD and CAD MS/MS spectra of other observed 
reaction products is ongoing. Digestion of the oligonucleotides into smaller, more approachable 
species is possible, but would likely cause unwanted side reactions/effect towards the metal-based 
modifications causing dissociation or possible chemical transformation and negatively affect 
experimental validity. 
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Figure 5.7: CAD MS/MS nESI-FT-ICR MS spectra of the diplatinated [DNA12+2(Pt(py)2(N3))-9H]6- 
species (top) with corresponding fragmentation map summarising assignable fragments (bottom). 
Coloured markers indicate fragments retaining a platinum-based modification, Pt* = Pt(py)2(N3)  
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Moving towards Duplex DNA-MS: 
Although the analysis and characterisation of metallodrug-DNA interactions using isolated DNA 
strands was effective and provided unique insights into the mechanisms of action for both the 
osmium and photoactivatable platinum compounds studied herein, all studies involved reactions 
with single stranded DNA, which was then observed in the resulting nESI-FT ICR MS spectrum. DNA 
usually is present within the nucleus of cells in a duplex helical form, with two complementary 
strands coiled around each other via hydrogen bonds between nucleotide base groups, thus the 
reactive bases can often be shielded from the metallodrug and possible binding to some degree. In 
order to study the effects of metallodrugs on representative DNA structures and provide insights 
into mechanisms which were similar to in vivo activity; the possibility of studying duplex DNA by 
nESI-FT-ICR MS was investigated. 
For standard peptides and proteins Native MS (described in Chapter 1: MS introduction) attempts to 
stabilise protein structure during ionisation, transport and detection within the mass spectrometer, 
attempting to retain structural features through the transition between solution phase solubilised 
protein to detectable gas phase ions. This is usually achieved by avoiding denaturing conditions such 
as organic solvents, acid/bases, and low desolvation temperatures etc. during ESI. Also the use of 
aqueous buffers instead of pure solvents is usually required, which are not optimal for ESI-MS of 
proteins, and can thus hinder effective ionisation, high concentration Ammonium Acetate (AA) (10-
200 mM) has become a particularly common buffer choice for Native MS as it is reasonably 
compatible with ESI and does not contain high amounts of additional sodium/potassium which 
would drastically complicate resulting spectra and hinder detection/ MS/MS. As mentioned 
previously Native MS usually produces lower intensity protein peaks, large amounts of buffer 
adducts, and charge state ions than that of aqueous ESI-MS of the same analyte, again reducing 
detected intensity of ions and most importantly reducing MS/MS efficiency drastically. It is for these, 
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and other reasons, that Native MS is particularly challenging, firstly to achieve, and secondly to work 
with in subsequent experiments/ MS/MS. 
Native MS of DNA structures is very different to that of poly(amino acids) such as proteins. Protein 
structure can (for the most part) be stabilised by non-ideal buffers such as AA or ammonium 
bicarbonate (ABC), however DNA strands are mainly stabilised by salt ions such as Na+, K+, and 
mostly Mg2+ which are usually disastrous additives for ESI-MS of biomolecules. Salt adduction to 
biomolecules is one of the key issues and hindrances when attempting to achieve effective ESI-MS. 
Salt adduction spreads out a single analyte distribution over many different m/z’s and detection 
channels, effectively “diluting” the detectable signal and reducing sensitivity, also salt adduction can 
help protein structure survive during MS/MS and hinder fragmentation, or at the very least alter the 
fragmentation channels available. As a result of the challenges salt adduction to biomolecules 
induce, extensive sample preparation to remove salt species from solution and samples is ubiquitous 
throughout the biological MS field. DNA/RNA in particular are extremely challenging to study if not 
extensively purified and desalted to eliminate such problems, as observed in the previous sets of 
results the DNA 10 and 12-mers studies were purified and desalted multiple times, by various 
chromatography and size-exclusion techniques in order to produce the very clear and nearly salt-
free nESI-FT-ICR MS spectra shown herein. 
To begin the investigation into Native MS of DNA by FT-ICR MS, a sample of the DNA 12-mer (used 
during the previous studies) was analysed both in aqueous conditions (as previously studied as a 
control) and using high (with respect to MS analysis) concentration of ammonium acetate (200 mM), 
as would be expected for particularly challenging proteins for Native MS. The samples were analysed 
using nESI-FT-ICR MS as previously, however Native MS samples were operated using extremely low 
ESI source temperatures, so as not to induce unfolding/dissociation during heat-aided desolvation. 
The usual source temperature for nESI would be 180-200oC, for native MS samples this was reduced 
to 20-40oC. Usually Native MS samples have been reported using source temperatures ~80-100oC, 
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however as DNA is particularly sensitive to thermal transitions a lower temperature was chosen. The 
results of the different solutions for nESI-FT-ICR MS of the DNA 12-mer are shown below in Figure 
5.8.  
 
Figure 5.8: nESI-FT-ICR MS spectra of the DNA12 (TAGTAATTACTA) in water (a, top) 200 mM 
ammonium acetate (b, middle), and a 200mM ammonium acetate + 1mM KCl solution (c, bottom). 
Though particularly unusual, the addition of KCl to the buffer solution proved effective in 
stabilising the DNA duplex, but required the species to be detected in positive nESI mode, instead 
of negative mode as for the previous samples. 
Unfortunately even at 200 mM concentrations, the AA buffer solution was unable to effectively 
stabilise the structure of the DNA duplex and produced a spectrum containing only the single 
stranded DNA species (albeit with more buffer adducts than previously). Similar challenges in 
studying the structural aspects of DNA were recently observed by Gabelica et al. when studying DNA 
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quadruplexes.12 DNA quadruplexes rely on a coiled duplex structure around central cations such as 
potassium (K+), but without these they fall apart. It was shown by Gabellica et al. that observation of 
the quadruplexes was challenging by MS, but by the unusual tactic of actually adding salt species 
(KCl) to the ESI solution they were able to observe the fully potassiated ([DNA+2K]+ and 
[DNA+3K]+)species, achieving native-like representation of the tertiary structure.  
 
Figure 5.9: Structural features of DNA G-quadruplexes shown by Gabelica et al. Reproduced from 
Gabelica et al.12 
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Figure 5.10: Results of the potassium-titration experiment performed by Gabelica et al. to show 
the uptake of K+ ions into the DNA quadruplex-G structure, note the particular preference for 2K+ 
ions in (a) and 3K+ ions in (b) due to the different tertiary structures present. Reproduced from 
Gabelica et al.12 
Addition of KCl to ESI samples is usually particularly unfavourable, for reasons discussed above, 
though for the DNA quadruplexes was effective. However the DNA quadruplexes could 
accommodate up to 2 potassium ions only, putting a hard upper limit on the possible adducts 
observed, which is particularly convenient compared to if the same tactic would be used for say a 
protein. Unfortunately the DNA 12-mer studied within this thesis does not have this low upper limit 
to salt/buffer adduction, containing 12 phosphate groups along its backbone, and many bases with 
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accommodating lone pairs for cation adduction, the DNA 12-mer is very capable of many, many 
buffer and salt adduct products. Despite this the 200 mM ammonium acetate DNA 12-mer sample 
was spiked with 1 mM KCl, as a “high” concentration from KCl titration experiments performed by 
Gabelica et al. and shown above in Figure 5.10a.12 The resulting negative-mode nESI-FT-ICR MS 
spectrum did not show the desired duplex DNA species, nor did it show any single stranded DNA 
species, believed to be due to the disruption of KCl to the nESI process and/or blocking of the narrow 
nESI tip orifice by KCl aggregates. However despite this the nESI and transmission/detection voltages 
were reversed and the sample was analysed using positive mode nESI-FT-ICR MS to test for heavily 
potassiated DNA species, which may have become cations in solution due to the high concentrations 
of cations available. The resulting nESI-FT-ICR MS spectrum produced clearly observable single 
stranded and even duplex DNA species. The resulting “Native DNA MS” spectrum is shown above in 
Figure 5.8c. 
Unfortunately although observable, the DNA species had expectedly acquired a significant amount 
of buffer and salt adducts. Careful simulations of each possible combination of salt adduct 
([DNA12+(H)w(Na)x+(K)y+(AA)z](w+x+y)+) showed that indeed there was extensive potassium and 
sodium salt adduction, but also that the DNA duplex dimer was also observable. Again simulations 
for the Duplex DNA species were required to distinguish correct isotopic patterns from the various 
adduct peaks, using [DNA12+(H)w(Na)x+(K)y+(AA)z](w+x+y)+. Surprisingly the fully protonated duplex-
DNA species was also observed, without potassium/salt adduction, despite the inability to observe 
the duplex-DNA 12-mer in aqueous conditions without additional salt, leading to the conclusion that 
adducted cations such as Na+ or K+ could move/dissociate during the ESI process, or could be 
displaced by the high concentration of H+ induced during desolvation etc. Regardless the species 
were observed, and assigned (see Figure 5.11), and showing that the observation of duplex DNA is 
possible by nESI-FT-ICR MS. 
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The next stage of characterisation after observation, as for all biomolecular MS, is tandem MS. 
Unfortunately as observed above the salt adducts and the protonated duplex DNA species are very 
close in mass and not easily separable, however they need not be separated unless overlapping with 
other reaction products (as would be the case for metallodrug reactions) or unless 
observing/investigating the dissociation differences between the various adducts and the 
protonated species. The entire observable envelope for the protonated and various salt-adducted 
duplex DNA was isolated in the quadrupole region of the FT-ICR, and then fragmented using low-
energy CAD MS/MS, fragments were then accumulated in the hexapole region and then transferred 
to the ICR cell for detection. The resulting MS/MS spectrum showed the DNA duplex dissociating 
easily into single stranded DNA 12-mer ions as observed before. The lowest energy fragmentation 
channel appeared to be (predictably) the dissociation of the intra-strand hydrogen bonds to form 
individual oligonucleotide ions post CAD. 
The individual chains could then be re-isolated, fragmented, and characterised using in-cell isolations 
such as Multi-CHEF and in-cell dissociation techniques such as IRMPD and ECD MS/MS. In this way 
any modification of the DNA strand, say in future reactions with metallodrugs, would be elucidated 
through the isolation of individual species and the choice of dissociation techniques could be 
optimised in order to retain the modifications (e.g. ECD would be required for the osmium and 
platinum species studied in previous chapters). The Species produced by CAD MS/MS were then 
dissociated using ECD MS/MS for MS3 analysis of the duplex DNA. The species were not re-isolated 
during this experiment using Multi-CHEF, though this is easily achievable, this initial proof-of-
concept experiment was to show the CAD-ECD MS3 analysis was possible and could provide 
sequence-informative data. As mentioned in Chapter 4, electron-based dissociation of 
oligonucleotides can be achieved by Electron Detachment Dissociation (EDD) MS/MS, however this is 
a negative mode-exclusive technique, and so ECD was adopted for characterisation in the second 
stage of MS/MS here. Surprisingly ECD MS/MS of the DNA species was achieved by tuning of the 1.5 
A ECD cathode to emit 1.8 eV electron for 0.1 seconds via a lens voltage of 15V. The resulting MS3 
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spectrum is shown below in the summarising Figure 5.11, along with the d, w, and z ions identified 
from the ECD MS3. 
 
Figure 5.11: Summarising figure for the native Duplex-DNA nESI-FT-ICR MS3 experiments 
conducted. Clockwise from top left: nESI-mass spectrum of the DNA12+200mM AA+ 1mM KCl 
aqueous solution, CAD MS/MS of the quadrupole-isolated DNA12-Duplex 5+ charge state, CAD-
ECD MS3 of the isolated duplex species, fragmentation map showing the SS-DNA peaks observed in 
the CAD-ECD MS3 experiments, along with comments on the results obtained. 
The observation of z ions as well as d and w ions (usually observed in EDD) was slightly unusual, 
however the dissociation mechanisms of ECD and EDD differ greatly, not least because of the 
addition of electrons compared to the removal of electrons as the initial reaction step (respectively), 
so the similarities could be considered more surprising than the slight differences. Regardless CAD-
ECD-MS3 of positively charged salt-stabilised DNA duplexes in the gas phase was possible using nESI-
FT-ICR MS, and should be the next target in studying metallodrug-DNA interactions in order to 
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provide more representative scenarios for targets metallodrugs should encounter during their 
mechanism of action.  
To that end preliminary experiments into the binding of the osmium drug studied in Chapter 4 (Os1) 
with the Native DNA sample were attempted, using the same 3 hour incubation time and conditions 
as those mentioned previously, also longer reaction times of 12 hours were attempted. 
Unfortunately the osmium drug was shown to not bind to the duplex DNA within the timescale 
tested. This is believed either to be due to the osmium drug binding to the nucleobase, which is 
tightly involved in intra-strand hydrogen bond when in the duplex (as mentioned previously) or due 
to the 1 mM KCl solution used, as the Os1 drug relies on the dissociation of the Chlorido ligand in 
order to form  the active complex and bind to target biomolecules, addition of KCl will shift the 
equilibrium of this reaction towards the inert Chlorido-bound Os1-Cl complex and prevent binding 
(according to le Chatelier’s principle). The first possibility, intra-stand hydrogen bonding, is 
particularly relevant as this is believed to be what “protects” “normal” DNA from attack by 
metallodrugs, for the most part, during treatment, as it is the cancerous DNA which is more often 
replicating, and thus exposing its nucleobases to the possibility of binding, while normal, healthy 
cells are not so exposed, this is also believed to be the basis of the selectivity of most classical 
metallodrugs to bind to cancerous cellular DNA instead of the DNA of healthy cells. The equilibrium 
disruption is unfortunate, but may be addressed in the future by using non-Chloride containing ionic 
potassium salts – such as KOH. It is also worth noting that the same equilibrium issue would not be 
expected for compounds such as the platinum(IV) drug studied in Chapter 3 – FM190, as it contains 
no Chlorido ligand functionality, however, the extensive salt adducts would cause issues with the 
small m/z differences in reaction products observed (e.g. [Pt(py)2(N3)]+ vs. [Pt(py)2(OH)]+ 
modifications), and this would have to be addressed. These reactions were not fully 
tested/optimised during the timespan of this thesis, but lay the basis for such investigations in the 
near future, which are already underway. 
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Assignment Observed m/z exact m/z error/ppm 
[w3]2- 461.07274 461.07274 0.00 
[w5]3- 512.74713 512.74728 -0.30 
[w6]3- 614.09565 614.09596 -0.51 
[w2]1- 634.10643 634.10638 0.07 
[a5-BH]2- 673.11184 673.11276 -1.36 
[w9]4- 692.86039 692.86046 -0.11 
[a10-BH+Pt*]4- 821.38135 821.37979 1.90 
[a6-BH]2- 829.64091 829.64156 -0.78 
[w7+Pt*]3- 849.46440 849.46484 -0.51 
[w6]2- 921.64760 921.64758 0.02 
[w3]1- 923.15299 923.15276 0.25 
[w11+Pt*]4- 951.65001 951.65025 -0.25 
[a9-BH+Pt*]3- 990.82420 990.82485 -0.65 
[a6-BH+Pt*]2- 1026.16522 1026.16607 -0.83 
  Absolute average error 0.54 
  Standard deviation 0.72 
 
SI table 5.1: fragmentation assignments for the CAD MS/MS spectrum of the [DNA12+Pt(py)2(N3)-
6H]5- species. Pt* = Pt(py)2(N3) 
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Assignment Exact mass Observed mass error/ppm 
[w1]- 330.060346 330.06035 0.01 
[a2-B]- 401.076085 401.07521 -2.18 
[w3]2- 461.0727395 461.07274 0.00 
[w6]3- 614.09596 614.09606 0.16 
[w4]2- 617.601542 617.6014 -0.23 
[w2]- 634.106383 634.10653 0.23 
[w7+Pt*]4- 636.846808 636.84644 -0.58 
[w3+Pt*]2- 657.59725 657.5972 -0.08 
[w9]4- 692.86046 692.86044 -0.03 
[w6+Pt*]3- 745.112301 745.11204 -0.35 
[w5]2- 769.62456 769.62458 0.03 
[w3]- 923.152755 923.15276 0.01 
[w9]3- 924.14971 924.14852 -1.29 
[w5+Pt*]2- 966.149071 966.14749 -1.64 
[a11-BH+2Pt*]4- 992.1587068 992.16016 1.46 
  Absolute average 0.55 
  Standard 
deviation 
0.84 
 
SI table 2: fragmentation assignments for the CAD MS/MS spectrum of the [DNA12+2(Pt(py)2(N3))-
6H]5- species. Pt* = Pt(py)2(N3) 
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Chapter 6: 
Studying electron-quenching-Iridium 
metallodrug-modified biomolecules using 
CAD and ECD FT-ICR MS/MS. 
Square-planar platinum compounds such as Cisplatin and Oxaliplatin have been shown to bind to an 
array of biomolecule targets, such as cancerous DNA, and off-target species, such as peptides and 
proteins, via loss of their bound ligands in vivo and creation of more active species (such as the 
aqua-modified cisplatin species) which can then bind to biomolecules. Piano-stool geometry 
transition metal complexes (such as Os1 shown in Chapter 4) have also been shown to effectively 
bind to target biomolecules via a reactive site in the piano-stool geometry, but again only after the 
chlorido ligand dissociation/displacement in solution.  
This Chapter focuses on interesting new iridium piano-stool complexes, based upon complexes 
which have been shown to bind effectively to peptides and proteins previously by Qi et.al., via the 
loss of a chlorido ligand. The complexes presented herein though have been modified to include 
reactive functional groups on the bidentate ligands in the piano-stool geometry, allowing the 
possibility of not only the standard metal-centred binding to biomolecular species (as with previous 
compounds) but also new reactivities and products via reaction with the ligand aldehyde functional 
groups.  
These added functionalities were not only shown to be effective at binding to poly(amino acids) by 
MS, but the reaction products produced also posed interesting challenges to subsequent MS/MS 
experiments, causing changes in fragmentation mechanisms, fixed charge-induced distortion of 
fragmentation patterns, and interestingly stabilisation/”quenching” of ECD electrons by the iridium 
centre while covalently bound causing a large charge-reduced species peaks and little dissociation. 
However when the ECD electron was quenched by dative-covalent bound iridium modifications, the 
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reduced iridium centre dissociated from the biomolecule species, hindering but not preventing 
MS/MS characterisation. These new functionalities were shown to not only provide new binding 
mechanisms but were also found to provide a new way of targeting specific amino acid residues 
which the non-functionalised iridium complex (studied by Qi et.al.) did not bind to. Furthermore the 
aldehyde functionality on the bidentate ligand of the Ir complex was also shown to alter the binding 
preference of the metal centre (in comparison to the un-functionalised complex), as the Ir 
complexes presented herein formed metal-biomolecule bonds at histidine residues, not methionine 
residues as expected from previous studies. Overall these new methods of functionalising piano-
stool complexes may be able to allow more tuning of metallodrug reactivity and allow targeted 
binding in more ways than previously observed, and may present similarly interesting mechanisms 
of action against cancer cell components in vivo. 
Although the results presented within this chapter are predominantly based on FT-ICR MS and 
MS/MS results from the thesis Author, this was a collaborative project and some elements were 
conducted by collaborating researchers; namely Adam Millet provided the Ir1,Ir2, and Ir3 
compounds and was responsible for the synthesis and purification of said compounds. Subsequent 
NMR and other non-MS data associated with the compounds originated from Adam Millet and/or 
his laboratory. All biomolecule-metallodrug reactions, analysis, MS/MS characterisation etc. 
presented were conducted by the Author. 
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Studying electron-quenching-Iridium metallodrug-modified 
biomolecules using CAD and ECD FT-ICR MS/MS. 
Christopher A. Wootton, Adam Millet, Andrea Lopez-Clavijo, Mark Barrow, Peter J. 
Sadler, and Peter B. O’Connor 
Department of Chemistry, University of Warwick, Coventry, UK. 
Abstract: 
Transition metal complexes represent a key force in developing effective anti-cancer 
treatments, but with platinum drug resistance cases increasing each year, new transition 
metals have been investigated and synthesised to offer increased potencies, selectivities, and 
possible circumvention of resistance mechanisms inside resistant cancer cells. Iridium piano-
stool complexes have been shown to offer many of these properties. Herein we present 3 
novel iridium(III) anti-cancer complexes and show, using MS and MS/MS techniques, how 
functionalising the bidentate ligand within the metallodrug complex can offer new binding 
mechanisms and alter the preferred binding location of the complexes to model biomolecules 
compared to the unfunctionalised complex previously studied. The presence of the Iridium 
complex modification within target ions was shown to have a drastic effect on both CAD and 
ECD MS/MS behaviour, requirements, and fragmentation channels. CAD MS/MS was 
shown to only be effective when studying the covalently-linked condensation products. In 
contrast, ECD MS/MS, though hindered by the electron-quenching iridium complex 
modifications, was found to be suitable for studying many species observed and locating 
modification binding sites and identities often to within a single amino acid residue.  
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Introduction: 
Platinum based metallodrugs are currently used in over 50% of all anti-cancer chemotherapy, 
they have shown to be effective against a wide variety of cancerous cells and have been 
studied extensively as a result, yielding insights into their mechanisms of action,1 
transformations in solution,2 and binding preferences with respect to peptides,3 proteins,4 and 
oligonucleotides.5 Unfortunately many traditional Pt(II) based metallodrugs, such as Cisplatin, 
Transplatin, and Oxaliplatin have been shown to cause a wide array of side effects and be less 
and less effective during long term courses of treatment where cancerous cells often develop 
resistance to the Pt(II) species and treatment becomes ineffective.6  
Other transition metals have shown great promise as chemotherapy agents, boasting potencies 
and selectivities exceeding that of Cisplatin.7 More interestingly these new transition metal 
complexes have been shown to have varying mechanisms of action against cancerous cell 
components, while some are able to bind to cancerous DNA, causing deformations and 
eventually apoptosis (in a comparable fashion to Cisplatin), other metallodrugs have been 
shown to disrupt other vital processes in cells in order to kill target cancer cells, such as 
metallodrug binding to mitochondria,7 or disruption of the NAD+/NADH balance inside 
cells.8 Exploring these new mechanisms of action against cancerous cells has become the new 
focus of the next generation of anti-cancer compound synthesis efforts in order to create 
compounds which can circumvent previous resistances and find more effective ways of 
killing cancerous cells. 
Unlike the square planar Pt(II) compounds described above, other d-block metals readily adopt 
an octahedral ligand geometry. Piano-stool octahedral anti-cancer complexes have been 
shown to be particularly potent with a wide variety of metals utilised including; ruthenium,9 
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rhodium10, iridium,11 vanadium,12 and recently osmium compounds13,7 have all been shown to 
express effective mechanisms of action against cancerous cells. 
  
Figure 6.1: Iridium based piano-stool complexes used in the study – all compounds 
possess aldehyde functionalised bi-dentate ligands.  
Herein a biomolecule binding study is presented exploring 3 iridium based piano-stool 
complexes which have been shown to possess high cytotoxicity/anti-proliferative effects 
against cancerous cells  (Figure 6.1, above).11 Methylated-cyclopentadienyl iridium 
compounds have been synthesised and studied using MS and MS/MS by Qi et al. 
previously.14  However, unlike many metal-based chemotherapeutic agents previously 
described, the iridium compounds presented were modified to possess functional groups on 
the bidentate ligands within the complexes, which allows the possibility of biomolecules of 
interest to bind not only to the active metal centre (the mechanism of the vast majority of 
metal complexes and metallodrugs), but also for species to react with the ligand functional 
groups and produce new covalent bonds in addition to the dative bonds formed at the metal 
centre. The enhanced reactivity of the ligand groups produced interesting new reaction 
pathways and both the ligand-bound and metal centre bound species showed interesting 
challenges to both MS and especially MS/MS analysis, with the iridium complex having a 
Ir3-Cl Ir1-Cl Ir2-Cl 
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drastic effect on both threshold based dissociations (such as CAD and IRMPD) and electron 
based dissociations (such as ECD).  
Materials and methods: 
Substance P, [Lys]3-Bombesin, and formic acid were purchased from Sigma Aldrich (St. 
Louis, MO).  LCMS grade acetonitrile (ACN) was obtained from VWR (Radnor, PA) and 
used without further purification. Low concentration tuning mix was purchased from Agilent 
Technologies (Santa Clara, CA) and used as received. The iridium based Metallodrugs Ir2 
and Ir3 were synthesised and characterised using previous methods.11 The di-aldehyde 
Iridium drug Ir1 synthetic procedure is presented below: 
2-(4’-formylphenyl)-5-pyridinecarboxaldehyde (ligand 1) 4-formylphenylboronic acid 
(250 mg, 1.67 mmol) and 6-bromo-3-pyridinecarboxaldehyde (222 mg, 1.19 mmol) were 
dissolved in 1:1:1 mixture of tetrahydrofuran:water:1M sodium carbonate aqueous solution 
and stirred at ambient temperature under nitrogen for 1 h. 
Tetrakis(triphenylphosphine)palladium (28 mg, 0.02 mmol) was added and the reaction 
mixture was refluxed at 100°C for 24 h. The reaction mixture was cooled to ambient 
temperature, extracted with dichloromethane, the organic layer was washed with saturated 
sodium hydrogen carbonate solution and brine, then dried with magnesium sulphate and 
concentrated to dryness, yielding the crude material. Purification by column chromatography 
was performed using 1:1 chloroform:ethyl acetate (Rf = 0.59), yielding an off-white solid 
(152 mg, 60 %). 1H NMR (400 MHz, dmso-d6): δ 10.17 (s, 1H), 10.11 (s, 1H), 9.21 (d, 1H, J 
= 2.0 Hz), 8.41 (m, 2H), 8.38 (dd, 1H, J = 8.3, 2.0 Hz), 8.32 (d, 1H, J = 8.5 Hz), 8.07 (m, 
2H). 13C NMR (100 MHz, dmso-d6, DEPT135): δ 192.89 (CHO), 192.05 (CHO), 151.63, 
137.49, 129.99, 127.93, 121.54. ESI-MS (MeCN) m/z = 212.1 [M+H]+. 
301 
 
[(η5-Cp*)Ir(2-(4’-formylphenyl)-5-pyridinecarboxaldehyde)Cl] (Ir1) 2-(4’-
formylphenyl)-5-pyridinecarboxaldehyde (42 mg, 0.202 mmol) was dissolved in 
dichloromethane (30 mL) followed by the addition of sodium acetate ( 33 mg, 0.40 mmol) 
and the reaction mixture was stirred at ambient temperature under nitrogen for 30 min. 
[(Cp*)IrCl2]2 (80 mg, 0.101 mmol) was added and the reaction mixture was heated under 
reflux for 46 h. The crude product was recrystallised from chloroform/hexane at 273 K to 
yield a red crystalline solid (65 mg, 57 %). 1H NMR (400 MHz, dmso-d6): δ 10.17 (s, 1H, 
CHO), 10.13 (s, 1H, CHO), 9.20 (d, 1H, J = 1.5 Hz), 8.46 (d, 1H, J = 8.3 Hz), 8.34 (dd, 1H, J 
= 8.3, 2.0 Hz), 8.26 (d, 1H, J = 1.5 Hz), 8.17 (d, 1H, J = 8.0 Hz), 7.55 (dd, 1H, J = 8.0, 1.5 
Hz), 1.67 (s, 15H). ESI-MS (MeCN) m/z = 538.1 [M-Cl]+. Slow evaporation of a 
chloroform/hexane mixture at 273K led to crystals suitable for X-ray diffraction. 
A crystal structure for the Ir1 complex is also included in the supporting information (Figure 
SI1). 
Reaction of Peptides with Iridium metallodrugs: 
Aqueous solutions of Substance P (1 mM) and Bombesin (1 mM) were prepared and mixed 
with a solution of an iridium metallodrug in ACN (250μM) to give solutions of 0.5:1 and 1:1 
(drug:peptide) ratio.  The samples were then placed in an incubator (Genlab, Cheshire, UK) 
at 37 ˚C for 1-4 days before being diluted 50 fold with ACN to MS concentrations (~2.5 μM 
summed concentration for all reaction products) and frozen at -80 ˚C ready for MS analysis. 
Freshly prepared samples were compared to those frozen for 1 week to several months and 
showed no observable variation in the mass spectra obtained. Frozen samples were thawed 
and placed on a multi vortexer (Grant Bio, Cambridge, UK) prior to MS analysis.  
 
 
302 
 
FT-ICR Mass spectrometry: 
Nano-electrospray (nESI) Mass spectrometry was performed on a Bruker SolariX Fourier 
Transform Ion Cyclotron Resonance Mass spectrometer (FT-ICR MS) fitted with an Apollo 
II Ion source and a 12 Tesla actively shielded magnet (Bruker Daltonics, Bremen, Germany).  
Aqueous Peptide samples (5 μM) were spiked with 0.3% formic acid to aid in effective 
ionisation during nESI.  Iridium containing samples were sprayed in ACN with no added 
acid. 
For CAD MS/MS analysis, species of interest were isolated in the first quadrupole and 
accelerated into the hexapole collision cell for Collisionally Activated Dissociation (CAD) at 
10-30 V and continuously accumulated for 0.1-4 seconds before transfer to the Infinity Cell© 
for detection. 
For ECD MS/MS analysis, the species of interest were isolated in the first quadrupole, 
externally accumulated in the collision cell for 0.1-7 seconds and then transferred to the 
Infinity Cell© for Electron Capture Dissociation (ECD) fragmentation and detection. Ions in 
the Infinity Cell© were irradiated with 1.3 eV (peptides)-2.5 eV (Ir adducts) electrons from a 
1.5 A hollow cathode dispenser for 50-1200 ms prior to detection.  
MS/MS spectra were internally calibrated using the minimal number of unmodified (peptide 
spectra) or modified (Ir adduct spectra) b/c ions and the charge reduced species [M+nH]n-1+· 
where possible (species used for calibration are marked).  
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Results and discussion: 
The iridium metallodrugs were shown to react readily with Substance P (SubP) and 
[Lysine]3-Bombesin (L3BBS); the resulting spectra (below, Figure 6.2, and supporting 
information Figures SI6.2 and SI6.3) show few species; unreacted iridium drug+solvent 
adducts (minus the Cl ligand, lost during the ESI process), unreacted peptide species, and 
iridium modified peptides. Iridium containing species were readily assigned as such due to 
iridium’s characteristic isotope pattern (Figure 6.2 inset). The Ir drug+Substance P mass 
spectra all showed a single iridium containing species as a result of the reaction with 
substance P, this species corresponded to the mass of the iridium drug+peptide minus the 
mass of a water molecule (hereafter referred to as the condensation product), since the 
amidated Substance P used in this study contains no amino acid group which would readily 
lose a water molecule, even if the species were additionally collisionally activated (which it 
was not), the reaction product could have resulted from a  condensation reaction with one of 
the aldehyde functional groups contained within the iridium ligand.  
The Ir drug+L3BBS mass spectra showed the same reaction products as the Ir 
drug+Substance P reaction; unmodified drug+adducts, unmodified peptide species, and a 
condensation product ([Ir drug+L3BBS-H2O]
2+), the spectra also showed an additional 
reaction product; that of a non-condensation product; [Ir drug+L3BBS]2+, due to the 
observation of both the Ir drug without the Cl ligand and water/solvent molecule adduction 
([IrC10H15C10H6N2]
+ and [IrC10H15C10H6N2+H2O]
+ respectively for Ir1-containing spectra, 
Figure 6.2 inset), the identity of the iridium metallodrug modification for the L3BBS species 
was ambiguous, even with accurate mass-mass spectrometry (readily achieved on the FT-ICR 
MS used), the 2 species have exactly the same mass and only varied by the location of the 
H2O. Both Collisionally Activated Dissociation (CAD) and Electron Capture Dissociation 
(ECD) were conducted on all iridium-modified species in order to elucidate not only the 
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identity of the Iridium metallodrug once bound to poly(amino acids) but also to locate the 
preferential binding locations of these novel therapeutic agents. It is noteworthy that after a 
24 hour incubation with the iridium drugs the Substance P peptide had a near-complete 
reaction with the iridium drug and produced a single reaction product. Although reaction with 
L3BBS produced 2 distinct reaction products for each iridium drug, the extent of reaction 
was much lower (as observed by the lower relative intensity in the Ir-L3BBS spectra, Figure 
6.2).  
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Figure 6.2: nESI-FT-ICR Mass Spectra of Iridium metallodrug+peptide mixtures, reacted for 24 
hours at 37oC prior to analysis. In the SubstanceP+Ir1 metallodrug (top) only the condensation 
reaction product ([SubP+Ir1-H2O+H]2+) is observed outside of reagent peaks. In the Lys3-
Bombesin+Ir2 metallodrug spectrum 2 Iridiated peptide species are observed (inset) both the 
condensation product ([L3BBS+Ir1-H2O+H]2+) and the non-condensation (metal bound) product 
306 
 
([L3BBS+Ir2+H]2+). Inset: Observed Iridiated peptide/Iridium containing peaks, showing the 
influence of the transition metal on the observed isotopic distribution. 
Tandem MS of Iridium modified species: 
Previous studies of piano-stool iridium compounds binding to poly(amino acids) by Qi et al. 
showed that the non-aldehyde functionalised analogues of the metallodrug bind to methionine 
residues in target proteins, and could be effectively studied using both Collisionally Activated 
Dissociation (CAD) and Electron Capture Dissociation (ECD).14 Many peptide and protein 
modifications, be they natural Post Translational Modifications (PTM’s) such as 
phosphorylation, synthetic modifications, or metal-based modifications, are easily lost using 
slow-heating/threshold based dissociation techniques (such as CAD), but can be retained 
using electron based dissociation techniques such as Electron Capture/Transfer Dissociation 
(ECD and ETD respectively), with metal complex-based modifications being particularly 
susceptible to loss during CAD.1513 However, standard CAD and ECD MS/MS of the 
reaction products shown in Figure 2 provided interesting results and non-standard 
dissociation mechanisms compared to the unmodified peptide species, each of which are 
detailed below.  
The irdium metallodrug-Substance P reactions showed only one iridiated-peptide reaction 
product ([Irx+SubP-H2O+H]
2+). The subsequent ECD MS/MS spectrum of the quadrupole-
isolated species is shown below in Figure 6.3. 
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Figure 6.3: ECD MS/MS spectrum of SubstanceP+Ir1-H2O condensation product. The 
available aldehyde group on the bidentate ligand binds to a lysine residue via a 
condensation reaction to form a covalently bound imine. ECD MS/MS of the imine-
bonded peptide-Ir complex species leads to electron quenching by the Ir centre and little 
to no dissociation (top) though low intensity fragments (<1% of precursor) can be 
observed with high number of summed acquisitions (bottom), so much so that even the 
suppressed harmonic signals from the precursor can be observed (w3). 
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Interestingly not only did the iridium modified species require very different electron 
energies and pulse lengths to achieve effective ECD MS/MS (compared to the corresponding 
unmodified peptide ions), but the parent ion-charge reduced species intensity ratio was 
drastically different. For instance, Substance P ECD MS/MS shows very effective electron 
capture, resulting in a charge reduced species (CRS, [SubstanceP+2H]+.)~5-10% intensity of 
the parent ion ([Substance P+2H]2+) and good intensity ECD fragments (~10-25% of parent 
ion intensity).16 For the iridium modified Substance P the intensity of the CRS compared to 
the 2+ parent ion was 41%, which is unusually high for peptide ECD MS/MS, the resulting 
ECD fragments were also of very low intensity (≤1%) compared to unmodified Substance P 
ECD MS/MS, indicating the iridium-based modification is having a drastic effect upon the 
ECD process.  
The iridium metal centre within the metallodrug modifications was in the 3+ charge state (i.e. 
IrIII), with 2 charges neutralised via bonds to ligands (Cp* and the NC- ligand), leaving the 
iridium ccomplex in an overall 1+ charge state, which explained the addition of a single 
proton to produce the [Peptide+Irx+H]2+ species detected. The Ir+ complex can be easily 
reduced to Ir0 by electron capture during ECD MS/MS to produce a charge reduced species in 
which the electron has been effectively quenched by the iridium centre, rather than a more 
typical CRS where the electron has caused backbone/sidechain dissociation, with the 
individual fragments remaining adducted together via hydrogen bonds/other 
covalent/backbone bonds.17,18  
The quenching of electrons during electron-based dissociations has been observed before 
when studying covalently-bound heme-containing biomolecules, such as Cytochrome c, and 
when studying species with particularly high histidine content, the conjugated pi-systems 
were believed to be able to stabilise incoming electrons and the resulting radical species 
generated, preventing/subduing ECD/ETD fragmentation during MS/MS.19 Europium-
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adducted biomolecules and some other heavy metal adducts are also believed to be so-called 
“electron sinks” and quench electrons,20 however these effect have been observed only with 
heptadentate ligands surrounding the metal centre or with bare metal centres as 
adducts/charge carriers and not as specific biomolecule modifications as metal complexes.  
Despite the partial quenching of ECD electrons by the iridium centre, low intensity fragments 
were observed in all ECD MS/MS spectra of Ir-containing reaction products (Figure 6.3 and 
in SI). These fragments are summarised in the corresponding fragmentation maps (Figure 6.3 
and in SI). For the iridium complex-modified Substance P species there is a clear preference 
for lysine binding, accompanied by a water loss during the process, indicating a condensation 
reaction between the terminal primary amine on the lysine side chain and the aldehyde group 
present on the bidentate ligand within the iridium complex. The condensation reaction 
between the complex and the biomolecule results in the formation of an imine, a strong 
covalent bond which surprisingly does not involve the metal centre directly. Also surprisingly 
there seems to be no evidence of methionine binding between the terminal methionine 
residue of either peptide and the Iridium centre, which is in contrast to previous studies by Qi 
et al.,14 who showed the non-aldehyde functionalised iridium(III) complex analogue binds 
strongly to methionine residues in the calcium-binding protein Calmodulin; the presence of 
the aldehyde functional group(s) seem(s) to be affecting both the mechanism of binding 
(additional binding via the ligand) and the preferential location of said binding (lysine over 
methionine). 
ECD MS/MS of the Irx+L3BBS condensation products (x=1, 2, or 3) (Figure 4, below and in 
SI) also showed an unusually high CRS relative intensity compared to the parent ion 
(~250%), showing severe quenching of ECD electrons. ECD of the unmodified L3BBS was 
much more routine, with a CRS intensity ~10-20% compared to that of the precursor. ECD 
MS/MS analysis of the iridium complex-modified peptides was hindered greatly by the 
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iridium-induced electron stabilisation/quenching, limited fragments were assigned showing 
iridium metallodrug binding towards the N-terminus of the peptide (see below). 
 
Figure 6.4: ECD MS/MS of the condensation reaction product between Ir2 and L3BBS 
([L3BBS+Ir2-H2O+H]2+). The spectrum shows the iridium complex modification is 
effectively quenching the ECD electrons producing electron capture, but little 
dissociation (top). Zoom in of the spectrum shows when the small proportion of 
electrons are captured along the backbone, low intensity fragments can be observed 
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(middle), fragments can then be assigned (fragmentation map, bottom). Orange squares 
indicate fragments containing the Ir modification. 
 
Figure 6.5: ECD MS/MS of the iridiated K3-Bombesin non-condensation product  
[L3BBS+Ir2+H]2+ (top) and zoom in of ECD fragments produced (middle) by the small 
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proportion of electrons captured along the peptide backbone and not quenched at the 
iridium centre, which caused dissociation of the complex and an abundant unmodified 
peptide peak. Resulting ECD MS/MS fragmentation is summarised in the 
fragmentation map (bottom), orange squares indicate the iridium modification is 
present on a given fragment. 
ECD MS/MS of the non-condensation product produced ([Irx+L3BBS+H]
2+) are shown in 
Figure 6.5 and in the SI. The effect of the iridium complex bound to the peptide was shown to 
have a drastic effect on the ECD spectrum, with the main fragmentation pathway appearing 
to be electron capture at the iridium centre (as seen in the condensation product ECD 
spectrum), unfortunately the reduction of the iridium centre by captured electrons caused the 
complex to dissociate from the biomolecule and produce a large peak corresponding to 
unmodified [L3BBS+H]+. Fortunately being a 1+ ion, the [L3BBS+H]+ species produced was 
not able to undergo further ECD MS/MS fragmentation and produce detectable fragments 
due to the charge being neutralized upon electron capture. Though most of the precursor ions 
fragmented via loss of the iridium complex modification, low intensity fragment ions were 
observed and were used to locate the modification binding site. All 3 Iridium complexes were 
shown to preferentially bind to the [histidine]11 residue within L3BBS in a non-condensation 
(i.e. metal-centred) fashion via a dative covalent bond to the Ir centre. The detection of 
histidine-centred binding via the Ir metal centre showed a change in the binding preference of 
these functionalised iridium compounds in contrast to the unfunctionalised ligand iridium(III) 
compounds studied previously14 which showed a preference for methionine residues and to 
the condensation products described above (preference for lysine residues). The change in 
binding behaviour of these functionalised iridium complexes compared to other transition 
metal complexes, which often show a distinct preference for sulphur containing residues 
(such as methionine), especially those based upon platinum, show that the behaviour of 
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transition metal complexes, even when based upon the same metal centre, can change 
dramatically with even small changes to ligand composition and reactivity. 
The formation of the covalent imine bond suggested that the condensation Iridium 
modification should be able to survive (even partially) a threshold based dissociation 
technique. CAD MS/MS was conducted on the condensation and non-condensation reaction 
products observed in the L3BBS spectrum. As expected CAD of the non-condensation 
product resulted in loss of the Iridium complex modifications at low CAD energies/voltages 
(~5-8V) whereas backbone fragmentation would not occur to a useful extent without the use 
of high voltages (15-20V). CAD MS/MS of the L3BBS condensation products on the other 
hand was very successful (Figure 6, below). Though CAD caused some loss of the bidentate 
ligand from the CRS (shown in Figure 6.6 and in SI tables of assignments), this was a minor 
fragmentation pathway. The vast majority of peaks observed were readily assigned to 
unmodified/Iridium complex-modified b/y fragments and side chain loss ions therefrom. The 
CAD MS/MS provided correlating and complementary data to the ECD MS/MS of the 
condensation product, summarised in Figure 6.5 fragmentation maps, the complexes are 
clearly shown to bind preferentially to the Lysine residue, via loss of a water molecule. 
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Figure 6.6: CAD MS/MS spectrum of iridium-modified peptide (Ir2+L3BBS) via a 
covalent imine bond caused by a condensation reaction, allowing the usually fragile 
metal modification to survive CAD MS/MS. Orange squares indicate a fragment 
modified with the Iridium complex. Binding of the complex was readily located to the 
Lysine3 residue. 
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Although the Ir1 complex contained 2 aldehyde functional groups within the bidentate ligand, 
no cross-linked, di-condensation product was observed (i.e. a product formed from 2 
condensation reactions, one at each aldehyde group), even during subsequent experiments 
using higher ratios of Ir1 to peptide, nor with longer reaction times (up to 7 days). This lack 
of further reaction could indicate a difference in reactivity between the aldehyde groups. Due 
to the different compositions of the aromatic rings within the bi-dentate ligand, a difference 
in reactivity could be possible (due to one being pyridine-based and one phenyl-based). 
Though comparisons with Ir2-peptide and Ir3-peptide spectra showed that regardless of 
which ring the aldehyde group is positioned, only one condensation reaction occurs, 
indicating that another factor inhibits future binding once the first imine bond is formed – 
most likely steric hindrance of the peptide biomolecule coiling around/blocking further 
access to the areas of the metal complex post-Imine formation.  
It is worth noting that a low intensity peak was detected in the mass spectrum of the Ir1-
L3BBS reaction mixture corresponding to a possible cross-linked Ir1-peptide species 
([Ir1+2xL3BBS-H2O+2H]
3+). Though it should also be noted that a peptide dimer peak 
([2xL3BBS+3H]3+) was observed – resulting from 2 peptide ions held together via non-
covalent interactions (such as hydrogen bonds). Since both a peptide dimer and an Ir1-
modified species containing 2 peptides were both observed the identity of the Ir1 modified 
species was ambiguous, possibilities include a crosslinked peptide species (resulting from a 
condensation product (imine bound to one peptide) and a metal centre-bound peptide) or an 
L3BBS dimer modified at one lysine residue (as described above). CAD and ECD MS/MS 
were carried out on the possible dimer species. CAD MS/MS predictably caused dissociation 
of the dimer at low CAD voltages (as discussed above), and little information beyond other 
than typical lysine modified fragments (as observed in the CAD MS/MS of the individual 
condensation products). ECD MS/MS was hindered greatly by the low intensity of the 
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species and by the loss of the Iridium complex forming the most popular fragmentation 
channel. Very few sequence informative fragments were assigned, but those that were 
(summarised in the SI) showed correlating information to that of the ECD MS/MS of 
individual modified peptides – i.e. that of a metal complex bound via an imine linkage to the 
lysine residue and the complex bound via a metal centred dative bond from the histidine 
residue, indicating the species was in fact an iridium-cross-linked reaction product. Similar 
iridium-cross-linked products were also observed in the Ir2-L3BBS and Ir3-L3BBS mass 
spectra, again re-enforcing that only one aldehyde group and one metal centred bond are 
required for crosslinking using these iridium(III) complexes. The Substance P+Ir1/Ir2/Ir3 
spectra did not show any evidence of iridium-cross-linking, despite the methionine residue 
availability and the presence of two reactive aldehyde groups present on the Ir1 complex.  
The various different binding modes of these functionalised iridium-based modifications are 
summarised below in Figure 6.7: 
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Figure 6.7: Summarising figure showing the range of reaction products observed during 
the reaction of functionalised iridium complexes with the model peptides 
Conclusions: 
Iridium piano-stool complexes have been shown to be effective anti-cancer metallodrugs, 
with potencies and selectivities exceeding that of widely used compounds such as Cisplatin. 
However studying more exotic metal-based modifications poses interesting challenges for 
both MS and especially MS/MS experiments. A study has been presented exploring how 
aldehyde-functionalised iridium(III) complexes can bind to model poly(amino acids), and the 
unusual effects these modifications have upon usually routine MS and MS/MS analysis.  
The aldehyde-functionalised compounds were shown to bind to peptide via a dative covalent 
bond between the iridium metal centre and histidine residues of biomolecules when available. 
CAD MS/MS of dative covalent bonded species resulted in loss of the metal based 
modification and subsequent secondary fragmentation of the unmodified peptide produced, 
losing all sequence informative fragments related to modification location. ECD MS/MS of 
the dative covalent bonded species was challenging due to the electron quenching effect of 
the iridium based modification, but did produce fragments revealing the modification 
locations. The functionalised iridium compounds were also shown to bind to lysine residues 
within biomolecules via a condensation reaction, creating a covalent imine based linkage. 
CAD MS/MS of the covalently bonded imine species was very effective, with the iridium 
modification remaining on subsequent fragments and enabling location of the modification 
site.  
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SI Figure 6.1: X-ray crystal structure of the Ir1 dialdehyde functionalised Iridium(III) piano-stool 
complex and associated information. 
  
 2 
Ir-C (Cp* ring)  2.155(2) 
 2.160(2) 
 2.166(2) 
 2.251(2 
 2.259(2 
Ir-C (centroid) 1.826 
Ir-C  2.032(2) 
Ir-N  2.0789(19) 
Ir-Cl  2.4051(6) 
  
C-Ir-N  77.86(9) 
C-Ir-Cl 87.08(6) 
N-Ir-Cl  84.91(6) 
 2 
Formula C23H23ClIrNO2 
MW 573.07 
Crystal Colour Brown 
Cryst size (mm) 0.25 x 0.20 x 0.15 
λ (Å) 0.71073 
Temp(K) 150 
Cryst system Monoclinic 
Space group P2(1)/c 
a (Å) 17.3889(2) 
b (Å) 7.66780(10) 
c (Å) 16.5920(2) 
α (°) 90 
β (°) 113.945(2) 
γ (°) 90 
Vol (Å3) 2021.89(4) 
Z 4 
R(Fo2) 0.0195 
Rw(Fo2) 0.0502 
GOF 1.088 
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SI Figure 6.2: ECD MS/Ms spectrum, assignments and fragmentation map for the analysis of the 
[SubstanceP+Ir1-H2O+H]2+ species 
  
Fragment Observed mass Exact mass Error (ppm) 
[C4•]+ 1013.45049 1013.4506 -0.11 
[C5•]+ 1141.50907 1141.50919 -0.11 
[C6•]+ 1269.56765 1269.56763 0.02 
[C7•]+ 1416.63606 1416.63635 -0.20 
[C8•]+ 1563.70447 1563.70452 -0.03 
[Z9-H•]+ 1595.67789 1595.67722 0.42 
[C9•]+ 1620.72593 1620.72693 -0.62 
[M+H]+• 1865.858328 1865.8583 0.02 
[Sub P –NH3]+ 1330.70897 1330.70886 0.08 
[C7•- CH4N2]+ 1372.62245 1372.598902 -0.19 
[C8•- CH4N2]+ 1519.69438 1519.667072 -0.33 
[M+H – CpMe5]+ 1730.73857 1730.740386 -1.05 
[M+H – Me]+ 1850.83652 1850.834835 0.91 
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Fragment Measured Theoretical ppm 
[z3•+Ir2]+ 891.33643 891.33657 -0.16 
[z6•+Ir2]+ 1118.46426 1118.464091 0.15 
[z7+Ir2]+ 1303.53558 1303.53558 0.00 
[z7•+Ir2]+ 1304.54389 1304.543401 0.37 
[z8+Ir2]+ 1431.59435 1431.59416 0.13 
[z8•+Ir2]+ 1432.60186 1432.601981 -0.08 
[z9+Ir2]+ 1545.63665 1545.63709 -0.28 
[z9•+Ir2]+ 1546.64474 1546.644911 -0.11 
[z10+Ir2]+ 1602.65836 1602.65855 -0.12 
[z10•+Ir2]+ 1603.66588 1603.666371 -0.31 
[z11+Ir2]+ 1715.7425 1715.74261 -0.06 
[z12+Ir2]+ 1843.83686 1843.83757 -0.39 
[c12+Ir2]+ 1854.82214 1854.821796 0.19 
[c13+Ir2]+ 1967.90497 1967.905856 -0.45 
  Absolute average 0.20 
  Standard deviation 0.23 
 
 
SI Figure 6.3: Assignments and fragmentation map for the ECD MS/MS analysis of the 
[L3BBS+Ir2+H]2+ species. 
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Assignment measured theoretical ppm 
[b3+(Ir2-H2O)-H]+ 857.313 857.313005 -0.01 
[b4+(Ir2-H2O)-H]+ 970.39702 970.397065 -0.05 
[b5+(Ir2-H2O)-H]+ 1027.41868 1027.418525 0.15 
[b6+(Ir2-H2O)-H]+ 1141.46129 1141.461455 -0.14 
[b7+(Ir2-H2O)-H]+ 1269.52003 1269.520035 0.00 
[b8+(Ir2-H2O)-H]+ 1455.59958 1455.599345 0.16 
[b9+(Ir2-H2O)-H]+ 1526.63602 1526.636455 -0.28 
[b10+(Ir2-H2O)-H]+ 1625.70466 1625.704865 -0.13 
[b11+(Ir2-H2O)-H]+ 1682.72557 1682.726325 -0.45 
[b12+(Ir2-H2O)-H]+ 1819.78479 1819.785235 -0.24 
[b13+(Ir2-H2O)-H]+ 1932.86903 1932.869295 -0.14 
[b8+(Ir2-H2O)-H+-NH3]+ 1438.57279 1438.5728 -0.01 
[b9+(Ir2-H2O)-H+-NH3]+ 1509.60922 1509.60991 -0.46 
[b10+(Ir2-H2O)-H+-NH3]+ 1608.67813 1608.67832 -0.12 
[b8+(Ir2-H2O)-H+-CO]+ 1427.60488 1427.60443 0.32 
[b9+(Ir2-H2O)-H+-CO]+ 1498.64119 1498.64154 -0.23 
[b10+(Ir2-H2O)-H+-CO]+ 1597.71107 1597.70995 0.70 
[b8+(Ir2-H2O)-H+-CO2]+ 1411.60967 1411.609516 0.11 
[y5]+ 555.30719 555.30715 0.07 
[y6]+ 626.3443 626.34426 0.06 
[y7]+ 812.42356 812.42357 -0.01 
[y8]+ 940.48218 940.48215 0.03 
[y9]+ 1054.52498 1054.52508 -0.09 
[y10]+ 1111.54644 1111.54654 -0.09 
[y11]+ 1224.63048 1224.6306 -0.10 
[y5-NH3]+ 538.2806 538.280605 -0.01 
[y6-NH3]+ 609.31776 609.317715 0.07 
[y7-NH3]+ 795.39692 795.397025 -0.13 
[y8-NH3]+ 923.45555 923.455605 -0.06 
[y10-NH3]+ 1094.51992 1094.519995 -0.07 
[y11-NH3]+ 1207.60419 1207.604055 0.11 
[b10+Ir2-H2O-H]+2 813.35599 813.3560725 -0.10 
[b12+Ir2-H2O-H]+2 910.39616 910.3962575 -0.11 
[b13+Ir2-H2O-H]+2 966.93832 966.9382875 0.03 
[b13+Ir2-H2O -H-NH3]+2 958.42511 958.425013 0.10 
[b13+Ir2-H2O-H-CO]+2 952.94074 952.94083 -0.09 
[b13+Ir2-H2O -H-CO-NH3]+2 944.42731 944.4275555 -0.26 
[L3BBS+(Ir2-H2O)+ H+ ]2+ 1040.97159 1040.971808 -0.21 
[(L3BBS+(Ir2-H2O)+ H+-NH3]+2 1032.45839 1032.458533 -0.14 
[L3BBS+(Ir2-H2O)+ H+ -2NH3]+2 1023.94508 1023.945259 -0.17 
[y12+(Ir2-H2O)-H]+2    921.4265 921.426775 -0.30 
 
Absolute average =  0.15 
Standard deviation =  0.20 
CAD 25V 
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Si Figure 6.4: Assignments and fragmentation map for the CAD MS/MS analysis of the    
[L3BBS+Ir2-H2O+H]2+ species 
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Fragment Expected mass Observed mass ppm 
[b3-CO+Ir1-H2O]+ 857.313005 857.31314 0.16 
[b3+Ir1-H2O]+ 885.30792 885.30792 0.00 
[b4+Ir1-H2O]+ 998.39198 998.3919 -0.08 
[b5+Ir1-H2O]+ 1055.41344 1055.41309 -0.33 
[b6+Ir1-H2O]+ 1169.45637 1169.45623 -0.12 
[b7-CO2+Ir1-H2O]+ 1253.52512 1253.52463 -0.39 
[b7-CO+Ir1-H2O]+ 1269.520035 1269.51992 -0.09 
[b7-H2O+Ir1-H2O]+ 1279.504385 1279.50412 -0.21 
[b7+Ir1-H2O]+ 1297.51495 1297.51479 -0.12 
[b8-CO2+Ir1-H2O]+ 1439.60443 1439.60517 0.51 
[b8-CO+Ir1-H2O]+ 1455.599345 1455.59912 -0.15 
[b8-NH3+Ir1-H2O]+ 1466.567715 1466.56765 -0.04 
[b8+Ir1-H2O]+ 1483.59426 1483.59429 0.02 
[b9-CO2+Ir1-H2O]+ 1510.64154 1510.64096 -0.38 
[b9-CO+Ir1-H2O]+ 1526.636455 1526.63648 0.02 
[b9-NH3+Ir1-H2O]+ 1537.604825 1537.60477 -0.04 
[b9+Ir1-H2O]+ 1554.63137 1554.63148 0.07 
[b10-CO2+Ir1-H2O]+ 1609.70995 1609.71108 0.70 
[b10-CO+Ir1-H2O]+ 1625.704865 1625.70489 0.02 
[b10-H2O+Ir1-H2O]+ 1635.689215 1635.6895 0.17 
[b10-NH3+Ir1-H2O]+ 1636.673235 1636.67331 0.05 
[b10+Ir1-H2O]+ 1653.69978 1653.7002 0.25 
[b11-CO+Ir1-H2O]+ 1682.726325 1682.72685 0.31 
[b11+Ir1-H2O]+ 1710.72124 1710.72187 0.37 
[b12-CO2+Ir1-H2O]+ 1803.79032 1803.79105 0.40 
[b12-NH3+Ir1-H2O]+ 1830.753605 1830.75434 0.40 
[b12+Ir1-H2O]+ 1847.78015 1847.78068 0.29 
[b13+Ir1-H2O]+ 1960.86421 1960.86419 -0.01 
[b12+Ir1-H2O]2+ 924.393715 924.39371 -0.01 
[M+H-NH3]2+ 1046.455993 1046.45595 -0.04 
[a12+Ir1-H2O]+ 1803.78978 1803.79159 1.00 
[y10]+ 1111.54654 1111.54641 -0.12 
[y10-NH3]+ 1094.519995 1094.51987 -0.11 
[y11]+ 1224.6306 1224.63046 -0.11 
[y11-NH3]+ 1207.604055 1207.60385 -0.17 
Average error 0.06 RMS 0.09 
Standard deviation 0.29 RMSD 0.30 
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Si Figure 6.5: Assignments and fragmentation map for the CAD MS/MS analysis of the    
[L3BBS+Ir1-H2O+H]2+ species 
Ir1-L3BBS 0.5-1X I1 ISO 
1056-5 IRECD 002 Observed m/z Theoretical m/z Error/ppm 
[z8]+ 924.46343 924.46346 -0.03 
[z8•]+ 925.471255 925.47126 -0.01 
[z9]+ 1038.50636 1038.50595 0.39 
[z9•]+ 1039.514185 1039.51411 0.07 
[z10•]+ 1096.535645 1096.5355 0.13 
[z11]+ 1208.61188 1208.6119 -0.02 
[z11•]+ 1209.619705 1209.62037 -0.55 
[c8• -H+ Ir1-H2O]+ 1499.61298 1499.61322 -0.16 
[c10• -H+ Ir1-H2O]+ 1669.7185 1669.71832 0.11 
[z12-H+ +Ir1-H2O]+ 1853.822465 1853.82123 0.67 
[M+Ir1-H2O-NH3]+• 2108.9307 2108.93071 -0.005 
 
 
SI Figure 6.6: Assignments and fragmentation map for the IRECD MS/MS analysis of the [L3BBS+Ir1-
H2O+H]2+ species 
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Chapter 7: 
Super-acid supercharging using CH5+ 
 The effective characterisation of any molecule by MS requires effective ionisation, which can 
be particularly challenging for some analytes and/or conditions. Particularly for biomolecule 
characterisation the challenge not only lies in ionising large biomolecules, but transferring enough 
charge to each species to observe and interrogate high charge-state ions. Subsequent MS/MS 
experiments on biomolecules of interest are heavily affected by the charge state of the parent ion, 
with higher charge states always being desirable for their increased MS/MS cleavage efficiency, 
increased sequence/cleavage coverage of fragmentation, and increased sensitivity on all mass 
analyser platforms. It is therefore of ubiquitous benefit to make progress into achieving these high 
charge states for effective biomolecule and modified-biomolecule characterisation. One thriving 
field of research is the investigation of solution-phase additives to alter the properties of sample 
solutions, usually via changes in surface tension, to affect the resulting droplets produced during 
electrospray ionisation-MS. The changes to droplet characteristics have been shown to alter the 
charge states of solvated biomolecules, sometimes producing higher charge states. This process of 
solution-phase “supercharging” of analytes has shown great promise over the years and has been 
improved upon greatly with a range of additives now available, the majority of which achieve their 
effect via increasing the surface tension of the ESI droplets formed, thus enhancing charge of 
droplets and the resulting protein analytes solvated within.  
Though solution-phase additives have been shown to be very effective at enhancing analyte 
(and particularly protein) charge states, resulting in corresponding benefits to MS and MS/MS 
analysis, they are unfortunately not consistent benefits for all samples, each supercharging agent 
seems to be effective for certain samples, but not others, they also require optimisation for the 
amount and solvent conditions they are used with, and they require extra sample preparation steps, 
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which although not extensive can have negative side effects with some species. As a result it has 
been an area of great interest to not only find new species/ways of supercharging analytes, but also 
to see if supercharging may be achievable without solution phase additives, and to achieve 
enhanced charging through instrumentation improvements instead of chemical ones.  
The content of this chapter focuses on enhancement of analyte charging through a novel ion source, 
a marriage of electrospray ionisation and atmospheric pressure chemical ionisation, which utilises 
one of the strongest acid species known (CH5+) to charge droplets produced during ESI and achieve 
supercharging without solution phase additives and without modification of analytes. The source 
and subsequent supercharging of a range of analytes in various conditions are presented, along with 
a detailed discussion on the underlying mechanism of the supercharging concerned, most notably 
the repulsive force between the positively-charged ESI droplets formed and the incoming CH5+ ions.  
Although the results presented within this chapter are predominantly based on FT-ICR MS and 
results from the thesis Author, this was a collaborative project and some elements were conducted 
by collaborating researchers, namely; Haytham Hussein and Cookson Chiu assisted with the design 
of the supercharging source at stages of development, and creation of various Figures related to the 
source and mass spectra. Lewis Baker, Scott Habershon, and Anthony Stace were collaborators in 
the investigation of the calculation of electrostatic forces between ESI droplets and CH5+ ions. 
 
The work presented within Chapter 7 was used to file a patent for the supercharging of analytes 
using CH5+ and ESI-MS, the details of which are below: 
“IONISING MOLECULES AND ELECTROSPRAY IONISATION APPARATUS” 
Peter B. O’Connor, Christopher A. Wootton, Haytham Hussein, Man-ying Wong, 2016 
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Abstract: 
   Supercharging of protein ions can be achieved by reaction with the super-acid CH5
+. 
Analyte ions are supercharged in the gas phase immediately before entering the mass 
spectrometer inlet via reaction with super-acid CH5
+ ions produced adjacent to the ESI 
plume; the method enabled enhanced charging of proteins, producing charge states 
previously unobserved for the non-supercharged samples. Supercharging of Native MS 
protein samples also produced a 500% increase in intensity for the most abundant charge 
states observed, while retaining native MS conditions. Super-acid supercharging was also 
shown to increase the intensity of singly charged small molecules and small molecule 
dimers by 22% and 291% respectively, and was shown to preserve the analyte from 
modification, as no methyl adduction was observed. The experiment was implemented by 
interfacing a standard electrospray ion source with a custom-built glow discharge 
chamber at the FT-ICR mass spectrometer inlet. The location of CH5
+ creation and 
interaction with the ESI plume was shown to be critical to achieving ESI stability and 
effective supercharging. 
   Electrostatic repulsions between CH5
+ and the charged droplets created during 
electrospray ionization cause a Coulombic repulsion force, hindering interaction between 
the two species. Taking a purely Coulombic force approach this interaction is shown to 
be always repulsive and will tend towards infinity as an incoming CH5
+ ion approaches a 
charged droplet, preventing proton transfer, and the positive supercharging effect. A 
modified electrostatic model was then applied to take into account the polarizable nature 
of solvent molecules and their ability to re-orientate to cause ion-induced dipole 
polarizabilities creating an attractive force between the charged droplet and incoming 
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CH5
+ ions, at very small distances and lowering the charge repulsion “barrier”. The 
modified electrostatic model showed an attractive force was possible at low charge 
densities. However this attractive force dissipated quickly at higher charge densities and 
the resulting force calculations approached that of a purely mean-field model. Though the 
attractive force is believed to be a contributing factor in enabling CH5
+ ions to overcome 
the coulombic barrier and allow transfer of additional protons to ESI droplets, allowing 
the supercharging effects observed in experiment, it is clear that other forces (such as 
turbulent motion and high-velocity CH5
+ ions) are likely to be the deciding factors in 
enabling the supercharging process. 
 
 
 
Introduction: 
   The CH5
+ cation is considered a “super-acid” as it has an extremely low proton affinity, 
even lower than that of sulfuric acid (531.4 vs. 699.6 kJ/mol, respectively).1 CH5
+ was 
first introduced as an ionization reagent by Talrose et al.2,3 and subsequently utilized 
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extensively by Munson and Field, 1966,4,5,6,7 a method later referred to as “Chemical 
ionization” (CI) which was capable of producing even-electron [M+H]+ ions from 
analytes, rather than the fragile and unstable [M]+• ions produced by the widely used 
electron ionization (EI).8 CH5
+ can be readily produced by reaction with high-energy 
electrons, as shown in equations 1&2.  
CH4 + e
-
  CH4
+. + 2e
-
        [Eq.1] 
CH4 + CH4
+•  CH5
+ + CH3
•
         [Eq.2] 
 
   CH5
+ ions are the primary, stable reaction products from equations 1&2 and are thus 
available for further reaction with target analytes. CH5
+ ions act as extremely strong 
BrØnsted acids (the so called “super-acid”) which readily transfer protons to nearby 
species within range, producing a protonated analyte species (M+H)+ as shown in 
Equation 3.9  
CH5
+ + M  [MH]+ + CH4 (proton transfer)     [Eq.3] 
   Although chemical ionization greatly assisted in the analysis of many polar and non-
polar chemicals, it was not a viable ionization method for the study/interrogation of large 
biomolecules as it involves a gas-phase proton-transfer reaction, meaning CI is of limited 
use when attempting to ionize non-volatile molecules (such as peptides and proteins). CI 
also generally only produced singly charged products10 which limited its use to smaller 
species of interest. With the advent of electrospray ionization (ESI and nanoESI), mass 
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spectrometry analysis of large biomolecules, such as multiply charged protein ions 
became viable.11,12  
The introduction of the supercharged biomolecules concept by Iavarone et al., 2001, 
showed that enhanced charging of analytes can be achieved, allowing observation of 
higher charge states for analytes via ESI than previously observed.13,14 Addition of 
supercharging reagents such as glycerol, sulfolane, or m-Nitro benzyl alcohol increases 
the maximum observed charge states, with increased signal intensity of biomolecules and 
lower mass-to-charge ratios, allowing for increased achievable resolving powers for 
FTMS based instruments (such as FT-ICR MS and Orbitrap platforms).13,15–18,19 
Accessing higher charge states has also been shown to dramatically improve 
fragmentation efficiency and cleavage coverage during MS/MS experiments,20 increasing 
with higher charge-states of selected precursor ions,21 especially for electron capture 
dissociation and electron transfer dissociation MS/MS.18 Enhancing the charge state 
enables a higher degree of fragmentation, thus more molecular sequence information, 
which is critical for effective identification of unknown proteins and peptides via MS/MS 
fragmentation and the analysis of any proteomic-based sample.22,23 Studies of post-
translational modifications could also be facilitated by this increase in fragmentation 
efficiency, especially in the ever-growing field of Top-Down MS/MS.24,25  
 
   Other supercharging methods and reagents have been explored; in late 2007, Kjeldsen 
et al. introduced supercharging reagents (m-NBA) to the LC mobile phase of LC-ESI-MS 
system.21 Sterling et al.26 studied the effect of DMSO as supercharging reagent and the 
relationship between the supercharging reagents, analyte solution and protein 
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conformation.26–28 In May 2012, Miladinovic et al. demonstrated the introduction of a 
supercharging reagent into the ESI Taylor cone using a dual-sprayer ESI microchip.18 
Recently, Teo and Donald showed that solution additives, ethylene carbonate, propylene 
carbonate, and o-nitroanisole could be used to enhance the charging of proteins and form 
significantly higher protonation states.29 
   Despite the exciting efforts to increase the observed charge state of protein analytes, the 
mechanism of supercharging remains unclear.18,17,30,31,32 Iavarone et al. outlined that the 
surface tension of the electrospray droplet is a major factor in determining the analyte 
charge,16 adding high surface tension solvents with low vapor pressure to the analyte will 
increase the surface charge density of the droplet due to the significant increase in the 
concentration of the supercharging reagent in the ESI droplets while evaporation occurs; 
as droplets undergo evaporation and reach the Rayleigh limit, Equation 4, the 
electrospray droplet will undergo Rayleigh fission and, due to increasing surface tension, 
increase charge density leading to an enhanced protein charge state.15,16  
ZRe = 8 π( ϵoγ R
3)1/2       [Eq. 4] 
From Equation 4, the Rayleigh charge limit theory indicates the direct proportionality 
between the surface tension (γ) and the charge availability of the droplet.33 
   The investigation of ion supercharging efficiency displayed appears to be protein 
dependent and the supercharging process may depend on a conformational change of the 
analyte proteins as an unfolded protein could accommodate more charges than the folded 
conformer, as proposed by Williams et al.27,28 Other research by Loo et al. provided 
claims to the contrary and pointed out the role of proton transfer reactivity in 
supercharging from aqueous solution.31 Overall, many factors such as solvent surface 
335 
 
tension, gas phase and solution phase basicity of both analyte and solvent, charge 
competition between molecules of analyte and solvent play a major role in the extent of 
charging and ion charge distribution.17,26–28 
 
   The work presented herein shows supercharging, through a direct reaction between 
methane super-acid, CH5
+ ions (BrØnsted acid), with the sprayed solution droplets of the 
analyte at atmospheric pressure during the ESI process. Due to their inherent strong 
protonation capability, and extremely low proton affinity, CH5
+ “super-acid ions” are 
ideal species for exploring the combination of ESI and gas-phase supercharging via APCI 
generated reagent ions. Enhanced droplet charge translates to increased protonation of 
charge sites in proteins and increased intensity and/or higher observed charge states of 
analyte species. Potentially, supercharging MS analytes with superacid CH5
+ ions will aid 
the analysis of slightly polar compounds, large and small biomolecules (such as peptides 
and proteins) and enable increased cleavage coverage during subsequent MS/MS 
experiments which can benefit Top-down protein analysis and the entire Bottom-Up 
proteomics field as it is possible to readily hyphenate this concept to liquid 
chromatography. Computational models are utilized and explored to help understand how 
this proton transfer between the superacid CH5
+ and charged droplets may occur.  
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Materials, design, and methods: 
Materials and chemical reagents 
   Bovine heart Cytochrome c, chicken egg-white Lysozyme, and Equine heart 
Myoglobin were obtained from Sigma-Aldrich, UK. The samples were prepared by 
dissolving the proteins in a solvent system that consists of either purified water 18 M 
cm-1 only, 50/50 %, v/v water/methanol (for denatured protein studies), or aqueous 
solutions of 200 mM ammonium acetate (for native MS studies). Methane reagent gas 
was purchased from CK special gases (UK). L-(+)-ascorbic acid (C6H8O6), was 
purchased from Alfa Aesar (Heysham, Lancashire, UK). High purity grade N2 (99.99 % 
BOC, UK) was used as the nebulizer gas for ESI and APCI-ESI experiments. Ultrapure 
water (18.2 MΩ cm-1) was obtained from a Direct-Q water purification unit (Millipore, 
Watford, UK) and LC-MS grade methanol (VWR Chemicals, UK) were used in the 
sample preparation. All reagents were used as received. 
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ESI-APCI Supercharging Ion Source: 
   The experimental setup is shown in Figure 7.1. The ion source was constructed by 
interfacing a modified Analytica ESI source with a home-built super-acid glow discharge 
chamber to produce CH5
+ ions.  
 
Figure 7.1: Schematic of the ESI-APCI supercharging source (left) and 3D 
representation (right). 
   The super-acid CH5
+ is produced by ionizing a stream of methane gas flowing through 
a potential difference region between a needle and the exit of a custom brass glow-
discharge chamber to the ESI needle tip. The glow-discharge chamber consists of a tailor-
made threaded brass cylinder isolated from both the discharge needle and the ESI sheath 
via insulating Teflon caps. The tapered shape along the inside of the chamber and the 
position of the discharge needle ensures the flow of methane is focused into the exit of 
the chamber, where the electrical discharge occurs, improving the efficiency of CH5
+ 
production, which occurs just 6 mm from the ESI needle tip. The glow discharge 
chamber was connected to a tailor made brass sheath (length 58 mm, O.D. 9.55 mm, I.D. 
5.44 mm), fitted with a 15 cm ESI stainless steel capillary (I.D. 0.20 mm, O.D. 0.22 mm, 
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Bruker Daltonik, Bremen, Germany), housed inside a stainless steel tube (length 68 mm, 
O.D 1.25 mm., I.D 1.20 mm.). The distance between the tip of the ESI needle and the 
mass spectrometer capillary inlet was 1.7 cm. Methane was introduced from the top of 
the source and connected to the glow discharge chamber using PTFE tubing. A pressure 
relief valve (1/4 inch, VRV 250, Generant, Butler, NJ, USA) is used to regulate the 
pressure within the source chamber (~5 psi), and to purge O2 from the chamber prior to 
operation in order to avoid igniting the methane gas.  
   Analyte solution was delivered to the ESI needle via a 250 μL syringe connected to a 
PTFE transfer line and driven via a syringe pump at a rate of 100-200 μL/hour. 
The ESI needle was biased from +4000 to +6000 V to achieve stable ESI. A voltage 
difference of +3500 V was applied to the glow discharge system via an external high-
voltage power supply (Applied Kilovolts, KS20/43, Exelis, West Sussex, UK), input 
power was provided via a 24 V power supply (EL301R, TTI, Huntingdon, UK). A 
cylindrical mesh surrounded the ESI assembly and was held at positive potential to focus 
the ions, allowing the improved interaction between the generated super-acid CH5
+ and 
the sample solution in the gas phase and preventing charge build up on the source walls. 
Finally, a home-built Aluminum flange connects the super-charging source to the inlet of 
the FT-ICR mass spectrometer. 
   The effect of super-acid CH5
+ as a supercharging reagent depends on geometry, 
pressure, flow rate, and the potential difference between the ESI needle and mass 
spectrometer inlet. Different pressures/flow rates of methane did not show appreciable 
differences on the supercharging effect past 0.3 bar above atmosphere, at which point ESI 
and instrument performance began to degrade due to high source pressure. The distance 
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between the tip of the ESI needle and origin of super-acid CH5
+ generation played a 
major role in the supercharging process.  
 
FT-Ion Cyclotron Resonance Mass Spectrometry:  
   All experiments were conducted on a 12 Tesla SolariX Fourier Transform Ion 
Cyclotron Resonance Mass Spectrometer (FT-ICR MS) (Bruker Daltonik GmbH, 
Bremen, Germany), all mass spectra were collected in positive ion mode. Supercharging 
experiments were conducted using the modified APCI-ESI source described above, 
varying the ESI high voltage, methane gas flow, and glow-discharge high voltage. 
Control spectra conducted with methane flowing through, but without the glow discharge 
external high voltage yielded the same mass spectral results as the normal ESI control. 
The FT-ICR instrument was tuned to scan 147 to 3000 𝑚 𝑧⁄  and 10-20 spectra were 
signal-averaged per run. Ions were externally accumulated in a hexapole collision cell for 
0.1-0.2 s before being transferred to the infinity cell34 for excitation and detection.  
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Results and Discussion: 
 
Figure 7.2: a) Normal ESI-mass spectrum of 1 μM aqueous Lysozyme (LZ) solution, 
showing 2 main charge states; 8+, 9+, and a minor charge state of 10+. b) 
Supercharged ESI-APCI-mass spectrum of the same 1 uM aqueous Lysozyme 
solution, showing increased analyte charging, main charge states observed now 
being 9+, 10+, and 11+. 
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Aqueous protein solution analysis: 
   Figure 7.2a shows the ESI-FT-ICR MS spectrum of 1 µM Lysozyme dissolved in 
water, a very narrow range of charge states was observed (8+, 9+, and 10+), correlating 
with Konermann et al.35  
   Figure 7.2b shows the same protein-containing solution ionized with the supercharging 
ESI-APCI source active. The supercharged lysozyme spectrum shows the 11+ charge 
state of the protein appearing in good intensity and a decrease of lower charge states (8+ 
and 9+), focusing ion populations into the higher charge states. The weighted average 
charge state for each spectrum was calculated via equation 5 (below) where N is the 
number of observed charge states ith, qi is the charge value and Wi is the signal 
intensity.14,36 The calculations show a distinct increase in average charge from 9.41 (ESI-
MS) to 10.02 (ESI-APCI-MS). The incorporation of APCI derived CH5
+ ions has clearly 
enhanced charging of the protein analyte species. 
qaverage =  ∑ qi Wi
N
i  ∑ Wi
N
i⁄        [Eq. 5] 
   Figure 7.2 insets (a.1-3 and b.1-3) show the protonated lysozyme species from both the 
ESI-MS and the ESI- APCI-MS spectra, along with the sodium adducts. The comparison 
of the 2 spectra shows that no change/modification of the analyte species has been 
observed (e.g. via methylation, CH5
+ adduction, or reaction with any other intermediates 
from equations 1-5 (above)), the ESI-APCI-MS ionization method is shown to produce a 
similar distribution of protonated and sodium-adduct peaks, only with the benefit of 
enhanced charge states. 
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Denatured protein supercharging: 
   Figure 7.3a and 7.3b show the ESI and ESI-APCI-mass spectra of denatured myoglobin 
(a 16.9 kDa oxygen transport protein)18 electrosprayed from a 50:50 v/v water:methanol 
solution. Denatured Myoglobin shows a range of charge states upon ESI-MS ranging 
from 10+ to 17+ (Figure 7.3a). The denatured myoglobin ionized via the supercharging 
ESI-APCI source attained much higher charge states (see inset), previously unobtainable 
without supercharging. Denaturation of Myoglobin also causes loss of the non-
covalently-bound Heme group, however ESI-MS does not show a detectable Heme 
species released. The ESI-APCI source shows increased signal of the [Heme+H]+ ion 
released upon Myoglobin denaturation, allowing it to be detected. The normal ESI-MS 
spectrum of denatured Myoglobin showed a weighted average charge of 14.5+, a base 
charge state of 15+, and a max charge state of 18+. The supercharged ESI-APCI-MS 
spectrum of Myoglobin showed an average charge of 16.7+, a base charge of 17+, and a 
maximum charge of 25+. The high abundance peaks observed in Figure 7.3 were assigned 
to the apo form of Myoglobin, produced due to denaturing conditions, producing the 
bimodal charge state distribution typical of denatured protein ESI-MS. Low levels of 
holo-Myoglobin were also visible, along the baseline. 
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Figure 7.3: ESI-MS of 1 μM Myoglobin in a water-ACN solution (a) and 
supercharged ESI-APCI-MS spectrum of the same Myoglobin-water-ACN solution, 
showing enhanced charging of analyte species.  
 
   The ability to access these increased charge states for protein analytes can have a 
drastic effect on the quality of MS/MS spectra and sequence information 
produced.18,20,37,38 McLafferty et al.20 showed that each individual charge state of proteins 
344 
 
can produce different MS/MS fragments during electron capture dissociation (ECD), and 
that higher charge states provided much more sequence information than lower ones, this 
effect has also been observed for the more commonly used collision based dissociation 
(CAD/CID). 
   Though other chemical-based supercharging methods have been developed, and 
successfully implemented, in many studies,15,18,36,31 the ESI-APCI source presented here 
represents a new method of achieving these charge states without the addition of 
chemical additives to the sample solution (process shown in Figure 7.4), and thus 
avoiding unwanted side reactions/changes in chemical equilibria which can occur upon 
addition of new species to solution chemical mixtures. In addition, use of the ESI-APCI 
source requires no further sample preparation steps, as each sample is simply introduced 
in the same way as a normal ESI-MS sample.  
 
Figure 7.4: Representation of the ESI-APCI supercharging processes – CH4 gas was 
ionized via a glow discharge chamber in close proximity to the ESI needle tip, 
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enabling the newly created CH5+ ions to interact with ESI plume and droplets and 
enhance charging of analytes. 
 
Supercharged-Native MS of proteins: 
   There is an increasing interest in attempting to retain protein structure during ionization 
and mass spectrometry analysis, called Native-MS.25,39 Usually involving the use of 
stabilizing buffers and possibly salt-containing solutions, Native MS attempts to keep 
proteins/analytes folded in their solution conformation as much as possible during 
analysis, thus charge state distributions,40 surface labelling strategies (such as HDX41 and 
FPOP42), and careful MS/MS experiments40,43 can then inform and interrogate tertiary + 
quaternary protein structure via mass spectrometry. 
  Unfortunately the use of high-concentration buffer solutions and/or salt solutions are 
detrimental to effective ESI, desolvation, and protein MS analysis as a whole. As a result 
Native MS usually produces low signal to noise spectra (due to ineffective desolvation), 
with protein species observed with many adducted salt/buffer ions (decreasing signal to 
noise further as analyte ions are distributed into many signal channels), and very low 
charge states compared to water/denatured conditions. The latter of these disadvantages 
decreases observed intensity of ions (as all MS techniques are inherently more sensitive 
for higher charge state ions), and dramatically impedes MS/MS fragmentation 
characterization and subsequent sequence coverage.25 Therefore effective 
characterization of proteins in their native state is particularly challenging, and would 
benefit greatly from the enhanced charging effects supercharging MS can offer. As a 
result Native MS of Lysozyme in 200 mM ammonium acetate buffer was conducted 
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using the Supercharging ESI-APCI source. The results, shown in Figure 7.5, show that 
Native MS of the Lysozyme protein presents a narrow charge state distribution, at lower 
charge states than the water solution above (Figure 7.2a). Lysozyme in the 7+, 8+, and 9+ 
charge states were observed at relatively low signal to noise ratio. 
 
Figure 7.5 – Native ESI-MS of Lysozyme a) and supercharged Native-MS of the 
same sample (b), showing a vast increase in signal of lysozyme peaks due to 
enhanced charging. 
 
   ESI-APCI of the same solution of Lysozyme (aqueous 200 mM ammonium acetate 
buffer), shows the effect of enhanced supercharging on the sample; the observed intensity 
of the Lysozyme peaks has increased by on average 285%, and >500% increase in signal 
intensity for the 8+ isotope distribution, a dramatic increase over ESI-MS. The same 
charge states are observed in both ESI-MS and supercharging ESI-APCI-MS, despite the 
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obvious enhanced charging, suggesting that, in its native conformation, the available 
protonation sites of lysozyme have been fully protonated, with multiple charge states 
being observed due to subtly different conformations, as has been suggested previously 
by Barren et al.40 
   The large increase in both intensity and signal to noise for the native lysozyme species 
is of great benefit for both detection and accurate characterization of the protein species 
by MS, and should be readily applicable for other protein species in the future, and aid in 
subsequent Top-Down MS/MS analysis. 
 
Small molecule supercharging: 
   In addition to biomolecule supercharging, small molecule ionization can vary greatly 
depending on the chemical nature of the groups within the analyte, with some 
(particularly non-polar) species being particularly difficult to ionize effectively via ESI.44 
As a result, the effect of the ESI-APCI source on small molecule ionization was 
investigated using ascorbic acid. Ascorbic acid (C6H8O6) is a small (176.032088Da) 
molecule, a form of vitamin C, believed to provide anti-oxidant activity in the body.33 
Figure 7.6a and 7.6b show the ESI-MS and ESI-APCI-MS spectra of Ascorbic acid. The 
main species observed in the ESI-MS of Ascorbic acid were the protonated and sodiated 
forms of Ascorbic acid ([C6H8O6+H]
+ and [C6H8O6+Na]
+), along with a high intensity 
peaks for the protonated and sodiated Ascorbic acid dimer ([C6H8O6 C6H8O6+H]
+ and 
[C6H8O6 C6H8O6+Na]
+).  
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Figure 7.6: ESI-MS of the Ascorbic acid solution (a) and ESI-APCI-MS spectrum of 
the same Ascorbic acid solution, showing increased signal intensity due to enhanced 
charging of protonated Ascorbic acid (22% increase) and the Ascorbic acid dimer 
(291% increase). 
   The ESI-APCI-MS spectrum is shown in figure 7.5b, though no peak corresponding to 
doubly charged Ascorbic acid [C6H8O6+2H]
2+ was observed, the singly protonated 
ascorbic acid species was shown to increase in intensity by 22%, with respect to ESI only 
(Figure 7.6b, inset a.1 and b.1), this increase is believed to be a result from the increased 
proton transfer from the CH5
+ reagent gas to the droplet. Figure 7.6b (inset a.2 and b.2) 
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also shows a much larger increase in observed intensity for the ascorbic acid dimer 
species of 291%, which is a substantial increase over traditional electrospray. 
It appears that not only can CH5
+ assist in attaining higher charge states for biomolecules, 
but also increase the ionization efficiency of small molecules, on average peak intensities 
increased by 103% (and up to 291% for some species), this could lead to improved limits 
of detection (LOD) for small molecule species and enable more sensitive MS detection of 
key compounds during analysis where low LOD’s are crucial, e.g. trace organic analysis, 
forensic testing, trace heavy metal quantitation etc.  
 
Combinations of charge-enhancing techniques: 
Since the Superacid-supercharging ESI-APCI Ion source is not a solution-phase 
supercharging reagent, it can be readily combined with current solution-phase procedures 
for enhancing analyte charge and supercharging reagents. The Superacid supercharging 
ion source was used to ionize myoglobin protein samples containing denatured, acidic, 
and/or chemically supercharged solvent systems, in order to explore the potential benefits 
of combining multiple techniques and any possibility of enhancing the charging of 
analytes even further than previously observed. The results for the supercharging 
combination experiments are shown below in Figure 7.7: 
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Figure 7.7: Denatured and/or supercharged myoglobin protein spectra produced by 
acidic denatured conditions (top), followed Superacid supercharging (middle), and a 
combination of denatured acidic conditions with m-NBA solution phase 
supercharging and Superacid-supercharging (bottom) showing the possibility of 
combining enhanced charging techniques to achieve even higher charge states than 
individual techniques. 
The results presented in Figure 7.7 (above) show marginal increases to the charge states 
of acidically denatured myoglobin samples by the ESI-APCI supercharging. However 
this could be further enhanced by the use of acidic denaturing conditions and both 
solution phase supercharging reagents (m-NBA) and the Superacid-supercharging ion 
source, producing appreciable increase in both average charge (17.0+ increased to 18.7+) 
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and maximum observed charge state (26+ increased to 29+). The results produced show 
promise for the combined used of various techniques for increased supercharging of 
analyte species and observation of even higher charge states when needed. 
CH5+-droplet interaction and proton transfer calculations: 
   The interaction of CH5
+ with positively-charged ESI droplets involves a repulsive 
coulombic force between these two positively charged entities. If the magnitude of 
repulsive force between the incoming CH5
+ ions and the charged ESI droplet is too high 
then the CH5
+ ion will be deflected before reaching a close enough distance to allow H+ 
transfer to the droplet/analyte species contained within. Since CH5
+ ions were clearly 
shown to enhance the charging of analyte species within the ESI droplets (as shown 
above) this repulsive force must have been overcome at some point during the 
electrospray process.  
   Beauchamp et al. 45  have shown through careful measurements of ESI droplet size and 
average charge that ESI droplets undergo many discharge events during the ESI process, 
splitting up into many daughter ions with each discharge event. These discharge events 
occur as the droplet solvent evaporates, while the charge remains, until the droplet 
eventually reaches the Rayleigh limit of stability and discharges. The exact point where 
the charged  droplet fissions is dependent on the solvent used, methanol and acetonitrile 
were shown to fission at 100% to 120% of the Rayleigh limit, while water was shown to 
fission below/at the calculated Rayleigh limit (85-100%).  
   The electrostatic interactions between the charged ESI droplet and a CH5
+ ion was 
evaluated computationally using two approaches; first a mean field calculation of the 
coulombic forces between the charged droplet and a CH5
+ ion at varying distances and 
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varying charge, second using coulomb and Particle-particle dielectric electrostatic model 
(PPDEM) theory to model the same interaction. 
Mean field calculations.  The force between the CH5
+ ions and ESI droplets was 
calculated using Coulomb’s law, detailed measurements from Beauchamp et al. focused 
on droplets in the 5-20 μm range, with no discharge/fission events occurring in a droplet  
above 20 μm, as a result 20 μm was used as the droplet diameter in all calculations as a 
starting diameter condition, though the Rayleigh limit scales with diameter of droplet, as 
a result the calculations would be applicable regardless of chosen diameter.    
   For the calculation, a spherical 20 μm droplet was randomly populated with a certain 
number of charges upon its surface (a varying percentage of the Rayleigh limit for a 20 
μm droplet; Rayleigh limit of charge for 20 μm droplet of water is ~12.6 Me). Once the 
droplet was populated with point charges a CH5
+ ion was introduced, at distance x, the 
force between every individual charge on the droplet surface and the CH5
+ ion was then 
calculated and summed for distance x. The distance x was varied and each summed value 
plotted for the specific number of charges, the number of surface charges was then 
altered and the process repeated, the summation of these calculations is shown in Figure 
7.8.  
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Figure 7.8 - Mean field calculation results of the repulsive force between a CH5+ ion 
and a 20 μm charged ESI droplet at a varying distance and T=300K, each curve 
represents calculations for a varying number of charges (as a percentage of the 
Rayleigh limit for the 20 μm droplet: 12.6 Me).  
 
Particle-particle dielectric electrostatic model (PPDEM).  As mentioned previously the 
mean-field calculations are based on pure-coulombic interactions, only mitigated by the 
dielectric constant of the solvent. However as a charged species approaches a charged 
droplet of polarizable solvent, the individual solvent molecules will re-orientate in order 
to minimize their repulsive interaction with the incoming charged species, and thus 
present their other polarity (δ-) outward towards the incoming charge – causing a more 
𝐸 =  
1
4𝜋𝜀𝑜
𝑄1𝑄2
𝑟2
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attractive force and reducing the energy barrier of approach. If enough of the droplet 
molecules are affected by the ion-induced dipole rearrangement then the overall barrier 
could be lowered enough to become attractive.46,47 As a result additional calculations 
were conducted using a modified Coulombic repulsion model, taking into account ion-
induced dipole, induced quadrupole, and induced octapole interactions using equation 6, 
below, from Stace et al.47 
𝑈1 = 𝐾
𝑄1𝑄2
ℎ
−
𝐾𝑄1
2
2
  ∑
(𝜀2−1)𝑚
(𝜀2−1)𝑚+1
𝑎2
2𝑚+1
ℎ2𝑚+2
∞
𝑚=0
                                 [eq. 6] 
Where the static interaction energy (U1) between a point charge (Q1) and a sphere of 
radius a2, charge (Q2), and dielectric constant ε2, separated by distance h for m= 1-3, and 
K = 1/4πε0 (≈9x109 V m C-1) 
Equation 6 can be evaluated analytically to produce equation 7, below, and was then used 
to model the same 20 μm diameter charged droplet of water at varying proportions of its 
Rayleigh limit as conducted in the mean-field calculations. 
𝑈1 = 𝐾
𝑄1𝑄2
ℎ
− 𝐾
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3
ℎ2(ℎ2−𝑎2
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                                          [eq. 7] 
 
   The initial results of the Coulombic force calculations between the ESI droplet and 
CH5
+ ion are shown below in Figure 7.8. Although the force between the species 
increases as the separation distance decreases, as before for the mean field calculations, 
the PPDEM shows clearly that at very close distances (<~20 nm) there can be an overall 
attractive force between the CH5
+ ion and the charged ESI droplet, allowing close 
interaction between the two species and as a result – proton transfer.  
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Figure 7.9 – Initial results from the PPDEM calculations for a 1 µm droplet with a 
very low number of surface charges,  showing that although initially repulsive, due 
to dielectric effects within the droplet, at close distances CH5+ ions can be attracted 
to positively charged electrospray droplets, enabling proton transfer and 
supercharging. 
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Figure 7.10 – Final results from the PPDEM calculations showing that at high 
numbers of surface charge the slightly attractive force previously observed becomes 
unfortunately negligible and the calculations approach the mean-field 
approximation. 
 
   As before, the force between the CH5
+ ion and a 20 µm positively charged aqueous ESI 
droplet was calculated at varying distances, and for various numbers of surface charges, 
the results of which are shown above (Figure 7.10). Although the initial results shown in 
Figure 9 could potentially explain a drop in the activation barrier of CH5
+ interacting with 
the droplet, when the surface charge density increase to the levels calculated in the 20µm 
droplet, the charge-induced reorientation of solvent molecules based on the variables 
chosen seemed to be negligible in reducing the magnitude of force. As a result for higher 
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charge densities the PPDEM model values seemed to closely approach the pure-
electrostatic model discussed above. 
Energetics and evaluation: 
   The energy of the CH5
+ ion was then estimated for temperature of 300K (assuming a 
purely thermal process), taking the energy of the system to be 3/2kBT where kB is 
Boltzman’s constant and T is temperature, this simplistic model does not take into 
account chaotic effects such as Brownian motion, turbulent forces, and/or solvation 
effects.  However, using this Boltzman distribution of energies (shown below in Figure 
7.11) the probability of a CH5
+ ion overcoming the repulsive force from the charged 
droplet could then be calculated for each charge density.   
 
Figure 7.11: Results from the calculation Boltzmann energy curve for CH5+ ions at 
room temperature, assuming the energy of the system to be equal to 3/2kBT. The 
main proportion of species are shown inset, along with the corresponding energy of 
the most populated energy state. 
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The resulting CH5
+ energy calculations showed the most populated state for CH5
+ at RTP 
corresponded to an energy of 0.0233 eV, which is substantially lower than even the 1% 
Rayleigh limit charge density calculations performed during the electrostatic models (~18 
eV).  
The models proposed do not take into account various processes which may assist the 
interaction of CH5
+ with the charged droplet (such as Brownian motion/solvent shielding 
of charge), the substantial difference between the theoretical calculations of available 
energy and repulsive interaction indicate that the interaction process must be enabled by 
other factors. It is entirely possible that the electrostatic repulsive forces, though large 
with respect to the energy of stationary CH5
+ ions (as calculated above), become much 
lower, or even negligible when considering other obvious processes such as the 
turbulence force provided from the inert nebulizing gas and the electric field actively 
attracting both species to a common, intersecting path into the mass spectrometer inlet. It 
is also likely that CH5
+ ions are not able to travel to the ESI droplets without side-
reactions occurring. With the large amount of water/solvent vapour present within the 
ESI-APCI ionisation the reactive CH5
+ ions would quickly transfer the bound proton to a 
more stable species, such as H2O, forming H3O
+ ions. The H3O
+ ions could well then 
travel further and interact with the ESI droplets to cause the observed supercharging, 
however ambiguity still remains in the mechanism at this time. Further working into 
investigating this ionisation mechanism is currently underway. 
   The super-acid supercharging experimental results and the calculations performed lead 
to two possible mechanisms for the supercharging effect, either: 
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 a) the addition of CH5
+ ions accelerates charge build up at each ESI droplet’s surface due 
to proton transfer from the CH5
+ to the surface - up until the Rayleigh limit is reached, at 
which point the droplet will discharge into smaller daughter droplets and continue to 
evaporate, as with normal ESI. As a result CH5
+ creates a faster and more efficient means 
of causing coulombic explosions within ESI droplets, leading to increased charging of 
analytes. 
And/or b) protons transferred from the CH5
+ ions are sequestered into the ESI droplets, 
lowering the pH of the bulk solution within the droplet which will then increase the 
addition of protons to analyte molecules during the ESI process, which will increase the 
charge states observed. 
Further experiments focused on probing the supercharging mechanism of the ESI-APCI 
via the use of various reagent gases through the glow-discharge source to produce proton-
donors with varying proton affinities and study the resulting effect on the resulting ESI-
MS analysis. Due to the extreme ability for CH5
+ to donate the additional proton to nearly 
any species, it is possible that the CH5
+ ions do not directly interact with the ESI droplets 
in question. As there would be a substantial concentration of water vapour available, is is 
likely the CH5
+ ions will first protonate/ionize water vapour molecules/clusters which 
could then interact with the positively charged ESI droplets. The additional solvent 
system could screen the repulsive forces more effectively, and promote a different 
mechanism of reaction. Further experimentation using gases which would produce 
slightly less effective proton-donors may be able to avoid donation to stray solvent, avoid 
additional intermediates, and directly interact with/penetrate ESI droplets and directly 
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increase surface charge/protonate analyte species. These experiments are currently 
underway. Examples of possible reagent gases are shown below in Table 7.1: 
 
 
 
Table 7.1: Examples of CI reagent gases used in previous studies possessing a range 
of proton affinities (based on the neutral species), which could be suitable for 
probing the mechanism of superacid-supercharging. 
Reagent 
gas 
Reactant ions Neutral form 
reactant ions 
Proton affinity of 
neutral product 
Analyte ions 
H2 H3+ H2 424 [M+H]+, [M-H]+  
CH4 CH5+ 
(C2H5+ and 
(C3H5+) 
CH4 522 [M+H]+ 
([M+C2H5]+ and [M+C3H5]+ 
possible with pure-CI) 
i-C4H10 t-C4H9+ i-C4H8 820 [M+H]+ 
([M+C4H9]+, eventually 
[M+C3H3]+, [M+C3H5]+, and 
[M+C3H7]+) 
NH3 NH4+ NH3 854 [M+H]+ and [M+NH4]+ 
 
Conclusions: 
   Reaction of the super-acid CH5
+ with droplets formed during electrospray ionization 
(ESI) mass spectrometry was achieved via implementation of a methane glow discharge 
chamber near the tip of an ESI needle in an enclosed reaction chamber. Addition of CH5
+ 
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ions to the Taylor cone during ESI-MS resulted in an increase in the observable charge 
states of protein analytes, causing a distinct “supercharging” effect.  Average and base 
peak charge state increases were observed for both native-like protein samples (protein 
dissolved in pure water) and for denatured protein samples (protein dissolved in 
methanol-water solutions), with the greatest increases observed for the denatured protein 
sample.  
   Application of the ESI-APCI source to native protein MS provided an increase to 
protein peak signal intensity of over 500% compared to standard ESI MS. 
   Super-acid supercharging was also used to study the effect on a small molecule sample 
– Ascorbic acid. Peak intensity for the protonated Ascorbic acid peak was shown to 
increase by 22% when exposed to CH5
+ ions. Peak intensity of the protonated Ascorbic 
acid dimer species was shown to increase by 291% when exposed to CH5
+ ions, a 
considerable enhancement compared to traditional ESI alone, with potential increase to 
sensitivity and limits of detection for small molecules of interest. 
   Theoretical calculations were performed to evaluate the repulsive force between the 
positively charged droplets formed during ESI-MS and the incoming superacid CH5
+ 
ions. Using two different modelling approaches (mean field coulombic repulsion and 
Particle-particle dielectric electrostatic models (PPDEM)), it was found that the CH5
+ 
ions were not likely to be able to transfer additional protons the charged ESI droplets 
when at/near the Rayleigh limit, but was possible at (much) lower charge density levels. 
Though the mean field approach predicted an ever-increasing repulsion between the CH5
+ 
ion and the charged droplet the PPDEM calculations showed that at small distances 
(<~20 nm) and low charge densities the repulsive force between the two species can 
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become attractive and can lower the coulombic barrier and facilitate the proton transfer 
process.  
   Though many potentially reactive species are produced during methane ionization, no 
modification (methylation or otherwise) of protein/small molecule species was observed 
during the supercharging process. This method is widely applicable to any mass 
spectrometer using an electrospray source interface, and can easily be 
activated/deactivated within seconds if desired.  
   The ability to supercharge analytes in the gas phase enables attainment of high charge 
state biomolecule species, without the addition of solution-phase chemical reagents. 
Accessing higher charge states enables more comprehensive tandem MS (MS/MS) 
cleavage coverage during fragmentation, which is of particular interest to both Top-Down 
protein analysis and any bottom-up proteomic style studies of poly-amino acids, enabling 
higher confidence in peptide/protein assignments. 
   Moreover gas-phase supercharging provides an alternative/complementary technique to 
enhance charging of particularly challenging/ large biomolecules in order to bring them 
into a more moderate m/z range to enable study of these species via MS/MS more easily. 
Due to the use of the standard ESI needle set-up, there is little reason why this 
methodology cannot be hyphenated to Liquid-Chromatography (LC) systems for the 
online supercharging of species of interest. 
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Chapter 8:  
The Rhodium Revolver: how transition 
metal complexes can facilitate Hydrogen-
Deuterium Exchange in bound ligands 
 
Hydrocarbon C-H bonds are particularly weak bases, usually requiring strong acids to achieve 
deprotonation, and especially stable and chemically inert as a result. However it was recently 
observed that certain rhodium-based compounds, designed as metallodrugs, might be able to 
exchange hydrogen atoms on bound arene ligands to other species and possibly deuterium atoms if 
available.  
This chapter of the Thesis is centred around a study of these remarkably enabling rhodium 
complexes and their ability to facilitate the exchange of protons on particularly stable bound arene 
ligands with deuterium atoms from deuterated solvent. Resembling the Hydrogen-Deuterium 
eXchange (HDX) experiments used frequently in mass spectrometry for the study of protein 
structure, HDX with the rhodium complexes showed not only the surprising ease and speed of the 
HDX with bound ligands, but also the steric and proximity requirements to allow the metal centre to 
facilitate the exchange. 
Although the MS-based results presented within this chapter are produced and interpreted solely by 
the thesis Author, this was a collaborative project with the FT-ICR MS analysis providing a proportion 
of the evidence and data. As a result some elements were conducted by collaborating researchers, 
namely Joan J. Soldevila-Barreda synthesised the complexes studied and characterised them by 
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standard NMR etc. prior to MS analysis, Juliusz A. Wolny performed the molecular modelling 
calculations for the HDX reactions, and Guy J. Clarkson performed the X-ray diffraction experiments. 
The Author’s contribution to this work was centred around performing and monitoring the HDX 
reactions by FT-ICR MS and chemically altering bound mono-dentate ligands/conditions to study the 
effect on subsequent HDX. 
 
This chapter is based predominantly on results of the following paper, with a large amount of 
additional nESI-FT-ICR MS data collected for the study, not all of which was used in the final 
manuscript: 
“Molecular “Twister” for facile sequential deuteration of methyl groups on cyclopentadienyl rings” 
J. J. Soldevila-Barreda, Juliusz Wolny, Christopher A. Wootton, Abraha Habtemariam, Guy J. 
Clarkson, Peter B. O’Connor, Volker Schunemann, and Peter J. Sadler. Submitted to Nature 
Chemistry, 2016.  
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8.1 Introduction: 
Transition metal complexes have shown a wide variety of activities and have been able to “activate” 
many different groups in chemistry, e.g. oxidation of alcohol groups to ketones and polymerisation 
catalysis via transition metal intermediated such as the Grubb’s metathesis catalysis.1 However 
carbon-hydrogen bonds in pure hydrocarbon structures still remain particularly inert to most 
reaction conditions, they are exceptionally poor acids, rarely relinquishing protons, and to do so 
often require extremely strong bases, such as caesium cyclohexylamide. However C-H bond 
activation is of particular interest in chemistry, and a very sought after goal in heterogeneous 
catalysis. 
Transition-metal compounds have been at the forefront of C-H bond activation for many years, and 
have been successful in activating bonds from many species, usually by lowering activation energies 
for reactions, or by stabilising usually energetically-unfavoured intermediates, making them 
accessible. However this C-H bond activation has almost ubiquitously been applied to external 
species outside of the metal-complex, or available solvent molecules after binding to the metal 
complex/centre. It is particularly rare for these species to activate bonds within the complex itself 
and not external solvated species/solvents.  
Therefore it was particularly interesting when a series of rhodium compounds, synthesised by J..J. 
Soldevila-Barreda, appeared to lose arene-bound hydrogen atoms from methyl groups bound to the 
cyclopentadienyl ring of the piano stool complexes (shown below in Figure 1). The H-NMR signal for 
the methyl protons decreased steadily over time while in deuterated NMR solvent, believed to be 
due to the deuteration of the bound ligands by the solvent. However the methyl protons of the Cp* 
rings are particularly stable and very unlikely to be deprotonated, both due to the extremely low 
acidity of C-H hydrocarbon bonds, and due to the fact the methylated-cyclopentadienyl ligands are 
bound via an η6 interaction with the metal centre and are already negatively charged, meaning it is 
unlikely they would be easily deprotonated beyond this state. 
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Figure 8.1: The range of metal complexes synthesised and studied during the course of the project. 
All are rhodium complexes with varying ligands, aside from one iridium compound as a 
control/test for Ir metal centres, but was ineffective at achieving the same HDX reactions. 
Reproduced from Soldevila-Barreda et.al.2 
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8.2 C-H bond activation and subsequent HDX-MS: 
Since the 1H-NMR signals for Cp* protons was decreasing it was believed to be due to exchange with 
deuterium from the deuterated NMR solvent, low resolution quadrupole MS confirmed a mass shift 
to higher m/z but suffered with overlapping isotopes and lack of isotopic resolution. nESI-FT-ICR MS 
was then employed to study the observation of this exchange, but also the rate and rate accelerants 
associated with the reaction.  
8.2.1 nESI-FT-ICR mass spectrometry:   
Samples were analysed via nano-electrospray ionisation (nESI)-Fourier Transform Ion Cyclotron 
Resonance Mass Spectrometery (FT-ICR MS). All experiments were carried out on a Bruker SolariX FT-
ICR Mass Spectrometer, fitted with a 12 Tesla actively shielded magnet (Bruker Daltonik GmbH, 
Bremen, Germany).  Samples were diluted 1000-fold from NMR samples/reaction mixtures with 
appropriate deuterated/non-deuterated solvents (to ~1 µM), an aliquot of each sample (10-20 µL) 
was ionised from ~1 µm glass nESI capillaries using a capillary voltage of 900-1200 V, ions were 
accumulated for 0.01 s in the hexapole-based collision cell before transfer to the ICR cell for detection. 
Ions of m/z 147-3000 were excited using a frequency sweep excitation and detected for 3.2 s transient 
length (8 mega-word data points), producing a resolving power of ~850,000 (at 400 m/z) for all 
spectra. Mass spectra were externally calibrated using a quadratic calibration function/internally using 
single point calibrations and then manually interpreted and assigned via Data Analysis v4.2 (Bruker 
Daltonik GmbH, Bremen, Germany). 
The majority of samples had been pre-deuterated via exposure to deuterated NMR solvents (D6-
MeOH) for 72 hours prior to analysis. These samples were then diluted 1000-fold for nESI-FT-ICR MS 
analysis, the dilution produced a sample of unusually high concentration for nESI-MS analysis, 
however it accounted for the large variation between NMR samples and due to the low volume 
consumption of nESI (~2-5 uL/hour) and low sample complexity these high concentrations were not 
an issue and caused no contamination/carryover with the source or MS. 
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Selected rhodium samples were reacted with Silver Nitrate (AgNO3, 0.95 molar equivalents) to 
transform the chlorido complexes into the Aqua species and form silver chloride salt, which then 
precipitates out of solution and drove the reaction to ~completion within minutes. Samples were then 
filtered through Celite to remove the silver chloride salt formed prior to nESI-FT-ICR MS analysis. Non-
deuterated (all H-containing) samples were dissolved in deuterated solvent and then immediately 
analysed via nESI-FT-ICR MS, then re-analysed every 10 minutes for the first 80 minutes, then hourly 
from then on until 14 hours at which point the sample were then left in deuterated solvents overnight 
and re-sampled at 24, 48, and 72 hours reaction time.  
Results and discussion: 
8.3 Deuteration kinetics: 
The rhodium complex 1 [Cp*)-Rh-(Bipy)Cl]+ was selected for kinetic HDX measurements, the 
compound was transformed to the aqua species via silver nitrate (as discussed above), filtered through 
celite and then analysed via nESI-FT-ICR MS at various time points. The exchange of hydrogens on the 
cyclopentadienyl methyl groups was surprisingly fast, the first time point was taken at 20 minutes (due 
to filtration time) and a number of hydrogen atoms had already exchanged to deuterium atoms. 
Continuing to take scans at 10 minute intervals it was found that the fully deuterated species (D15 for 
the 15 H’s, now D’s, on the Cp* ligand) was detectable within 60 minutes and the reaction reached 
completion/hit equilibrium within 80 minutes. These results are summarised in Figure 8.2 below: 
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Figure 8.2: nESI-FT-ICR MS spectra of the deuteration (HDX) of Complex 1 (shown inset), at various 
time points, creating the D15-Complex within 60 minutes and reaching ~equilibrium within 80 
minutes, subsequent time point spectra (hourly up to 14 hours, then at 24, 48, 72 hours and 7 days 
showed only incremental increase in D15 and little decrease in D<15 species). 
Though HDX on small molecules/singly charged species is readily achieved on most mass 
spectrometers, and does not require the 900,000+ resolving power (at 400 m/z) achieved here during 
nESI-FT-ICR MS analysis, the UHR-MS provided allowed observation of the individual rhodium species’ 
isotopic fine structure, allowing a “true” representation of the HDX reaction, without overlap between 
isotopologues, and the disruption of the chloride isotope interfering with the M+2 isotopologue. The 
isotopic fine structure of the rhodium species is shown below in Figure 8.3, along with the 3 mD 
374 
 
difference between certain species, and a representation of the same mass spectrum, but at lower 
resolving power performance achievable by standard MS instruments.  
 
Figure 8.3: A rhodium metallodrug complex (Complex 1, below) simulated mass spectrum of the 
[RhC10H15C10N2H8Cl]+ ion produced during ESI/nESI MS analysis. Inset: a zoom-in of the M+1 
isotopologue, at two different resolving powers standard performance for a high-resolution ToF-MS 
50,000 resolving power (bottom) and standard performance for the 3.3 s transient acquired using 
the Bruker Solarix UHR-FT-ICR MS used for all spectra within this chapter 900,000 at 400 m/z (top). 
The higher performance allows observation and assignment of the isotopic fine structure, providing 
additional elemental composition information and reducing overlap between isotopes. 
The lower resolving power simulations show that the apparent HDX patterns are distorted due to the 
inability of isotopic fine structure separation and although the HDX is still visible is it not as 
representative of each H exchanging sequentially and could give false conclusions about the 
mechanism of HDX with the rhodium complex. If every other isotopologue was seen to be at artificially 
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high intensity due to the chloride isotope, one would be led to believe that the H’s were exchanging 
in pairs, however the UHR allows the isotopologues to be separated and see that the process is indeed 
sequential and the extent to which it occurs for each compound species (discussed later). These 
important accurate observations of HDX, time scale, extent of exchange, and sequential reaction 
helped inform subsequent molecular modelling and insights into the mechanism of HDX for these 
species conducted by the collaborator Juliusz A. Wolny, the findings of which are summarised in Figure 
8.4, below: 
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Figure 8.4: Key structures from DFT calculations produced by Juliusz A. Wolny and Volker 
Schunemann. Molecules with optimised geometry modelled with DFT (CAM-B3LYP/CEP-31G) The 
important weak interactions are shown. a) Rh(Cpx)(bpy)OH b) Ir(Cpx)(bpy)OH c) Rh(Me4Cp=CH2) 
(bpy)∙OH2 d) Rh(Me4Cp=CH2) (bpy)∙OH2 e) Rh(Cpx)(en)OH f) Rh(Me4Cp=CH2) (en)∙OH2 g) 
superimposed structures of Me4Cp=CH2 dianion in the optimised structure of Rh(Me4Cp=CH2) 
(bpy)∙OH2 (in black) and the optimised structure of free dianion (in blue). 
The molecular modelling simulations, informed by the NMR and FT-ICR MS experiments were able to 
calculate that the HDX reaction was most likely to occur through a deprotonated Cp*Mex intermediate 
containing a Cp=CH2 bond which will then be deuterated to Cp-CH2D, and so on until each and every 
methyl is deuterated. The deprotonation is believed to be facilitated by the Rh metal centre when it 
has an available co-ordination site which can be aquated/hydroxylated, the OH2/OH/OD2/OD ligand 
can be the proton/deuterium acceptor in the reaction. Since there is only one available co-ordination 
site in the piano stool complex, due to the bidentate ligand occupying 2 fixed sites, the HDX of methyl 
protons across the Cp* ring relies on the free rotation of the arene above the rhodium centre, with 
each methyl exchanging when orientated with the available/aquated/hydroxylated site, thus the 
rhodium revolver. 
The HDX was shown to be accelerated when the complex was aquated (hence the AgNO3 addition), 
though non-aquated samples were also analysed (see below) and the same deuteration was observed, 
only slower (hours compared to minutes). The belief that the Cl ligand must dissociate in order to 
allow deuteration was tested through the use of excess sodium chloride salt solubilised within the 
deuterated solvent which would, in theory, encourage the Cl ligand to remain bound to the Rh metal 
centre through shifting the equilibrium.  
All complexes synthesised, with and without additional 1 mM NaCl, were dissolved in deuterated 
solvent an allowed to react/remain for 72 hours, then analysed with nESI-FT-ICR MS. Zoom-ins of the 
resulting spectra are shown below, along with a table of assignments showing the observed species 
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within each mass spectrum. It should be noted that during ionisation of charged/neutral metal 
complexes, loss of the Cl ligand is common during ESI/nESI to produce a positively charged species, 
loss of this ligand can often be accompanied via loss of an available proton/deuterium, producing an 
[M-HCl]+ and/or [M-Cl]+ peak. Since the study was of deuteration it can be hard to differentiate 
between a [M-Cl]+ species with say 14 deuterium atoms and 1 hydrogen atom and a [M-DCl]+ species 
with 15 deuterium atoms. This ambiguity was settled by observation of the 2+ ion in the spectrum 
(see assignment table) and the corresponding [M+Cl]+ peak if available. The correct number of 
deuterium atoms was decipherable in every nESI-MS spectrum by one or both of these methods and 
the assigned species are summarised in the table below. 
Complex 1: [Rh(Cp*)(Bipy)Cl]+ 
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Complex 2: [Ir(Cp*)(Bipy)Cl]+ 
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Complex 3: [Rh(Cp*-biphenyl)(Bipy)Cl]+ 
 
Complex 4: [Rh(Cp*)(Bipy)Cl]+ 
 
Complex 5: [Rh(Cp*)(Me-Bipy)Cl]+ 
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Complex 6: [Rh(Cp*-phenyl)(Me-Bipy)Cl]+ 
 
Complex 7: [Rh(Cp*-biphenyl)(Me-Bipy)Cl]+ 
 
Complex 8: [Rh(Cp*)(Phen)Cl]+ 
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Complex 9: [Rh(Cp*-phenyl)(Phen)Cl]+ 
 
Complex 10: [Rh(Cp*-biphenyl)(Phen)Cl]+ 
 
Figure 8.5: Structures, Mass spectra, and theoretical simulations of assignments for the 11 
compounds studied for metallodrug HDX, all samples were analysed after 72 hours in deuterated 
solvent and both with and without excess (1mM) NaCl added, those species for which one set of 
spectra are provided indicate no added salt spectra, as the additional salt spectrum did not produce 
detectable target analyte signal. 
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# Complex Salt? 
y/n 
Assignment Assignment composition #D's Observed 
Mass 
Exact 
mass 
1 Rh-Cp-B n [M-DCl]+ [RhC10D14N2C10H8]+ 15 407.16752 407.17113 
  n [M-DCl]2+ [RhC10D14N2C10H8]2+ 15 203.58376 203.58529 
  n [M]+ [RhC10D14N2C10H8DCl]+ 15 444.15045 444.15408 
  y [M-DCl]+ [RhC10D14N2C10H8]+ 15 407.16779 407.17113 
  y [M-DCl]2+ [RhC10D14N2C10H8]2+ 15 203.58388 203.58529 
2 Ir-Cp-B n [M-HCl]+ [IrC10H14N2C10H8]+ 0 481.134 481.13834 
  n [M-HCl+H2O]+ [IrC10H14N2C10H8H2O]+ 0 499.14451 499.14891 
  n [M-HCl+ 
CD2HOH]+ 
[IrC10H15N2C10H8CD2HOD]+ 0 516.17871 516.18494 
  y [M-Cl]+ [IrC10H15N2C10H8]+ 0 482.14189 482.14617 
  y [M-HCl]+ [IrC10H14N2C10H8]+ 0 481.13608 481.13834 
  y [M-Cl+H2O]+ [IrC10H15N2C10H8H2O]+ 0 500.15306 500.15673 
  y [M-HCl+H2O]+ [IrC10H14N2C10H8H2O]+ 0 499.14747 499.14891 
  y [M-HCl+ 
CD3OD]+ 
[IrC10H15N2C10H8CD3OD]+ 0 518.18476 518.19749 
  y [M-HCl+ 
CD3OH]+ 
[IrC10H15N2C10H8CD2HOD]+ 0 517.18719 517.19121 
  y [M-HCl+ 
CD2HOH]+ 
[IrC10H15N2C10H8CDH2OD]+ 0 516.18203 516.18494 
3 Rh-Cpph-B n [M-DCl]+ [RhC9D11C6H5C10N2H8]+ 12 466.16389 466.16795 
  n [M-DCl]2+ [RhC9D11C6H5C10N2H8]2+ 12 233.08253 233.08370 
  n [M-Cl]2+ [RhC9D12C6H5C10N2H8]2+ 12 234.08788 234.09075 
  y [M-DCl]+ [RhC9D11C6H5C10N2H8]+ 12 466.16372 466.16795 
  y [M-DCl]2+ [RhC9D12C6H5C10N2H8]2+ 12 234.08783 234.09075 
4 Rh-CpBph-B n [M]+ [RhC9D12C6H4C6H5C10N2H8Cl]+ 12 579.182203 579.18220 
  n [M-DCl]+ [RhC9D11C6H4C6H6C10N2H8]+ 12 542.198697 542.19925 
  n [M-Cl]2+ [RhC9D12C6H4C6H5C10N2H8]2+ 12 272.104581 272.10640 
  y [M-Cl]2+ [RhC9D12C6H4C6H5C10N2H8]2+ 12 272.10281 272.10640 
5 Rh-Cp-M n [M-Cl]+ [RhC10H2D13C10N2H6CH3CH3]+ 13 435.1999 435.20398 
  n [M-Cl]2+ [RhC10D15C10N2H6CH3CH3]2+ 15 218.60586 218.60799 
  n [M-DCl]+ [RhC10D14C10N2H6CH3CH3]+ 15 435.1999 435.20243 
  n [M]+ [RhC10D15C10N2H6CH3CH3Cl]+ 15 472.18399 472.18538 
  y [M-Cl]2+ [RhC10D15C10N2H6CH3CH3]2+ 15 218.60621 218.60799 
  y [M-Cl]2+ [RhC10HD14C10N2H6CH3CH3]2+ 14 218.10324 218.10485 
  y [M-DCl]+ [RhC10HD14C10N2H6CH3CH3]+ 15 436.2059 436.21025 
  y [M-DCl]+ [RhC10D15C10N2H6CH3CH3]+ 16 437.21201 437.21653 
6 Rh-Cpph-M n [M-DCl]+ [RhC9D11C6H5C10N2H6CH3CH3]+ 12 494.19515 494.19925 
  n [M-DCl]2+ [RhC9D11C6H5C10N2H6CH3CH3]2+ 12 247.09842 247.09935 
  n [M-Cl]2+ [RhC9D12C6H5C10N2H6CH3CH3]2+ 12 248.10367 248.10640 
  y [M-DCl]+ [RhC9D12C6H5C10N2H6CH3CH3]+ 13 496.20739 496.21335 
  y [M-DCl]+ [RhC9D12C6H4DC10N2H6CH3CH3]+ 14 497.21337 497.21963 
  y [M-DCl]2+ [RhC9D12C6H5C10N2H6CH3CH3]2+ 13 248.10457 248.10640 
  y [M-Cl]2+ [RhC9D12C6H3D2C10N2H6CH3CH3]2+ 14 249.11046 249.11268 
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Table 8.1: Assignments of all identifiable species in the metallodrug samples for complexes 1-11 
after 72 hours in deuterated solvent. Please refer to above figure for structure of each species. 
8.4 Stability tests: 
Deuterated rhodium compounds which were shown by nESI-FT-ICR MS to be fully deuterated (D15, or 
higher for different arene ligands), were then re-dissolved in pure protic solvents (H6-MeOH and ACN) 
to test the stability of the deuterium back-exchange and see if the exchange was purely equilibrium 
based (due to excess of deuterated solvent), or was based on kinetic isotope effects favouring the 
deuterated species as a more stable composition.  
Deuterated compounds were dissolved in LCMS grade MeOH/ACN (60/40 v/v) to match their previous 
solvent composition (above) and were sampled at 1 day, 2 days, 3 days, and 7 days to observe the 
protonation/stability. Surprisingly the compounds, once deuterated, did not seem to exchange bound 
deuterium atoms for the available hydrogens atoms in the solvent. Complex 1, i.e. Rh-Cp*-Bp species 
7 Rh-CpBph-M n [M-DCl]2+ [RhC9D11C6H4C6H5C10N2H6CH3CH3]2+ 12 285.11472 285.11500 
  n [M-Cl]2+ [RhC9D12C6H4C6H5C10N2H6CH3CH3]2+ 12 286.11926 286.12205 
  n [M-DCl]+ [RhC9D11C6D4C6H5C10N2H6CH3CH3]+ 16 574.24752 574.25566 
  n [M-DCl]+ [RhC9D11C6D4C6H5C10N2H5DCH3CH3]+ 17 275.25584 575.26193 
  y [M-DCl]+ [RhC9D11C6H4C6H5C10N2H6CH3CH3]+ 12 570.22592 570.23055 
  y [M-DCl]2+ [RhC9D11C6D4C6H5C10N2H6CH3CH3]2+ 16 287.1265 287.12755 
  y [M-Cl]2+ [RhC9D12C6D4C6H5C10N2H6CH3CH3]2+ 16 288.13143 288.13460 
  y [M-Cl]2+ [RhC9D12C6D4C6H4DC10N2H6CH3CH3]2+ 17 288.63456 288.63774 
8 Rh-Cp-P n [M-DCl]+ [RhC10D14C10N2H8C2]+ 15 431.16777 431.17113 
  n [M-DCl]2+ [RhC10D14C10N2H8C2]2+ 15 215.58405 215.58529 
  y [M-DCl]+ [RhC10D14C10N2H8C2]2+ 15 431.16717 431.17113 
  y [M-DCl]2+ [RhC10D14C10N2H8C2]2+ 15 215.58379 215.58529 
  y [M-Cl]2+ [RhC10D15C10N2H8C2]2+ 15 216.5894 216.59234 
9 Rh-Cpph-P n [M-DCl]+ [RhC9D11C6H5C10N2H8C2]+ 12 490.16394 490.16795 
  n [M-DCl]2+ [RhC9D11C6H5C10N2H8C2]2+ 12 245.08273 245.08370 
  y [M-DCl]+ [RhC9D11C6H5C10N2H8C2]+ 12 490.16433 490.16795 
  y [M-DCl]2+ [RhC9D11C6H5C10N2H8C2]2+ 12 245.08285 245.08370 
  y [M-Cl]2+ [RhC9D12C6H5C10N2H8C2]2+ 12 246.08799 246.08705 
10 Rh-CpBph-P n [M-DCl]+ [RhC9D11C6H4C6H5C10N2H8C2]+ 12 516.19428 566.19925 
  n [M-DCl]2+ [RhC9D12C6H4C6H5C10N2H8C2]2+ 12 284.10353 284.10640 
  y [M-DCl]+ [RhC9D11C6H4C6H5C10N2H8C2]+ 12 566.19467 566.19925 
  y [M-DCl]2+ [RhC9D11C6H4C6H5C10N2H8C2]2+ 12 283.09894 283.09935 
  y [M-DCl]2+ [RhC9D11C6H3DC6H5C10N2H8C2]2+ 13 283.60129 283.60249 
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(as the [M(D15)]+ ion, [RhC10D14N2C10H8DCl]+)  is shown below at t0 and at 7 days in protic solvents, 
showing very little back exchange with hydrogens: 
 
Figure 8.6 : nESI-FT-ICR MS spectra of the Rhodium compound Rh-(Cp*)-bipy), aka Complex 1, above 
(as the [M(D15)]+ ion, [RhC10D14N2C10H8DCl]+), analysed immediately after deuteration and 
after 7 days in pure protic solvent (H6-MeOH/ACN), showing no observable back-exchange 
with protic solvent, and remains deuterated. 
The observation of such rapid deuteration in deuterated solvents, but little back exchange in protic 
solvent, even after 7 days, is a clear indication that the deuterated compounds are either much 
more energetically stable than the protonated analogues or are much more stable towards de-
protonation/de-deuteration to achieve the Cp*=CH2/Cp*=CD2 intermediate shown in Figure 8.4. 
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8.5 Future outlook/prospects: 
The facile deuteration of usually very inactive methyl groups is chemically very interesting and may 
open avenues in the future for other C-H bond activation, which is of exceptional interest in the field 
of catalysis.2,3 Unfortunately this deuteration does nothing to enhance the metallodrug mechanism 
of action against cancerous cells, and does not have a practical use in the study of metal-
biomolecule interactions, or could it? This section briefly discusses applications of this serendipitous 
discovery towards anti-cancer research and metallodrug-biomolecule interactions. 
The main technique to exploit the facile deuteration is for accurate, easy, and stable isotopic 
labelling of rhodium compounds. It has long been the technique of chemists to isotopically label 
species in order to study changes in subsequent analytical experiments such as NMR, IR etc. 
However isotopic labelling has also been exploited by mass spectrometrists, commonly for 
proteomic quantitation/labelling, such as SILAC4 and its high-resolution neutron labelled relative 
NeuCode.5 These isotopic labels have assisted in quantitation, mass tagging specific amino acid 
residues, and mechanistic investigations of reactions during MS/MS.5,4,6  Hydrogen-deuterium 
Exchange has also been used to study protein structure, with solvent-accessible amino acids 
exchanging hydrogen atoms for deuterium atoms available from solvent, either in the solution 
phase,7 or in the gas/droplet phase during ESI-MS.8  
However these approaches would not be assisted with the use of the presented rhodium 
compounds, even if they were shown to selectively target specific residues/functional groups the 
protonated species are equally as adept as a mass tag as the deuterated species.  
One key feature of many transition metals is the unique and abnormal isotopic distribution the 
transition metal centre possesses, and thus the influence it would have when attached to other 
species, such as biomolecules. This influence and the characteristic patterns are evident in previous 
chapters for the different metals studied. The impact of these characteristic patterns is detrimental 
to mass spectrometry analysis, as they “spread out” the MS signal for a given species over many 
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isotopic detection channels, for example the Osmium Drug OS1 (chapter 4), contains one osmium 
metal centre, which has 7 natural isotopes, instead of the signal for the Os1 drug being directed into 
one detection channel (possible if all species had one observable isotope), the number of ions for 
the Os1 compound are split into multiple ion clouds, differentiated by mass, this occurs for common 
elements (such as CHNOS) but the unusual and extreme patterns from transition metals can in fact 
decrease the overall intensity and signal to noise ratio of metal-bound species, compared to their 
unmodified counterparts due to this “dilution” of signal into more masses.  
The only beneficial consequence of these unusual metal isotope distributions is that they can quickly 
highlight the presence of a given transition metal and can be used to identify metal bound species 
(as done so in previous chapters). Unfortunately not all transition metals have a distinguishable 
metal isotope pattern, and rhodium happens to be one of those species. Rhodium has one natural, 
stable, observable isotope at 102.905504 Da, thus the detection and characterisation of Rhodium-
containing compounds is not assisted by the rhodium metal centre’s presence. The use of either a 
fully protonated (e.g. H15 from above) or fully deuterated (e.g. D15) does not assist in this endeavour 
either.  
However since it has been shown that the deuterated rhodium compounds above are not only easily 
converted from the protonated to deuterated species with little effort and within ~1 hour, they are 
also stable for several days (at least 7-day stability shown above). These two factors allow for a way 
of inducing a custom isotopic pattern for a given Rhodium drug sample – by mixing the two species. 
If the rhodium Cmplex 1 H15 analogue was mixed with Complex 1 D15 analogue in a 50/50 molar ratio 
then in subsequent MS spectra one would expect to observe 2 sets of peak distributions ~15Da apart 
(H15=15.117375Da, D15=30.211527 => ∆=15.094152Da), and at ~equal intensity (assuming 100% D-
labelling and no kinetic isotope effects during ionisation, transmission, excitation, and detection 
during FT-ICR MS). These species could then be easily identified as rhodium-containing based purely 
on this mass difference.  
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The ability to detect rhodium species based on mass differences would also assist in the 
identification of rhodium complex-bound biomolecules as the species would also appear with ~15Da 
difference, allowing fast and effective identification even before MS/MS and without relying on the 
comparison of peaks to often unreliable/inappropriate biomolecule identification databases. This 
tactic for identification of modified biomolecules is discussed at length in Chapter 9, and was 
adapted into a specialist method for searching for transition metal isotope patterns. The deuterated 
labelling of rhodium compounds however allows the circumvention of the disadvantage some 
metals like rhodium have which is the lack of a characteristic Isotope pattern. In fact the ability to 
create custom-isotopic mixtures using different molar ratios of Dx:Hx complex allows for truly 
characteristic isotopic patterns. For example 50:50 molar ratio mixtures of deuterated complex with 
small numbers of deuterium atoms may overlap with Bromine containing species as Br also 
expresses a ~50:50 intensity ratio for its stable isotopes. However mixture of two unique masses, or 
indeed many isolated rhodium complexes, each with a different degree of deuterium labelling could 
be used to create custom isotopic patterns which could then be accurately searched for using the 
approaches discussed in Chapter 9. 
The power of this simple idea expands to being able to track the mixed-rhodium complex species 
through tissue and cell areas via the use of either imaging mass spectrometry or using proteomic 
assignments, filtered for metal-containing species, to see where the metallodrug moves to in vivo 
(via imaging MS), and what it binds to/reacts with (by proteomics). This and other approaches are 
already under investigation in order to assess their potential for the tracking of these and other 
compounds for accurate analysis.  
The remarkable stability of the deuterated products against back-exchange to their protonated form 
suggests an additional factor, outside of purely kinetic arguments, influencing the increased stability 
of the deuterated form over the protonated form. This factor could be structural, or subtle steric 
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factors, but warrants further investigation requiring molecular modelling calculations to elucidate 
these important influences. 
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Chapter 9:  
Scaling up – Moving from isolated 
biomolecule-metallodrug interactions to 
proteome-wide characterisation 
Progress made in previous chapters/studies was conducted under the premise that it would (aside 
from provide interesting mechanistic investigations) be able to inform larger scale “proteomic” style 
investigations of target cells, i.e. human cancer cells, in order to provide MS derived insights into 
metallodrug effects and possible mechanisms of action against cellular components.  
This chapter is focused on methodologies and subsequent results of such scaling-up studies and the 
challenges associated with them when attempting to incorporate metallodrugs and metallodrug-
modified biomolecules, eventually attempting to create effective and accurate ways of studying 
these species. 
 
The work presented herein was a collaborative effort and contains contributions from other 
researchers, though the MS-based acquisition of data was done by/with the Thesis Author, other 
parties did contribute to many steps and developments along the way, these are detailed below: 
- The nLC-HR-ToF data was acquired by the Author at Bruker Daltonics UK, Coventry with the 
gracious assistance of Julia Smith 
- Implementation of the Author-designed SNAP-LC concept into DA compatible VB code was 
conducted in collaboration with Matthew Willets, Bruker Daltonics, Billerica, USA 
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- Set-up, maintenance and operation of the EASY nLC-II was carried out both by the Author 
and by Yuko P. Y. Lam 
- Cancer cell growth, treatment, and harvesting was conducted by Dr. Isolda Romero-Canelon 
- Protein/Cancer cell lysis, digestion, and desalting was conducted graciously by Yuko P.Y. 
Lam, with some assistance from the Author 
- Implementation of the 2D-FTMS pulse-program onto the SolariX FT-ICR MS was conducted 
by Maria A. van Agthoven, shown in her previous publications (referenced where 
appropriate). Author-created instrument parameters were used in conjunction with this 
standard 2D-MS pulse program to acquire data 
- Processing and denoising of the raw 2D-FT-ICR MS data into a readable format, along with 
subsequent individual MS scan extraction was conducted by Maria A. van Agthoven 
- Implementation of the 3D plotting of processed 2D-FTMS data was conducted using the 
code and interface created by Alice Lynch 
The first section of this work, based around LCMS analysis of metallated biomolecules has since been 
used in the following submitted paper: 
“Automatic Assignment of Metal-containing Peptides in Proteomic LC-MS and MS/MS Datasets”  
Christopher A. Wootton, Yuko P. Y. Lam, Matthew Willetts, Maria A. van Agthoven, Mark P. Barrow, 
Peter J. Sadler, * Peter B. O’Connor. Submitted to RSC Analyst, 2016. 
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9.1 – The challenge of metal-modified biomolecules: 
The study of isolated biomolecules and modified biomolecule species is essential in understanding 
the species itself and the various Post-Translations Modifications (PTM’s) species they can be 
decorated with in vivo. Study of these species is also essential to understand the fundamental 
fragmentation patterns and mechanisms associated with each MS/MS technique and provide an 
accurate, detailed analysis of MS/MS spectra. The addition of modifications can complicate this 
further, be they natural, biological, synthetic, or as shown above organometallic. The unique 
modifications the body can impose on biomolecules are not only impressive, but vast on range, each 
imposing different requirements on sample preparation and MS tuning, instrumentation, and 
tandem MS application. Even common PTM’s can vary from small molecule addition such as 
glycation1 and phosphorylation,2,3 to addition of protein subunits onto already large 
biomolecules/macromolecules e.g. ubiquitination4–6 (addition of entire ubiquitin proteins of >7KDa) 
and Sumoylation7 (addition of a range of SUMO proteins each ~12kDa). Metallodrug modified 
biomolecules are just as demanding, and as shown in previous chapters produce large arrays of 
modifications, require careful handling and controlled conditions, and each have unique effects on 
the resulting MS/MS spectra acquired. Unfortunately regardless of the MS/MS technique metal-
bound biomolecules seem to be consistently challenging to study, even using a range of dissociation 
techniques. Moreover the vast majority of metallodrug modifications are solvent-sensitive, with 
various ligands able to be displaced if using incorrect/reactive solvents (such as methanol for the 
iridium metallodrugs discussed previously). Even if the metallodrug-modified species are stable in an 
MS-compatible solvent many other challenges need be addressed for effective MS and MS/MS 
analysis, including (but not limited to): 
- Use of extremely soft ionisation techniques to retain non-covalent/fragile interactions 
- Delicate tuning of MS optics to avoid excess energy deposition into fragile/high charge state 
ions resulting in loss of modification 
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- Use of compatible solvent system, for the biomolecule, the bound/non-covalent modification, 
and the metal-bound ligands 
- Aversion of acids and denaturing conditions which can disrupt equilibria and 
biomolecule/modification interactions 
- Ergodic MS/MS (e.g. CAD / IRMPD) induced loss of modifications 
- Metal-induced/enhanced sequence scrambling during MS/MS 
- Metal-enhanced side chain/small molecule losses during MS/MS 
- Extreme radical dissociation mechanism changes in electron-based dissociation techniques such 
as ECD, EDD, EID, hECD, and ETD 
- Alteration of predicted masses and data analysis procedure to account for changes in 
dissociation mechanisms 
- Partial loss of modifications during MS/MS causing creation of multiple products, which 
complicate spectra and data analysis. 
- Modification induced complexity of spectra by increasing original number of species by orders 
of magnitude 
- Increased complexity of isotopic pattern due to many metals having non-standard and varying 
ranges of isotopes and distributions; effects on resulting biomolecule-metal species patterns not 
only complicate spectra but leads to erroneous automatic data interpretation. 
Despite these challenges isolated biomolecule-metallodrug interactions can be effectively 
characterised using a range of MS and MS/MS techniques, and so with care scaling up from these 
isolated interactions to multiple/many biomolecules is possible in theory.  
9.2.1 – LC-MS of metal-modified biomolecules: 
Many contemporary mass spectrometry groups have shown great progress in attempting to 
effectively characterise cell-wide protein and peptide species, often referred to as the study of 
Proteomics. Due to the tens of thousands of different poly(amino acid) species present inside any 
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cell, the field of proteomics deals with extremely complex mixtures of biomolecules, including 
species not based upon poly(amino acid) structures. These complex mixtures are almost ubiquitously 
studied using some form of liquid-chromatography (LC),8–10 which although comes in a wide array of 
forms, is a solution phase separation technique and is thus easily compatible with electrospray 
ionisation.11 The coupling of LC and MS has been shown to effectively characterise a range of 
proteomes and their components, from relatively simple proteomes such as yeast (~6000 
proteins)12,13up to and including complex human proteome samples.14,15 To fully realise the potential 
effects metallodrugs have on their human cancer cell targets and to effectively utilise the data and 
mechanisms developed in the study of isolated biomolecules, the next logical step for the study of 
novel metallodrug compounds and biomolecule interactions was to scale up to proteome wide 
investigations to hopefully observe the effect these new compounds have on each and every cellular 
peptide, protein, nucleotide and eventually even metabolite.  
Though, as mentioned above there are a range of challenges and disadvantages to attempting to 
study metallodrug-modified biomolecules via Mass spectrometry, and these require specialised 
strategies to achieve accurate and truly representative data on the biomolecule mixtures in 
question. The “standard” proteomic methods such as use of acidified water/Acetonitrile (ACN) 
gradients for effective LC separations and harsh instrument tuning parameters to achieve good 
desolvation and adequate sequence coverage in subsequent MS/MS experiments are both not 
tolerable when studying metallodrug-modified species. Furthermore, the standard automated 
methods for MS and MS/MS peak-picking, analysis and database searching of species against 
genome-derived biomolecule predictions will produce extremely erroneous data when studying 
metal-modified species as these modifications are not yet known in many cases, will not be included 
in database search algorithms, and most importantly will be matched against the wrong isotope 
peaks from the MS and MS/MS due to the transition metal isotope pattern influences, see Figure 
9.1, below: 
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Figure 9.1: Typical Isotopic distributions for a small peptide, Substance P (top left) and then the 
same peptide modified with an array of transition metal modifications, showing the drastic effect 
on isotopic patterns some metals can induce. 
 Though the standard peak picking analysis could pick one or several peaks from the above 
distribution, only one would produce an accurate assignment for the modified biomolecule species. 
The consistent extraction of the correct mono-isotopic peaks for metal-modified species is more 
difficult than for simple CNOHS-constructed compounds such as unmodified peptides and proteins, 
as the number and intensity of individual isotopologues varies with each transition metal attached. 
However there have been numerous attempts to accurately pick and assign unmodified 
biomolecules in the past,16 many of which centred around assigning one species to a group of peaks, 
i.e. the multiple isotopes for a given species. One particular advancement of this concept from 
Bruker Daltonics was the Sophisticated Numerical Annotation Procedure, aka SNAP.17 The SNAP 
algorithm works by using a prediction of the isotopic pattern and matching it the to the observed 
peaks in a mass spectrum using a least-squares fit (Figure 9.2, below), any matched distribution are 
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then treated as one assignment, producing a much more accurate list of assignments and avoiding 
multiple species assignments for species in the same isotopic pattern, which is an unfortunately 
common occurrence as many assignable peptides in a genome are only a few Daltons apart. 
Obviously since SNAP is based on matching isotopic patterns with observed peaks, knowledge of the 
species is required, but unknown, as a result predictions have to be made to assign matching 
distributions, namely the elemental composition of target species. Since peptide and proteins are all 
based on amino acids, they are composed of a relatively limited number of different elements, 
namely CHNOS. Moreover the proportion of the individual elements in poly(amino acids) has been 
calculated and used in various studies by simply taking the human genome-predicted library of 
peptides and proteins and calculating the number of each amino acid, then calculating the 
composition of each and thus the contribution of each element to the “average biomolecule”. 
Named “averagine” the proportion of each element is thus set, and scalable for any mass of 
biomolecule. The ratio calculated and used for  the averagine proportions were C= 4.9384, N= 
1.3577, O= 1.4773, S= 0.0417, and H= 7.7583.16,18,17 Thus the composition of a poly(amino acid) of 
say 1000 Da can be predicted by simply applying the averagine composition ratios. Obviously the 
averagine predictions are more accurate with increasing mass of biomolecule, as small deviations of 
“uncommon” elements (such as sulphur) in small peptides can cause large deviations in the accuracy 
of averagine predictions. The Averagine assumptions are also slightly less accurate for non-standard 
proteins with a significantly atypical amino acid proportion distribution, e.g. collagen which is often 
>30% proline residues.  
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Figure 9.2: Basis of SNAP annotation procedure from Bruker Daltonics,17 showing (from top left) 
the least squares fit of the target isotope pattern for a modified peptide species (based on 
Bombesin), an example match of isotopic pattern for a biomolecule with a platinum metal centre 
attached showing SNAP to work with different elements, and the equations from Koster et.al.17 
which form the least squares fit SNAP uses. 
The key and subtle benefit of the SNAP peak assignment method is that the elemental composition 
predictions can be modified to include additional species of interest, such as metals, and thus the 
SNAP algorithm can be modified to search and assign only metal-modified poly(amino acid) species. 
By inclusion of a “constant unit” being the metal, and retention of the “repeating unit” being the 
averagine ratio, the isotopic patterns of only metal bound biomolecules can be extracted and 
assigned accurately, which would be otherwise impossible using standard peak picking techniques. 
In addition species with one, two, or more bound metal modifications can be differentiated and 
extracted, further increasing the amount of information and accuracy of assigned species. An 
𝐼(𝑀,  𝑅,  𝑡𝑝𝑜𝑖𝑛𝑡)𝑡ℎ𝑒𝑜𝑟𝑦 
∑(𝑀,  𝑅)2 = ∑(𝐼(𝑡𝑝𝑜𝑖𝑛𝑡)𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 − 𝐼(𝑀,  𝑅,  𝑇𝑝𝑜𝑖𝑛𝑡)𝑡ℎ𝑒𝑜𝑟𝑦 )
2
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example of the SNAP extraction of metal-containing biomolecules from a mass spectrum of both 
unmodified and metal-modified peptides is shown below in Figure 9.3: 
 
 
Figure 9.3: examples of modified SNAP peak picking to filter a given mass spectrum (top) for only 
Platinum containing biomolecules, then output the matched isotopic patterns (middle) species are 
marked according to the key presented and discussed in chapter 3 and included (bottom)Examples 
inset are the SNAP algorithm ignoring normal peptide distributions (which do not include the 
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Platinum constant unit) and matching Pt containing species accurately with a predicted isotopic 
pattern. 
The application of SNAP to mixtures of biomolecules is not only limited to assigning which peaks are 
metal-containing, and determination of how many metal species are bound to individual species, but 
also to filter/search for which metal/uncommon element may be bound to unknown species. SNAP 
could be used to search for any species with an uncommon isotopic distribution, which covers the 
majority of transition metal species, but also encompasses common halides etc. such as chlorine, 
bromine, and non-metals such as selenium. Since SNAP is based upon the matching of a theoretical 
isotopic distribution to the observed peaks in a spectrum, and no match will be perfect (due to 
sampling issues, natural deviations due to substance used, and detection limits), a statistical match 
score is applied to each match and this threshold can be adjusted in order to account for these small 
deviations. The match threshold is extremely useful, especially if the species contains many isotopes, 
some of which may be low abundance (e.g. <1% relative to the base peak) and frequently not 
detected. It was found that the highest match factor (0.95) was required for accurate assignment of 
metallodrug modified species in order to avoid assigning unmodified biomolecules simultaneously. 
Previously however, SNAP assignment of peptides and proteins had been limited to individual mass 
spectra, be they MS or MS/MS spectra. The content of the first section of scaling up to proteome 
analysis of metallodrug effects was the application of SNAP to full liquid chromatography-MS 
experimental runs to analyse which spectra contained metal/uncommon isotope species, and then 
extract them into a SNAP-chromatogram of target peaks. The SNAP’d peaks could then be extracted, 
peak picked (more accurately using a metal-corrected SNAP assignment) and then 
searched/assigned either manually (for small chemical studies) or databases (for full proteome 
analysis).  
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9.2.2 - SNAP-LC: 
The concept behind the SNAP-LC procedure was to load each chromatogram from an LC-MS run, 
apply the SNAP peak picking algorithm, specifying which metal to search for (e.g. Pt), to generate a 
peak picked spectrum, then store those peaks and move to the next peak, in theory then one could 
re-plot the LC chromatogram and see which LC peaks contained metal species.  
In practice this means applying the modified SNAP parameter to each spectrum, retrieving the 
SNAP’d peaks, summing their intensities, storing these values into an array and then moving onto 
the next data point until all spectra had been analysed, at which point the array could be plotted 
simply as a new chromatogram using the spectrum number (rescaled to be retention time) and the 
summed intensity to produce a total ion chromatogram (TIC) but only for metal-bound species.  
The automated procedure was achieved through the scripting functions within Data Analysis (Bruker 
Daltonics, Bremen, Germany), which is based upon Visual Basic (VB) coding language. The first 
attempts at this script were promising, but worked only for a limited number of spectra, regardless 
of the run chosen, it was eventually discovered that the SNAP-LC script would load each spectrum 
individually and remain loaded, quickly filling computer memory and preventing further calculations. 
A work around was then conceived that would output summed intensities into an external .csv file 
after each SNAP calculation/extraction, then delete the SNAP extractions before moving onto the 
next data point in the run via a loop. Although this work around deleted individual SNAP’d spectral 
assignment post summation, it worked effectively on entire LCMS runs (several thousand spectra) in 
one automated operation. The successful script (after several rescaling issue changes etc.) is shown 
below (Figure 9.4), annotated in figure caption for convenience. 
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Figure 9.4: SNAP-LC script Version 2.0 – brief summary, from top left to bottom right: declaration 
of variables (black), selection of LC data points to search and masses for SNAP (red), clear previous 
data and selection of first LC data point, load first spectrum and clear analysis (blue), Declare 
variables for SNAP LC then apply SNAP using inputted parameters followed by export of results to 
.csv file (underlined) then clear results for next spectrum (Black), write intensity results to new 
separate .csv file outside of loop (orange), clear data to save RAM (purple), finally create new 
chromatogram from .csv file and re-import into Data Analysis for plotting. 
The SNAP-LC code was then applied to a simple experiment (non-LC) showing 2 samples 
administered to the FT-ICR MS at separate time points, one an unmodified peptide, and the other a 
mixture of iridium-modified and unmodified species to see if SNAP-LC was correctly calculating only 
the contributions of the metal and metal-bound peaks, and not simply summing all peaks in a given 
spectrum. The results of which are shown below in Figure 9.5: 
 
Figure 9.5: Initial results using SNAP-LC analysis on two ESI-MS samples one metal containing (Ir-
peptide mixture, left), and one unmodified peptide with no metal (right). SNAP-LC was able to 
distinguish, purely from isotopic patterns, which sample contained iridium species. 
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The SNAP-LC search for Iridium modified species was effective at ignoring unmodified distributions, 
and only summing the Iridium-modified biomolecule peaks, resulting in a lower intensity for the 
chromatographic peak containing both unmodified and Ir-modified species, which is an important 
ability for analysis of co-eluting mixtures (i.e. all proteomic samples). 
The SNAP-LC analysis method was then applied to larger peptide mixtures modified with various 
metal-based drugs. Standard proteins (namely Lysozyme, bovine serum albumin (BSA) and 
myoglobin) were reduced, alkylated, and then trypsin digested using very standard procedures 
(detailed below in 9.31 - cancer cell preparation) to produce peptide mixtures of varying complexity. 
The peptide mixtures were then incubated with various metallodrugs mentioned previously in the 
thesis (namely Ir1 and Ir2, Os1, and FM190) using the same incubation/activation times and 
conditions as for their reactions with previous peptide and biomolecules. The resulting metal 
modified peptide mixtures were analysed using nESI-FT-ICR MS to ensure metal-peptide reaction 
products had been formed, examples of these spectra are shown below in Figure 9.6, along with the 
corresponding SNAP’d metal distributions plotted underneath. Though SNAP for full MS and MS/MS 
experiments is effective at extracting and recording metal-modified species, like most isotope and 
peak picking algorithms it suffers with overlapping isotopic patterns and often “misses” metallated 
peaks if their pattern is overlapped with another species, be it metal-modified or not. This further 
enhances the importance of SNAP for LCMS analysis as the LC separation assists in reducing the 
number of species, and more importantly the number of overlapping species in resulting mass 
spectra, enabling SNAP to work more to its full potential and suffer less from these close 
distributions.  
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Figure 9.6: Example protein digest peptide mixtures reacted with previously studied metallodrugs 
nESI-FT-ICR MS spectra, followed by SNAP-LC metal isotope searching to highlight corresponding 
metal-containing species. 
The peptide-metallodrug samples were then analysed by nLC-ToF-MS analysis using a Dionex 
Ultimate 3000 nLC, 25cm C18 reverse phase column, and a captive-spray micro-spray ESI source 
attached to a Maxis Impact II, High-Resolution Time of Flight mass spectrometer (HR-ToF-MS), 
(Bruker Daltonics, Bremen, Germany) operated in the positive ion mode. The ToF MS instrument 
provides fast scan times and reasonable resolution (40,000- 50,000 at 400 m/z for the Maxis Impact 
II) MS and MS/MS analysis.  
Unfortunately the majority of LC-MS based instruments are usually configured to acquire MS and 
MS/MS spectra, peak pick each spectrum individually, and then delete the original (profile) data, 
replacing it with stick-plot type spectra of only peak-picked points. The process, known as 
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Centroiding,19,20 assists in the reduction of the extremely large data files acquired during 
chromatography-mass spectrometry runs (up to dozens of Giga-bytes) into manageable sizes 
(~megabytes), and much faster display and processing speeds post-acquisition. Unfortunately it was 
quickly discovered that accurate SNAP assignment of species is not feasible using centroided data 
and requires full profile data to be successful. As a result spectra acquired in standard centroid-
mode were unusable for SNAP-LC post-acquisition analysis. A re-acquired profile nLC-HR-ToF-MS 
chromatogram, MS, and MS/MS spectra shown below in Figure 9.7 for the Lysozyme digest+Ir2 
metallodrug, example CAD MS/MS spectra are shown for a given time point. 2 precursors were 
isolated and fragmented separately and dissociated according to CAD energies on the pre-set rolling 
dissociation energy curve (CAD MS/MS was the only available MS/MS technique for the Maxis 
Impact II). 
 
Figures 9.7a-d: Example nLC-HR-ToF base peak chromatogram (BPC) chromatogram (top) followed 
by a mass spectrum from the time point marked (star) and 2 CAD MS/MS spectra from precursors 
405 
 
isolated and fragmented during the automatic LC MS/MS run (marked). The large peak in the BPC 
is the free Ir2 drug (-Cl). 
The nLC-HR-ToF effectively separated, detected, and fragmented a series of peptides and metal-
modified species. The SNAP-LC analysis of the resulting chromatograms though was not as effective 
as that for the FT-ICR data, though successful in some limited cases, SNAP-LC was shown to be more 
effective on FT-ICR MS and MS/MS data, this is currently believed to be due to the higher baseline 
noise level on the ToF and the difference in typical detected intensities between the two techniques, 
another possible hypothesis is the resolving power requirements and maximum # of assignments 
(see below). Though with continued improvements the SNAP-LC method could extend to LC-ToF 
runs, this is future work and the focus of the thesis will remain on FT-ICR MS characterisation of 
target metal-modified species. 
One stipulation for accurate SNAP assignment of peaks containing specific isotopic pattern is that 
the individual isotopes need to be very clearly isotopically resolved in order to generate reliable 
assignments and matches. For the majority of cases HR-ToF instrument are effective at resolving the 
isotopic patterns of peptides, small proteins, and even medium sized (~20kDa) proteins with some of 
the latest instruments.21 However separation of complex MS/MS spectra and even MS spectra of 
higher molecular weight species is more achievable using FT-ICR MS, additionally FT-ICR MS has 
access to the range of MS/MS techniques to effectively study the unique metal based modifications 
presented in this Thesis (particularly ECD and EDD). 
nLC-FT-ICR MS analysis of peptide-metallodrug reaction mixtures described above was achieved 
using an EASY nLC II (Proxeon, Denmark), equipped with a 10 cm C18 reverse phase capillary column 
(10 cm x 75 um, 2 μm particle size) and 2 cm C18 trap column (2 cm x 75 μm, 2 μm particle size), 
coupled to a captive spray micro-spray ESI source (Bruker Daltonics, Bremen, Germany, attached to 
the SolariX 12 T FT-ICR mass spectrometer described earlier. FT-ICR MS has a much slower scan rate 
(/longer ”duty cycle”) compared to ToF-MS, mostly due to the fact that the resolving power for FT-
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ICR MS is directly proportional to the acquisition time/duration of signal transient (discussed in the 
introduction section), and so typical high resolution scans for an FT-ICR MS instrument are on the 
order of 1-3 seconds, not including additional accumulation times for externally generated ions etc. 
In summary for a high resolution (500,000-1,000,000 RP) scan on a 12 T FT-ICR MS instrument the 
duty cycle is ~2-5 seconds, whereas many ToF mass spectrometers can achieve several if not dozens 
of scans per second.21 However the duty cycle of FT-ICR MS can be greatly reduced by acquiring 
shorter transients, of say 350 ms, reducing the resolving power from ~500,000 to ~125,000 (at 400 
m/z) but allows the scan rate to increase to around 1Hz, which is the standard benchmark for LCMS 
scan rate.8,22 The nLC-FT-ICR MS data shown herein was acquired using 1MW data points, equating 
to ~350 ms transients and the ~125,000 resolving power (at 400 m/z) stated above. Though higher (4 
MW, 500,000 RP) transient acquisitions were also attempted, the shorter scan time provided the 
improved LCMS chromatogram quality, and would enable more MS and MS/MS scans for the many 
species eluting from the peptide mixtures. An example of nLC-FT-ICR MS analysis of Cytochrome c 
digest peptides is shown below in Figure 9.8, showing the ability of the EASY nLC II system to resolve 
peptide peaks effectively despite using such a short (10 cm) C18 nLC column, and despite a fast 
gradient (0% ACN to 100% ACN in 25 minutes): 
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Figure 9.8: nLC-FT-ICR MS analysis of unmodified cytochrome c digest peptides via a 10cm C18 
column, 2 μm particles. Effective separation of all peptides was achieved using a particularly steep 
gradient and short run time (see main text). Below: typical peptides observed and resolving power 
for annotated peaks. RP= ~125,000 at 400m/z. 
The nLC-FT-ICR MS analysis was then attempted on an iridium metallodrug-peptide mixture, shown 
below in Figure 9.9; separation was achieved using the shallow gradient shown inset. The nLC 
performance was not as consistent as with the unmodified peptides, believed to be partly due to the 
acidified solvent conditions (0.1% formic acid in both the water and ACN solvents), the acidic 
solvents can cause dissociation of the iridium metallodrugs, which was observed in the extreme peak 
towards the end of the nLC run, identified as the free iridium metallodrug (shown inset). Despite the 
nESI FT-ICR MS spectrum of the same mixture (which showed little free Ir drug), the acidified solvent 
system used has disrupted the binding of the metallodrug to the peptides, again re-enforcing the 
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need for particular solvent systems and aversion of acidic solvents when studying metallodrug-
biomolecule interactions. 
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Figure 9.9: nLC-FT-ICR MS of Lysozyme digest peptides reacted with iridium metallodrug (IR2 – see 
previous section) producing a base peak chromatogram (BPC) of species (top) followed by SNAP-LC 
analysis to search for iridium isotope patterns (Blue). Examples of non-Ir containing species not 
counted in SNAP-LC (1) and species with the Iridium isotope pattern being successfully picked up 
(2). Finally, the nLC gradient used for separation on the 10 cm, C18, 2 μm particle nLC column. 
Regardless of the solvent and dissociation issues observed, a range of peptides, and iridium-
containing isotope patterns were recorded in the LCMS run, and provided a good trial for SNAP-LC 
analysis. The SNAP-LC analysis of the iridiated species shown above in Figure 9.9 (inset 2), iridium 
has a unique isotope pattern, shown above, and often extends peptide isotopic patterns when 
bound, unfortunately this modification usually results in 2 separate peak distributions being picked 
out with “standard” peak picking algorithms for peptide analysis (including standard unmodified 
SNAP), one being the first two (lower intensity) peaks and the other being the latter 3 peaks. 
However SNAP-LC with the iridium metal modification included accurately assigns one mass to the 
iridiated peaks which would enable accurate assignment in database/post-processing searches. 
Automatic CAD MS/MS was attempted on the same iridiated Lysozyme digest sample, using a 
constant CAD collision energy of 18V for all species and an additional 1.5s “MS/MS boost” (ion 
accumulation time) when a desired precursor MS/MS target was located, the iridiated peptide 
shown above in Figure 9.9 was successfully detected and fragmented automatically, resulting in the 
CAD MS/MS spectrum shown in Figure 9.10, below, and can be used to locate the iridium based 
modification on the digest peptide. 
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Figure 9.10: Summary of the SNAP-LC results with auto-CAD MS/MS of an Iridiated peptide 
detected during the nLC-FT-ICR MS analysis of the iridium-lysozyme digest peptide mixture. A 
series of iridiated and non-Iridiated peaks can be observed, with sequence, fragmentation map 
and derived location of the modification (based on MS/MS information and results from Chapter 
6) shown inset. 
Looking to the periodic table of elements, there are a great number of elements whose isotopic 
pattern deviates from the averagine predicted pattern enough to be considered viable candidates 
for SNAP-LC MS analysis, these potential “targets” for SNAP-LC MS searches are summarised in 
Figure 9.11, below: 
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Figure 9.11: The periodic table of elements including commonly observable isotopic patterns, all 
species with multiple isotopologues in distinctly different ratios to CHNOS are potential targets for 
SNAP-LC. Reproduced from http://zwz.cz/f/allgood788/KNLS74SW/COMPUTER-periodic-table-
isotope-distribution (accessed 16/04/2016). 
9.2.3 - Current challenges for SNAP-LC: 
Currently the largest challenges for SNAP-LC analysis are the LC related challenges of retaining 
metallodrug modifications, and the fundamental limitation of the SNAP procedure, i.e. assigning only 
peaks and not noise.  
Addressing point 1, retention of metal-based modifications, it is possible to run LC and nLC gradients 
without acidified solvents, though this tends to reduce LC chromatographic performance due to the 
presence of un-protonated silyl groups within the C18 reverse phase columns reducing the polarity 
of the column, and thus the quality of separation of polar analytes. nLC-FT-ICR MS analysis of metal-
modified species was attempted and successful and enabled the retention of iridium based 
metallodrug modifications. It is also worth noting that the nLC-ToF MS analysis of metallodrug-
peptide mixtures were all collected using pure, non-acidified solvents, following 2 days of purging 
the nLC system with non-acidified solvents to remove any residual acid from the system.  
Unfortunately although LCMS can be achieved without acidified solvents, it is not commonly 
achievable without the use of potentially disruptive organic solvents. LC is based upon the phase 
fractionation of species between the mobile phase and the stationary phase, and thus species are 
“removed”/eluted from LC columns by using solvents individual species have a stronger preference 
for than the stationary phase, for peptides and proteins this is (for the majority of cases) a 
water/organic solvent mixture, usually ACN or methanol. Though species such as the iridium 
metallodrugs above are reasonably stable in water/ACN mixtures, other species (especially platinum 
based metallodrugs) can be particularly vulnerable to certain solvents and their electron-donating 
groups (such as nitrogen lone-pairs for Pt), and so can easily displace the metal modification away 
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from the peptides in question, or displace metal-bound ligands and change the nature of the metal 
modifications themselves, resulting in an inaccurate representation of the biomolecule mixture. The 
choice of phases and solvents will continue to be a challenge for LCMS analysis of particularly 
fragile/sensitive species and modifications, though great strides are being made by particular groups 
to retain modifications, usually for accurate Top-Down MS/MS analysis of proteins and/or protein 
complexes, such as the Kelleher14, Pasa-Tolic23, and Chamot-Rooke groups. Use of monolithic 
columns23 for fast and effective separation of proteins and peptides, with various solvents has 
already allowed the effective analysis of many species, and even proteomes using the Top-Down 
approach,23,24 eventually this may be modified and applicable to systems which are more 
metallodrug-friendly. 
Addressing the second challenge for SNAP-LC, the effective assignment of peaks in LCMS data 
analysis is a field-wide issue and is ever under investigation and improvement. The particular issues 
with SNAP-LC of species on a larger scale are not uncommon ones, but are mainly focused around 
the effective analysis of ion-generated peaks and not baseline-noise. SNAP-LC has the ability to only 
assign peaks above a certain intensity level (threshold), like many other peak picking methods. The 
adjustment of this level dictates which peaks are chosen for consideration during peak picking, and 
thus will dictate how accurate the algorithm can assign target peaks. Setting a high SNAP intensity 
thresholds will miss potential assignments, while setting particularly low thresholds could result in 
erroneous peak assignments if noise is included in pattern matches, but could also cause issues with 
SNAP assignment limits (only 20,000 peaks can be assigned in each spectrum), causing the algorithm 
to crash. The first issue can be tuned over several baseline runs, and tuned with correct controls, in 
much the same way as standard LCMS proteomic analysis. The limit of assignments issue should be 
readily solvable by achieving a reasonable level of separation in LC, as there should not be a point in 
which thousands of co-eluting peaks are present and causing >20,000 peak assignments. However if 
the threshold of SNAP assignments is set too low then baseline noise will interfere with assignments 
and thus will trigger issue 2, as a result they are both solvable, but related.  
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Although the use of SNAP-LC on fully optimised proteomic nLC-FT-ICR MS runs was not achieved in 
the timescale of the thesis work, it is a promising avenue of research into metallodrug-biomolecule 
interactions and has already been included into plans of future study and application. 
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9.3 - 2D- FT-ICR MS: 
The effective LC-based retention of metal modifications is difficult to achieve as slight changes in 
solvent systems can not only affect the equilibria of binding interactions, as discussed and observed 
above in LCMS application. Incompatible solvent choices can also cause dissociation of non-covalent 
or dative-covalent bonds and loss of bound ligands, which induces inaccuracies in analysis. 
Furthermore certain (particularly transition metal) species can react with LC column packing 
(silyl/hydrocarbon groups) and cause disintegration of packing material/functional groups, 
contaminating LC-MS runs and irreparably damaging LC columns.  
Despite the advantages of LC-MS using FT-ICR MS, and even though it is capable of studying a wide 
variety of metal compounds and metallodrug-biomolecule conjugates (see above), there are notable 
challenges and disadvantages. From a purely MS position these challenges are dominated by 1) the 
slow duty cycle of high-resolution scans using FTMS instruments, 2) The lower fragmentation 
efficiency of the more advanced, and required, electron-based MS/MS techniques for metal-
biomolecule MS/MS (ECD/EDD/ExD), and 3) the effective isolation and tandem MS fragmentation of 
each species/precursor as they exit the chromatograph.  
In order to combat these disadvantages, and the various solvent system/column interaction/time 
based issues associated with LC-MS, another technique was investigated to explore its potential in 
studying metallodrug-proteome interactions; 2-Dimentional Mass Spectrometry (2DMS). 
2DMS or 2D-FT-ICR MS, is a purely MS based technique which attempts to exploit the modulation of 
ions within an ICR cell during MS/MS fragmentation in order to fragment all precursors within a 
sample, and analyse the fragments of each species, correlating them to the precursor, without a 
traditional quadrupole/in-cell isolation such as SWIFT/CHEF (see introduction). 
2D-FT-ICR MS was first introduced by Pfandler in 1987,25 and was developed by Ross, Marshall 
et.al.26 and more recently by Van Agthoven et.al.27 The basis behind 2DMS is the same as that for 2D 
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NMR; to attempt to create a coherence or correlation between two measurable factors using a 
sinusoidal modulation to enable a Fourier transform in a second dimension, for 2D-NMR these are 
the chemical shift and j-coupling values, for 2D-FT-ICR the correlation is not as obvious but has been 
adapted to use MS/MS fragmentation and use of a modulating excitation/de-excitation pulse to 
achieve the needed variability. The consequence of this is that each different parent ion species can 
be modulated using a pre-MS/MS modulation pulse (see Figure 9.12, below), then fragmented using 
a radius-dependent in-cell MS/MS technique (such as IRMPD, ECD, ExD, or other laser MS/MS 
methods), creating a mixture of remaining parent ions and MS/MS fragment ions.  
Gaumann et.al.28 achieved modulation by incrementally increasing the delay period (t1) between two 
identical excitation events. The first event was used to excite ions radially outward from the centre 
of the ICR cell. Then if t1 is exactly an odd integer multiple of half a period of the ICR frequency of a 
given parent ion that ion will be de-excited by the second pulse back to the centre of the ICR cell 
before MS/MS and thus not be fragmented by the MS/MS method achieved at high radius only (e.g. 
In-cell CAD, ECD, or ExD).26 However if t1 is exactly an integer multiple of one period of the parent 
ion ICR frequency then the second pulse will excite those parent ions out to twice the previous ICR 
radius achieved at the end of the first pulse and thus will be fragmented by the high-radius-
dependent fragmentation. t1 is then incremented with each scan, which will alter the phase at which 
the ions were excited at (=t1ωp) and thus the radius of parent ions in successive scans will be 
modulated at the frequency ωp as a function of t1. The fragments of those precursor ions within the 
fragmentation zone will also be modulated in the same way as their parent, and thus are correlated, 
there is coherence and thus the second dimension of mass spectrometry is accessible. 
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Figure 9.12: (A) Pulse sequence of a typical 2DMS experiment, the IRMPD/ECD pulse can be 
replaced with an ExD pulse. etc. (B) the subsequent effects of the 2DMS pulses depending on ion 
radius. Reproduced from Van Agthoven et.al.29 
Within a modern hybrid-FT-ICR MS instrument, the ECD/ExD MS/MS fragmentations are usually 
achieved via a hollow electron-dispensing cathode mounted on the rear of the ICR cell, which is the 
case for the Bruker SolariX 12T FT-ICR MS used herein. The cylindrical geometry of electron 
production is preferred in order to leave a hole along the z axis to allow laser-based MS/MS within 
the cell. The different MS/MS techniques will thus have different target zones within the ICR cell, 
with the laser dissociations passing through the centre of the ExD cathode and irradiating the centre 
of the ICR cell, and the ExD electrons irradiating a circular “donut-shaped” path along the z axis. 
These 2 mutually exclusive “fragmentation zones” are depicted below (Figure 9.13), along with the 
2DMS theory and pulses needed to achieve correlated, coherent MS/MS for successful 2DMS: 
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Figure 9.13: Representation of ion location during a typical 2D-FT-ICR MS experiment following the 
pulse sequence described above (Figure 9.12). Note: the ions in question will be rotating around 
the centre axis of the ICR cell at their reduced cyclotron frequency, as always, the stationary 
representation of ion location is purely for convenience/understanding. 
Obviously for ECD 2DMS the modulation-correlation relationship is as described above; those ions 
who’ll possess an ICR frequency period which is an integer multiple of one of t1 will be excited by the 
second pulse and gain an increased radius, moving into the ECD MS/MS fragmentation zone. 
Whereas ions with a frequency that corresponds to t1 being an integer multiple of half a period of 
the ICR frequency for those ions will be de-excited to the centre of the ICR cell and will not be 
fragmented by ExD MS/MS. For IRMPD 2DMS the correlation is simply reversed, those excited will 
not be fragmented and those de-excited are fragmented, the second pulse lengths are adjusted 
practically to achieve the correct amount of time within each zone and avoid loss of correlation, 
these values can be found in recent 2DMS studies achieved on the 12T SolariX instrument.29 An in 
depth study of the optimisation of 2DMS pulse sequencing has also been carried out.30 
419 
 
The 2DMS file produced will be a series of transient signals all recorded with different incremental 
delays, say 4096 iterations, resulting in 4096 scans, and 4096 individual transients, and creating very 
large data files (>5-30Gb, depending on individual transient data point values). The data will then 
need to be processed, in a similar fashion to the standard FT-ICR MS data, requiring Fourier 
transformation (but in 2 dimensions this time), halving, zerofilling, and conversion to frequency 
using the acquisition rate, before calibration to create an m/z scale for both directions. The resulting 
2D mass spectrum will contain a series of horizontal lines (4096 in the case above) being the 
individual scans, with varying increments. The Horizontal lines provide the individual MS/MS spectra 
acquired, the diagonal line across the spectrum will provide a reflection of the precursors which 
have been fragmented and has been dubbed the “auto-correlation line”. Any lines with a horizontal 
offset to the auto correlation line show a consistent fragmentation from precursors, but no charge 
change, and so reveal neutral losses from, precursor ions, referred to as the neutral loss line. Vertical 
lines taken from the 2D spectrum will show all of the precursors to produce a fragment at the line 
chosen. The nomenclature and axis are summarised in Figure 9.14 below: 
 
Figure 9.14: Axis, informative lines, and nomenclature for the interpretation of 2D mass spectra. 
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An example full 2DMS spectrum of cholesterol is below from Van Agthoven et.al.,29showing the 
various species produced from APPI of cholesterol, and then the IRMPD induced fragmentation of 
each and every species via 2D-IRMPD-FT-ICR MS is shown below in Figure 9.15: 
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Figure 9.15: 2D-IRMPD-FT-ICR MS spectrum of Cholesterol ions produced by APPI (a) and various 
lines from the 2D plot, including fragment ion scans (b, c, d, e), precursor ions scan (f) and neutral 
loss lines (g, h, i). Reproduced from Van Agthoven et.al.29 
 
Because 2DMS does not suffer from the reduced isolation efficiency associated with narrow-window 
quadrupole isolations, and does not require the individual tuning of In-cell isolations for each 
precursor, 2DMS is able to separate the fragmentation patters of extremely closely spaced peaks 
without loss of intensity, and was shown to be able to differentiate the different fragments 
produced by the Cholesterol-H2O radical cation and protonated cation species, separated by 1m/z, 
which would be otherwise challenging via quadrupole isolation without loss of sensitivity.  
2DMS has been successfully applied to such small molecules such as cholesterol,29 but also isolated 
poly(amino acids),27 and recently Van Agthoven, Wootton et.al. showed successful 2DMS of tryptic 
digest-derived mixtures of peptides. 31 With the recent advancements in 2DMS calibration and 
resolution,31 2DMS is finally becoming a viable technique for the study of biomolecules, and is even 
able to exceed standard MS/MS performance, as shown in Van Agthoven, Wootton et.al.31 where 
fragments from peptide precursors just 0.0156 m/z apart were effectively separated in 2D space 
using 2DMS and were able to be characterised effectively. The separation of the 2DMS peaks and 
resulting fragmentation maps from the tryptic digest species shown below in Figure 9.16: 
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Figure 9.16: Resulting fragmentation of Cytochrome c peptides analysed by 2D-FT-ICR MS using 
ECD and IRMPD as fragmentation techniques. Reproduced from van Agthoven et.al.31 
The ability to perform 2DMS using a variety of in-cell MS/MS techniques (such as ECD and IRMPD) 
allows complementary data to be acquired in a similar fashion to CAD and ETD/ECD for standard 
MS/MS, and the use of electron-based in-cell MS/MS provides the opportunity to study metallated 
biomolecules without losing fragile modifications to threshold based techniques such as CAD.  
Most importantly for the study of metallodrug-biomolecule interactions is that 2DMS operates via 
direct infusion, using any continuous/pulsed ion source available, with the only requirement being 
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that the production of ions needs to be kept as consistent as possible in order to avoid scan-to-scan 
variation of peaks and ion count, which will produce differences between scans. The scan-to-scan 
variation in 2DMS is a more pronounced problem than for normal 1D MS due to the second Fourier 
transform, any differences between the sequential spectra will be correlated with the fragmentation 
of that particular precursor ion, and thus will appear as a falsely generated noise-peak.  The ability to 
use standard nESI, and most importantly the solvent and scan conditions needed for effective 
metallodrug-biomolecule interaction study makes 2DMS a very attractive technique. nESI-2DMS 
would not suffer from the acid/solvent induced dissociation of metal modifications as observed in 
the LC-MS results presented above, 2DMS is also not hindered by the need to keep to a short duty 
cycle in the same way as LCMS, so long as there is a continuous spray of ions; 2DMS can continue to 
work effectively, enabling the use of high-resolution scans, long ion accumulation times, and 
complex/long MS/MS procedures (such as long laser/electron irradiation times). 
Of particular interest was the chance to use 2D-FT-ICR MS to attempt to study the proteomic 
changes inside a cancer cell before and after treatment with an active anti-cancer metallodrug. As 
another method to “scale up” to full proteomic analysis, 2DMS was attempted on a cancer cell line 
of interest and an osmium based metallodrug. The anti-cancer complex codenamed FY26 (shown 
below), has been repeatedly shown to be extremely active (up to 49x more active than Cisplatin 
against 809 cancer cell lines.32 FY26 Is also effective against ovarian cancer cells, which are currently 
inaccessible via photo-activated metal complexes (see PACT section of introduction). As a result FY26 
(structure below in Figure 9.17) was reacted with the cancer cell line A2780, an ovarian cancer cell 
line studied extensively by Sadler et.al.33–37 and shown to be effectively combatted using FY26. The 
Aim of the 2DMS analysis was to attempt to see differences in the proteome before and after 
treatment, and to attempt to see any osmium-modified biomolecules remaining.   
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Figure 9.17: Structure of the FY26 Metallodrug used in the proteomic study of A2780 cancer cell 
components.  
9.31: A2780 Cancer cell preparation and digestion method: 
A2780 cancer cell lines were grown and treated in 2 stages, first after the desired number of cells 
were available (5 million for each sample), one dish were allowed to grow in media for 2 days, 
unhindered and provided for (by the media), to provide a control, the other was allowed to grow for 
one day, they were then treated with FY26 at IC50 concentration (100 μM)32 the treated cells were 
then left for another 24 hours to allow the drug to take effect. This process is summarised in Figure 
9.18, below: 
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Figure 9.18: A2780 Cancer cell growth and treatment with FY26 summary, including usual 
outcomes from analysis via cell counting. 
Cancer cells for both control and treated samples were detached from the plates using trypsin 
+EDTA solution, washed with Phosphate Buffer solution (PBS), then stored in PBS prior to digestion.  
Cells were lysed using a variety of methods to attempt to study the differences/impact of lysis and 
the harsh chemicals often required on the fragile osmium-based modifications.  
Lysis buffers/conditions tested used a constant “base” solution (below) and 4 different lysis 
formulations added to the base. Sub-milimeter glass beads (purchased from Sigma Aldrich) were 
sought after as a method to rupture the cell membrane without the use of harsh buffer solutions in 
an attempt to help retain metal based modifications. Glass beads were cleaned with ethanol before 
and after use twice in order to ensure no bacterial growth and to wash off residue. 
Buffer base (50mL total): 
- 50mM TRIS-HCl (pH 7.5 – adjusted with conc. Hydrochloric acid) 
- 2.5% Glycerol (1250uL) 
- 50mM DTT (0.3856g/50mL) 
- 5mM EDTA (0.07306g/50mL) 
Lysis formulation variants: 
- Standard SDS lysis – 2% SDS added (0.0202g/mL) 
- Triton X-114 0.5% + glass beads  
- RLT lysis solution (2mL) + glass beads 
- Only glass beads (+ same base buffer) 
Cell pellets were mixed with the desired base buffer+lysis formulation (2 mL total) and sonicated in a 
cooled water bath (~4 oC) for 5 minutes, the samples were then placed in a 4 oC refrigerator for 2 
minutes, this cycle of sonication-refrigeration was then repeated 3 times. The now lysed cell samples 
426 
 
consisted of insoluble membrane material (pelleted in the Eppendorf) and solubilised peptide and 
protein lysate, the supernatant was extracted (~2 mL) and centrifuged at 6000 rpm for 10 minutes to 
ensure insoluble material, and remaining glass beads, were effectively separated. The supernatant 
was extracted again (~2 mL). SDS, RLT, and purely glass bead extracted biomolecule samples were 
then stored at 4 oC, while Triton X-114 samples were shaken and re-centrifuged, followed by 
extraction of the supernatant, until the solution was clear upon shaking (showing the majority of 
Triton X-114 was removed, lest it would become opaque). All samples were then filtered using a 
3kDa Molecular Weight Cut-Off (MWCO) filter (Amicron, Millipore) to remove buffer molecules and 
salt (glycerol, DTT, EDTA, remaining lysis formulation <3kDa, etc.). The MWCO filter was filled with 
450uL of solution for each filtration and centrifuged at 14,000 rpm for 25 minutes per cycle. The 
remaining >3kDa peptides and proteins of interest were then extracted from the MWCO filter using 
Urea (6M) to create a protein suspension which was sonicated for 5 minutes total (3 seconds 
sonication, 3 seconds rest, repeat) and then centrifuged to create a protein pellet. The resulting 
protein pellet was then quantified using a standard BSA calibration curve and Coomassie blue 
solution. Various BSA quantities (in mg/mL) were used to create a colour above and below that of 
the sample, the solutions were then analysed via a UV/Visible micro-plate reader to determine 
accurate absorbances of the known BSA quantities, and the unknown sample protein quantities, 
enabling reasonable quantitation of total protein content.  
After quantitation extracted protein samples were adjusted to 1 μg/mL using aqueous Ammonium 
BiCarbonate solution (ABC) (100 mM) and digested using a standard trypsin digestion procedure to 
yield peptides. For the digestion, the protein extract (1 μg/ mL, 50ug) was mixed with DTT (50 mM in 
100 mM ABC, 3 mL) for reduction of protein disulphide bonds and heating to 60 oC for 30 minutes, 
IodoAcetAmide (IAA) (100 mM in 100 mM ABC, 3 mL) was then added in the dark for 1 hour to 
alkylate the now free cysteine SH groups and prevent re-formation of disulphide bonds (which 
inhibit effective digestion and MS/MS analysis), after the reduction and alkylation the protein extract 
was digested using Trypsin solution (1 mg/mL in 100 mM ABC, 2 mL) and incubated at 37 oC 
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overnight for 16 hours. The resulting peptide and protein solution was then filtered through a 3kDa 
MWCO filter again to remove undigested protein and remaining Trypsin which could damage/block 
nESI tips/C18 nano-chromatography columns, all peptides under 3kDa could pass through the filter.  
The filtrate was then desalted using C18 disposable Solid-Phase Extraction (SPE) cartridges. The C18 
cartridges (SOLA, 1 mL capacity, 10 mg bed, Thermo scientific) were wetted with methanol (1 
column volume, 1 mL), washed with wash solution (80% ACN 19.9% H2O, 0.1% TFA) (1 column 
volume, 1 mL), and then conditioned (99.9% H2O, 0.1% TFA) (2 column volumes, 2 mL). The sample 
(1/10th bed mass = 1 mg, 1 mg/mL) was then loaded onto the prepared C18 cartridges, the loaded 
sample was then washed with acidified water (99.9% H2O, 0.1% acetic acid, 2 column volumes, 2 
mL). The washed sample was then eluted from the C18 cartridge using an acidified water-organic 
solvent mixture (80% ACN, 19.9% H2O, 0.1% acetic acid, 3 column volumes, 3 mL). 80% ACN was 
chosen as it was found to elute the target peptides in isolated protein digestions (lysozyme, BSA, 
etc.) without eluting remaining SDS buffer etc. (soluble in high ACN %’s). The eluted peptide sample 
(3mL) was then dried to solid powder via vacuum centrifugation overnight. The dried peptide 
powder was then reconstituted to 0.5mg/mL in water. Finally MS samples were created by diluting 
the stock peptide digest solution ~100 fold with water/ACN (final solvent ratio was 80% H2O, 20% 
ACN).  
A2780 Cancer cell digest control and treated samples were then analysed using nESI-FT-ICR MS to 
assess protein digest success and peptide recovery, example spectrum and zoom-in shown for the 
control in Figure 9.19 (below), the UHR-FT-ICR MS scans quickly showed the many thousands upon 
thousands of peaks able to be observed in a single FT-ICR MS spectrum and the complexity of the 
human cell lysate digests.  
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Figure 9.19: 1D-nESI-FT-ICR MS of A2780 cancer cell digest peptide mixture full mass spectrum 
(top, (a)) and zoom-in region (marked and in (b)) showing the high sample complexity and the 
~dozens of peptide peaks per m/z. 
3 
a) 
b) 
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Since the 1D-nESI-FT-ICR MS analysis was possible and showed abundant peptide recovery, 
subsequent 2D-FT-ICR MS analysis would be viable. Both the treated and untreated A2780 digest 
samples were analysed using both 2D-ECD and 2D IRMPD analysis. ECD parameters were as follows; 
pulse length = 0.2 s, bias = 1.2 V, lens = 18 V and IRMPD parameters; pulse length = 0.1 s, Laser 
power 70%, 25 W laser. Each 2D-MS was acquired using 256k data point transients and 4096 
increments of t1, creating a 2D-MS spectrum of 4096 lines with 256k data points per line, each 
shown below:  
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Figure 9.20: 2D-nESI-FT-ICR MS spectra of A2780 cancer cell control trypsin-digest derived peptide 
samples dissociated using IRMPD (top) and ECD (bottom). ECD parameters were as follows; pulse 
length = 0.2 s, bias = 1.2 V, lens = 18 V and IRMPD parameters; pulse length = 0.1 s, Laser power 
70%, 25 W laser. 
The resulting 2D-MS spectra show a huge number of parent ion and fragment ion peaks, all viewed 
in a single 2D-MS spectrum. The Autocorrelation line, easily visible on the diagonal is extracted for 
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each spectrum and presented below in Figure 9.21a-d, showing similar complexity to that in the 1D-
MS above.  
 
 
432 
 
 
Figure 9.21: Auto-correlation lines for the A2780 cancer cell digests control sample using IRMPD 
(a), control sample using ECD (b), FY26-treated sample using IRMPD (c) 
As mentioned previously every precursor along the Auto-correlation line will also possess its own 
fragment ion scan, showing the MS/MS fragmentation spectrum of that precursor by the MS/MS 
method chosen. Examples of extracted horizontal lines are shown below in Figure 9.22: 
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Figure 9.22: Example extracted lines from the 2D-nESI-IRMPD-FT-ICR MS analysis of A2780 control 
cancer cell digest proteomic sample, from top left; zoom in of small region, showing many isotopic 
distributions (fragments), a zoom in of an isotopic distribution featured in previous region, and 
finally an extracted horizontal (fragment/ MS/MS) line of a peptide precursor (966 m/z) 
fragmented by IRMPD MS/MS. 
Neutral loss lines may also be extracted, and can inform the analysis of not only the functional 
groups/amino acids present in the peptide precursor, but can also be used to track certain PTM’s, 
such as phosphorylation. IRMPD/CAD of phosphorylated peptides produces neutral losses of the 
phosphate group expressed at -80Da and -98Da losses from the precursor ion.38–41 Thus neutral loss 
lines of Auto-correlation line -80 Da/e and -98 Da/e can be extracted from the 2D mass spectra 
above to instantly show all peptide species containing the phosphorylation modification and thus 
those peptide could be readily searched using standard database search algorithms to identify all 
phosphopeptides in a given sample. Phosphopeptides are particularly useful targets for analysis of 
proteome changes as they have been linked extensively to cell-signalling pathways and triggered 
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changes within the cell.42,43 Examples of -80 Da and -98 Da neutral losses from the Auto-correlation 
line for each charge state are shown below in Figure 9.23: 
 
 
Figure 9.23: Example extracted neutral loss scans from the A2780+FY26 treated cancer cell digest 
samples, showing the characteristic losses for phosphopeptides under IRMPD fragmentation (-
80Da and -98Da), the resulting peptides could then be easily identified via accurate mass and/or 
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MS/MS fragmentation to readily reveal the identity of all fragmented phosphopeptides in the 
proteomic sample, a comparison of this with the untreated cell digest could reveal differences in 
cell signalling due to metallodrug exposure. 
Precursor ion scans revealing the precursors responsible for a given fragment ion can also be 
extracted if needed, this has the potential in future to be a useful marker for charged-metallodrug 
modifications which are easily lost in CAD/IRMPD (e.g. the Os1 and metal-bound iridium drugs 
shown in Chapters 4 and 6 respectively). Metallodrugs which dissociate and produce a detectable 
peak of their own could be extracted by a precursor ion scan, instantly identifying all species 
modified by the metal complex in that fashion, in a similar way to the phosphorylated peptide 
method discussed above. ECD-induced side chain losses could also be used to effectively identify 
modified amino acids (e.g. oxidised methionine produced by FM190) and to identify different 
metallodrug modifications showing unique side-chain/bound ligand losses under ECD MS/MS, as 
shown for FM190-induced modifications, and for Ir1, Ir2, Ir3 ECD MS/MS, and for Os1-DNA EDD 
MS/MS in previous chapters. The unique, but usually challenging metal-induced side chain 
losses/unique fragmentation pathways under ECD/EDD/ExD fragmentation may finally be exploited 
as characteristic identifiers for metal-modified species using 2D-MS. 
Effective mathematical peak-picking, calibration, and automated interpretation of 2D-MS data is 
underway, with the goal of automatically picking and assigning peptide/modified peptide species via 
standard proteomic tools (such as MASCOT searches etc.), in a similar way to LC-MS data. 
Advancements will enable interpretation 2D-MS proteomic data and characterisation of the 
biomolecule species observed, these will be applied to the results presented herein at the earliest 
opportunity. The possibility exists for future advancement in 2D-peak picking to apply a similar 
isotope searching method as used in the SNAP-LC MS methodology (above), to search 2D-MS data 
and be able to detect metal-bound/target-bound species and reveal metal-interactions and changes 
inside cancer cells both for natural and administered metals/target elements. 
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Chapter 10:  
Conclusions 
Over the course of this thesis work, many different systems have been tackled and studied using a 
range of Mass Spectrometry-based techniques, all with the overriding goal of being able to study 
metallodrugs and their interactions with biomolecules. This chapter introduces, summarises, and 
outlines the study, advancements, and conclusions of each of the results chapters discussed 
previously and what has been gained through these studies for the wider goal and use of this work. 
Chapter 3: Multi-targeted Photoactivatable Platinum Anticancer 
Complexes 
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The first of the results chapters focused on the study of a novel photoactivatable platinum(IV) 
complex (codenamed FM190) and its reaction products under activation with blue visible light 
(463nm) while in the presence of model peptide biomolecules (Substance P and [Lys]3-Bombesin). 
The reactions caused an unexpectedly large number of reaction products, modifying the peptide 
species with both platinum metal complex modifications and oxidation products. The Pt(II) 
modifications were shown to be influenced by the sequence of the biomolecule present during the 
photo activation process, with [Lys]3-Bombesin+FM190 solutions producing more expected bi-
pyridine functionalised modifications, but a major proportion also unexpectedly retaining one azido 
group functionality, despite the belief that both azido groups were released during Pt(IV) complex 
photo activation. Reactions of Substance P and FM190 with blue visible light produced an array of 
unexpected reaction products, many of which not retaining the two pyridine ligands on the Pt(II) 
centre, and many retaining azido functionalities, showing that the biomolecule binding to the Pt 
centre once activated/during activation has an impact on the photo activation process and the 
stable reaction products formed.  
High levels of biomolecule oxidation were also induced by activation of the Pt(IV) compounds, 
representing a metal-independent mechanism of attacking target biomolecules/cells. This oxidation 
was then located using MS/MS techniques within the FT-ICR MS, and was found to be targeting the 
methionine and tryptophan residues within the peptides. Methionine oxidation is routine and 
expected with many oxidation mechanisms. However, it was found that tryptophan oxidation in 
particular could be utilised as an indicator for the mechanism of oxidation. Different reaction 
products can be formed from the oxidation of tryptophan residues within poly(amino acids) and the 
products formed inform us of the species causing the oxidation – either singlet oxygen or hydroxide 
radicals. It was found that due to the products formed that the biomolecule oxidation was being 
formed by hydroxide radicals, which could be released during photo activation. This extensive, yet 
previously unobserved, oxidation (up to 3 oxidations in the 11/14 amino acid peptides) was not only 
an interesting additional mechanism of action against cancerous cell components, but could also be 
442 
 
a way of circumventing platinum resistance in cancerous cells, and a metal-independent way of 
increasing ROS and inducing apoptosis/cell death when and where desired using photo activation. 
Surprisingly, release of the azido ligands during photoactivation did not result in any azide-modified 
biomolecules, despite the expectation that such reactive species could easily modify various 
functional groups/areas within the peptides. 
MS/MS analysis of the platinum-containing species proved challenging, with more common CAD and 
IRMPD MS/MS techniques causing dissociation of the platinum complex modification. Unfortunately 
unlike the fragmentation these MS/MS techniques cause to fragile PTM’s such as phosphorylation, 
slow-heating MS/MS of the platinum modifications caused partial damage to the complex 
modifications, meaning dissociation of bound ligands, but not usually the Pt metal centre. The 
dissociation of ligands caused the creation of an extremely reactive platinum centre which was then 
believed to bind to any viable functional group along the peptide structure rapidly, causing cyclic and 
complex species, which were subsequently dissociated during the ergodic dissociation mechanism, 
causing complex sequence-scrambled MS/MS data and no sequence informative fragments. Thus it 
was quickly obvious electron-based MS/MS dissociation techniques were required. ECD was 
employed to fragment and characterise every available reaction product in the two reaction 
mixtures. ECD MS/MS showed that in the [Lys]3- Bombesin the metal complexes preferred to bind to 
the available histidine11 residue regardless of the structure/ligand combination of the Pt(II) 
modification. When FM190 was activated in aqueous solutions of Substance P, no histidine amino 
acid residue was present and the Pt(II) modifications were shown to preferentially bind to the lysine3 
amino acid residue, despite the availability of a terminal methionine residue, which is in stark 
contrast to all previous platinum-based metallodrugs studied, again representing key differences 
between traditional Pt(II) solution activation and the Pt(IV) photo activation mechanisms of action 
against biomolecules.  
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FM190 activity against cancerous cells was previously shown to be drastically affected by addition of 
free radical trapping agents (free tryptophan) during photoactivation. This control over the 
photoactivation process was believed to be utilisable as a “switch” for activity. The addition of free 
Trp during photoactivation of FM190 in the presence of the model biomolecules was also studied. 
The radical trapping agents had a drastic subduing effect on the abundances of products formed (up 
to 98% reduction in some species), with some Pt modified species affected more than others, and 
the oxidation products affected substantially less than the platinum-modified species. Indeed Trp 
could be used to affect the products formed, but only certain species were subdued, which could be 
correlated with the reduced biological activity and highlight particularly critical/active modification 
species key to killing cancerous cells. 
Platinum modifications bound to the biomolecules studied were shown to have drastic and unique 
effects on ECD fragmentation mechanisms, which for the most part complicated and hindered 
analysis of subsequent ECD MS/MS spectra and sequencing efforts. However after elucidation of 
certain fragmentation mechanisms it was also apparent that the unique losses observed during ECD 
MS/MS were driven from electrons captured/transferred to the platinum metal centres, causing 
ligand dissociation, and so could be used to identify platinum bound ligands and provide 
modification information. In addition the platinum modifications caused previously unobserved 
metal-enhanced ECD amino acid side chain losses, which provided information of amino acid groups 
within close proximity to the modifications present.  
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Chapter 4: Organo-Osmium complex-DNA interactions by FT-ICR 
MS/MS 
 
It has been shown that upon administration of the most common anticancer metallodrugs over 90% 
of injected compound becomes protein bound within just 24 hours in vivo. The majority of this 
peptide/protein metallation is believed to be deactivating and preventing the compounds reaching 
their target; cancerous DNA. Should the metallodrug be able to reach DNA it will bind and cause 
deformations in tertiary structure, preventing replication and/or inducing apoptosis/cell death. 
These metallodrug-DNA interactions have been well studied and characterised for traditional Pt(II) 
compounds such as Cisplatin, Transplatin, and Oxaliplatin. Platinum(II) compounds are now well 
known to bind preferentially to guanine residues, and can form inter-chain  bonds via two guanine 
nucleotides, and even intra-strand crosslinks in a similar fashion. However novel metallodrugs such 
as those based on different transition metals to Pt(II) and with different geometries than the square-
planar Cisplatin analogues have been shown to offer impressive potencies even in the face of 
cisplatin resistant cell lines, these drugs are believe to use different mechanisms of action against 
cancerous cell components, but these mechanisms are not fully understood, limiting drug 
development.  
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Although great proportions of many drugs react with peptides/proteins before reaching DNA, study 
of metallodrug-biomolecule interactions was extended to interactions with DNA (oligonucleotides) 
in order to study how these novel drugs will interact with their targets, if they should survive the 
journey. A novel osmium-based piano stool compound (Os1) was reacted with an extensively 
purified and isolated DNA 12-mer. The resulting reaction products were analysed by nESI-FT-ICR MS 
in the negative mode. Osmiated DNA was immediately assignable due to the osmium metal impact 
on the DNA isotopic distribution. It was found that the Os1 drug could bind to the DNA species two 
times producing the mono and di-osmium drug bound species. Both modified and unmodified DNA 
12-mer species were then isolated in the FT-ICR MS instrument and fragmented using a variety of 
MS/MS techniques, namely CAD, IRMPD, and EDD. Unlike poly(amino acids) DNA can acquire 
extremely high charge states (per monomer unit) and can thus be very fragile when within the mass 
spectrometer. This fragility in the gas phase, though in striking contrast to DNA stability in the 
body/solution, creates challenging situations for effective transmission and analysis. DNA ions also 
fragment readily using collision based dissociations such as CAD MS/MS, producing a wide array of 
fragments (47 assigned fragments for the 12-mer) and excellent sequence coverage (100% of 
available backbone cleavage locations). IRMPD produces similarly informative spectra. However 
these slow heating MS/MS techniques also caused extensive loss of the osmium-based modifications 
during MS/MS of the osmiated DNA species. Loss of the modification not only hinders location of the 
modification using the few remaining osmium-containing fragments, but also causes conflicting 
fragment productions, some with the remaining modification, some without. Electron detachment 
dissociation was then used to assist in the study. EDD requires very fine tuning of many instrument 
parameters, both relating to the electrons produced, and the ICR cell containing the target ions, but 
once carefully optimised can provide extremely informative data. EDD MS/MS enabled the effective 
fragmentation of the osmiated DNA species, without the loss of osmium modification followed by 
secondary fragmentation which hindered previous CAD and IRMPD MS/MS analysis. EDD also 
allowed the elucidation of two separate species within the same MS/MS spectrum; one a DNA 12-
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mer with the osmium metallodrug bound at the guanine, and the other with the Osmium drug 
bound at the cytosine, a previously unobserved target for osmium compounds. EDD analysis of the 
di-osmiated DNA species proved ineffective, producing MS/MS spectra characteristic of electron-
based MS/MS of cyclic species. This cyclic-biomolecule behaviour was believed to be due to the two 
osmium metallodrug bound at opposing ends of the biomolecule, but interacting in a pi-pi stacking 
arrangement via the biphenyl rings attached to each drug, the conclusion was supported by H-NMR. 
CAD MS/MS was effective at breaking these pi-pi interactions first, and then breaking apart the DNA 
backbone subsequently. Although CAD MS/MS of the di-osmiated DNA suffered similar problem as 
in the mono-osmiated species, it was able to provide enough osmium location information to 
support the previous findings that the osmium modifications were binding to the guanine and 
cytosine sites simultaneously. Thus it was obvious that a multi-platform MS/MS approach was 
needed to study these metallated DNA species in the gas phase, but was possible using FT-ICR MS. 
FT-ICR MS was also able to effectively resolve the complex MS/Ms fragmentation patterns produced 
during DNA fragmentation, with mass differences between certain assignments as little as <8mDa. 
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Chapter 5: Further DNA-metallodrugs investigations 
 
Following the success of the osmium-DNA study using CAD, IRMPD, and EDD MS/MS a study of DNA 
interacting with the platinum compound FM190 (from Chapter 3) was undertaken. The 
photoactivatable platinum compound was activated using blue visible light (463 nm) while in the 
presence of the DNA 12-mer used in Chapter 4 (TAGTAATTACTA). The FM190 compound was shown 
to bind to the DNA species extremely quickly, even more quickly than with the peptides. In less than 
30 minutes over 95% of the DNA had been modified with platinum species, producing a range of 
modifications similar to those observed in the FM190-peptide reactions. The species observed all 
retained the bi-pyridine functionalities as expected, but varied in the remaining ligands. Each species 
was then isolated and fragmented using CAD, IMRPD, and EDD MS/MS, in a similar fashion to the 
osmiated DNA. The FM190 compound was shown to bind to guanine nucleotide bases in a mono-
dentate fashion. While those Pt-based modifications studied with two biomolecule binding points 
were believed to be bound at the Guanine nucleobase and the Cytosine/Adenine bases. Though CAD 
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MS/MS caused partial dissociation of the platinum-based modifications, in a similar fashion to both 
chapters 3 and 4, EDD MS/MS was also found to be hindered/complicated by the platinum metal-
centre bound to the oligonucleotides. 
The vast increase in reactivity for FM190 to bind to DNA compared to peptides and proteins was in-
line with previous data and the ideal mechanism of action, with the platinum drug attacking 
cancerous DNA preferentially over peptide and protein biomolecules. However the expected and 
famous platinum-induced inter-strand DNA crosslinks were conspicuous by their absence. The lack 
of crosslinked species was also accompanied by lack of biomolecule oxidation, which was rife in the 
FM190-peptide reactions observed in Chapter 3. The mechanism of activation/biomolecule binding 
with DNA species was clearly very different to that of the platinum compound when activated in the 
presence of peptides. 
Although the analysis and characterisation of metallodrug-DNA interactions using isolated DNA 
strands was effective and provided unique insights into the mechanisms of action for both the 
osmium and photoactivatable platinum compounds studied herein, it was the reaction with single 
stranded DNA. DNA usually is present within the nucleus of cells in a duplex helical form, with two 
complementary strands coiled around each other via hydrogen bonds between nucleotide base 
groups, thus the reactive bases are often shielded to some degree from nearby metallodrugs, the 
notable exception to which is the N7 of guanine. In order to study the effects of metallodrugs on 
representative DNA structures and provide insights into mechanisms which were similar to in vivo 
activity the possibility of studying duplex DNA by nESI-FT-ICR MS was investigated. This “native DNA” 
experiment was unfortunately not as simple as native MS analysis of many proteins, where the use 
of non-ideal ESI buffers (with respect to ionisation/charging efficiency) can stabilise protein structure 
enough to provide a representative structure in the resulting protein ion to determine structural 
features via subsequent MS/MS analysis. Usually the use of high-concentration ammonium acetate 
(e.g.10-200 mM) buffer, low source temperatures and carefully tuned instrument optics can allow 
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protein structure to survive ionisation and transmission/detection during ESI/nESI-MS analysis. 
However these tactics were ineffective at producing duplex DNA ions. Work by Gabellica et al. had 
shown that stabilisation of DNA-G-quadruplexes was possible through the use of high-concentration 
aqueous potassium solutions (1-2mM) to produce ions charged purely by potassium during positive 
mode ESI, mainly [DNA+2K]2+ species. This approach was applied to the ionisation and study of the 
DNA 12-mer. Using nESI buffers containing both 200 mM ammonium acetate and 1 mM KCl salt, it 
was shown that the production and observation of DNA duplex ions was possible by nESI-FT-ICR MS. 
These DNA duplexes were present at high intensity, but also with many, many salt adduct peaks due 
to the added KCl. Despite the spectral complexity caused by many adduct distributions, duplex-DNA 
species were isolated using the quadrupole in the hybrid FT-ICR MS and then fragmented using CAD 
to break apart the duplex strands selectively. Low-energy CAD dissociated the duplex without 
causing extensive backbone fragmentation. MS/MS analysis was then performed on the resulting 
single-stranded DNA species using ECD MS/MS, providing MS3 analysis for duplex DNA 
characterisation. MS3 via CAD and ECD was shown to provide sequence informative fragmentation of 
the single stranded DNA from the duplex architecture. Thus this methodology would be a viable 
technique for studying metallodrug-DNA interactions in the native/duplex state and provide a more 
accurate reflection of reactions in vivo. Additional experiments using magnesium ions should be able 
to assist in such studies in future investigations as they are the ions utilised by cells to stabilise DNA 
tertiary structure, work to this end in ongoing. 
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Chapter 6: Studying electron-quenching iridium compounds 
 
Metallodrug-biomolecule interactions are predominantly based around reaction of biomolecule 
functional groups (such as methionine sulphur/histidine nitrogen lone pairs) binding directly to 
available metal centres in a dative covalent bond fashion. Such is the case for both traditional Pt(II) 
compounds, photoactivatable Pt(IV) compounds such as FM190 (Chapter 3) and the osmium 
metallodrug (Os1) studied in Chapter 5. The reactivity and preferential binding site for the metal 
centre can be tuned by variation of the ligands used and their configuration/orientation, but for the 
majority of cases it is the metal centre where the reaction/binding takes place. 
However the metal-bound ligands also present an opportunity for functionalisation and can be 
modified to include reactive groups/sites of their own. Functionalised small molecules have been 
shown to be able to target specific residues in peptides and proteins, and to bind preferentially to 
specific sites in DNA strands. Thus functionalising metallodrug ligands could be a way of directing 
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these compounds to specific targets, and so enhancing their selectivity and enabling binding to 
specific target sites.  
A series of aldehyde-functionalised ligands were used to create a range of Iridium(III) based piano-
stool metallodrug compounds with either 0, 1 (2 isomers), or 2 aldehyde functional groups. These 
aldehyde functionalities present the possibility for condensation reactions with primary amine 
groups available from peptides/proteins, and so can form imine linkages between the metallodrug 
and target biomolecules.  
Two model peptides were chosen for the initial study; Substance P and [Lys]3-Bombesin. Indeed 
upon incubation with any of the 3 aldehyde-functionalised iridium metallodrugs, a condensation 
reaction occurred between the aldehyde functional group and an amino acid residue. Reactions with 
substance P followed by nESI-FT-ICR MS analysis showed near complete reaction within just 24 hour 
incubation at 37oC. Reactions of the Ir compounds with [Lys]3-Bombesin produced both a 
condensation product and a non-condensation product (metal complex bound to biomolecule 
without water loss and imine formation). Subsequent MS/MS analysis of the iridiated peptides 
proved unusually challenging, even for metallodrug modified biomolecules. ECD MS/MS, usually 
being the first choice for such analysis, was shown to be drastically hindered due to 
quenching/stabilisation of captured electron by the covalently bound iridium modification in the 
condensation product, producing charge reduced species (parent ion after subsequent electron 
capture) of extremely high intensities compared to what is observed in the unmodified peptide ECD 
MS/MS; 150-250% relative intensity to parent ion against the usual 10-20%. This stabilisation or 
quenching of ECD electrons hindered effective ECD MS/MS and subsequent analysis greatly, but was 
shown to be possible using very carefully tuned ECD and ICR cell parameters, the slightest deviation 
from which would cause large drops in already low (<1%) fragment intensity and/or loss of certain 
fragments, limiting sequence/cleavage coverage. Despite these challenges the modified 
biomolecules were successfully fragmented using ECD MS/MS and the imine-bound iridium 
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modifications were located on the Lysine3 residues of both substance P and [Lys]3-Bombesin. ECD 
MS/MS analysis of the metal-bound iridiated biomolecules showed similar challenges of iridium ECD 
electron quenching, however upon electron capture and without the tethering imine bond, the 
capture/transfer of the ECD electron to the Ir centre caused dissociation of the iridium 
modifications, hindering analysis. However the use of carefully tuned ECD and ICR cell parameters 
enabled effective ECD fragmentation, while retaining enough of the Iridiated fragments to accurately 
locate the Ir binding location to the histidine11 residue in [Lys]3-Bombesin. CAD MS/MS was also 
attempted on the iridiated biomolecules. CAD MS/MS caused dissociation of the metal-bound 
iridium modification long before fragmentation of the peptide backbone could occur, and so 
produced no sequence informative fragments to lead to the modification’s location. CAD MS/MS of 
the imine-bound iridiated peptides proved extremely fruitful, with the imine linkage tethering the 
iridium complex to the biomolecule, and thus allowing normal CAD MS/MS trivially, effective 
fragmentation of the peptide backbone and location of the imine bound species was successful. The 
presence of the fixed charge site at the iridium centre was shown to alter the fragments produced 
and observed in both CAD and ECD MS/MS. In addition the iridium modification was shown to 
produce unique CAD and ECD MS/MS fragments/side chain losses, showing an influence on the 
fragmentation mechanisms beyond electron quenching. These unique fragmentation channels could 
be used to help identify iridium ligands present, given a high enough mass accuracy, which FT-ICR 
MS can offer. Careful calibration was also shown to be critical in assigning these novel iridium 
modifications and fragmentation channels, with deviations of less than an electron in mass being 
unacceptable, examples of the level of discrimination needed were investigated. Reactions of the 
iridium metallodrugs were also carried out on model proteins (lysozyme, myoglobin, and BSA) and 
showed similar condensation product formation as with peptide reactions. Information gathered 
within this chapter later informed experiments in Chapter 9 and enabled advances in scaling up 
metallodrug-biomolecule reactions to proteome level analysis. 
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Chapter 7: Superacid Supercharging of analytes using CH5+  
 
The analysis of all species by mass spectrometry relies on the effective ionisation of analytes of 
interest. In particular electrospray ionisation has become the ionisation method of choice for the 
majority of biomolecule analysis. Due to its ability to ionise peptides, proteins, and various other 
biomolecules into multiply charged species, instead of purely singly charged ions as with MALDI and 
CI, ESI and its variants have allowed the analysis of extremely large species by lowering the mass to 
charge ratio (through high charge states) into a more convenient and easily detectable region. 
Another key benefit of higher charge states for biomolecule MS is the increased efficiency and 
sequence coverage gained from conducting tandem MS on high charge state precursors compared 
to their low charge state equivalents. The increased cleavage coverage and fragment ion abundance 
greatly assists in characterising these species, which becomes more challenging as the parent ion 
mass increases. 
Thus it is of ubiquitous benefit to biomolecule analysis to explore the possibilities of enhancing the 
charge state magnitude during the ionisation process. Great strides towards this goal have already 
been achieved, mostly via the use of solution phase additives which alter the surface tension of 
droplets formed during ESI. By increasing the surface tension of droplets, it was shown that the 
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charge density of the droplets could be increased and the resulting protein ions formed were of 
higher charge states than before. These so-called “supercharging agents” have greatly assisted 
biomolecule characterisation, both offline through direct-infusion ESI, and online through LC-ESI-MS 
experiments. The increased availability of higher order charge states increases fragmentation 
efficiency and sequence coverage during MS/MS experiments and since all MS detectors are 
inherently more sensitive for higher charge states, these techniques can also increase the sensitivity 
of measurements.  
Though Chemical supercharging agents have been investigated for several years now, and have 
shown great improvements to MS and MS/MS analysis, they are not commonly used techniques as 
individual additives do not effectively supercharge all analytes and can have negative side effects, 
such as contamination, decrease in ESI spray stability, and disruption of delicate non-covalent/fragile 
interactions/PTM’s. As a result there is still a desire to find new ways to access these higher levels of 
charging in a more direct, commonly implementable fashion, with or without the use of solution-
phase supercharging additives such as sulfolane or m-NBA. 
Chemical ionisation utilises CH5+ ions created by passing methane gas through an electrical discharge 
region. These CH5+ ions are incredibly acidic and have extremely low proton affinities, so much so 
they have been termed “superacid” ions, and are able to transfer protons to even non-polar entities 
in order to create ions. Unfortunately chemical ionisation is notoriously reliable for producing only 
singly charged ions, despite the use of such potent acidic reagents such as CH5+. If the proton 
transfer power of CH5+ could be combined with the multiple-charging capability of ESI, then it might 
be possible to enhance the ionisation and charging of biomolecule analytes into higher charge 
states. 
To this end, the novel ESI-APCI supercharging source was developed, over many design iterations, 
the eventual course was able to effectively introduce CH5+ ions created from a glow-discharge 
chamber orthogonal to the ESI needle and with proper optimisation could direct them towards the 
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ESI droplets formed during nebulisation. The effect of the CH5+ ion s interacting with the ESI droplets 
was the enhancement of charge of protein analytes in the positive mode. Great increases in the 
charge states for a range of protein-containing solutions was achieved, for a range of solvent 
conditions, including aqueous samples, denatured protein samples, and even high concentration 
ammonium acetate for so called “native MS” protein samples. All showed enhanced charging due to 
the supercharging source via CH5+ ions. The benefits of using the supercharging source against 
solution phase additives induced; no additional sample preparation steps to optimise the volume/% 
of solution phase additive to add, the use of buffer/solution conditions is not affected by the 
supercharging reagent, increased charge states for proteins and peptides, increased intensity for 
small molecules, easily interfaced with existing LC systems, without addition/change of elution 
buffers, and enhanced MS/MS fragmentation efficiency and sequence coverage to name a few.  
The ESI-APCI source was shown to be most effective on denatured biomolecule samples, most likely 
due to the open protein structure exposing possible protonation sites, and allowed observation of 
many more charge states for the myoglobin protein (maximum charge state increase from 17+ to 
25+). Native MS samples benefitted from the supercharging mainly via increased intensity of the 
currently observed charge states, with large increases of over 500% measured, but no new charge 
states were observed, this is believed to be due to the folded tertiary structure of the proteins 
chosen with only a limited number of charge sites available. Small molecule supercharging showed 
intensity increases of nearly 300%. 
Theoretical modelling calculations were then undertaken to investigate the possible factors and 
mechanisms involved in the interaction of CH5+ ions and charged ESI droplets. The interaction of the 
two positively charges entities instantly suggests a repulsive force between the two, but the MS data 
clearly showed an interaction. A pure electrostatic model was first investigated which consisted of 
randomly populating a sphere of a given diameter with a number of positive charges up to the 
Rayleigh limit for the droplet size. A point charge (CH5+ ion) was then introduced and the 
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electrostatic interaction between the CH5+ ion and every individual charge on the surface of the 
droplet was then calculated and summed together. The charge was then moved closer and the 
process repeated and iterated until the two were touching. The electrostatic model gave a 
predictable constantly increasing repulsive force, tending towards infinity at the point of contact. 
Though simplistic the model shows that there should be a high repulsive barrier to interaction 
between the two entities. A particle-particle dielectric model was then undertaken to account for 
the orientation of water molecules within the ESI droplet at low separation distances, and showed 
that at low charge density the repulsive barrier can revert and become attractive as the CH5+ ion 
moves close enough to the droplet to re-orientate the water molecules, repelling the δ+ hydrogen 
atoms and exposing the CH5+ ion to the δ- oxygen lone pairs, creating an attractive force. This model 
was promising and helped explain the MS data acquired, though it was quickly shown that at higher 
charge densities this effect was negligible and although the particle-particle model showed a slower 
increase in repulsion between the 2 entities, the repulsive force still increased dramatically at 
shorter separation distances. As a result it was believed that the interaction of CH5+ ions with ESI 
droplets must occur at lower charge densities and well before the droplet reaches its Rayleigh limit.  
The supercharging ESI-APCI source was successful in assisting protein ionisation and could assist in 
subsequent MS/MS fragmentation and characterisation of biomolecules, and possibly metallodrug-
modified biomolecules in the future. The use of supercharging instrumentation over the solution 
phase additives offers potential advantages for metallodrug modified species, especially the lack of 
changes to the solution conditions, as it has been shown many times, both within this thesis and 
without, that the addition of other solvents can easily disrupt/alter the metallodrug-biomolecule 
interactions, displacing modifications/altering equilibria and eliminating the chance of truly 
representative analysis. The supercharging ESI-APCI source could be a path to assisting 
characterisation without such disruptions.  
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The source has already found additional use in further investigations into CH5+-assisted ionisation 
and supercharging for other projects, and has been shown to drastically increase the fragmentation 
efficiency for protein MS/MS.  Detailed tandem mass spectrometry techniques and analysis have 
already been undertaken to investigate the effect CH5+ ions and other supercharging agents have 
upon protein structure; the work is ongoing. The source also holds the potential to readily be 
coupled to liquid chromatography and assist in the ionisation and supercharging of eluted 
biomolecules, potentially enhancing the characterisation of entire proteomes by increased 
sensitivity and MS/MS efficiency already confirmed for protein MS and MS/MS respectively, this 
could also help overcome various issues associated with true top-down proteomics, such as low 
intensity precursor peaks, and lack of fragmentation efficiency. 
Chapter 8: The Rhodium revolver  
 
Novel metallodrug compounds are often shown to be very reactive towards biomolecules (as shown 
in previous chapters), however they can also be used to catalyse unique and seemingly unlikely 
reactions by utilising the unique chemistry of the metal centre and ligand combinations. As was the 
case for the rhodium-based compounds studied in Chapter 8, all of the species were shown to be 
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able to exchange the hydrogen atoms bound to the methylated cyclopentadienyl ring of the piano-
stool complexes with deuterium atoms from deuterated solvent species. A simplistic view of this 
reaction is that it is synonymous with widely used Hydrogen-Deuterium Exchange (HDX) reactions in 
protein analysis MS and MS/MS. However, unlike protein/biomolecule HDX, the exchange occurring 
within the rhodium compounds was centred around the deprotonation of methyl groups and a 
thermodynamically beneficial substitution with deuterium atoms, a particularly unique and 
previously unobserved phenomenon. These reactions were then followed using a variety of 
techniques, including nESI-FT-ICR MS, to show that the exchange of the hydrogen atoms was 
sequential and complete exchange of all methyl-bound hydrogen atoms could occur in less than 1 
hour at room temperature and pressure, a remarkably fast reaction for such unreactive hydrocarbon 
groups. This study quickly expanded to similar rhodium piano stool complexes, 10 in total, with 
varying ligand configurations and sizes, extending the aromatic ligand system of the piano-stool 
complex, and varying bidentate ligand identity to probe then extent of HDX, and the reactive area 
accessible from the metal centre, which was believed to be critical for this exchange process. It was 
shown that all rhodium piano-stool complexes were able to undergo HDX reactions while in 
deuterated solvents, to varying degrees depending on the ligand structure, with groups close to the 
rhodium centre being substituted effectively, while those further away remaining unsubstituted. 
Molecular modelling of the reactions by collaborators showed that the process was most likely 
proceeding through a deprotonated cyclopentadienyl ligand intermediate, causing a C=CH2 bond 
between the ring and deprotonated methyl group. This C=CH2 bond could then react with 
deuterated solvent bound to the rhodium centre and cause a deuterium atom to re-saturate the 
hydro carbon into a CH2D group and so on until complete deuteration of the groups was achieved. 
This process was attempted on an analogous iridium compound with identical ligands to that of the 
first Rhodium compound studied ([(Cp*)-Ir-(Bipy)Cl]. Iridium being directly below rhodium in the 
periodic table seemed as though it may be able to reproduce this effect, but to no avail, the 
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compound remained fully hydrogenated despite days in deuterated solvent, truly this appeared to 
be a rhodium-specific reaction. 
Though not directly related to their interaction with biomolecules, the rhodium revolver reactions 
serendipitously provided a method of effectively tagging rhodium species with deuterium atoms 
easily and quickly. The deuterated rhodium compounds were shown to remain deuterated once 
placed in pure H2O, with no back-exchange to hydrogenated species even after 7 days. The HDX 
products were obviously more thermodynamically stabilised than the original complexes. This stable 
isotope labelling strategy enables the possibility of exploiting these effects via MS analysis and 
tracing of the compounds , possibly in vivo. By mixing a known proportion of H15 and D15 (all 
deuterated) Rhodium complex, a characteristic pair of isotopic distributions would be observed 
during ESI/nESI-MS, separated by ~15 Da. This mass difference could then be tracked using isotopic 
search algorithms (see Chapter 10) and used to track the distribution of the drug in vivo and possibly 
to help identify biomolecule targets. Usually this sort of isotopic labelling is not required for analysis 
of transition metal-containing species, as many already possess a unique isotopic pattern, however 
certain elements (such as rhodium) express only one stable isotope and so are not amenable to this 
analysis and tracking. The rhodium revolver HDX strategy provides and alternative, effective, and 
fast way of inducing unique and traceable isotopic distributions using just deuterated solvent. nESI-
MS of rhodium-based metallodrugs was also shown to be affected by metal complex-specific 
phenomena during ESI/nESI based ionisation, namely loss of bound negatively charged ligands 
during the ionisation process. The loss of (negatively charged) ligands during ionisation often 
resulted in the increase of charge of the analyte species, enabling detection, the driving force of 
which was attributed to the electric field imposed to enable ESI/nESI. Such affects were documented 
and followed the trends observed in Chapter 6 for iridium-based compounds. The same trends were 
not observed for the square planar Pt(II) complex modifications observed in Chapter 3, showing 
again the influence of inorganic/organometallic chemistry of metal centres on the process.   
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Chapter 9: Scaling up to proteome wide investigations 
 
Chapters 3-6 were focused on the detailed characterisation of isolated biomolecule and metallodrug 
interactions in order to study the novel compounds being developed to combat cancer. These in 
depth studies provide the detailed chemical information about metallodrug behaviour and allow 
knowledge and tactics for effective MS and MS/MS characterisation, which can often be much more 
challenging than unmodified biomolecule MS analysis. However this has all been done with the end 
goal of scaling up these isolated biomolecule studies into effective and accurate strategies to 
tackling proteome-wide characterisation of biomolecules in cancerous cells and to provide insights 
into cellular changes due to metallodrug administration. This proteome-wide information would be 
able to provide the information needed on the impact of individual metallodrugs, to see which 
pathways the drug is interrupting/amplifying and to see how the cancerous cells respond to these 
foreign agents and finally provide the critical data needed for better intelligent drug design. 
Unfortunately although MS-based proteome characterisation has been well established in recent 
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year and is now able to provide proteome information readily, the addition of metallodrug 
modification greatly complicates the task and introduces challenges in not only performing the 
analysis but mainly in retaining the unique metal-based modifications and providing accurate and 
reliable analysis which is able to compensate for these non-standard entities. Without these 
alterations to strategies the usual, and readily available, techniques, methods, and subsequent data 
analysis would be possible, easily achievable, but would drastically misrepresent the sample and 
would not provide the accurate information needed to the level MS is known to be able to achieve 
with the correct care and strategy.  
The final chapter of the thesis brings together the information  gathered in the detailed MS and 
MS/MS studies from previous chapters and applies them to the idea of moving on to larger, 
biological scale systems, the methods available, how they may be adapted for metallodrug-
containing samples, and what complementary information these tools can provide. The first section 
deals with the challenge associated with identifying which peaks have been modified by metal-based 
compounds, and then accurately assigning a mass to them, which is unfortunately impossible using 
the standard automated peak picking associated with LCMS for proteomics. The second section 
explores the use of a new MS/MS technique to characterise complex mixtures of biomolecules 
without using chromatographic separation, 2-Dimensional Mass Spectrometry, offering not only a 
different way to analyse the complex proteomic mixtures, but also to avoid the disruption of 
metallodrug-modifications which occur during chromatographic separations and to avoid the time-
scale limitations of LCMS analysis on FTMS instruments. 
The main barrier preventing the use of standard proteomic strategies for the characterisation of 
metallodrug modified proteomes are the use of organic solvents and acids which can disrupt 
metallodrug-biomolecule interactions, and the unique, but complex isotopic patterns of transition 
metals influencing biomolecule MS signals, preventing standard peak picking algorithms from 
assigning accurate masses to detected peaks. 
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The first strategy to accurately achieving proteomic analysis of metallodrug-modified proteomes was 
based on LC-MS for separation and tandem mass spectrometry characterisation, in a similar fashion 
to standard proteomic analysis, with the main goal of combatting the metal element influence on 
isotopic distributions. Every individual element has a number of stable observed isotopes, the 
combinations of which influence the overall distributions of isotopologues observed in MS spectra, 
these are predictable and often very easily calculated. However transition metals often have many 
more isotopes, in varying ratios, than the standard CHNOS elements observed in poly(amino acid) 
MS and MS/MS. Standard biomolecule and proteomic peak picking algorithms are designed to either 
pick all peaks observed in a spectrum for database searches, or are designed to analyse peak 
distributions, assume CHNOS compositions, and assign monoisotopic masses for more accurate 
assignments when searching databases thereafter. The more complex isotopic patterns of transition 
metals are not compatible with either of these approaches, with the first leading to many 
assignments for each isotopic distributions (for example for 6/7 observable osmium isotopes 
broadening the usual isotopic pattern), and the second leading to fewer, but still multiple 
assignments at the wrong m/z values as it will ignore isotopologues which increase in abundance 
with increasing m/z (the reverse of usual CHNOS species), and/or would pick out many peaks each as 
a new species due to the expectation and bias of CHNOS predictions. Though they may seem simple 
data analysis issues, the accurate peak picking and assignment of species is the cornerstone of 
effective LCMS characterisation of proteomes, without it the data collected will at the very least be 
not fully interpretable while at most (and much more likely) lead to extremely erroneous outcomes, 
completely misrepresenting both the data and the proteome, which can have large negative effects 
in drug development processes if trusted. In order to be able to assign accurate masses to metal-
containing peaks, but also to identify them in the first place, these isotope distributions needed to 
be taken into account.  
Despite all of the challenges faced in the study of the metallodrugs and the metallodrug-modified 
biomolecules studied over the course of the Chapters, one of the few advantages of metal-
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containing species was that the unique and characteristic isotopic patterns immediately revealed the 
presence of the metal centre. This influence could then be exploited to assign metal or non-metal 
containing peaks, and if this could be done over an entire LCMS chromatographic run then all of the 
metal-containing LC peaks could be revealed. If these isotopes could then be taken into account 
when assigning these species then accurate masses could then be assigned autonomously, 
circumventing the assignment-accuracy issues of metallo-proteomics.  
To this end isotopic prediction algorithms have been modified to include metal isotopic patterns and 
generate metal-matched peak spectra by Bruker Daltonics. These algorithms were originally 
designed to accurately assign unmodified biomolecules, but were easily modified for metal species. 
The use of these peak picking algorithms was shown to be extremely effective at discriminating 
metal-containing peaks for normal MS scans. However LCMS runs contain many thousands of 
individual MS spectra. The goal was to apply the algorithm to each spectrum in turn and plot the 
presence of metal containing species in each LCMS data point, once iterated through the thousands 
of spectra contained within the run all metal-containing LC peaks were revealed to high accuracy. 
This analysis was specific to the type and number of transition metal centres desired, with custom 
isotope distributions able to be programmed in as desired. The SNAP-LC algorithm developed was 
altered through several designs to achieve accurate assignment of metal containing peaks only, and 
to enable desktop computers to be able to process the many thousands of spectra without memory 
issues. In addition the algorithm was attempted on both nLC-UHR- FT-ICR MS data acquired and nLC-
HR-ToF-MS data; it was shown that although viable on both platforms, the isotopic searches 
required high-resolution separation between isotopic peaks, and suffered with lower resolution data 
where individual isotopes may not be completely resolved from one another. Regardless there were 
no issues when using UHR data, and attempts are already underway to use modified algorithms to 
cope with lower resolution data if needed. 
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The second strategy, of using 2DMS to study metallodrug-modified proteomes was then investigated 
by application to A2780 cancer cell line trypsin digests. The A2780 cells were grown with or without 
treatment with a potent osmium piano-stool metallodrug, and were then lysed, protein extracted, 
purified, digested and the resulting peptides desalted before nESI analysis followed by nESI-2D-
ECD/IRMPD-FT-ICR MS characterisation. 2DMS has already been shown in a number of studies to be 
an effective analytical method for the assignment and characterisation of biomolecules, the 
application shown herein was a larger scale application, requiring high resolution isolation of 
precursors not available using convention quadrupole isolations. Many thousands of precursor peaks 
were observable in the nESI-FT-ICR Ms of the cancer cell digest samples, all of which were then 
characterised using 2DMS via ECD and IRMPD analysis separately. The resulting 2DMS spectra were 
extremely complex, with each of the thousands of precursor species fragmented producing many 
more fragments separated in 2-dimensional space in the 2DMS plot. 2DMS was shown to be a viable 
tool in producing effective MS/MS spectra of all observable species, which can then be searched and 
matched against proteomic databases, using tools produced for traditional LCMS based proteomics, 
to assign the biomolecules observed and highlight proteome wide changes due to metallodrug 
administration. The detailed analysis of this data is ongoing, but rapidly improving. The main 
benefits for metallodrug-modified proteomic analysis brought by 2DMS is the long-awaited ability to 
use metal complex-friendly solvent systems, which will enable retention of the metal complex once 
bound to the biomolecules, unlike LCMS where they were shown to readily dissociate and/or 
relocate. In addition 2DMS enables careful, and often lengthy MS/MS experiments which are not 
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compatible with the duty-cycle limitations required by LCMS. The rapid scan rate needed for 
effective LCMS (~1 Hz) is a limitation for UHR-MS instruments which often require several seconds 
per scan to achieve UHR. ExD MS/MS experiments, as shown throughout this thesis to be critical for 
effective metallodrug-modified biomolecule characterisation, can also take additional time to apply 
(~0.1-1 s) and reduce scan to scan rates even more, with standard dissociation techniques (CAD) not 
suitable for metallo-proteomics, this can hinder the acquisition of acceptable data. 2DMS 
circumvents these issues by eliminating the need for LC and LC-induced scan rate requirements, and 
using standard nESI ionisation for sensitive and prolonged acquisitions.  
 
Future applications of both the SNAP-LC and 2DMS techniques to characterisation of metallodrug 
modified proteomes are underway and are expected to be applied to many systems, utilising the 
data and knowledge of metallodrugs gained from the initial detailed studies in Chapters 3-6 to 
inform better tuning and analysis of the resulting data. It is the hope of the Author that these 
techniques will eventually mature into viable, effective, and most importantly accurate methods for 
the analysis of proteomes, without the erroneous assumptions made in many proteomic studies. 
Constant improvements in MS and computational instrumentation are being developed and will only 
help improve the acquisition of data and analysis of the resulting data, eventually detailed and 
accurate proteome wide characterisation of metallodrug-biomolecule interactions will be readily 
achievable and will help to inform better drug design, synthesis, and application to help combat 
many diseases and conditions including and beyond cancer. 
